TWI300414B - Modified peptide yy and conjugates thereof - Google Patents

Description

1300414. IX. INSTRUCTION DESCRIPTION: The present invention relates to an improved therapeutic peptide. In particular, the present invention relates to the protection of endogenous therapeutic tablets from peptidase activity by an improvement in the selective conjugation of the plate to a blood component, thereby protecting the peptide from protection. The peptidase activity is two and increases during the action of the therapeutic peptide for treating various diseases. BACKGROUND OF THE INVENTION Many endogenous peptides have been described as the main building blocks for biological processes. Some of these wins have been identified by bees as the primary therapeutic substance for the treatment of various diseases. In general, endogenous peptides are more suitable as therapeutic substances than a synthetic peptide having a non-native sequence because such synthetic peptides are unable to produce an immune response elicited by such endogenous properties. In addition, endogenous peptides are highly specific to their target receptors and are easy to synthesize and formulate. However, the main difficulty in the delivery of such therapeutic peptides is their relatively short plasma half-life, which is primarily due to rapid serum clearance and proteolytic degradation via peptidase. - The chymase disrupts the peptide bond in the peptide by inserting a molecule of water across the bond. In general, most of the peptides are degraded in a few minutes or less by way of peptidase in the human body. In addition, certain peptides encapsulate specific types of peptides with specificity, allowing them to degrade more rapidly. Therefore, if a peptide is used as a therapeutic substance, then 1300414

When the peptide is rapidly degraded in vivo by the action of a peptidase, its activity is generally lowered. One of the ways to overcome this shortcoming is to give the patient a high dose of the desired therapeutic version so that even when some of the peptide is degraded, there is still a sufficient amount of therapeutic peptide to achieve therapeutic effect. . However, this method is quite uncomfortable for the patient. Since most of the therapeutic peptides cannot be administered orally, the therapeutic peptide must be continuously injected by intravenous injection, once or frequently, or by the path of discomfort by subcutaneous injection. Administered. The need for such recurrent dosing also results in a variety of peptide peptide therapies that are highly unacceptable for each treatment session. The presence of this large amount of degradation also has undesirable side effects. The discomfort and high cost of administration are two reasons why most of the therapeutic peptides with attractive bioactive properties cannot develop into drugs. On the contrary, these therapeutic peptides are used as templates for simulating the development of compounds of peptides in place of therapeutic peptides. Biotech and large pharmaceutical companies have often embarked on lengthy and expensive refinements to try to develop non-skinned, organic compounds that mimic the activity of the therapeutic peptide without creating an unacceptable side effect. . For example, cyclic peptides, analog peptides, and small gems from expensive SAR (structural activity relationships), and molecular model studies have reached an unbelievable development of peptide mimetic. These peptide mimetics are unable to reflect the correct original biological properties of the therapeutic peptide, and are therefore inferior to the endogenous therapeutic peptide as a therapeutic substance. 1300414 Another used to replace the production of the scorpion mimetic The method is to block the effect of each of the plates to prevent degradation of the therapeutic peptide or to alter the therapeutic prevailing condition, in which the degradation of the cells is slowed down while still maintaining their biological activity. The method comprises conjugating with a polymeric substance (such as dextran, polyvinylpyrrolidone, glycopeptide, polyethylene glycol and polyamino acid), and conjugating with adroitin sulfates, And conjugation with polysaccharides, low molecular weight compounds such as amino lecithin, amino acid 'vitamins, and glycosides. However, such conjugates are generally still sensitive to protein peptidase activity. In addition, the peptides are Treatment Sexuality usually decreases due to the addition of the polymeric substance. Finally, when the substance is injected into the body, there is a risk factor for an immune response due to the conjugate. Some methods include in vitro and carrier. The protein is conjugated to cause the production of the random conjugate. The conjugate is difficult to manufacture, and its benefits are limited by the commercial availability of the carrier and by its Poor pharmacy economy. Therefore, there is a need for a novel method of improving therapeutic serotypes, so as not to be affected by peptidase activity and to provide a longer period of action in vivo while maintaining low toxicity and retaining the improvement. Therapeutic advantages of the peptides. Brief Description of the Invention The present invention relates to the problem of overcoming the degradation of the serotype in vivo by modifying the therapeutic trait of interest and attaching it to a protein carrier, in order to avoid peptidase Role or degradation. In particular, the present invention relates to a chemically reactive derivative of a novel therapeutic peptide, particularly a therapeutically superior 肷 顺 顺 -7-7 1300414 ene diimine (male) Imide derivatives which form covalent bonds with effective functional groups on blood proteins. The invention also relates to novel chemically reactive derivatives or analogs of such therapeutic peptides. The invention also relates to the therapeutic use of such compounds. The present invention relates to the improvement of a therapeutic peptide by in vivo or in vitro techniques and attachment to a protein carrier, preferably albumin. The effect of the low-peptidase is prevented by the 苐-residue-synthesis modification of the sputum to be excised. The N-terminus, C-terminus, or intermediate portion of the peptide chain of the therapeutic peptide is usually It is activated. The technique of the present invention is used to modify the inactive position of the therapeutic peptide with reactive groups which form a functional group with the blood component. Covalent bond. The reactive group is placed in a position such that when the therapeutic peptide is bonded to the blood component, the peptide retains a substantial portion of the activity of the native compound. The improvement of the myxonal therapeutic sputum is carried out by the chemical modification method used in the present invention, under which the specificity of all or most of the peptides can be retained regardless of whether it is attached to a blood component. . The therapeutically superior-blood component complex can be delivered to various parts of the body without being degraded by peptidases' and the peptide retains its therapeutic activity. The present invention is applicable to all known therapeutic peptides and is readily measured under physiological conditions by direct comparison to pharmacokinetic variables with or without the modified therapeutic peptide. The present invention is directed to an improved therapeutic version which forms a peptidase stable therapeutic version which is comprised of 3-50 amino acids. The winner 1300414 has a slow-base amino acid, an amino-terminal amino acid, a therapeutically active regional amino acid, and a poorly treated active region amino acid. The peptide comprises a reactive group that reacts with an amine, hydroxyl, or thiol group on the blood component to form a stable covalent bond, thereby forming a stable therapeutic therapeutic effect of the peptidase Peptide. In the peptide of the present invention, the reactive group is selected from the group consisting of a succ ini mi dy 1 and a cis-butadiene diamine group, and the reactive group The reactive group is attached to the amino acid position of the amino acid located in the poor therapeutically active region. In a particular embodiment, the therapeutically active region of the peptide comprises a carboxy terminal amino acid and the reactive group is attached to the amino terminal amino acid. In another embodiment, the therapeutically active region of the peptide comprises the amino terminal amino acid and the reactive group is attached to the carboxy terminal amino acid. In yet another embodiment, the therapeutically active region of the peptide comprises the carboxy terminal amino acid, and the reactive group is attached to the amine group at the amino terminal and the carboxy terminal amino acid. On the amino acid. In still another embodiment, the therapeutically active region of the peptide comprises the amine-terminated amino acid and the reactive group is attached to the amine-based acid and the carboxy-terminal amino acid. On the amino acid. The invention also relates to a method of synthesizing the improved therapeutic peptide. The method includes the step of 歹'j. In the first step, if the therapeutic version does not contain cysteine, the peptide is synthesized starting from the carboxy terminus and the reactive group is added to the dibasic amino acid. Further, one end is added to the thiol amino acid from the amine group, and the reactive group is added to the terminal -9 - 1300414 amine acid. In the second step, if the therapeutic peptide contains only half of the hexamine k, the cysteine is associated with the amino acid before the reactive group is added to the poor therapeutically active region of the winner. A protective group reaction. In the third step, 'if the therapeutic peptide contains two cysteine as a disulfide bridge, then the dicysteine is oxidized and the reactive group is added to the therapeutic victory. The amine-terminated amino acid is added to the dibasic amino acid or to an amino acid disposed between the carboxy terminal amino acid and the amino terminal amino acid. In the fourth step, if the therapeutic peptide contains more than two cysteine as a disulfide bridge, the cysteine in the disulfide bridge is sequentially oxidized, and the reactivity is The winning plate was purified before the group was added to the carboxy terminal amino acid. The present invention also relates to a method for protecting a therapeutic tablet from peptidase activity in vivo, the victory plate being composed of 3 to 50 amino acids, and

V has a carboxy terminal and an amine terminal, and a carboxy terminal amino acid and an amine terminal amino acid. The method comprises the steps of: (a) attaching a reactive group to the carboxy terminal amino acid, the amine terminal amino acid, or attaching to an amine-terminated amine An amino acid between the carboxylic acid and the carboxy terminal amino acid to modify the peptide such that the modified peptide forms a covalent bond with the reactive functional group on the blood component in vivo; (b) The reactive group forms a covalent bond with the reactive functional group on a blood component to form a peptide-blood component conjugate, thereby protecting the peptide from peptidase activity; 10-1300414 (c) The stability of the sputum-blood component conjugate was analyzed to assess the protection of the peptide from the action of the enzyme activity. These steps can be carried out in vivo or ex vivo. The invention also relates to a method for protecting a therapeutic tablet from peptidase in vivo, wherein the peptide consists of 3 and 50 amino acids and has a therapeutically active amino group. Acid and a poorly acidic amino acid in the therapeutically active region. The method consists of the following steps:

(a) determining the amino acid of the therapeutically active region; (b) by attaching a reactive group to the amino acid, in an amino acid included in the poor therapeutically active region The amino acid positionally changes the peptide to form a modified peptide, and the improved peptide is therapeutically active and forms a covalent bond with a reactive functional group on the blood component in vivo; (c) forming a covalent bond between the reactive group and the reactive functional group on a blood component to form a peptide-blood component conjugate, thereby protecting the Shengli plate from the enzyme activity And (d) analyzing the stability of the peptide-blood component' composition to assess the protection of the peptide from peptidase activity. These steps can be carried out in vivo or ex vivo. The advantages of the compositions and methods used in the present invention include, but are not limited to, the peptides represented by SEQ ID NO: 1 to SEQ ID NO: 1617. -11 - 1300414 DETAILED DESCRIPTION OF THE INVENTION Definitions In order to determine a complete understanding of one aspect of the present invention, the following definitions are provided: Reaction. Sexuality: The reactive group is a group that forms a covalent bond. This reactive group is kneaded or bonded to the desired therapeutic tablet. The reactive groups are generally stable in an aqueous environment and are typically carboxyl groups, a base, or a suitable sulfhydryl group (which may be a hydrazine or a mixed anhydride), or an imidate Thereby, a covalent bond can be formed with the functional group, such as an amine group, a hydroxyl group, or a monothiol at a target position on a moving blood component. For the most part, the ester is involved in a phenolic compound or is a thiol ester, an alkyl ester, a phosphate ester or the like. Reactive groups include succinimidyl and maleimide groups. The functional group is a group on the blood component which includes a mobile and immobilized protein which reacts with a reactive group on the modified therapeutic peptide to form a co-bond. The functional group generally includes a thiol group for bonding to an ester-reactive group, a thiol group for bonding to a cis-butyl iodide, an imidate, and a thioester group, and is used for bonding. As for the activated carboxyl group, phosphonium group, or other mercapto group on the reactive group. Also the liquid component blood component can be fixed or mobile. The fixed blood component is a non-moving blood component and includes tissue, membrane receptor, interstitial protein, fibrin protein, collagen, platelets, endothelial cells, a 12-1300414, and related cell membranes. Membrane receptors, somatic cells, body skeletal and smooth muscle cells, nerve components, bone cells and osteoclasts, and all body tissues, especially those associated with the circulation and lymphatic system. The mobile blood component is included for a period of time which typically does not exceed 5 minutes, more typically does not exceed 1 minute, and does not have a fixed location of blood components. The blood components are not attached to the membrane and are present in the blood for a prolonged period of time and are present at a concentration of at least 〇·1 #g/ml. Moving blood components include serum albumin, transferrin, ferritin, and immunoglobulins such as IgM and IgG. The half-life phase of the mobile blood component is at least 12 hours. The protective group is a chemical moiety for protecting the peptide derivative from its own action. A variety of singularity groups are disclosed in U.S. Patent No. 5,493, the entire disclosure of which is incorporated herein by reference. Such protective groups include ethenyl, fluorenyl oxycarbonyl (Fm〇c), butyloxycarbonyl (Boc), benzoquinoneoxycarbonyl (Cbz) and the like. This particular protective amino acid is described in Table 1. A linking group is a chemical moiety that links or links a reactive group to a therapeutic peptide. The linking group may comprise one or more alkyl, alkoxy, alkenyl, alkenyl, alkynyl, or alkyl, cycloalkyl, polycyclic, aryl, polyaryl, substituted aryl An amino group substituted with a heterocyclic group and a substituted heterocyclic group. The linking group may also comprise a polyethoxylated amino acid such as hydrazine ((2-amino)ethoxyacetic acid) or a preferred linking group-13-1300414 ([2-(2-amino)) Ethoxy)]ethoxyacetic acid). A preferred linking group is aminoethoxyethoxyacetic acid (AEEA). The i-functionality - a sensitive functional group is a group of atoms that exhibit a possible reactive position on the therapeutic peptide. If present, a sensitive functional group can be selected as the attachment point for the attachment-reactive group 0 modification. Sensitive functional groups include, but are not limited to, carboxyl groups, amine groups, thiols, and hydroxyl groups, and the therapeutic peptides are improved by attaching a reactive group. A therapeutic peptide that penetrates the 5 to the blood component to form a peptidase stable victory. The reactive group can be attached to the therapeutic peptide by a linking group or, optionally, without a linking group. One or more additional amino acids may also be added to the therapeutic skin to facilitate attachment of the reactive group. The improved peptide can be supplied in the living body so that it can be conjugated to the blood component to be produced in vivo, or it can be conjugated to the blood component prior to the in vitro and the resulting - Peptidase-stabilized peptides (as defined above) can be supplied in vivo. The modified therapeutic peptide '·' and the "modified peptide are used interchangeably in this application. The therapeutic peptide of the peptidase is stable with or without a linking group. a modified peptide conjugated to a blood component by a covalent bond 1300414 formed between a reactive group of the modified peptide and a functional group of the blood component. Peptidase stable therapeutic victory Peptides are more stable in vivo than in the presence of peptidases than a non-stable peptide. A peptidase-stabilized therapeutic peptide generally has a half-life of at least 10-50% increase over a sequence-unstable non-stable peptide. The peptidase stability is determined by comparing the half-life of the unmodified therapeutic peptide in serum or a blood with the half-life of a therapeutically superior victory in serum or blood. q Sampling the serum or blood of the modified peptide after the supply of the modified and unmodified peptides, and determining the activity of the peptide. In addition to determining the activity, the length of the therapeutic tablet can also be determined. _therapy - as in the user of the invention, therapeutic success The peptide system is a therapeutically active amino acid chain between 2-50 amino acids, as described above. Each therapeutic peptide has a phenyl terminus (also known as a terminal or amine terminal amine group). An acid), a carboxy terminal (also known as (:-terminal or carboxy-terminal amino acid), and an intermediate amino acid disposed between the amine terminal and the carboxy terminal. The amine terminal system is only one A free alpha-amino group is defined by an amino acid within the therapeutic peptide chain. The carboxy terminal is defined only by a therapeutic peptide chain having a free a-carboxy group, the internal amino group S. The therapeutic peptide of the present invention contains a therapeutically active region, which is typically placed on the amino terminus, the carboxy terminus, or on an intermediate amino acid. The therapeutically active region may utilize blind or structural activity correlation (SAR). Identification by driver action, as defined in detail in this application. SAR is an analysis of the correlation between the molecular structure of a compound and a pharmacological activity and its pharmacological activity. Therapeable active area available in the literature. 15-15 - 1300414

Domains can be obtained from designated references such as scientific journals. Knowledge of the location of the (7) therapeutically active region of the peptide is important to improve the therapeutic peptide, as defined in detail below.

The therapeutic peptides useful in the present invention also contain a poor therapeutically active region which is generally disposed at the amino terminus, at or near the carboxy terminus, or at or near an intermediate amino acid. The poor therapeutically active region is a region of amino acid that does not coincide with the therapeutically active region of the therapeutic peptide. The poor therapeutically active region is generally disposed away from the therapeutically active region such that the improvement in the poor therapeutically active region does not substantially affect the therapeutic activity of the therapeutic peptide. For example, if the therapeutically active region is disposed at the amine end, the therapeutic victory is modified at the carboxy terminus or an intermediate amino acid. Alternatively, if the therapeutically active region is disposed at the carboxy terminus, the therapeutic peptide is modified at the amino terminus or an intermediate amino acid. Finally, if the therapeutically active region is disposed in an intermediate region, then the therapeutic Shengxin D "therapeutic activity" is modified at the amino terminus end to be any activity associated with curing or treating the patient's biological disease. . Examples of such therapeutic peptides include pituitary hormones such as vasopressin, oxyt〇cin, melanocyte st imulating hormones, adrenocorticotropic hormones, Growth hormone; / lower vision chrysanthemum (lower hypothalamic hormone), such as growth hormone releasing factor, corticotropin releasing factor, prolactin releasing hormone, gonadotropin releasing hormone and its related peptides, luteinizing hormone Luteinizing hormone release hormones, gonadotropin releasing hormone-1, 1300414 AI (thyrotropin releasing hormone), leucoxin, and inhibitor of growth hormone release (s_at〇statin);篆 'such as calcitonins (calcitonins), calcitonin precursors, peptides associated with the scorpionin gene; scorpion scorpion and its related protein shells 'surgical hormones, such as insulin and Insulin-like sputum, spleen and blood • Uucag〇n, growth hormone releasing inhibitor (somatostatin), pancreatic polypeptide, Starch meridian (AmyHn), peptide γγ, {·^ and brain wins Y); digestive hormones, such as gastric hormone (gastrin), gastric hormone release, stomach hormone inhibition, gallbladder pigmentation (cholecyst okinin ), small intestinal endocrine (secretin), motilin, and vaSQactive intestinal peptide; natriuretic peptides, such as atrial natriuretic peptide, brain sodium urinary peptide , with C_type sodium urinary sputum; neurokinins (such as nerve stimulator A, nerve stimulator B, and substance P; vasopressin (reni n) related to victory or defeat, such as blood vessels Tensile chymase receptors and inhibitors, and angi〇tensins; ervdothelins, including big (endo) endothelin, endothelin-accitrin A receptor antagonist, and sirolimus Toxin (sarafotoxin) wins; and other peptides, such as adrenal medullary peptide, altolastatin peptide, beta amyloid fragment, antibiotics and antimicrobials, cell planning; Weekly death wins (apoptos is re 1 ated p Eptides), bag cell peptides, bombesin, bone glycogen peptides, CART peptides, chemotactic peptides, cortical abundance 1300414 Ο

(cort: stat iη) peptide, fibrin fragment, blood fiber related peptide, FMRF and similar peptides, galanin and its related peptides, growth factors and their related peptides, G therapeutic leap - Binding protein fragment, guany 1 in and ur〇guany 1 in, statin sin, cytosine and cytosine receptor protein, laminin fragment, lyptine Ueptin Fragment leap, white A-kinase (leuc〇kinins), mast cell degranulation, and a pituitary adenylate cyclase activation polypeptide (a (Jenyiate cyCI_ase activating polypeptides), pancreatic balance (pancreas1; Peptide T, polypeptide, virus-related peptide, message transducing substance, toxin, and various other peptides, such as adjuvant peptide analogs, alpha mating factor, anti-arrhythmia Anthraquinone, anti-coagulant polypeptide, anorectic peptide, bovine pineal antireproductive peptide, purine base, C3 peptide P16, tumor necrosis factor, adhesion factor (cadherin) Winning version , chromogranin A fragment, contraceptive tetragen (contraceptive tetrapeptide), conant〇kin (G), nectar gold T, clam shells (crustacean) Cardioactive peptide, C-telopeptide, cytochrome b588, plate, decorsin, delicious peptide, △-sleep-triggered peptide, benzodiazepine- Binding inhibitor fragment, nitric oxide synthase blocking peptide, 0VA Sheng plate, platelet calpain inhibitor (Pl), blood plasminogen activator inhibitor 1, rigin , schizophrenia related peptide, serum thymus factor, sodium 18-1300414 potassium A therapeutic peptidase inhibitor _1, speract, sperm activation, system in, coagulation Enzyme receptor agonist, thymic humoral gamma 2 factor, thymopentin, thymosin cd, thymus factor, tuftsin, adipose hormone (acjip〇kinetic hormone) ), urinary toxic disease And other therapeutic peptides. In considering such definitions, the focus of the present invention is to improve the therapeutic sputum, to win the trait, to protect it from the effects of peptidase activity in vivo, and thereby extend the therapeutic period of the therapeutic victory. The effective treatment period is the problem found when the victory itself is administered to the patient. 1 . The peptide sequence of the amino acid sequence selected from the therapeutic peptide of the present invention selected from the group consisting of a therapeutic peptide (provided by the accompanying SEQUENCE LISTING) comprises the present invention. The starting point for development. The peptide is between the range of 2 to 50 amino acids. The interchangeable noun "peptide fragment," and "successor" include both synthetic and naturally occurring amino acid sequences derived from a naturally occurring amino acid sequence. In one embodiment, the 'peptide and peptide fragments are by conventional methods. Cheng, which is synthesized by the experimental table (bench_t〇p> square method or by automatic peptide synthesis machine, as detailed below). However, it is also possible that the straw is naturally produced by using a protein such as proteolytic enzyme. The amino acid sequence is cut into fragments to obtain a fragment of the peptide. Further, it is also possible, for example, by M^iatis et al. in Molecuiar B1〇1〇gy: A Lab〇rat〇q Ml -19- 1300414

As disclosed in Spring Harbor, New York (1982), the use of recombinant d;\:a techniques to obtain fragments of the therapeutic peptides of interest is hereby incorporated by reference. Other new improvements and the use of existing methodologies can also be considered. The invention includes a peptide derived from the sequence of a naturally occurring therapeutic peptide. A peptide can be synthesized by cleaving a naturally occurring sequence or by synthesizing a sequence of naturally occurring amino acids or by knowledge of the genetic material (DNA or RNA) encoding the sequence. It is referred to as 'a sequence derived from a naturally occurring amino acid.' Included within the scope of the present invention are those molecules which are referred to as "derivatives" of a peptide. The ''derivative' has the following characteristics: (1) it has substantial homogeneity with the therapeutically victorious or similarly sized fragment of the peptide; and (2) it has functional complement to the peptide The same therapeutic activity. If the amino acid sequence of the derivative of a peptide is at least 8%, and preferably at least 90%, and optimally at least 95% is similar to other peptides or one having the same number of amino acid residues When the amino acid sequence of the peptide fragment is obtained, the winning version of the bamboo biological system is said to have "substantial homogeneity" with the winning version. Derivatives of the invention include a peptide fragment which, in addition to containing a sequence which is substantially homologous to a naturally occurring therapeutic peptide, may also contain one or more % of the amine or/and carboxyl terminus thereof Amino acid, as described in detail below. Accordingly, the present invention relates to polypeptide fragments of therapeutic peptides which may contain one or more amino acids which are not present in the naturally occurring therapeutic peptide sequence provided, The peptide fragment has a therapeutic activity higher than that of the therapeutic peptide. Ύ0 1300414 Similarly, the invention includes a polypeptide fragment that, although it contains a sequence substantially identical to the naturally occurring therapeutic peptide, may be deleted one or more at its amino terminus and/or carboxy terminus Other amino acids, which are generally found naturally on the therapeutic peptide. Thus, the present invention is directed to a multi-version fragment of a therapeutic skin which may be depleted of one or more amino acids' and such amino acids are generally present in the naturally occurring peptide sequence provided, the polypeptide Has a therapeutic activity above the therapeutic peptide. The present invention also includes various forms of the above-described fragments that are apparent or unimportant, having amino acid substitutions (and thus amino acid sequences different from the natural sequence) that are different before and after the sequence provided, This different form of product has an activity substantially equivalent to the above-described derivatives. Examples of obvious and unimportant substitutions include substitution of one base with another (ie, replacing Lys with Arg), substitution of another hydrophobic group with one hydrophobic group (ie. replacing lie with Leu), or One aryl group is substituted for another aryl group (a), 匕 is replaced by Phe (Tyr) and the like. (As is known in the art, the amino acid residues may be present in protected or unprotected form, using a suitable amine or carboxyl protecting group as discussed in more detail below. The peptide may be present as a free amine group (in the N-%) or an acid addition salt thereof. A general acid addition salt is a hydrophilic acid salt, i.e.HBr, HI, or, more Preferably, the cation is an alkali metal or alkaline earth metal cation (ie, Na, K, U,

Ca, Ba, etc.), or an amine cation (丨·e. tetraalkylamine, trialkylamine, wherein the alkyl group can be (: "C12) 〇 any peptide having a therapeutic activity can be used in the present invention The following -1 - 1300414 listed wins are examples of what can be provided for the present invention 'but are not complete and are not limited to the number and type of peptides that can be used in the present invention. The therapeutic peptides and the fragments produced by the peptides can be modified according to the present invention and can be therapeutically made in the same human body. A· Vine ptosis TT hormone (SEQ ID NOS: 1 - 72)上上上腺皮素素 (ACTH. aka injury kidney h 杳赘 ( (SEQ ID NOS·· 1 -22) - the endocrine function of the adrenal cortex is regulated by a anterior pituitary hormone, ACTH, ACTH is a 39 amino acid peptide which is produced in the cortical cells of the anterior pituitary gland under the control of the corticotropin releasing factor. ACTH is called morphine-like nerve The peptide (pro-opicDmelanocortin (P〇MC)) f 241-amino acid precursor is translated and improved. The biological role of the ACTH Maintaining the amount and viability of the adrenal cortex and stimulating the production of steroids in the adrenal cortex, the steroid is essentially corticosteroid and corticosterone. The mechanism of action of ACTH involves its binding to the ACTH receptor and subsequent activation of the adenylate. The amount of cyclase 'Tinan's adenosine monophosphate ( cAMp) and the activity of protein kinase A (PKA) which increases the adrenocortical tissue. The main effect of these events is to increase the side chaincleaving enzyme (side chaincleaving enzyme) The activity of this enzyme converts cholesterol to pregnenolone. Since these enzymes are distributed in the subdivisions of each adrenal cortex, the important physiological role of ACTH is 22-1300414 for glucocorticoids. The production of (glucocorticosteroids) In addition to the function of controlling adrenal cortical activity, acch has been shown to have different biological roles, including regulation of endocrine and exocrine glands, temperature regulation, and its effects on nerve regeneration and differentiation. And its fragments can affect exercise, learning and behavior. Therefore, ACTH is used as a therapeutic substance. It can help control these functions. ACTH is released by the anterior pituitary gland, which is regulated by corticotropin releasing factor (CRF). Bio-long peptide (SEQ ID NO: 23-24, 45) - Human placental lactogen (hPL), growth hormone and prolactin (Prl) are included in the growth hormone population. All of them have about 200 amino acids, two disulfide bonds, and no saccharification. Although each has a specific receptor and a unique property relative to its activity, it retains the activity of promoting growth and prolactin. Mature O GH (22, sputum auricular) is produced as a single polypeptide chain in the somatoporous body cell (somatotr〇Pes). Because of the alternate RNA splicing, a small number of smaller molecules are also secreted. There are a number of GH-related genetic defects. The GH-deficient short stature lacks the ability to synthesize or secrete GH, and these short-sized individuals respond fairly well to GH treatment. Pygmies lack IGF-1 that responds to GJ], rather than the metabolic stagnation that lacks GH. Therefore, in gnomes, it lacks a posterior receptor. Finally, the short man of Laron has a plasma GH of 23,1300,414 or more, but it lacks the liver GH receptor and has a lower amount of 'decyclic IGF-1. Defects in these individuals are clearly related to their ability to respond to GH caused by the production of IGF-1. Excessive GH production can cause gigantic sputum (gigantlsm) before the closure of epiPhWea丨, and when the GH becomes too much after the sputum is closed, the growth of the extremity bone leads to hypertrophy of the extremity. The characteristics appear. The use of GH as a treatment Q-object will be used to help treat these diseases and can stimulate the growth of other patients with small or short cases with lower or normal GH levels.坚mpiSmiSEQ ID NOS: 25-391 - Melatonin (MSH) is produced in the middle pituitary gland under the control of dopamine. MSH may have important physiological roles in melanogenesis, melanogenesis, neurological function associated with learning and behavior, and in fetal development. It can be found in Sawyer, T.K. et al., in Proc. Nat. Acad. Sci USA, 79, 1 751 (1982). ^4jt(〇xytociiiKSEQ ID NOS: 40-44^ An oxytocin^ is involved in promoting milk secretion, contraction of the uterus, and loosening of the pelvis prior to infant production. The secretion of oxytocin in lactating women is due to the cause of lactation The nipple is stimulated to obtain direct neurofeedback to stimulate its secretion. Its physiological effects include the contraction of mammary gland epithelial cells (my〇epi1丨al) (which includes milk from the mammary gland) and the contraction of uterine smooth muscles that give birth to the baby. Stimulation. Oxytocin causes contraction of myoepithelial cells around the secretory acinar (SeCret〇ry acini) of the breast, while pushing the milk through the catheter. In addition, it stimulates the release of prolactin, and prolactin acts on the breast and stimulates the milk. The formation of acinus. Therefore, a conjugated oxytocin can be used to help lactose-24-1300414 juice secretion and can help the relaxation of the pelvis before production. It can also be used to prevent uterine bleeding after childbirth.素 (ADH) (SEQ ID NOS: 46-7W - vasopressin is also known as vasopressin (ADH), because it is the main regulator of humoral osmotic pressure, it will Causes antidiuresis and increases blood pressure. The vasopressin binds to the serosal receptor and activates the cyclic AMP/protein kinase A (cAMP/PKA) in the circulatory system through G-protein. The fraction of the hormone; it must be regulated by the parasitic receptor (〇SniQrecept〇rs) in the hypothalamus, which will sense the concentration of water, and when the plasma osmoticity increases, it will stimulate the secretion of vasopressin. This secreted vasopressin increases the rate of reabsorption of water in the tubular cells, which causes urine discharge (the concentration of urine is Na+) and thus a net decrease in the osmotic pressure of body fluids. The absence of vasopressin causes watery urine and thirst, a condition called diabetes insipidus. Therefore, the use of vasopressin or vasopressin fragments after conjugation will prevent these diseases and maintain the body's normal condition. Osmoticity B. Lower ventricle hormone (release factor)? C〇rti co tropin Rg_leasinKU〇r (CRF)-& Phase M 酞 (SEO ID NOS: 73- im - Corticotropin releasing factor (CRF) is a The 41 amino-based S texts have a very important role in the coordination of the total response of the pressure between the brain and the surrounding parts. In the brain, the 'CRF is mainly from the hypothalamus of the sub-chamber. The tiny cell nerve of the paraventricula r hypQthalamic nucleus is produced and secreted. Since then, the 1300414 CRF-containing nerve system has extended to the portal microvascular region of the medial eminence and acts to stimulate the sag of the brain. Anterior vestibular hormone (ACTH), cold-endorphin and other morphine-like neuropeptide (P0MC)-derived peptides are secreted from the cerebral gland. This subsequent ACTH-primed adrenal glucocorticoid is the last step in the hypothalamus-pituitary-adrenal axis (ΗΡΑ), which regulates the response of endocrine to stress. In addition to its neuroendocrine role, CRF can also act as a neurotransmitter (neu:r〇transmi tter) and a neuromodulator to induce a wide range of autonomic, behavioral, and immune responses to physiological, pharmacological, and pathological stimuli. . Clinical studies have shown that CRF over-secretion is associated with a variety of diseases, such as most depression, anxiety-related disorders, anorexia, and inflammatory symptoms. Low levels of CRF have been found in Alzheimer's disease, dementia, obesity, and many endocrine diseases. Therefore, the use of CRF as a therapeutic substance against a high or low amount of Crj? will provide a therapeutic basis for diseases associated with abnormal CRF secretion. A variety of peptide antagonists and non-peptide antagonists have been discovered and widely studied, including a-helix CRF (9-41), Astressin, D_?1^〇{^(12- 41) (peptide antagonist) and 0?-154526 (non-suppressant antagonist). These CRF antagonists provide a novel drug for the treatment of depression, anxiety and other CRF-related diseases. Thus, the conjugated CRF peptide can be used to maintain the health and survival or use of the adrenal gland as an anti-inflammatory agent during prolonged use of the steroid. Gonadotropin Releasing ID NOS·Ifitiifn _ GAP ～ 9 fS — 1300414 is contained in the precursor molecule of gonadotropin releasing hormone (GnRH). G “p has the property of inhibiting prolactin. Gn -RH is the release of the hormonal secretory hormone (FS Η) and luteinizing hormone (LH) from the hypothalamus secreted by the hypothalamus. The low hormones will reduce the sex hormones. The feedback inhibition on synthesis leads to an increase in the amount of FSH and LH. The latter's stagnation hormone binds to the gonad tissue, which causes the sex hormone to be produced via the pathway regulated by the ring AMp (cAMP) and protein kinase A (PKA). A combination of GnRM can be used to help fertility, or as a contraceptive for men or women. The substance can be used on animals as it is for humans.

Production of a long-term too release factor - _ (GRF) (SEO ID NOS · · 111 - KW GRF is a hypothalamic peptide, which plays an important role in controlling the synthesis and secretion of growth hormone in the anterior pituitary The role of some structurally unrelated short-chain success has also been published by different mechanisms to trigger the secretion of growth hormone. Under the influence of GRF, growth hormone is released into the systemic circulation, resulting in The tissue of the sputum secretes IGF-1. Growth hormone also has other more direct metabolic effects (both hyperglycemia and metabolic effects of lipolysis). The main source of systemic IGF-1 is in the liver, although most other tissues It can help and secrete systemic IGFM. The liver's ιπ-丨 is considered to be the main regulator of tissue growth. In particular, IGF-1 secreted by the liver is believed to synchronize the growth of the body as a whole, resulting in tissue A stable balance of size and volume in the body. IGF-丨 secreted by surrounding tissues is generally considered to be autologous (aut〇crine) or peripherally secreted (paracrine) in its biological action. A conjugated GRF is used. As a rule Sexual substances to increase the release of sputum, -27 - 1300414 will help treat diseases associated with growth function regulated by GRF. 隹-xanthine hormone releasing hormone (LH-RH) (SEQ ID NOS: 135- Luteinizing hormone releasing hormone is the main mediator of neuroregulation of gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion. LH-RH can regulate plasma gonadotropins and sex steroids. To improve sexual behavior. See Vale, wW et al., Peptides, Structure and Biological Function, Proceedings of the Sixth American Peptide Symposium,

Gross, E. and Meienhoier, M., eds, 781 (1 979). A conjugated LH_RH substance can be used to stimulate ovulation in the human or animal body as an aid to fertility. The latter new Orexins (SEQ ID NOS: IfiiO - Orexi ns) is a group of neurogenics derived from the lower hypothalamus, which has recently been discovered and characterized. 〇rexins can stimulate appetite And the consumption of food. The gene lines are symmetrical on both sides of the hypothalamus, and the early stage is measured. It is the "feeding center" of the hypothalamus. Conversely, the general The satiety center is expressed in the ventral and medial hypothalamus and is regulated by the leptin-regulated neuropeptide network. Strong. Lactate #片胜版(SlgJD NOS: Lactin The eosinophilic pituitary gland is produced by lactotropes. The prolactin release-peptide acts on the pro-lactic acid cells to release prolactin. PRL initiates and maintains lactation in mammals, but generally only in breast tissue. It has been activated by the sex hormones of estrogen. A PRP conjugated to 1300414 can be used to increase lactation in humans or animals. Health & hormones release inhibitor (Somatostatin) (SEQ ID NO: Lli; 201) --- also known as growth hormone Release inhibitory factor (Growth

Hormone Release Inhibiting Factors (GIF)), a growth hormone's release inhibitor is a peptide of 14 amino acids, which is derived from the inferior colliculus and pancreatic d cells (the pancreas description is described below) Secreted. Growth inhibitors of growth hormone have been reported to regulate physiological functions in a variety of different locations including the pituitary gland, pancreas, digestive tract, and brain. It inhibits the release of growth factors, insulin and glucagon. It has many biological roles, including: inhibition of basic and stimulating hormone secretion from endocrine and exocrine cells, effects on motor activity and cognitive function, and possible therapeutic value in small cell lung cancer. See Reubi, J. c. Endocrinology, 110, 1〇 49 (1 98'2). A conjugated growth hormone release inhibitor can be used to treat large deformities in children or acral and hypertrophy in adults. ^ and its analogues THR stimulates the production of thyroid stimulating hormone (also known as gonadotropin) and the secretion of prolactin. In adults, TSH is responsible for improving the production of normal proteins and inducing a positive nitrogen balance. In the embryonic period, it is necessary for normal normal development. HypothyroidismHi in the embryo (HypothyroidismHi is characterized by dysplasia, which is characterized by congenital defects and impeded mental retardation. Therefore, a group of human THR can be used as a therapeutic substance for the treatment of these diseases. It can also be used to treat the thyroid gland caused by the pituitary gland for the diagnosis of human (tetra) glandular tumors. c. Thyromycin Calcitonin English_垦农imjD N0S: 215-224) - Calcium reduction CT (CT) is a 32-amino acid peptide, which is composed of a scorpion

Secreted by cells. Calcitonin is therapeutically useful for relieving osteoporosis, although its detailed mechanism of action is not known. However, it has been found that agaridine can induce the synthesis of parathyroid hormone in isolated cells, which results in an increase in the amount of plasma Can in vivo. In addition, CT has been shown to reduce the synthesis of osteoporosis factor (〇 〇 〇 P〇rin) (〇pn), a protein from the bone blast cells and responsible for attaching osteoblasts to bone. on. Thus, the use of a conjugated ct as a therapeutic peptide can increase the amount of plasma Ca2+ via induction of PTH and reduce bone resorption by reducing attachment of bone blast cells to bone. The successor of the transgenic gene (CGRP\rSF.q welcomes N〇s: 225 I): The CGRP is a 37 amino acid peptide derived from the father of calcitonin gene transcription. It exists in at least two forms: alpha (or CGRP-I) and stone-CGRP (or CGRP-II). CGRP is quite homogenous to Amylin and Adrenomedullin, and is widely and centrally and peripherally distributed in organs including skin, heart, septic, lung, and kidney. (3) Rp has a variety of biological roles, such as affecting the nervous and cardiovascular systems, immune response and metabolism. A 30-1300414 D· Parasitoid and its related protein are thyroxine (PT-H) (SEQ ID NOS: 2FU-parathyroid hormone (PTH) is a major cell in the parathyroid gland. Produce and divide/must to reflect the amount of systemic Ca2T. It plays a major role in the regulation of blood concentration, thereby affecting the physiological action of minerals and bone metabolism. The parathyroid Ca2+ system is used by Increase the amount of pa, Ca2+ and IP3 in the cells to reflect Ca2+. After a period of protein production, this step is followed by the secretion of PTH. The production and expression of PTJ in the main (ch i ef) cells The secretion system is basically present, but when the amount of blood MOM rises, + regulates the amount of ρτΗ in the chief cell (and the secretion of PTH) by increasing the rate of PTH proteolysis. When the amount of Ca 2+ decreases, it borrows Decrease the rate of pth proteolysis to regulate the amount of PTH in the primary cells. The role of PTH is to regulate the concentration of Ca2+ in the extracellular fluid. Therefore, the feedback pathway regulating pth secretion involves parathyroid gland, Ca2+ and the following The organization of the subject. PTH by combining The CAMP-coupled serosa receptor acts on it, which initiates a cascade reaction that achieves extremes in the biological response. The body's response to PTH is complex 'but its tissue with increased Ca2+ content in all extracellular fluids is PTH stimulates the breakdown of bone by stimulating the activity of osteoclasts, which leads to an increase in plasma Ca2+ and phosphoric acid. In the kidney, PTH reduces renal Ca2+ clearance by stimulating renal Ca2+ reabsorption. At the same time, 'PTH will reduce the reabsorption of the acid and increase the clearance of tannic acid. Finally, 'PTH will act on the liver, kidneys and intestines to stimulate the steroid hormones 1,25 - a gallbladder alcohol (1 , the production of 25-dihydroxycholecalciferol (calcitriol), which is responsible for the absorption of intestinal Ca2+. 1300414 A conjugated PTH can be used to regulate the balance of calcium in patients with a hypothyroid deficiency state. Inhibitor antagonists can be used to block PTH in kidney failure or other patients with excess PTH.

Parasitoid-like protein (ΡΊΈγΡ) (SEQ ID NO: 294-309) - Parathyroid hormone-related protein (PTHrP) has been noted as a physiological regulator to reduce chondrocyte differentiation ( Chondrocy tic differential: ion) and prevent planned apoptosis. At first, the PTHrP line was considered to be a secretory protein derived from tumors. Its structure is similar to that of parathyroid hormone (PTH), which is the main regulator of calcium homeostasis in the body. The PTH and PTHrP lines bind to the G-protein-coupled cell surface receptor (PTH/PTHrP or PTH-1 receptor), which recognizes the N-terminal (1-34) portion of this victory. Thus, when tumor-derived PTHrP enters the circulatory system, it activates receptors in standard PTH-labeled organs such as bones and kidneys and elicits PTH-like biological activity. By promoting bone resorption and inhibiting the excretion of dance, circulating PTHrP causes symptoms of hypercalcemia in general malignant fluids. Although initially found in tumors, PTHrP is then shown to be present in most of the most notable normal tissues, including the bones of young children and adults, where PTH-1 acts on its associated amino terminus. In vivo, it is used to regulate the growth and differentiation of cells. The anabolic effects of intermittent PTH supply to bone and its therapeutic potential for osteoporosis have been extensively studied. Since PTHrP is recognized as an endogenous ligand of a PTH/PTHrP receptor in osteoblasts, its use as an anabolic agent has been studied. The improved PTHrP peptide can be used for indicators similar to sputum. 1300414 Ε 狭 《 《 姨 姨 姨 姨 姨 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四 四. 31〇m-pancreatic point - cell charge _ Meng "Amylin", the _37 amino acid wins the skin is related to CGRP and blood transfusion. It is co-secreted with 姨-cell-t insulin. Starch meridians are found in type 1 diabetes. It is lacking. The starch mesogen is shown to act in conjunction with insulin to regulate the concentration of plasma glucose in the bloodstream, which inhibits the secretion of pancreatic hyperglycemic hormones after meals and inhibits the rate of gastric emptying. Patients with diabetes have a phenomenon of insufficient secretion of collaterals, which is equal to the deficiency of insulin secretion, which causes excess glucose to flow into the bloodstream during the postprandial period. Although insulin replacement therapy is one of the treatments for diabetes, the replacement of both the function of starch and insulin can allow for a more complete recovery of the normal physiological function of glucose control. Type 2 diabetes is characterized by the deposition of powdery protein from the island, which is mainly composed of the human type of amyloid protein produced by the amyloid polypeptide. A conjugated starch meridian can be used for the management of diabetes to limit postprandial hyperglycemia. Shame hormone"·_mouMzilii - pancreatic hyperglycemia The hormone is a 29 amino acid hormone synthesized by a cell of the island of Langerhans, which is a larger membrane hormone molecule. Similar to insulin, glucagon hormone lacks a plasma carrier protein, and similar to insulin, it has a circulating half-life of 1300414 5 minutes. As a series of features, the main role of glucagon is in the liver, which is the first tissue perf used by blood containing pancreatic secretions. The glucagon hormone binds to the serosal receptor and is translocated to the adenylate cyclase via the G_ protein. The resulting material increases cAMP and PKA, which reverses all of the above-described effects of insulin on the liver. Increasing _ also causes a significant increase in circulating glucose, which is produced by the formation of glycogen in the liver and the glycolytic action of the liver. A conjugated pancreatic hyperglycemic hormone can be used to treat hyperglycemia with periodic treatment. Risk of diabetes or to prevent or treat iatrogenic hyperglycemia.

Ul and class m shy (SEO TD N0S: 377-382) - these hormones were first considered insulin, a two-win version of 21 and 3 amino acids bound by disulfide bonds. It is produced by the pancreas, and its main function is to counteract the hormone-related effects of most hyperglycemia and to maintain low blood glucose. The insulin system is a member of a molecular group including structural and functional similarities such as IGF-1, IGF-2, and relacin (re laxi η). The four secondary structures of the ^3 are similar, and all have growth-promoting activities', but the main role of the island is metabolism, and the main role of IGFs and flarufoam is cell growth and differentiation. On the regulation. The Tengdao strain is synthesized in the b cell of the island of Langerhans by the form of the hormone j. The message is removed from the cell of the endoplasmic reticulum ((3)d〇p 1 asmi c reticulum). And it is encapsulated in a high-base body (G〇lgi) into a two-stage cyst 'folding into its natural structure, and this configuration is maintained by forming two double-strand bonds. The specific protease activity can excise the third molecule in the center, which is separated into a c-peptide, and is released by a disulfide bond to the carboxyl group 34.

1300414 A terminal amino acid b peptide. Insulin is produced by binding to a membrane-containing receptor, which is the same as all cells. The receptor system is a double-bonded * protein. One of the functions of insulin (except for its angle of signal transmission) is to increase the transmission of glucose in extrahepatic tissue by increasing the number of glucose transport molecules within one. Glucose transport molecules continue: Continued conversion State. Increasing the number of transport molecules in the plasma membrane is derived from the rate of replenishment of the new transport molecule into the human envelope, which is derived from: in a specific group of pre-formed transport molecules within the cytoplasm In addition to its regulatory role of glucose metabolism (and its use in the treatment of diabetes), insulin stimulates lipid production, reduces lipolysis, and increases the transport of amino acids into cells. Insulin also regulates transcription and changes. The cellular content of most mRNAs, which stimulate growth, egg A synthesis, and cell repair, have the combined effect of & 1 (^3 and flavin. A conjugated insulin can be used to treat diabetes. (SEQ ID NO: 383-389) - Neuropeptide γ (Νργ) is a peptide with 36 amino acid groups, which is the most abundant in both the peripheral and central nervous systems. One of the neuropeptides. It belongs to the Pancreatic Polysaccharide group of the peptide. Like its related substances, namely, the peptide γγ (ΡΥΥ) and the pancreatic polypeptide (ΡΡ), the Νργ system is a lost configuration. It is important that the free ends of the molecules are brought together to bind to the receptor. The central nervous system (CNS) and the surrounding parts produce a wide range of shadows. Its effects on the CNS include the main effects of feeding and energy utilization. Role, and the role of the transition to heartbeat, blood pressure, excitement and mood. On the side of Zhou 1300414, NPY causes vasoconstriction and hypertension, which is also found in the gastrointestinal and genitourinary tract, which acts by The organs of the gastrointestinal and renal organs play their roles. In recent studies, the hypothalamus ργ has been discovered _ plays an important role in the development of obesity characteristics, and its path to transmit the body obesity message to the hypothalamus It is an important transmitter in the regulation of body fat content. Leptin is a product of an obese gene that has been found to reduce the performance of NPY genes in obese (ob/ob) mice. Steroid hormones are also involved in the regulation of NPY synthesis in the hypothalamus, that is, insulin reduces Νργ expression and corticosteroids increase ΝΡΥ. A conjugation can be used to treat obesity and MODM (type 11 DM) in obese patients. Multi-version _(PP)-(SEQ ID NOS: 390-396^) - Pancreatic multiple plate (PP) is a hormone with 36 amino acids, which is between the pancreatic islets and the exocrine pancreas. Produced by cells, which is a member of the pp-folding group that regulates peptides, which increases saccharide breakdown and regulates gastrointestinal activity. Therefore, a conjugated pancreatic plate can be used to alter food absorption and metabolism. SEQJD NOS: 397-400) - PYY is a peptide having a length of 36-amino acids which was originally isolated from porcine intestinal tissues and is mainly located in endocrine gland cells of the intestine. It has many biological activities, including multiple activities in the digestive system and possible inhibition of intestinal electrolytes and liquid secretion. Growth stimulating hormone release __ inhibitory factor (SEO ID NOS· mQn The growth hormone releasing inhibitory factor secreted by d cells of the ventral gland is an amino acid-winning version of the growth hormone secreted by the hypothalamus The release inhibitory factor is the same. In nerve tissue, growth hormone release inhibitors inhibit the secretion of 1300414 GH and therefore have systemic effects. In the parotid gland, growth hormone release inhibitors act as other stagnation factors. Therefore, it also has a systemic effect. It is speculated that the growth of the dysregulated release inhibitor is mainly related to the amount of glucose in the blood, which increases when the amount of glucose in the blood rises, and thus causes the pancreas to rise. The decline in the secretion of blood sugar hormones " Zhou let, therefore, a conjugated growth hormone release inhibitor can be used to help the treatment of diabetes. 〇, F · digestive hormone fishing" L ^ Mjt (Cholecystokigin) (ccn; g ear and Guan Shaozhuang映^^JLLJMl^.01-416) - CCK is a 33 amino acid peptide originally isolated from the small intestine of piglets, which stimulates gallbladder contraction and bile And increase the secretion of digestive enzymes derived from the pancreas. It exists in various forms, including CCK-4 and CCK-8, ^ is an eight-peptide and exists in the main molecular species showing maximum activity. It belongs to CCK/stomach The hormone peptide family is distributed in the nervous system and is distributed in the gastrointestinal system. It has many biological roles, including stimulation of pancreatic juice secretion, gallbladder contraction, and digestion. The peristalsis and satiety and painful stimulation of the intestine A possible adjustment. A conjugated CCK can be used for the diagnosis of gallbladder and can be used for chronic cholecystitis.

I hormone release (GRP) (SEO ID N0S; 417-429) - GRP is a peptide of 27 amino acids, which was originally isolated from the non-sinus stomach tissue of pigs and is homogenous to The peptide of the frog skin, which is called the new growth factor of Bangbu. Its center and periphery are widely distributed in tissues including brain, lung, and gastrointestinal tracts. It regulates the physiological processes of a variety of cells, including secretion, smooth muscle contraction, nerve conduction, and cell growth. A conjugated GRP can be used to treat adynamic ileus or constipation in the elderly. 1_Adults& Related wins jfe (SEQ ID NO: 417-429) - The stomach hormone is a polypeptide of 17 amino acids which is produced by the stomach chamber (st〇mach antrum) Acid and pepsin secretion. Stomach hormones also stimulate the secretion of pancreatic juice. A variety of active products are produced by gastric hormone precursors and have multiple control points in the synthesis of gastric hormones. Synthetic precursors and intermediates (pro-gastric hormone and G1 y-stomach hormone) are inferred growth factors, and the product of 4 is the imidized gastric hormone, which regulates the proliferation of epithelial cells and produces acid-like parietal cells. Differentiation with enterochromatic chromium (ECL) such as histamine secretion and expression of genes involved in histamine synthesis and storage in ECL cells, as well as severe stimulation of acid secretion. Stomach hormones also stimulate the production of members of the epidermal growth factor (EGF) family, which in turn inhibits the function of parietal cells but stimulates the growth of epithelial cells. At the time of infection, if) the concentration of blood polyhemagglutinin is increased, which is known to have a risk factor for increasing duodenal ulcer disease and gastric cancer. Therefore, 'stomach hormones and stomach hormone antagonists' can be used as a therapeutic substance to treat most diseases of the upper gastrointestinal tract. .1. Inhibition wins USEQ ID NOS: 417-429) A gastric hormone suppressor peptide is a polypeptide of 43 amino acids which inhibits secretion of gastric hormones. A conjugated GIP can be used to treat severe gastric ulcer disease. Motilin (motili〇U^Q_ID NOS: 430-433) - Motilin is a polypeptide of 22 amino acids that controls gastrointestinal muscles. Motilin-producing cell lines are distributed in the duodenum, upper je junum, and rectum -38-1300414 adenocarcinoma and cancers in the middle gastrointestinal tract. Motilin stimulates peristalsis in the intestines. A small endocrine hormone system is a polypeptide having 27 amino acids secreted by the duodenum at a pH lower than 4.5, which stimulates the release of pancreatic cells. Carbonate and H2 hydrazine. The small intestinal endothelin is a neurotransmitter (a chemical signaling factor) in the neuron group. It is one of the hormones that control digestion and decomposition (others are stomach hormones and cholecystokinin). It is a polypeptide composed of 27 amino acids and is secreted by cells in the digestive system when the stomach is empty. Intestinal secretion stimulates the pancreas to release digestive juice, which is rich in bicarbonate, which neutralizes the acidity of the intestine, which also stimulates the stomach. Pepsin (a enzyme that helps protein digestion) and liver Produce bile. Small intestinal secretions can be used to treat autism. In a study, children with autistic symptoms underwent upper gastrointestinal endoscopy and intravenous administration of small intestinal secretions to stimulate pancreatic and bile secretion. When compared with non-autistic patients, all of them had an increased secretion of pancreas and bile (7.5 to 1〇1]11/111丨11 to 1_2 1111/11^11). Within 5 weeks of the injection of the small intestine, it was found that the child's gastrointestinal symptoms were significantly improved, and the behavior of the child was also significantly improved. The improvement was improved by visual contact, sensitivity and verbal expression. Progress to detect it. These clinical findings suggest a correlation between gastrointestinal and brain function in patients with autistic behavior. Vasoactive Intestinal Peptide (VTP, NOS NOS·· 442-464) - After VIP, it is a 28-residue version produced by the hypothalamus and the gastrointestinal tract. It relaxes the gastrointestinal tract, inhibits the acid-39-1300414 and the secretion of pepsin, and acts as a nerve-transferring molecule that automatically controls the nervous system and increases the secretion of h2◦ and electrolyte from the pancreas and digestive tract. It is first found in the lungs and intestines and is also found in the tissues of the brain, liver, pancreas, smooth muscle and lymphocytes. It is structurally related to a peptide family including pACAp, PH I, small intestinal endothelin, and glucagon. It has a wide range of biological functions, including vasodilation, secretion of electrolytes, regulation of immune function, and neurotransmission. A conjugated VIP can be used to treat acid deficiency, ischemic col it is, and irritable bowel syndrome (IBS). G. Natriuretic Peptides - has three members in the sodium urinary peptide hormone group. · Atr ial natriuretic peptide (ANP), B type natriuretic peptide (BNP: brain Sodium urinary peptide, C-type sodium urinary peptide (CNP), which is related to the 3-CO / τ λ τ of blood pressure and body fluid stability. Natriuretic Peptides (ΑΝΡ) CSEQ ID NOS: 465-507) - ANP is a peptide hormone with 28 amino acids containing a double bond. It exhibits effects of natriuretic, diuretic, and blood pressure lowering and plays an important role in body blood volume and blood pressure stability. See Smith, F.G. et al., L Dew Physiol. 12, 55 (1 989). The mechanism for controlling ANP release has been the goal of a high degree of research, but it is not clearly understood today. The decisive factor in amp secretion is the stretch of muscle cells. Although little is known about the factors that regulate the release of p from the heart, the stretching of muscle cells has been reported to stimulate the training of p- 414 1300414 from both the house and the ventricle. However, regardless of whether the extension of the wall acts directly or via angiotensin II, such as endothelin-丨, nitric oxide, or reactive vasodilatation, it remains unresolved. Recent studies have pointed out that in conscious animals, by stimulating the type A endothelin receptor, the endothelin secretes an impetuous body in the atrial myocytes. The amount of ANP mediators caused by the stowage plays an important role. The physiological role. In fact, the release of the endogenous peripheral secretory/autologous secretory factor line that responds to the atrial wall extension rather than the direct extension of the reaction is shown to be used to respond to the activation of anp secretion to reflect the volumetric load, which is in the A/B type. The inhibition of binding of endothelin and angiotensin receptors was confirmed by the almost complete inhibition of ANP secretion. Furthermore, under certain conditions, angiotensin and nitric oxide may also exhibit a significant regulatory effect on the apoptotic ANP secretion. The molecular mechanism of anp secretion activated by the synergistic regulation of endothelial hormone-1, vasopressin and nitric oxide is still unclear. Abstrac1: Volume 75 Issue 11/12 (1997) ρρ 876-885, Journal of Molecular Medicine. A conjugate can be used to treat hypertensive hypertension and severe high blood pressure and renal failure. Rope Emperor (BNP) - (SEQ ID NOS 507-516) - Brain Natriuretic Peptide (BNP) is a member of the family of sodium urinary peptides that is produced and released by the ventricles. BNP regulates the volume, blood pressure, and vascular tone of body fluids through the receptors of A-type scorpion nucleotide cyclase. BNP plays a role in electrolyte-humidal stability, such as the role of atrial natriuretic peptide (ANP). A conjugated BNP can be used for the treatment of heart failure. C-type sodium urinary tract (CNP) (SEQ ID 517i524) - c-type 1300414 Sodium urinary sputum (CNP) is the third member of the urinary sinusoidal family, produced by vascular endothelial cells (ECs) And the effect is an endothelium-derived pine gin peptide. Although atrial natriuretic peptide and brain natriuretic peptide are known to involve cardiovascular and internal division; the regulation of function must be a cyclic hormone, but the role of [-type Nasal Victory Edition (CNP) is still Unknown. Although ANP and BNP are cardiac hormones, CNP is mainly found in the central nervous system and vascular endothelial cells. ANP is mainly produced in the atrium of a general adult heart, while BNP is produced by both the atrium and the ventricle. H. tachykinin (SEQ ID NO: 525-627) __ The group includes the peptides of neurokinin A and substance P, which share a common c-terminal sequence (FX-GLM-NH2), which includes Neurogenic plates a, B and substance P, and are substances required for complete biological activity. The 5kA (neur〇kinin A)-neurokinin is a ten-peptide, and the early line is regarded as a substance K. It is a member of the kinesin that includes the substance p and the neuropeptide of nerve stimulating b. It exhibits a variety of activities associated with smooth muscle contraction, pain transmission, vasodilation, and regulation of the immune system.攻 碉 素 ( N N N 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 神经 uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro uro Iike), neuropathic sputum and neuromodulin U. These neurological syllabuses and their systems are confined to the sputum, and all components of the pituitary gland axis, the exception of the genus is neurokinin Β, which is not found in the pituitary glandular leaf (adenohypophysis) . Neuromodulin exhibits a variety of effects on the axis of the iliac crest 2, 1300414, and its effect on the adrenal gland suggests that it involves the regulation of growth, structure, and adrenal function. Neurotonin acts directly and indirectly on the adrenal cortex. Direct action is achieved by stimulating mineral corticosteroids and glucocorticoid therapeutic peptides and by the flow of [Ca2+] in the body, while 4-inch hormones are obtained by isolating or culturing adrenocortical cells. The other side effects can be regulated by ACTH's arginine-vasopressin, angiotensin π, catecholamines or other medullary regulatory substances. - The substance tanning is an 11 amino acid peptide which is first isolated from the brain and intestine. It is expected to be a neuromodulator associated with painful transmission of the spinal cord. It also affects the contraction of smooth muscle, the reduction of blood pressure, the stimulation of secretory tissues, and the release of constituent amines of mast cells. I. RONin-related serotonin (SEQ ID NO: 628-677) - angiotensin is a peptide with 10 amino acids, which is caused by renal enzymes Peptidase is enzymatically cleaved by a2-hemoglobin. Then, the c-terminal two amino acids are released to obtain angiotensin I, which is a hypertensive which is essential for the reaction by stimulating the synthesis of the adrenal cells and releasing the alcohol-fixed copper. 1 rabbit _ 彳 彳, hook and eve function hormone, can regulate blood pressure 'plasma volume, neuronal function thirst (neuronal function thirst), and water intake. Angiotensin 11 is an acetonin-derived bacterium derived from angiotensin I, and its center is widely distributed around the heart, kidney, and liver. In the organ. Angiotensin I is a six-peptide fragment I which is a side of angiotensin II which is formed by proteolytic cleavage and metabolism of angiotensin I or angiotensin II. It plays a role in blood 3, tube control, heart growth, renal blood flow and memory function. ^ Angiotensin 11 is an important peptide hormone that regulates vascular smooth muscle tone, blood pressure, free water intake, and sodium retention. It uses 0 to stimulate the increase of vasospasm tension, the increase of sodium retention, and the increase of free water intake to control the stability of blood vessels to compensate for the loss of intravascular volume. Matrix and inhibitory factor (only 叩iD — _ - angiotensinogenase is a very specific aspartic protease, which is differentiated by the vasculature of the kidney. Smooth muscle cells (called granulocyte epithelial cells) are synthesized and released. Angiotensinogenase has specificity for its matrix and pro-angiogen contractor, and it specifically removes the bond of LeulO-Valll to form a ten-peptide. That is, angiotensin I (AI). The vasopressin-angiotensin system is involved in the control of fluid and mineral balance in the vertebrate body. Angiotensinogenase can be found in mammals, blacks, reptiles, teleosts, cartilage, and scorpion. * Specific angiotensinogen inhibitors can be designed for therapeutic use in the treatment of conditions such as blood pressure and septic heart failure (β } i et al., 1987). J. Endothelin and its related winning form (SEQ ID NOS: 685-744) ~ The endothelin peptide family is composed of 21 amino acid isoforms, namely, endothelin-1, endothelin-2, Endothelin-3, saurofuxin (a snake venom) and scorpion toxin. · 1300414 Skin stimulating f) and large endothelin-endothelial hormones are found in endothelial hormones in a variety of organ systems. Examples of pathological and physiological processes associated with changes in the amount of endothelin and synthesis include: atherosclerosis and hypertension, coronary vascular stenosis, acute sorrow, intracellular Ca"+ changes, and The effect of vascular stress on the peri-blood system. Endothelin is released to respond to angiotensin, vasopressin and cytokines (Cyt〇kineS) (eg·, ^ TNF-α, - The amount and other changes in physiological phenomena including increased blood flow. 5 Xuan Sheng version of the endothelial hormone family is composed of high-potency endogenous vasoconstriction 1 'which was originally isolated from the supernatant of endothelial cells It is obtained by regulating the blood flow to the organs by outputting a vasoconstriction effect on the arteries. Endothelins are derived from macro-endothelins, which are composed of a unique cell membrane-bound metalloproteinase (endoendothelina). The conversion enzyme is cleaved into a biologically active form of 21 amino acids (ET-1, ET-2 and ET-3). 于此 In the three isomeric forms (ET-l, ET-2, ET-3), Endothelin-1 is the most important isoform and is in the blood The regulation of the function of the tube plays an important role. The endogenous endothelial hormone peptide and its receptors are distributed differently in various smooth muscle tissues throughout the body, including blood vessels, uterus, gallbladder, and intestine. Through its broad distribution and local distribution, it has biological functions in regulating vascular tone and triggering mitosis. Ets and its receptor subtypes are also present in various endocrine organs. Gonadotropin GH and TSH secretion regulator. Endothelin -45- 1300414 can be ischemic heart wax, skin disease, sputum-like sclerosing, septic heart failure, renal failure, systemic hypertension, Gu Qiu Gu, ~ Lung. 卩 1 pressure, and cerebral vasospasm and other diseases signal or etiological factors. External supply of endothelin has been confirmed to increase peripheral resistance and blood pressure in a dose-dependent manner . However, when the first time of intravenous drug administration, hormones also reduce peripheral resistance and blood pressure, which may be due to vascular expansion compounds (such as nitric oxide, prostacyclin, and atrial natriuretic peptide) Release. ET(A) receptor antagonistic factor-endothelin receptor system exists in two types. A (ET-A) and b (ET-B1 and ET-B2h£TA are used in the system for reaction when ET-B1 and ET-B2 regulates vascular spasm and vasoconstriction separately. Pi. rofotomin is superior to the above. Endothelin (ET) peptide is a potential growth factor that binds to protein-coupled receptors. The serotonin toxin (S6) isolated from /5* 677 (a snake) is highly homologous to endothelin. The serotonin peptide has significant vasoconstrictive activity and is used to react to snakes or wax bites. Ischemic limb loss. It can be used therapeutically as an enzyme-stable peptide to act as a pressor for shock and sepsis. K. Opioid (SEQ ID NOS: 745) -927) - The opioid is a large group of drugs that are clinically used as analgesic 'It includes bioassays obtained from plants and synthetically and endogenously found in the brains of breast milk animals. Although the bioassay obtained from plants has been known and used for thousands of years, endogenous The opiate peptide peptide 46-1300414 was discovered only in the mid-1970s. Opium includes casom〇rphin, demorphins, endorphins, and enkephalin. Version, deltorphins, dynorphin and its analogues, as well as its derivatives, __焉, Sheng Edition - Casomorphine is a novel derived from the road protein morphine The opioid peptide. The stone-casomorphine Q system is the most widely studied opioid peptide, which is produced by the food protein (wan-road protein), which was originally isolated from bovine casein. And the same sequence was found in the stone-casein of sheep and buffalo. The bottom morphine is a 7-amino acid-winning version which is first separated from the skin of the sigh e/ suitable. a ligand that binds highly to the mu opioid receptor and has a variety of Roles, including analgesia, endocrine regulation, immune regulation, increased sputum + conduction, sputum and inhibition of action potentials. _ Formerly acquainted with dynorphin - a group of '£) endogenous cranes A flavonoid, which is present in the central nervous system in a variety of forms. The dynorphin is derived from the precursor dynorphin (pre-enkephalin oxime). The dynorphin is also known as the dynorphinic version, which is a A known opioid having the following sequence: Tyr-G丨y-Gly-phe-Uu5-Hongyunyi

Arg-Ile-Arg-Pr〇1Q-Lys-Leu-Lys_Trp-Aspl5_Asn-Gln, SEQ D NO·1. Most morphine derivatives and analogs thereof are known to include Dyn A1-13, SEQ ID NO: 2, Dyn A2-13, SEQ ID NO: 3.

Dyn M-12, Dyn A2-12, and Dyn A2-17, morphine analogs as described in U.S. Patent No. 4,462,941 to Lee et al., N-terminal excision ~47-1300414 dynorphin Analogs, such as those described in International Patent Application No. 96/06626 to Lee et al., and analogs of des-Tyr or des-Tyr-Gly, such as the international patent application filed by Lee et al. /2521 7 revealed. The dynorphine version is an extremely useful opioid and demonstrates an alternative affinity kappa receptor. See G〇idstein, A·, peptides, ' Structure and Function, Proceedings of the 8th American 〇 Symposium, Hruby, V. J. and Rich, D. H. , eds., 409 ( 1 983) 〇

Mi-endorphin is derived from the precursor protein, 1 ipot fop in. It has been found that it can elicit a variety of biological responses, such as analgesia, behavioral changes, and release of growth hormone. See Akil, Η· et al., Ann Rev. Neurosci·, 7, 223 (1984). According to the edition & related version of enkephalin and endorphins, the neurogenic hormone is a neurogenic hormone that inhibits the transmission of pain pulses. The neuronal activity of the central and peripheral nervous systems is affected by a majority of neurohormones, which are used on cells that are released from their specialized release sites. Neurogenic hormones • Change the ability of nerve cells to respond to synaptophysin neurotransmitters. Recently, a number of small peptides with profound effects on the nervous system have been found, for example, a morphine version (i.e., Met-enkephalin and Leu_enkephalin) and endorphins (i.e., cold-brain endorphins). These three contain a shared four peptide sequence (Tyr - Gly - Phe), which is necessary for its function. Enkephalins and endorphins serve as natural analgesics or opiates (〇piates) and can reduce the response to pain in the central nervous system. Also available in Akil, H, eU a丨., Am

Rev. Neurosci., 7, 223 U (10). A 48 - 1300414 L · Thymus Syndrome (SEQ ID NOS: 928-934) - The thymus gland is considered to be used in both the reaction and the adult - the development and regulation of cellular immunity. The thymus can exert its regulatory functions through a variety of non-cellular, hormone-like products secreted by epithelial cells (called thymus gland). • The thymus is reported to have many functions on the sputum cells. A variety of studies have reported that thymus gland can help immature, precursor cells develop into fully competent D-t cells. When the immune system is invaded, the thymus gland can regulate the expression of various cytokines and monokines receptors on T cells, as well as induce IL-2, interferon alpha and interferon 7 (disease antagonists) The secretion. It has been reported that the use of thymus hormones in children with immunodeficiency caused by chemotherapy can cause an increase in circulating sputum cells, normalization of sputum cell subfamilies, and delayed hypersensitivity reactions. Reply. The elk-producing hormone. iThymopoietiiQ-thymogenin is the largest of the known thymus hormones, and it is composed of 49 amino acids. - Thymulin - The earliest known thymus serum factor, the thymus polyphosphate hormone, is the smallest of the chemically characterized thymus hormones, which consists of 9 amino acids. The thymosin peptide is a hormone used to respond to the stimulation of T cells produced by the immune system. Thymopentin-thymidine is a small, synthetic thymosin drug, also known as the therapeutic peptide-5 or Timunox. In the United States, it has been developed into an AIDS treatment by the Center for Immunology. Thymus-like peptides are more widely studied than other thymus-peptide drugs. At least one study has been requested to significantly increase the amount of tau cells' and compared with control subjects who did not receive thymus-like leptin, there was a slight clinically significant number of patients receiving thymus-like lectin three times a week. improve. Compared with 14 control participants who did not receive thymus-like leptin, these patients who took the drug showed better "immune stability, and some clinical improvements. ^ 座素_ThymosH-thymosin Is a mixture of 15 or more proteins. One of these proteins is thymosin α-1, which is composed of 28 amino acids. Thymosin has therapeutic use and can treat innate immune deficiency' It can be used as a supplement for influenza vaccine in kidney dialysis patients. It is now undergoing clinical trials against chronic sputum and hepatitis C, HI V infection, and some types of tumors. Limb Night 罔 罔 (THF) - The THF is a recently tested thymus peptide as a primary anti-treatment of V. In a preclinical trial of rabbits with CMV-related immunosuppression, 'THF can reactivate immune activity through T-cell regulation. Ο The treatment of herpes, the rapid recovery of viral infections (to-lessly found in a study) and the increase in the number of T-cells have therapeutic applications. L. Other peptides are free of cover Dong JLf Sheng Edition (AM) (SEQ ID NO S: 935-945) An adrenomedullin is an effective vasodilator peptide whose primary function is to exert cardiovascular function. Its systemic administration causes rapid and significant decrease in blood pressure' and pulmonary blood The increase in flow. Adrenal gland quality other work 50-1300414 闬 lies in bronchial tube expansion, which is an inhibitor of drunkenness and an inhibitor of aldosterone secretion caused by angiotensin. Journal of Biological Chemistry, Vol. 270, No. 43, pp 25344-25 347,1 9 95 and references cited therein. Allatostatin (SEQ ID NOS: 946-

Mil-Yastostatin is a 6-丨8 amino acid peptide synthesized by insects to control the production of juvenile hormones, which is the same as f; J, the sample is also controlled including metamorphosis and Production, function. Although the neurotropin of the Atostatin family inhibits the production of immature hormones in vitro, the immature hormone regulates the development and reproduction of sputum, ^, and the astostatin on the hemolymph, intestine, and Deactivation by binding to peptidases in internal tissues is quite sensitive. Amvloid Beta-Protein fragments (SE0 ID NOS: 950-101 m - these are the main components of powder-killing protein plaques, which are intracellular and extracellular 3 accumulated in Alzheimer's In the brain plaque of the brain (Alzheimer, s Disease). The Αβ system is a 4·5 kD protein, about 40-42 amino acid length, which is derived from the amyloid precursor protein (APP) C. Derived from the end. APPfe is a glycoprotein that spans the cell membrane, in the normal mechanism pathway, (d, cleaves the internal Αβ protein to produce α ~ Si \ pp, which is a secreted form of APP. α-sAPP The formation hinders the formation of Αβ. It has been assumed that the Αβ will accumulate due to the abnormal treatment of ΑΡΡ, and it is sought to find the inhibitory compound for the enzyme activity of Αβ production. See, for example, Wagner et aL Bi〇tech.

Report (1994/1995), pp. 106-107; and Selkoe (1 993) TINS-51-1300414 Αβ-peptide will first aggregate, then 16:403-409. Under certain conditions, deposition refers to the structure of the β-sheet, which is characteristic of amyloid fibers. The β-dial powdery protein (1_42) aggregates at a significantly faster rate and reaches a larger extension than β-amyloid (丨_4〇). Pulling microbes NOS: ltrn-1047) - anti-micro

The peptide is the major component of the immune systems of most multicellular organisms and is activated against one or more microorganisms such as bacteria, molds, protozoa, yeasts, and mycobacteria. . Examples of such wins include defensin, cecropin, buforin, and magainin. In addition to the vast differences in sequence and taxonomy, most antimicrobial peptides share a common mechanism of action, namely the permeability of the cell membrane of the pathogen. They are divided into two broad groups: linear and circular. In the linear antimicrobial victory, it has a subgroup: a linear peptide that tends to adopt an alpha-helical amphoteric configuration, and a linear victory with a less unusual composition, such as Pro, Amino acid of Arg ' or Trp. The cyclic group comprises all of the cysteine-containing peptides and can be further divided into two subgroups according to single or multiple disulfide structures. Most antimicrobial peptides cause an increase in serosal permeability. It also has evidence of other mechanisms, such as inhibition of specific membrane proteins, synthesis of stress proteins, inhibition of DNA synthesis, destruction of single-stranded dnA by antagonists, and interaction with DNA caused by infeverin. (does not block its synthesis), or the production of hydrogen peroxide. Antimicrobial peptides can also act by triggering self-destruction (such as cellular apoptosis or bacterial markers in eukaryotic cells -52-1300414)

effect. . The anti-microbial version is also known as a two-factor inhibitor, which can be used as a pseudo-active region (which hinders the entry of the receptor).

The type of infection is increased by the genus Mycobacterium, Pasteurella, or Cryptosporidium, and the inflammatory or stimulating state in blisters and injured body fluids is also associated with an increase in the amount of antimicrobial peptides. The induction is related. The reduction in the amount of antimicrobial peptides is associated with a variety of pathological conditions. Therefore, patients with specific particle deficiency syndromes, which are completely deficient in alpha-activin, face frequent and severe bacterial infections. In HIV patients, a small amount of histidine derived from saliva is associated with a higher incidence of oral: candidiasis and mold infection. For human pathology, the most powerful example of this antimicrobial peptide may come from cystic fibrosis (cyst) c G) fi bros is ) 'a disease associated with airborne infection with recurrent bacteria - disease. The defective gas ion channel that causes the disease increases the oral fluid, salinity, and thus the bactericidal activity of the /3 -container, which is a salt-sensitive peptide. Andreu D, (Ed· ) ( 1 998) π Antimicrobial peptides Bicpolymers (Peptide Science) vol 47, Ν. 6, pp413-491. A. Andreu, L. Rivas (1 998) Animal Anti-Microbial Edition: An Overview, Biopolymers (Pep. Sci.) 47: 〕 p415-433. Anti-gasification wins (SEQ ID NOS: 1048-lMfn - / antioxidant 1300414. ^ milk cell line constantly violent

Hydrogen is produced during the breathing of most living organisms, especially by stressed and injured cells. The agent is a chemical agent that prevents oxidation damage to tissues, such as hydrogen peroxide, hydrogen radicals, and hydrazine.

One example of an antioxidant peptide is Natural Killer Cell Promoter B High Retention (NKEF-B), which belongs to the recently discovered (c〇nserved) population of antioxidants. The natural killer cell promoting factor (like £1?) was discovered and selected based on its ability to increase the cytotoxicity of NK. Two genes, NKEF-A and -B, encode NKEF proteins and the analysis of the sequences present suggests that they each belong to a highly conserved population of antioxidants. The role of NKEF_B, which is an antioxidant, has been described by protecting it against oxidative damage of hydrogen peroxide. (10) π - Β has an antioxidant activity against the former oxide such as alkyl peroxide and MeHg. In combination with its antioxidant activity, the induction of N K E F - B by ΗP indicates that n κ E F - B is an important oxidative stress protein to protect against toxic substances from a variety of xenobiotics. The singularity of the casual singer (SEO) D 1GW- •^75)—animal cells can self-destruct through an internal plan of cell death (Steller, 995). Cellular planned apoptosis is a planned cell 1300414 Form of death 'characterized by specific appearance and biochemical properties lie et al., 198 〇). In terms of appearance, cell-planned apoptosis is characterized by a series of structural changes in dead cells: blistering of the serosa (ie, blistering), contraction of the cytoplasm and nucleus, and cell breakage into a membranous cell plan. Apoptotic bodies (Steiier, 1 995; Wyl lie et al, 1980). In terms of biochemistry, the planned apoptosis of cells is characterized by the degradation of chromatin, the initial line becomes a large fragment of 50-300 kilobases, and then becomes a smaller piece, and it is a monomer with more than 200 tests. Mumniers (Oberhammer et al., 1 993; Wyllie, 1980). The biochemical indicator of planned apoptosis in other cells is the induction or increase in the amount of protein Clusterjn (also known as D-RpM-2 or SGP-2) (pearse et aL, 1 992), and the 苐11 type of trans-shell ammonia Activation of amphoteric enzymes that crosslink proteins to the envelope of a cell-planned apoptotic body (FaUS e: t al., 1991). Cellular planned apoptosis is a complex phenomenon associated with shape and biochemical processes that can vary with tissue and cell type (Zakeri et al:, 1995). The implementation of planned apoptosis in this cell reduces the leakage of cellular constituents from the dead cells (complexation of cells due to planned cell apoptosis). For example, proteases can damage nearby cells or stimulate an inflammatory response. This kind of cell plan: sex; the main feature of the weekly death is different from cell necrosis, which is usually caused by trauma. It causes the injured cells to enlarge and decompose, and releases the cytoplasm that stimulates the inflammatory response. Substance (Steller, 1 995; Wyllie et al., 1980). -55- 1300414 Bag Cell Wins & CBCP) (SEO ID NOS: 1076-1080) A marine mollusc neurogenic bag cell line involved in animal spawning behavior. These neurosecretory cells produce a production-producing hormone (ELH) precursor protein that produces a variety of biologically active peptides, including ELH, several cell-cell peptides (BCP), and acid peptides. The mollusk-cell line of the marine mollusc has been identified as a neuroendocrine cell that initiates spawning behavior. During sexual maturation, these cells (bag cell neurons) develop the ability to store hormones that are released during stimulation of the nervous system. These hormones are important in the process of spawning and are therefore largely unreleased before the animal matures. — — bag cell 胜版 is a small group of constitutively related traits that trigger bag-cell activity in vitro. (4) New (SEQ ID NOS: 1081-a Bunbuxin is a one, · 'the fourteen peptides with biological activity, the neuropeptide, which belongs to a shared C-terminal sequence (TYp-Ala -X-Gly-His-Met-ΝΗ2) and a peptide group in the scorpion region, which has been found to have an accommodative angle-color in the cranial nerves and intestines, which can be released by endogenous gastric hormones. Avoid stomach damage. Mammalian - the new homologue of the bonbutin is gastric hormone releasing factor (GRP). Rabbit type Gla protein wins N0S: 1091 -1097 Osteocalcin (Bone Gu_protein, or BGp) It is produced and secreted by bone blast cells during bone formation. Like collagen, this protein is a component of bone. When the speed of bone formation increases, the serum factor of the bone will rise. During the fastest thinking period, the summer is more than two. In the disease of skeletal height conversion (such as dysarthystalgia 1300414 hyperparathyroidism and hyperthyroid hyperthyroidism (hyper fine 0ldlsm)) High in osteoporosis in women after menopause, osteocalcin Occasionally, it increases in response to the increased bone turnover secondary to rapid bone resorption. In the bones of the old scorpion = the pine, it usually occurs in a longer case, the amount of bone dance factor may be less, Reacting at both the rate of bone turnover and bone formation

drop. A therapeutic food therapy that increases bone formation can also increase the amount of bone ginger factor in serum. -1100) Ashi Keling, y verbylamine The propylamine-regulated transcription peptide is a recently discovered hypothalamic peptide with an effective appetite (desire) inhibitory activity. In rabbits, the CART gene encodes a peptide with 129 or 116 amino acid residues, however, only a small version exists in humans. The expected signal sequence is a 27 amino acid residue that results in a erbium quinone having 502 or 89 amino acids. The C-terminus of CART, which consists of a 48-amino acid residue and three disulfide bonds, is considered to consist of one molecule of biologically active site. In the middle frame of the nervous system, the 'CART line is highly expressed in the nucleus of many hypothalamus' and some of its parts are related to the regulation of eating behavior. The Mrna line of ^ is regulated by leptin, and the CART line expressed is an effective inhibitor of eating, which even rejects the feeding reaction caused by the neuropeptide γ. Therefore, the intended CART system may be a subject for the therapeutic/potentiometric drug. This can be seen in CART, a new anorect ic peptide Thim L; Kristensen P; Larsen PJ; Wulff BS, Int J Biochem Cell Biol, 30(12): 1 28 b 4 199 Pan. -57 - 1300414 - Cell-attached peptides are directly related to the response of cells to external stimuli. It is expected that during the onset of white blood cells must leave the blood room (. (10) Yang _ 〇 and swim: / = intrusion. The mechanism of the migration event is the interstitial 细胞 between the cells and the decidua.跆1 complex interactions.

The soluble cell chemotaxis factor produced by a variety of resident cells establishes a chemical concentration gradient towards the _ compartment. These factors, which are equal to the parental interaction between the forks on the white blood cells, cause the white blood cells to increase toward the chemotaxis factor concentration. Tong Xiao's various positive adhesions on white blood cells are regulated by 'the initial movement on the endothelial tissue, the specific ligand on the activated endothelium, and finally the endothelium. Move between cells to the tissue. The cascade of events is regulated by the interaction of specific cell surface proteins U, which are cell attachment molecules, such as E-selectin, endothelial leukocyte attachment molecule-1), ICAM-1 (intracellular The attachment molecule - 丨), and (vascular cell attachment molecule - 丨). - Chemotaxis peptides are peptides that stimulate white blood cells, white blood cells, and macrophages to move into the tissue of the susceptible wood or the wounded site, or prevent such identical cells from moving away from such locations. (SEQ ID NO: 1114-1120) - Inhibition of complement The challenge of xenografts can be achieved by the use of complement inhibitors. The rejection of such organ transplants may involve both a very rapid and extremely severe rejection (HAR) and a chronic cellular rejection. Heterotransplantation A 58-1300414 phytohorm is initiated by a preformed "native" antibody that binds to the donor's organ endothelium and is attacked by the recipient's immune system. Activation of complement leads to the production of fluid phase (C3a, C5a) and cell membrane-bound proteins (C3b and C5b-9, ie, C5b, C6, which have chemotaxis, pre-agglomeration, pre-inflammatory, adhesion, and cytolysis. Generation of C7, C8, and C9). Complement inhibitors inhibit this process. Skin Jt Balancer CCortistatin) wins JfeCSEQ ID N0S: 1121 -

Leg) - Cortical balance is apparently effected by antagonizing the cortical inflammatory acetylcholine, thereby causing synchronization of brain slow waves, which accumulate during sleep deprivation. Cortisol- 14 (CST-14) shares 11 of 14 residues with growth hormone-releasing inhibitor SR4 (SRIF-14)' However, its inhibitor of growth hormone release for sleep physiology, The behavior of movement and the function of the hypothalamus are very different. The shy-web egg-舎 fragment & fibrin-related skin wins fSEQ ID NOs: 1125-1174) - The fibronet protein is a large glycoprotein composed of three kinds of repeats. The plurality of homologous segments form functional domains arranged in a straight line on the arms of two adjacent subunits. Each arm can be divided into functional regions' which are commonly referred to as regions that bind to the substrate, such as heparin-binding fragments, fibrin-binding fragments, and cell-binding fragments. In a variety of cell types, the Arg-Gly-Asp (RGD) sequence on the cell binding region of fibronectin can be named

Glycoprotein interaction on the cell surface of Iib/II la. Fibrin can also bind to the components of extracellular and basal cell membranes, the envelope glycoprotein of the virus ~59-1300414 (envelope glycoprotein), bacteria including a variety of staphylococcus and streptococcus, and binding to such as Still on the parasite of the plant and its species. Web confession has a variety of attachment functions, such as cell-to-cell attachment, cell-to-basal cell membrane attachment, and clot stability (c丨〇t stabi 1 izat ion). In addition, fibroin promotes embryogenesis, neuronal regeneration, fibroblast migration, macrophage function, and the promotion of the binding of pathogens (such as viruses, molds, bacteria, and protozoa) to mammalian cells and extracellular matrices. Therefore, the fibrin lineage is associated with the etiology of infection from the initial stage of infection to the final step of wound healing. This can be seen in

Proctor, R.A., Rev. Infect· Dis., 9, 317 (1987). E1P1 and similar triumphs (SEQ ID NOS: 1175-11R7, - FMRF is a neuron encoded by the fmrf-enamined gene and has a common C-terminus but a different N-terminal extension. FMRF guanamine The basal-related peptides (FaRPs) are present in all animal kingdoms and affect both the function of the nerves and the gastrointestinal tract. The organisms have a variety of codes that can be coded to have a common C-terminal structure but different Amino acid extended FaRPsw gene. JL twisted peptide (SEQ ID NOS: 1188-1208V Jalazin is a peptide with 2 9 - 30 amino acids, the earliest of which is from the small intestine of pigs Isolated. It was found to have two bioactive forms: (1-1 9) and GAL (1-30), which are non-guanamine types. They have a variety of biological roles, including: lower hypothalamus Inhibition of biogenic amine release, pre- and post-synaptic inhibition of the cholinergic dysfunction, maintenance of gastrointestinal tract stability, and regulation of insulin and pancreatic hyperglycemic hormone secretion. ' 一 60 - 1300414 相纯 _ Version (SEQ ID NOS: 1209-1240) - Growth factor is a group of proteins that regulate cell division. Some growth A sub-line is a cell-specific factor that only stimulates the division of cells with appropriate receptors. Other growth factors are more common in their action. There are also extracellular factors that antagonize the effects of growth factors. Slows or prevents cell division (such as transforming growth factor 0 and tumor necrosis factor). These extracellular signals act through cell surface receptors, which are very similar to hormone receptors and are similar Mechanism: the production of secondary information in the cell, protein phosphorylation, and the final changes in gene expression. G Therapeutic (Gtherapeutic) conjugated protein fragment (SEQ ID NOS: 1241 -1246) - G therapeutic success a member of the group that binds to the regulatory protein protein) can transduce a signal derived from a cell membrane-bound receptor into a factor of action in the cell. The group includes '( and is used for the reaction of adenine cyclase) Individual stimulation and inhibition. Transduction proteins (T) located in the discoid cell membrane of the retinal rod outer segment (retinal r〇4 outer segments) are illuminated by light. Bonded to the activated rhodopsin (rh〇 (j〇pSin) and increases cyclic GMP phosphodiesterase activity found in bovine brain initially based G〇 fourth member of the group for this.

The purified G protein has similar physical properties. It is a heterodimer which is composed of α, /3, and r subunits. The alpha subunit binds and hydrolyzes the G therapeutic peptide. It can be found in s. M. Mumby et al., PNAS 83, 265 (1986) and Lehninger ρ· 764.

JL^J^(GiianyligJ) and urine are glucosides (Uroguanvlin) CSEQ ID-61-1300414 Boats 4 Ning and urine ^ Ning is the < Intestinal septum and urine peptides, the regulation The cyclic GMP produced in the outer blood cells binds and activates the black quinone nucleotide cyclase. It also controls the salts and moisture of various epithelial cells in the vertebrate and mimics the effects of a variety of thermostable cell enterotoxins. In the renal pelvis, both of them have a known effect on potassium. The secretion of chlorine in the intestine is regulated by the activation of the scorpion cyclase C (GC-C). This dipeptide is expressed in various tissues and organs, including the kidneys. These hormones can cause natriuresis and diuresis in isolated kidneys and in vivo. However, their location and cellular mechanisms in the kidney remain unclear. Also prepared is Sushen Edition (SEQ T-D N0S.·12ΗΠ-- statin is composed of two subunits (α is 134 amino acids; lanthanide is 115 and 116 amino acids). It inhibits the secretion of FSH. The two isoforms of the statins 'inhibin A and inhibin B, which are produced by the gonads during gamete maturation, are equal to the different secretory modes during the menstrual cycle. Inhibin can also be produced by the placenta and fetal membranes' and may be related to the physiological adaptation of conception. Clinically, statins can be used as markers for tumor sensitivity in postmenopausal women, or as a measure of reversal of infertile women's ovaries. An effective tool; it can also be used for the diagnosis of maternal-fetal symptoms to avoid the maturation of egg cells or to inhibit ovulation. Ilterleukin CIL and cytosolic protein 皙1PL..NQ.S; 1256^1263 ) - Baibaisu is a growth factor targeting cells of hematopoietic origin. Various types of life related to immune and inflammatory reactions —f) 2 — 1300414 The activity of the organism has been attributed to the ubiquitin. These reactions include fever, glassy cartilage, bone resorption, proliferation of thymocytes, activation of T and B lymphocytes, induction of acute proteins synthesized by liver cells, proliferation and differentiation of fibroblasts, and Proliferation of bone marrow cells. Krebine K-segment (SEQ ID NO: 1264-1284) - laminin

It is a major non-collagen protein of the basement membrane that has been shown to promote attachment, extension, and migration of a variety of tumor cell types in vitro. In particular, the most recent research in the laboratory utilizes intact laminin, purified proteolytic kumbumin, and synthetic laminin to functionally determine this large protein. Active location. The composition of this basal cell membrane is an important regulator of the growth, development, and differentiation of various cell types. A conjugated laminin can be used to prevent tissue inflammation and tissue fibrosis. This category also includes the peptide kringle-5 (or K-5). The term "kringle 5" as used herein refers to a region of mammalian plasminogen with three disulfide bonds that contributes to the fifth of mammalian plasminogen. a specific three-dimensional configuration bounded by the kringle g domain. This disulfide linkage links the cysteine at positions 462 and 541 of the amino acid, and the second linkage links the amine. The cysteine at positions 483 and 5^4, and the third link to the cysteine at positions 51 2 and 536. The term " Kenning may be called a) 5 peptides The peptide refers to a peptide having an anti-angiogenic activity between (inclusive) 4 and 104 amino acids, and the 4 and 104 amino acids have substantially the same victory as the mammalian plasminogen. Sequence of homologous peptide fragments. A 63-1300414 菜普亭> 1 segment peptide (SEQ ID NOS, 1285-1288) A leptin is a protein product of the obese gene secreted by sputum fat cells. The Putin family is involved in the regulation of male body weight and metabolism and may be involved in the pathophysiology of insulin rejection syndrome, which is associated with the development of cardiovascular disease. Leukokinins (SEQ ID NO: 1289-98) - Ο

The leukocyte kinase system is a group of widely distributed insect hormones that stimulate the rate of gastrointestinal motility and fluid secretion. In the tube, its primary function is to enhance the permeability of the gas ions by binding to the receptor located on the basal membrane.琏 ft ft 肢 肢 肢 肢 肢 肢 PA ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( It also found a pattern of 27 amino acids called PACAP-27. PACAP is distributed in the inferior colliculus, other parts of the brain, the respiratory tract and the gastrointestinal system. It has a variety of biological functions, including neurotransmitter and hormonal functions, regulation of energy metabolism, and neuronal cell protection activity. Pancreastatin (SEQ ID NO: 1312-1324) - The pancreatic balance is a 49 amino acid peptide that was originally isolated, purified, and characterized by the pancreatic pancreas. Its biological activity in different tissues can be attributed to the C-terminal part of the molecule. Pancreatic balance has a prohormonal precursor, chromogranin A, a glycoprotein found in neuroendocrine cells, including the endocrine pancreas. Polypeptide (SEQ ID NOS. 1325-1326) - these are repeat strands. -64- 1300414 w \ ) This provides two examples: (pro-Hyp-Gly) 10*20H20 and Poly-L-lysine Hydrochloride. Wind-Conducting Material (SEO ID NOS: 1327-1367)—The message transmission system is a process of amplifying an extracellular message (such as a chemical, mechanical, or electrical message) and transforming it into a cellular response. Many substances are involved in this process, such as achat in-1, glycogen synthase, autocamtide, calcineurin autoinhibitory peptide, dependence. Calmodul in dependent protein kinase 11 (dependently, calmodulin-dependent protein kinase receptor, calcitonin-dependent protein kinase receptor analog, CKS-1 7, Cys-Kenbo skin ( Kempt ide), self-cultivation version 2, malant ide, mel i tti.n, disc acid acceptor peptide, protein kinase c fragment, P34cd2 kinase fragment, 泠: ' P60c-src receptor 11, protein kinase a fragment, tyrosine protein kinase receptor, synthetic peptide 2, S6 kinase receptor peptide 32, tyrosine-specific protein kinase inhibitor, derivatives and fragments thereof . Tomb 嗨 嗨 inhibition factor (SEQ ID NOS: 13fiR-1377) - The thrombin system is the major regulatory enzyme in the coagUlati〇n cascade, which serves as a multiple role for both positive and negative feedback regulators. In addition to its direct action in hemostasis, thrombin also exerts a direct effect on a variety of different cell types, supporting and expanding the pathological role of arterial thrombosis. This enzyme is the strongest platelet activating factor that causes platelet aggregation and release substances (i.e., ADp TXA, sub 2 NE), which further increases the agglutination cycle. The platelets in the interfering fibrin network contain a major component of 6 5 - 13 〇〇 144 white blood sputum. Thrombin also acts directly on endothelial cells, which causes the release of vasoconstrictor and the displacement of attached molecules, which are used for the attachment of immune cells. In addition, the enzyme causes mitosis of smooth muscle cells and twinning of fibroblasts. From the #analytical observation, it is apparent that inhibition of the blood coagulation bee by thrombin inhibitors provides a viable treatment for the blockade of proliferative events associated with blood test formation. 1 (SEQ ID NOS: 1378-1415) - Toxin can be targeted to cancer cells, receptors, viruses, or hematopoietic cells using the method of the present invention. Once the toxin binds to the target cell, the toxin is allowed to be endocytosed and causes cytotoxicity and most cell death. Toxins have been widely used as a treatment for cancer. One example of this group of toxins is a degranulated peptide of mast cells, which is a peptide of 22 amino acid residues having two bis-sulfide cations, which are separated from bee venom. At low concentrations, it causes degranulation of mast cells and release of histamine, but at high concentrations it has anti-inflammatory activity. It is an effective anti-inflammatory substance which is 100 times more effective than corticosteroids in reducing inflammation. Because of its unique immunological properties, MCD peptides serve as a secretory mechanism for studying inflammatory cells such as mast cells, basophils, and white blood cells to guide the design of compounds with therapeutic potential. One example of a mast cell degranulation version is the massoparans, which is derived from the wasp venom. It can granulate the mast cells at a wave of 0.5 #g/ml and release histamine from the cells at the same concentration. This can be seen in IY. Hirai et al., Chem. Pharm. 1300414

Bul 1· 27, 1942 (1 979). Other examples of such toxins include Q-Asian toxin (agat 〇χ丨η), guanine, agelenin, apamin, calicidine, and calcideptine. ), gabdotoxiη, lactotoxin, toxin (c〇n〇t〇xins), endotoxin inhibitor, gegraphut〇xins, iberiotoxin, card Kalo iotoxin, obese cell degranulation, margarine (margat〇xin), neurotoxin, PLTX-II, skela toxin (%711 to 〇}^11), sea anemone toxin ( Stichodactyla toxin), and derivatives and fragments thereof. The chymase inhibitor is early (SEQ ID NO: 1416-1418, - trypsin inhibitor is functionally an inhibitor of trypsin and other serine proteases. It is effective for treating lung inflammation, pancreatitis, myocardial infarction , cerebral vascular ischemia. 'Fuji Sheng version (SM ID NOS: 1419-152W a virus-related peptide is a protein with the virus, such as viral receptors, viral inhibitors, and envelope proteins ( Enve丨〇pe pr〇teins. This example includes, but is not limited to, peptide inhibitor of human immunodeficiency virus (HIV), peptide inhibitor of respiratory syncytial cell virus (RSV), human parapinovirus (HPV) Peptide inhibitor, melittin (MeV) peptide inhibitor, monkey immunodeficiency virus (SIV) peptide inhibitor, fluoride-producing human CMV protease receptor, Hcv nuclear protein, HCV NS4A protein, hepatitis 8 Viral receptor binding fragment, hepatitis B virus pre-region, Fan therapy virus 67-1300414 inhibitor 2, HIV envelope protein fragment, HIV gag fragment, sputum, receptor, HIV-1 inhibitor peptide, peptide τ, Τ21, V3 decapeptide, viral replication inhibition peptide, and other fragments and derivatives thereof. The peptides can be used for therapeutic administration. For example, the peptide Τ is - V2 derived from ΗIV 1 gp 120 8 amino acid bonds in the region. These amino acids are similar to the part of the mantle membrane of hi γ -. The study is used to treat the neurological and constitutional symptoms associated with ΗIV, and the peptide τ can slow down fever. Symptoms such as night sweats, weight loss, and fatigue. It has been shown to resolve psoriasis symptoms. ZHAO Shengsheng (SEQ ID NOs: 1529-16171) includes adjuvants, alpha-binding factors, heart rate irregularities, peptides, appetite Control Sheng version 'α-l antitrypsin, bovine pineal anti-reproductive peptide, bursin, C3 peptide Ρ16, adhesion, sub-peptide, chromogranin fragment, contraceptive tetrapeptide , nectar gold G, nectar gold τ, crustacean active peptide, C-terminal victory plate, cytochrome b588 peptide, chlorhexidine, drizzle 〇 肷, △-sleep induction Peptide, diazempam-knot-binding inhibitor fragment, nitric oxide synthesis Enzyme blocking peptide, OVA peptide, - platelet calcium inhibitor (P1), plasminogen activator inhibitor 1, rutinin, schizophrenia related peptide, sodium potassium A treatment Inhibitory factor-1, Spoel, sperm-activated peptide, systemin, thrombin receptor agonist (three wins), Dufuxin, lipotrophic hormone, uremia, ten peptides, antibiotics Coagulated peptide, tumor necrosis factor, leech [Des AsplO] low renewable, l-urethane heptasulfonic acid hydrogenation, p-aminophenyrene, new, Ac-Glu-Glu-Val-Val-Ala -Cys-pNA, Ac-Ser-Asp- 1300414

Lys-Pr〇, Ac-rfwink-NH2, Cys-Gly-Tyr-Gly-Pro-Lys-Lys-Lys-Arg-Lys-Val-Gly-Gly, DAla-Leu, DDDDD, DDDDDD, NPNANPNA, VAIT-1V , -LVK, V-G_ VR-''-R, V-1-HS, VPDPR, Val-Thr-Cys-Gly, -R, sea urchin sperm-activated peptide, SHU-9119 MC3-R and MC4-R Antagonist, glaspimod (immune stimulator, for combating bacteria, invasion of the bacterium, immunological disorders of immunodeficiency, leukopenia), Hp_228 (melanocortin), for anti-chemotherapy Caused by vomiting, toxicity, pain, diabetes, inflammation, rheumatoid arthritis, obesity), α2-plasmin inhibitor (plasmin inhibitor), APC tumor suppressor (tumor) Inhibitory factor, which is used against the tumor, early conception factor (immunosuppressive factor), endozepine, benzodiazepine binding inhibitor (receptor peptide), 7 interferon (for confrontation) Leukemia), glandular kallikrein-1 (immunostimulator), placental ribonuclease inhibitor, meat Sarc〇lecin binding protein, surface agent protein D, wilms, tumor suppressor, lm, s tumor inhibitor, GABAB lb receptor peptide, prion-related peptide (1 PrPl 3), Cholesterol: binding protein fragment (bacterial-related peptide), telomerase inhibitory preparation, cardostatin peptide, endothelin, endostatin-derived peptide (angiogenesis inhibitor), protein Infectin inhibits the triumphant, N-methyl D-aspartate receptor antagonist, c_ sputum analog (used to combat diabetic complications). A 69 — 1300414 2· Improved therapeutic victory plate The present invention relates to improved therapeutic peptides and derivatives thereof. The improved therapeutic susceptibility of the present invention comprises a reactive group which forms a covalent bond with an effective reactive group on the blood-liquid component. The present invention is also directed to such improvements, combinations of such components with blood components, and the like. Such methods include prolonging the half-life of the therapeutic treatment of the improved therapeutic peptide in vivo. In order to form a covalent bond with a functional group on a protein, a majority of the reactive carboxyl groups can be used as a reactive group, particularly an ester, wherein the hydroxyl group is also physiologically acceptable to the extent required to modify the therapeutic peptide. Although a large number of different hydroxyl groups can be used in the linker, the most common ruthenium is Ν-hydroxysuccinimide oxime (NHS) and Ν-hydroxy-sulfonic acid succinimide sulfonate (sulfonic acid-NHS) ). ^

Primary amines are the primary targets for NHS esters, as shown in Figure 1a below. The presence of an acceptable 〇c-amine group at the N-terminus of the protein can interact with the NHS ester. However, the alpha-amine group on the protein is not suitable or available for coupling to the NHS. Although the five amino acids have nitrogen on their side chains, only the epsilon-amino group of the amino acid can be effectively reacted with the MHS ester. When a conjugation reaction occurs between the NHS ester shown in the following Figure 1A and a primary amine, and the N-state group is released, a tie-forming amine bond is formed. -70- 1300414 Figure 1A

NHS-steroidal reaction diagram In a specific embodiment of the invention, the functional group on the protein may be a thiol group and the reactive group may be a group containing a maleimide group, such as r - Maleimide-butyraldehyde guanamine (GMBA) or hydrazine. When the pH of the mixture is maintained at 6.5 to 7.4, the maleimide group is preferably selected from the sulfhydryl groups on the singular plate, as shown in Figure 1B below. At pH 7, 0, the reaction rate of the maleimide group with the sulfhydryl group is 1,000 times faster than that of the amine group. A suitable thioether attached between the maleimide group and the sulfhydryl group is formed, which cannot be cleaved under physiological conditions.

-71- l3〇〇414 The therapeutic peptides of the present invention and their peptide derivatives can be modified for specific labeling and non-specific labeling of blood components. - Α· Specific labeling, the therapeutic peptide of the invention is preferably designed to produce a specific reaction with the thiol group on the moving blood protein. Preferably, such a reaction is established by covalently bonding a quinone peptide, which is a cis-butenylene-imide group (eg, made of G_, hydrazine or other cis-butyl iodide). The winner is improved by attaching to a thiol group on a blood protein (blocking serum albumin or IgG). In some cases, specific ratios to the maleimide-based ratio of the 1 protein provide additional advantages in a non-specific calibration such as NHS and sulfonic acid-NHS groups. Mercaptans in vivo are less common than amine groups. Therefore, the maleimide derivative of the present invention will be covalently bonded to less protein. For example, in albumin (the most blood protein), only one early thiol group is contained. Thus, the therapeutic peptide-cis-succinyl S&imine-albumin complex will contain a molar ratio of about 1:1 for the therapeutic peptide to albumin. In addition to albumin, the 1 Qiu molecule (category II) also has free sulfur, #基°#(4) molecules and serum albumin which make up most of the dissolved proteins in the blood, which also constitute most of the blood. The free thiol group's thiol group can be covalently bonded to the tunable TU imine modified therapeutic trait. Furthermore, although in the blood protein containing free thiol, the specific labeling with the cis-butanthine-imine group leads to the preferential treatment of the therapeutic peptide-cis-butadiene-imine-albumin conjugate. Formation, which is attributed to the characteristics of albumin itself-72-correction supplemental supplementation of the patent application specification No. 94112549, December 1996. A single free per alcohol group in the highly retained albumin between the genus is located on amino acid residue 34 (Cys34). Cys34 of this albumin has recently been shown to have increased reactivity relative to other free sterol groups on free thiol proteins. This is due in part to the very low 5. 5 pK values on Cys34 on albumin. It is generally lower than the standard ρΚ value of the cysteine group, and the pi of the cysteine group is generally about 8 & due to this low pK value, under normal physiological conditions, the Cys34 major line of albumin Exist in ionic form, which surprisingly increases its reactivity. In addition to the low pK value of Cys34, other factors that increase the reactivity of Cys34 are at selected positions, which are close to one of the V regions of albumin. In the gap on the surface, this localization makes Cys34 available for all kinds of ligands and is an important factor for the biological role of Cys34', such as a free radical trapper or a free mercaptan scavenger. These properties allow Cys34 to react highly with the therapeutic peptide, maleimide, and the rate of reaction is increased relative to the therapeutic peptide-m-butyleneimine group. The free thiol protein has a reaction rate of up to 1 〇〇〇. The other advantage of the therapeutic peptide-m-butyleneimine-albumin conjugate is that it is 1:1 for albumin. The load-related reproducibility, which is mainly in the albumin Cys34 Other techniques, such as glutaraldehyde, DCC, EDC, and other chemical activations, such as free amine groups, lack this selectivity. For example, 'albumin contains 52 lysine residues, etc. 25-30 Located on the surface of albumin and can be used for conjugation. Activation of the isotropic acid residues or modification of the peptide by chelating the amino acid residues will result in a heterogeneous conjugate. Even if 1 is used : 丨 molar ratio of peptide to white egg 1300414 white 'this product will contain a variety of conjugate products, sometimes each albumin contains 〇, 卜 2 or more peptides, and each conjugate is freely coupled to 25_3 胜 可 可 可 可 可 可 可 可 可 可 可 可 可 可 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 (batch-to-batch reproduci bi 1 ty) is impossible, and this conjugate is less suitable as a therapeutic substance. In addition, 'although it shows the splicing of the amino acid residues through albumin, It can have at least multiple therapeutic properties per albumin molecule The advantages of matter, but studies have shown that the ratio of therapeutic substances to albumin is better than that of 丨. In Stehle, et al, "The Loading Rate Determines

Tumor Targeting Properties of Methotrexate-Albumin

Conjugates in Rats," Anti-Cancer Drugs, Vol. 8, pp 677 - 685 (1 997), the authors point out that conjugated to glutaraldehyde >* anti-cancer thyme (methotrexate) The most promising results are obtained when the ratio of protein is :::!, the entire contents of which is incorporated herein by reference. These conjugates are absorbed by tumor cells, however, containing 5: 丨 to 20 · 1 atmosphere. The conjugate of the molecule has an altered HPLC pattern and can be rapidly absorbed by the liver in vivo. Of course, at high ratios, changes in the conformation of albumin reduce its effectiveness as a therapeutic carrier. Specific markers of albumin and IgG in vivo can be controlled by controlling the supply of cis-butyl iodide-therapeutic tablets in vivo. In a typical drug delivery, 80-90% of the supplied cis-butyl diimine-therapeutic peptide will label albumin and less than 5% will label IgG. Tracking markers for free thiol groups such as glutathione also occur. When this mark allows accurate calculations — 74 — 1300414 This particular mark is preferably used in vivo during the half-life period determined by the supplied substance. In addition to providing specific markers of control in vivo, the maleimide-therapeutic version provides specific markers of serum albumin and igG in vitro. This in vitro label involves the addition of a cis-butadienyl-therapeutic peptide to blood, serum, or serum albumin and/or (4)

In the salt water. The blood, serum, or physiological saline solution can be re-supplied into the solution i for in vivo use when it is changed in vitro with cis-butanediamine-therapeutic sputum. In contrast to the NHS-peptide, the maleimide-therapeutic peptide is generally very stable in the presence of aqueous solutions and free amine groups. Once the maleimide-therapeutic peptide is only reactive with a free thiol group, generally no protective group is required to protect the cis-butyr, the bis-imine-therapeutic peptide is free of Its own role. In addition, the increased stability of the peptide allows it to be used in further purification steps, such as Ηριχ, to prepare high purity products suitable for use in vivo. Finally, the increased chemical stability provides a product with a longer period of use. B. Non-specific labeling. The therapeutic peptide of the present invention can also be modified for use in non-specific components of blood components. It is generally utilized for the incorporation of amine groups, particularly with the formation of amidoxime, for non-specific labeling. To form this bond, a wide variety of activated carboxyl groups, particularly esters, can be used as a chemically reactive group coupled to the therapeutically successful substrate, wherein the base moiety is physiologically accessible -75-1300414 One of the ten i. Although, most of the different hydroxyl groups can be used in this fish, and the most commonly used ones are hydroxy amber amidoxime (Sheng version) and N % base - continued acid number. Acid - off s). . Other linkers that can be used are described in U.S. Patent No. 5,61, 2,034, the disclosure of which is incorporated herein by reference. The various positions at which the chemically reactive groups of the non-specific therapeutic peptides act in vivo include cells, particularly red blood cells (erythrocytes) and platelets, and proteins such as immunoglobulins (including IgG and IgM), serum albumin, ferritin, steroid binding protein, transferrin, thyroxine binding protein, alpha-2-macroglobulin, and the like. The body that reacts with the therapeutic peptide derived therefrom, which is not long-lived, will typically be removed from the human host within three days. The protein (including protein of the cell) will remain in the bloodstream for at least three days, and may remain for five or more days, based on its concentration in the bloodstream, which may remain for more than 60 days. It usually does not exceed any other days, especially for the half-life period. For the most part, it reacts with moving components in the blood, especially blood proteins and cells, more particularly blood proteins and red blood cells. "Moving," means that the component does not have a fixed position for an extended period of time, which typically does not exceed 5 minutes, more often 丨 minutes, while certain blood components may remain relatively - segment At the beginning, there are _ groups of relatively heterogeneous labeled proteins and cells. However, for most of them, within a few days of drug delivery, the group will change to the initial group, @ It depends on the half-life of the labeled protein in the blood flow of .76 - 1300414. Therefore, pe ^ τ 〇, 巾 10,000, one day longer Β, ^ will become the main marker protein in the bloodstream. r usually 'in the drug 5 After the day, 'IgG, serum albumin and red ▲ balls will lick the 6 ◦ mol% of the sensitizing component in the blood, usually at least 75 y, while IgG, IgM (which is a substantially smaller range) And the serum white protein will be at least 5 〇 mol% of the non-cellular conjugate component, at least 75 mol%, and more usually about 8 〇 mol%. The ideal combination of the therapeutic peptide conjugated to the blood component can be prepared in vivo by The therapeutic peptide is directly administered to the patient, and the patient may be a human or other animal. The drug may be supplied in the form of pellets or slowly introduced by injection using a metering flow or the like. If desired, the subject conjugate can also be prepared in vitro by combining blood with the improved therapeutic trait of the invention, allowing the modified therapeutic peptide to be covalently bonded to the blood group. Dividing the reactive Luenengji, and then recovering or supplying the conjugated blood to the host. Further, the above may also be achieved by the following method, that is, first purifying a single blood component or A limited number of components, such as red blood cells, immunoglobulins, serum albumin, etc., and the component or components are bound to the chemically reactive therapeutic peptide in vitro. Blood or blood components can be delivered to the host to provide the therapeutically effective composition of the target in vivo. The blood can also be processed to prevent agglutination during in vitro treatment. -77 - 1300414 3 · Used in this Invention The synthetic winning fragment of the therapeutic victory can be synthesized by standard methods known to the skilled artisan as solid state chemistry. For example, peptide fragments can be synthesized by standard methods of solid state chemistries. It can be synthesized following the procedure described by Steward and Young (Steward, JM and Young, JD, Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Company, Rockford) 111., (1984), which utilizes an applied biological system. Synthetic machine (Applied Biosystem synthesizer). Similarly, most of the peptides can be synthesized and then joined together to form larger fragments. Such synthetic peptide fractions can be made from amino acid substitutions at specific positions. In terms of solid state synthesis, a brief description of many techniques is found in J. M. Stewart and J. D. Young, ^ Solid Phase Peptide

Synthesis, W. H. Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, P. 46, Academic Press (New York), 1 973. A typical solution synthesis method can be found in G. Schroder and Κ·Lupke, The Peptides, Vol. 1, Acacemic Press (New York). Generally, such methods comprise the sequential addition of one or more amino acids or the addition of a suitable protective amino acid to form an extended peptide chain. Typically, the amine or carboxyl group of the first amino acid is protected by a suitable protecting group. The protective or derivatized amino acid is then attached to an inert solid support or used in solution by the addition of the next amino acid having a complementary group (amine group or slow The base 5' has a suitable protection and is suitable under the conditions to form a 78-1300414 bond. Then, only the % of the protective group is removed from the newly added amino acid residue, and the next toughness/polybasic acid (with appropriate "protection") is added. Wait.

After all of the desired amino acids have been linked in a suitable order, any protecting groups present (in any solid form) are removed sequentially or simultaneously to provide the final multi & By simple modification of the process, it is possible to add more than one amino acid simultaneously to obtain an extended chain, such as by coupling a protective tripeptide to a suitable protective dipeptide. A five-peptide is formed after deprotection (under the condition of racemize the chira centers). A preferred specific method of preparing a compound of the present invention involves the synthesis of a solid sulfonate wherein the amino acid is protected by an acid or base sensitive group. This protective group must have the property of being stable to the conditions under which the peptide is formed. On the same day, it can be easily removed without destroying the extended peptide chain or none of the materials included in it. Chiral center. Suitable protective groups are 9-fluorenylmethoxycarbonyl (Fm〇c), t-butoxycarbonyl (B〇c), benzomethoxycarbonyl (Cbz), diphenylisopropoxycarbonyl, t-pentyl Oxycarbonyl, iso-boxoxycarbonyl, α,α-dimethyl-3, 5-dimethoxybenzoquinoneoxycarbonyl, indole sulfhydryl sulfenic acid, 2-cyano-butoxycarbonyl, and the like. The 9-mercaptomethoxycarbonyl (Fmoc) protective group is preferably used for the synthesis of therapeutically successful fragments. Other car owners' side chain protective groups are as follows, for side chain amine groups, such as 2, 2, 5, 7, 8- quinolyl group 6 for the group of amine acid and arginine. - sulfonyl (pmc), nitro, p-toluenesulfonyl, 4-methoxyphenyl monosulfonyl, Cbz, Boc, and hard rock oxycarbonyl; the group for tyramine acid is benzyl a 79-1300414 base, 0-bromo anthracenyloxycarbonyl, 2,6-dioxadecyl, isopropyl, t-butyl (t-Bu), cyclohexyl, cyclopentyl and acetyl (Ac) The groups used for the serine are t-butyl, τ-based, and tetrahydrogen. The group used for histidine is di-methyl, benzyl, Cbz, p-曱, sulphate, and 2,4-dinitrophenyl; the group for tryptophan is hydrazine The group for aspartic acid and glutamic acid is benzyl and t-butyl; and the group for cysteine is triquat (trimethane). In the solid peptide synthesis method, the α-C-terminal amino acid is attached to a suitable support or resin. Suitable support systems for the above synthetic methods are those which do not react with the reactants and reaction conditions of the condensation-deprotection reaction of the respective steps, and which are also insoluble in the medium used. The preferred solid support for the synthesis of the a-C-terminal carboxyl peptide is 4-tetrahydroxymethylphenoxy-co-polymer (styrene-1% diethylene). The preferred solid support for the synthesis of the aC-terminal guanamine peptide is 4-(2,4,4-dimethoxyphenyl-Fmoc-amine fluorenyl)phenoxyethylaminoethyl resin. Can be applied

Biosystems (Foster City, Calif.). The aC-terminal amino acid is coupled to the resin by the following substances, namely N, N, - dicyclohexyl carbonized diazide (DCC), N, N'~ diisopropyl carbodiimide (pic) Or 〇- 笨 醯 醯 azide-1-yl-N,N,N,,N,-tetramethyl-urea cation hexafluorophosphate (HBTU), and the following is optional: 4 - two Mercaptoguanidine pyridine (DMAP), 1-hydroxy azide azide (H〇B butyl), awkward azido-mono-oxy-tris(diamine)phosphorus-hexafluorophosphate (B〇 p) or bis(2-keto- 3 -oxazolidinyl)phosphine chloride (B0PC1), which is equivalent to -80-1300414 such as di-methane or DMF, which is controlled to couple about 1 to the solvent, at 10. And 24 hours between temperatures of 50X.

When the solid support is 4-(2,4,monomethoxy-fmoc-aminomethyl)oxyethylaminoethyl resin, the stomach Fm〇c group is preferably attached to the above Before the coupling of the cx-C-terminal amino acid, it is cleaved with a secondary amine, preferably hexahydropyridinium. The method for the 4-(2,,4,-di-f-oxyphenyl, %-aminomethyl)phenoxyethylaminoethyl resin to be used for the protection is hydrazine-benzene dissolved in DMF And trisazo-1-yl-N,N,N,,N,tetradecyl-urea cation hexafluorophosphate (HBTU, 1 equivalent) and hydroxy succinyltriazo (h〇bt, i equivalent). The coupling of a successful protective amino acid can be found in automated polypeptides known in the art. In progress. In a preferred embodiment, the extended peptide chain N & amine group g is protected by Fm〇c. The removal of the Fm〇c protective group from the α-Ν~end side of the extended peptide is accomplished by treatment with a primary amine, preferably a hydrogen ratio well. Then, each protective amino acid system is introduced in an amount of 3 times the molar amount, and the composition reaction is preferably carried out in DM?. The light combination agent is generally 0-stuppy tris-azo-l-yl-indole, hydrazine, hydrazine, hydrazine-tetradecyl-urea cation hexafluorophosphate (HBTU, 1 equivalent) and 卜搜基笨和三偶Nitrogen group (Η0ΒΤ, 1 equivalent). At the end of the solid state synthesis, the multi-version is removed from the tree and deprotected by continuous or single operation. The removal and deprotection of the polypeptide is facilitated by treating the resin-bound multiple plate with a refining agent, and the refining agent comprises thi an iso le 'water, 乙烧Diterpene alcohol and trifluoroacetic acid. In this example, the α-C-terminus of the polypeptide is a hospitalized amine. The resin is excised by hydrazinolysis of an alkylated decylamine. This 81-1300414 outer peptide can be removed by transesterification, i.e., with methanol, and then the heptyl group is hydrolyzed or directly converted to guanamine. The protective peptide can be purified at this step or directly in the next step. The removal of the side chain protecting group is accomplished using the above-described tail end exclusion. The fully deprotected peptide is purified by a series of chromatographic steps which can be applied to any or all of the following steps: ion exchange on a weak base resin (acetate form in underivatized polystyrene) Hydrophobic adsorption chromatography on ethylene-diethylbenzene (such as Amberl i te XAD); alumina gel adsorption chromatography; ion exchange chromatography on carboxymethyl cellulose; Hierarchical chromatography, such as Sephadex G-25, LH-20 or countercurrent partitioning; high performance liquid chromatography (HPLC) 'especially in octyl- or octadecyl siloxane-alumina Reverse column HPLC coated with phase column. The molecular weight of this therapeutically superior 系 is based on the rapid atomic charge (ΡΑβ) ···· Quality Spectroscope (Fast Atom Bombardment (FAB) Mass Spectroscopy) The phenotype can be synthesized as a prodrug with a protective group at the N- and C-termini. (1) The N-terminal protective group is as described above, and the term "N-protecting group" means It can protect the α-N-end of the amino acid or the Sheng version during the synthetic process, or protect the amine. The base group or the amino group of the sulfonium is free of undesired groups. The oxime-protecting group generally used is disclosed in Greene, " Protective Groups In Organic Synthesis," (John Wiley & Sons, New York, 8 2 - 1300414 (1981)), which is incorporated herein by reference. In addition, a protective group can also be used as a former _, which can be easily removed in vivo, such as Enzymatic hydrolysis to release the biologically active substance itself. The α-Ν-protective group contains a lower alkanol group (aRan〇yn base map, such as fluorenyl, ethyl (" Ac"), propyl, tridecyl, t-butyl butyl, etc.; other thiol groups, including 2-oxoethyl, bromoethyl, trifluoroethyl, tri Ethylene ethion, phthalic acid, nitrogen oxetidyl, acenaphthyl, alum, sulfonyl, bromobenzylidene, 4-nitrobenzhydryl Etc.; a sulfonyl group, such as a sulfonyl group, a P-toluenesulfonyl group, etc.; an amino phthalate forming group such as a benzomethoxy group, a p-gas methoxycarbonyl Base, p-methoxybenzomethoxycarbonyl, p~nitrobenzoxanthene, 2-nitroxylmethoxycarbonyl, p-bromophenylhydrazineoxycarbonyl, 3,4-dimethoxybenzoquinoneoxycarbonyl, 3, 5-dioxaoxybenzyloxycarbonyl, 2,4-dimethoxyoxanoxy, 4-ethoxybenzyloxy, 2-acyl- 4,5-dimethoxy-indolyloxycarbonyl, 3, 4, 5-Dimethoxy methoxycarbonyl, j-(p-diphenyl)-p-methylethoxycarbonyl, α,α-dimethyl-3, 5-dimethoxybenzoquinoneoxycarbonyl, Dihydrooxocarbonyl, t-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropoxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2, 2, 2,-trisethoxy , phenoxycarbonyl ' 4-nitrooxycarbonyl, fenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, cleavage, etc., arylalkyl The group 'such as benzyl, trityl, oxalyl fluorenyl, 9-fluorenylmethoxycarboxy (Fmoc) and the like, and a silyl group such as a trimethylsilyl group and the like. 1300414 (2) Carboxyl protecting group As described above, the term "carboxy protecting group" refers to a carboxyl protecting ester or amidino group which is used to block or protect the carboxylic acid functional group. 'At the same time, the reaction involving other functional group positions of the compound is still in one line. Carboxyl protecting groups are disclosed in Greene, "Protective Gr. Ui^ in Organic Synthesis" pp. 1 52-186 (1981), which is incorporated herein by reference. In addition, a monocarboxy protecting group can be used as a prodrug, whereby the carboxy protecting group can be easily excised in vivo, such as by enzymatic hydrolysis to release the biologically active substance itself. . Such carboxy protecting groups are known to those skilled in the art and are useful in the protection of carboxyl groups which are widely used in the range of penicillin and cephalosporin, which are disclosed in U.S. Patent No. 3,840,556. 3, 719, 667, the disclosures of which are incorporated herein by reference. A typical carboxy protecting group is 〇. C! -C8 lower alkyl (eg, methyl, ethyl, or butyl, etc.) fluorene, such as phenethyl κ, and its substituted derivatives. , such as, alkoxyphenyl or nitrophenyl; arylalkenyl, such as styryl, etc. aryl and substituted derivatives thereof, such as 5-2,3-dihydrogenation : and so on: — 'Ammonia burning base' such as, - A its 3 ^ 7 Ganzi ~ - Methyl private ethyl temple, etc.; Keyyard alcoholic alkyl group, such as, B, oxymethyl, D Oxygen methyl, oxymethyl, isobutyl oxymethyl 'isoamyl oxymethyl, bu ( , ft, 1 7 I Ί 1 ethyl, 1-(pentanyl) 1-ethyl , 卜基基-I-(propyl oxo)-Buethyl, dimethyl, propionyloxymethyl, etc. Calculated soil - soil ethoxylated oxygen, nuclear alkanoloxyalkyl rolling, such as cyclopropyl -84 - 1300414 2 carbonyloxycarbonyl, cyclobutylcarbonyloxycarbonyl, cyclopentylcarbonyloxymethyl, cyclohexyloxycarbonyl, etc., arylalkylalkyl, such as alum, oxime, Alum oxyethyl, etc.; aralkylcarbonyloxyalkyl, such as awkward Oxyfluorenyl, - 2 oxatol ethyl, etc.; alkoxycarbonylalkyl or cycloalkoxycarbonylalkyl, such as, oxime oxycarbonylmethyl, cyclohexyloxycarbonylmethyl, hydrazine Carbonyl-1-ethyl or the like, alkoxycarbonyloxyalkyl or cycloalkoxycarbonyloxyalkyl, such as 曱Q oxycarbonyloxycarbonyl, heptabutoxycarbonyloxyl, ethoxylated Carboxyoxy-1-ethyl, hexacyclohexyloxycarbonyloxy-anthracene-ethyl, etc.; aralkylcarbonyloxyalkyl, such as (stupidyloxy)ethyl, 2-(5- 2,3_Dihydrodecyloxy oxy)ethyl oxalate 'alkoxy oxyalkyloxyalkyl, such as 2 - (1 - oxime - 2 - fluorenyl-2- fluorenyloxy Ethyl, etc.; arylalkoxycarbonyloxyalkyl, ketone 2 (alum oxycarboxyoxy)ethyl%•etc; aryl chain dioxy oxyalkyloxyalkyl, such as 2- (3-phenylpropan-2-oxycarbonyloxy)ethyl and the like; alkoxycarbonylaminoalkyl, such as t-butoxycarbonylaminomethyl, etc.; alkylamine carbonylamine alkyl, Such as, mercaptoamine carbonyl amine hydrazino, etc.; alkyl mercapto fluorenyl alkyl, such as acetamidoamine hydrazino, etc.; heterocyclic oxygen An alkyl group, such as, for example, a 4-alkylaminocarbonylcarbonyl group, or the like; a dialkylaminecarbonylalkyl group, such as, 'monomethylaminocarbonyl, monoethylamine sulfhydryl, and the like (5-(lower alkyl)-2-keto-1,3-dioxan-4-yl)alkyl, such as, (5-t-butyl-2-keto-1,3-di Ethyl-4-yl)methyl and the like; and a phenyl-2-yl-1,3-dioxo-4-yl)alkyl group such as (5-phenyl-2-one) 1,3-Dioxo-4-yl)indenyl and the like. Typical guanamine-protecting groups are amine carbonyl and lower alkyl amines - 85 - aryl. Μ

The modified carboxy-protective compound of the present invention is a compound of the following formula wherein the protective carboxyl group is a lower alkyl group, a cycloalkyl group, or an aralkyl group. Esters such as oxime esters, ethyl esters, propyl esters, isopropyl esters, butyl esters, second butyl esters, isobutyl esters, pentyl esters, isoamyl esters, octyl esters, cyclohexyl esters, stupyl ethyl esters, etc. Or a monoalkyloxyalkyl, cycloalkyloxyalkyl, aryloxyalkyl or monoaralkylcarbonyloxyalkyl ester, preferably a guanamine carbonyl protecting group is a lower alkylamine carbonyl. For example, aspartic acid can be protected at the α-C-terminus by an acid-labile group (eg, t-butyl), and protected by a hydrogenation-reactive base (eg, benzyl). At the β-Ο end, it is selectively deprotected during synthesis. Furthermore, it is also possible to obtain fragments by cleaving the naturally occurring aminocarboxyl sequence by a method known as protein hydrolyzing enzyme known to those skilled in the art. Furthermore, it is also possible to obtain fragments of the desired therapeutic peptide by using the DNA technology method known to those skilled in the art. 4. Improvements in therapeutic peptides 86 - The manner in which the improved therapeutic peptides of the present invention are produced varies widely, depending on the nature of the various elements comprising the molecule. The synthetic process can be selected to be simple, to provide high yields, and to allow a highly purified stable product. In general, the reactive group can be produced in the final step, such as the esterification of a consensus group to form an active ester system which can be the last step in the synthesis. The specific method for producing the improved therapeutic peptide peptide of the present invention is as follows. 1300414 In general, the improved therapeutic peptides of the present invention can be made using blind or initiated substitution as the structure activity correlation (SAR). The SAR system is an analytical method that defines the correlation between the molecular structure of a series of compounds and their pharmacological activities. A variety of studies related to unique therapeutic peptides have shown how the activity of peptides varies depending on chemical structure and chemical properties. In particular, the therapeutic activity of the free peptide was first analyzed. Next, the peptide is modified according to the method of the present invention, i.e., using only one linking group to improve at the N-terminus, the C-terminus, or the intermediate portion of the triumphant. The linking group includes the reactive groups disclosed above. The modified sputum-linking group is then analyzed and a decision regarding the modified position is made based on the detected activity. Next, the peptide conjugate was prepared and its therapeutic activity was determined. If the therapeutic activity of the winning version is not substantially reduced after the conjugation (ie, if the therapeutic activity is reduced by no more than 1 Q times), then the stability of the victory is measured and is equal to the living body. The existence time is expressed. If the stability is not promoted to a desired level, the other location of the peptide is modified and the process is repeated until a therapeutic level as far as desired is desired and an ideal stability is achieved. The therapeutic scores of the selection of the selected group and a reactive group will be improved according to the following criteria: if one side carboxyl group is available on the therapeutic peptide And the retention of the pharmacological activity of the carboxyl group is not critical, and when no other sensitive functional group is present on the therapeutic peptide, the carboxyl group can be selected as the linker-reactive group. Contact point. If the carboxy group at the side is involved in pharmacological activity, or if a carboxy group is not available, then any other pharmaceutically active group that is not a decisive sensitive functional group will be selected as the linker-reactivity. Improved contact points for the group. If a plurality of sensitive functional groups are available on the therapeutic peptide, the collection of protective groups can be used to improve by the attachment of a linking group/reactive group to all protective properties. After deprotection of the sensitive functional groups, a reservation of pharmacological activity can still be obtained. If there is no sensitive functional group on the therapeutic peptide, or if a simpler, improved route is required, the effect of the synthesis will allow the original peptide to be modified in such a way that it is available The retention of a biological activity and the retention of a receptor or target specificity. In this example, the improvement occurs at the opposite end of the winning version. An NHS derivative can be synthesized from a monocarboxylic acid in the absence of other sensitive functional groups in the therapeutic peptide. In particular, the therapeutic peptide is reacted with a non-aqueous CH2Cl2 and N-hydroxysuccinimide in the EDC, and the product is by chromatography or from the appropriate The NHS derivative is obtained by recrystallization from a solvent system to purify. Further, the 'NHS derivative can be synthesized from a therapeutic peptide containing an amine group and/or a thiol group with ~ and a carboxyl group. When a free amine or thiol group is present in the molecule, it is preferred to protect the sensitive functional group prior to the addition of the NHS derivative. For example, if the molecule contains a free amine group, the amine group must be converted to Fmoc or, preferably, to the tB〇c protective amine group prior to the above chemical reaction. The amine functional group is not deprotected prior to the preparation of the NHS derivative. Therefore, this $-party can only be applied to a compound whose amine group does not need to be in a free state to cause a pharmacological effect. If the amine group must be in a free state to maintain the original biological properties of the molecule from 88 to 1300,414, the other chemical species described in Examples 3-6 must be carried out. In addition, an NH derivative can be synthesized from a therapeutically successful version containing an amine group or a thiol group but no carboxyl group. When the selected molecule does not have a carboxy-pathway, a column of bifunctional linking groups can be used to convert the molecule to a reactive NHS derivative. For example, ethylene glycol-bis(succinimide succinate) _ (EGS) and triethylamine are dissolved in DMF and added to the free amine containing the molecule (10:1 ratio favors EGS) ) which will produce the single NHS derivative. In order to produce an NHS derivative from a thiol-derived molecule, it is possible to use hydrazine-[γ-m-butyleneimine butyl sulfoxide] succinimide oxime ester (GMBS) and three dissolved in DMF. Ethylamine. The maleimide group will react with the free thiol, and the NHS derivative can be purified from the reaction mixture by chromatography on the celite or by HPLC. An NHS derivative can also be synthesized from a therapeutic compound containing more than one sensitive functional group. The examples will have to be analyzed and solved in different ways. However, the present invention can be applied to any therapeutic peptide thanks to a commercially available broad array of protective groups and a bifunctional _ linking group, and the method of the present invention preferably has a chemical step, That is, only the therapeutic peptide (as described in Example 1 or 3), or two steps (as described in Example 2, which involves the protection of early sensitive groups), or three steps (Protect, activate, and protect). In exceptional cases only, multiple steps (more than three steps) of synthesis are required to convert a therapeutic peptide into an activated nhs or maleimide derivative. The maleimide derivative can be synthesized from a therapeutic peptide containing a free amine group and a 1300414 free oxic acid. In order to produce a maleimide from a molecule derivatized with an amine group, it can be used as a ruthenium dissolved in DMF: -[γ- cis-butyl-i-imine-butanol-oxyl] Cool g is intended to {this) with triethylamine. The amidoxime group can be reacted with a free amine group, and the maleic iminoimide derivative can be obtained from the reaction mixture by chromatography on alumina or by HPLC. Purified out. Finally, the cis-butadiene-one-boiled imide bamboo organism also has a therapeutic skin-synthesis synthesis that contains a plurality of other 〇, sensitive functional groups and does not contain free acid. When the selected molecule does not contain a carboxylic acid, a list of bifunctional cross-linking materials can be used to convert the molecule to a reactive NHS derivative. For example, cis-butyl diimide propionic acid (MPA) can be coupled to the free amine group by reaction of the free amine with a carboxylic acid of MPA to produce a maleimide derivative, The reaction was carried out in DMF using activation of HBTU/HOBt/DIEA. Further, an lyophilic acid residue may be added to the C-terminal edge of the sulfonium to allow conjugation to the amine group of the above-described amine acid. The added amine loss allows for a single and efficient modification of the C3 winning end while maintaining the end capped by the monoamine functional group of the initial resin choice design. In addition, many other commercially available heterobifunctional crosslinkers can be used as needed. Many bifunctional compounds can be used to link all of them. The cross-linking agent includes: azide alkaloid, N-[4-(p-azidolinyl)butyl][2, σ-pyridyldithio)propaninyl), double- Acid amber, aminate, dimercaptodiphenyldiamine, disuccinimide tartaric acid, Ny-succinimide, butyl sulfoxide Oxime ester, N-hydroxy acid acid amber oxime amino group "4-laminated benzoic acid-90- 1300414 ester, N-amber amidino group μ-azido]]-1,3'-dithio group Propionate, N-succinyl and amino[4-iodoethenyl]amine acetoate, glutaraldehyde' and amber oxime 4-[N-m-butyleneimine fluorenyl ] cyclohexanecarboxylic acid. More specifically, such successes are preferably improved by the nature of their substituents and their presence or absence of free cysteine. Most of the winning peptides are aggregated into the following four individual species: (1) a peptide containing no cysteine; (2) a peptide containing one cysteine; and (3) two Cysteine is a peptide of a disulfide bond (photoamine); and (4) a peptide containing a plurality of cysteine. A. Cysteine-free peptide When the peptide does not contain cysteine, all residues excised from the support resin are added from the C-terminus and completely protected. The solution phase activation of the C-terminus by DEC and NHS can be carried out in a vessel with an amino-alkyl-m-butyleneimine. The peptide is then completely deprotected. In addition, a mono-amino acid residue can be added to the C-terminus of the peptide to allow modification on the E (epsilon) amine group of the amine acid while simultaneously setting the carboxyl end group with an amine group. live. The addition of this amino acid residue is only carried out when the addition does not substantially affect the therapeutic activity of the peptide. A generalized reaction chart for the c-terminal modification of the cysteine-free peptide is illustrated in the following table. One 91 one 1300414

Γ/oTFA 5% TiS

RH ΠΊ

Resin

4 m Resin R =巳oc or Ac R* = Ac or H RM = NH2 or H P=protective group Mtt or Aloe

Or Pd(0), HOAc, NMM dissolved in CHCb

/\^C02H Amino acid 包括 containing a Boc-protected Lys

RH 〇C〇2R" RH is in a'A^^Resin 〇, if an N-terminal improvement is appropriate, and again, it is a cysteine-free peptide, which is on the N-terminus. The addition is preferably carried out with all the residues still present on the support resin and is completely protected. The addition of the activated NHS-Mai bifunctional linker can protect the N- still on the resin. The peptide is completely deprotected. The example of the peptide which does not contain cysteic acid and is modified at the C-terminus is described in Examples 7-26. Examples of amino acids and modified peptides at the minor end are described in Examples 27-38. The general reaction chart for the N-terminal modification of the cysteine-free peptide is illustrated in the following chart. Each of them uses iso-NHS maleimide (like GMBS) and 3-MpA. 92--1300414 〇

〇 Ο NH NH NH NH NH NH NH ( ( (10) GMbs)

r\ pot heat 〇

Aaa\^ N π Resin Η

3-ΜΡΑ -93- 1300414 In addition, the peptide is improved on the amino acid at the intermediate position (i.e., 1 is not at the C-terminus or at the N-terminus). The general reaction chart for the improvement of the intermediate amino acid free of free cysteine is illustrated in the following chart, which is the use of the same double NHS and iso NHS cis-conazole.

〇 same double NHS ~94~ 1300414

Ac

Human|^C'〇2R Iso NHS maleimide (like GMBS) These cysteine-free peptides can be modified as described above, 'which includes kringle 5 peptides Fragments, fragments of GLP-1 peptide, fragments of dynorphin A peptide, human growth hormone releasing factor, 1-24 fragment of human god 0 peptide, and human enterocollage. A complete description of the chemical nature of such peptides is described in the paragraph of the practical example - 95 - 1300414 B. The winning version containing one cysteine when the triumph contains a cysteine acid 'the cysteine must Covered after the addition of maleimide. If the cysteine is involved in the binding position, it must be estimated how much potential activity is lost when the cysteine is covered by a protective group. If the cysteine is present in the covered state, then the route of synthesis is similar to the route described in Section A above, i.e., a modification of the C or N-terminus. In addition, the peptide can be modified at the position of the intermediate amino acid (i.e., not at the C-terminus or at the N-terminus). The general reaction chart for the improvement of the intermediate amino acid containing a cysteine acid is illustrated in the following chart, which uses homobromoiminimide and iso-NHS-butylene. Yttrium (like GMBS) 〇

Homo-cis-butenylene imino group 1300414 Ο

Aaa) RHN1 H R ~ Ac or H R' = NH2 orH Aaa = - amine group g

RHN

Iso NHS maleimide (like GMgS)

Examples of the therapeutic peptide containing a cysteine include G α (the α-subunit of the G therapeutic-suppressed binding protein, the 724_739 fragment of the rat nitric oxide synthase blocking protein in the brain, the human [Tyj~〇] a 32-fragment of the α-subunit of inhibin, a 254-274 fragment of the HI V envelope protein, and a P34cdc2 kinase fragment. C· contains two cysteines as a dithizone bridge ( The peptide of cytosine) has two cysteines as a disulfide bridge, and the syllabic system is removed from the (four) resin before the addition of the imine. The end side improves the winning version, and all protective groups are present in addition to the rebel end and the knot-* ..., Μ - + cysteic acid (based on its support from the support y / 1300414 The resin is cut off, so it exists in the unprotected state. When the singularity is removed from the resin, it must be deprotected. Mild gas oxidation will produce the disulfide bridge, and the peptide can be This step is purified. Then the 'liquid phase chemistry system activates the c-end when a disulfide bridge is present and J is the same as that required when the imine is added to the C-terminus (through an amino-carbo-alkyl-p-butylene imine). Then, the peptide is completely deprotected. The skin is modified to be present on the resin of the building. The two cysteine acids are selectively deprotected prior to the addition of maleimide. (heterogeneous) to help the gas oxidation can produce the disulfide bond, and the winning plate is still present on the resin. Then the 'cis-butylene-imine is added to the Ν-end and cut from the resin The winning version is completely deprotected. The general reaction chart containing the improvement of the two cysteine acids as a disulfide bridge is illustrated in the following chart. U fat I! LCh% Bu,,, sound brain

Acm Acm 5-S 1 20% N-six ©ill pyridine 2. 2-cis hydrazine disimidate propionate Π

Further, the peptide can be modified at the position of the intermediate amino acid (i.e., not at the C-terminus or at the N-terminus). A generalized reaction chart of the improvement of the intermediate amino acid containing the two cysteine acids as a disulfide bridge is illustrated in the graph below.

NHP

NHP 〇如如如如如 Cys 1Tys 0 Ν \ \ Η If 〇 〇

RH

Acm Acm R = Boc or Ac R' = Ac or H RM = NH2 or H P=protective group Mtt or Aloe

Aaa = - Amino acid phthalate resin including a Boc-protected Lys faa} kaa) RH Cys W 咚 \ \ H y Ss soluble in ch2ci2 ^h2 1% TFA and 5% TIS or ^ 1. 3-cis Acetylimine propionate 2. removal

Dissolved in CHCl;

Pd(0). HOAc, NMM . faal· p resin

Faa) J^aa) ^faaV RH Cys " N 〇

〇

-99 1300414 Examples of therapeutically successful tablets containing two cysteines as a disulfide bridge include: human bone dance factor 49, human diabetes related traits, human/dog room nasourea 5-28 fragments of peptides, bactenecin of cattle, and human [Tyr〇]-cortical balance 29. D· Contains multiple cysteines. When the peptide contains multiple cysteines as a disulfide bridge, the sputum must be added to the stil Cut it off. In order to improve the peptide from the C-terminal end, all protective groups are present at the position other than the slow base and the dihalophilic acid which is believed to establish a _ disulfide bridge (due to The support resin is cut off and thus exists in an unprotected state. When the peptide is removed from the resin, it must be deprotected. These relate to other disulfide bonds which are sequentially protected by the choice of a protecting group. It is recommended to simultaneously establish and purify each disulfide bridge before moving to the next disulfide bridge. Mild gas oxidation produces a disulfide bridge and the peptide can be purified in each step. Then, the liquid phase chemistry activates the c-terminus in the presence of a disulfide bridge and adds the maleimide to the c-termin (via an amino-alkyl-m-butyleneimine) When needed. The peptide is then completely deprotected. In order to modify the peptide from the N-terminal end, it can leave the peptide on the support resin and selectively deprotect the first two cysteine for mild gas oxidation. Establish the disulfide bond. The sequential deprotection will provide additional disulfide bonds prior to the addition of maleimide. This gas oxidation can be assisted by a catalyst (heterogeneous) to produce the bis-100-1300414 sulfur bond' and the peptide is still present on the resin. Then, the cis-butanthine was added to the N-terminus, and the peptide was cleaved from the resin and completely deprotected. In addition, the peptide can be modified at the position of the meta-amino acid (i.e., not at the C-terminus or at the N-terminus). A peptide containing a plurality of cysteine acids includes human endothelial hormone and [Lys4] sauroxoxin S6c. 〇5_ Administration of the modified therapeutic peptide The modified peptide is soluble in a physiologically acceptable medium, such as deionized water, phosphate buffered saline (PBS), physiological saline. Water, aqueous ethanol or other alcohols, plasma, protein solutions, mannitol, aqueous glucose, alcohols, vegetable oils, and the like. Others may be included therein = the additive includes a buffer, wherein the medium is generally buffered between pH 5 and 10 祀, and the concentration of the buffer is generally between 50 and 250 mM. Wherein the concentration of the salt is generally between about 5 and 5 〇〇 _ range = physiologically acceptable stabilizers and the like. The compositions can be freeze dried for storage and transfer. That big. The improved therapeutic peptide can be administered orally, parenterally = with / such as intravenous (IV), intra-arterial (IA), muscle (IM), subcutaneous (sc) = and the like. Where appropriate, 'transiusion' can be administered, in some cases, ie when the response of the functional group is rather low, can be administered, nasally, rectally, transdermally or sprayed, The properties of the conjugate herein allow for its transfer into the vascular system. Although multiple injections can be used as a & need, 101-1300414, usually a single injection per week. The improved therapeutic peptide can be administered by any conventional means including syringes, ancient & Ten guides & etc. The particular mode of administration is a change in the dosage of the agent to be administered, whether it is a single bolus or a continuous drug delivery or the like. Preferably, it is administered intravascularly, and the position of introduction is not absolute for the present invention, but is preferably at a location where rapid blood flow, such as a peripheral vein or a central vein. Other routes of administration may also be found, where the technical means is combined with a slow release technique or a protective matrix. The intention is that the therapeutic peptide is effectively distributed in the blood and acts with the blood component. The concentration of the conjugate varies widely, generally ranging from about 1 pg/ml to 50 mg/ml. The total intravascular dose is generally in the range of from about 0.1 mg/ml to about 1 mg/mi, and more often between 1 mg/ml and about 5 mg/ml. A number of advantages are created by binding to long-lived blood components such as immunoglobulins, serum albumin, red blood cells, and platelets. The activity of the modified therapeutically active compound is extended to days to several weeks. During this period, only one dose is required. When the active compound first binds to a macromolecule, a strong specificity can be achieved, which is less suitable for absorption in an intracellular manner and interferes with other physiological procedures. The formation of covalent bonds between blood components can occur in vivo or in vitro. If a covalent bond is formed in vitro, the modified therapeutic trait is added to blood, serum, or a physiological saline solution containing human serum albumin or IgG' to the therapeutic therapeutic skin of the modified A covalent bond is formed between the blood components. In a preferred form, the therapeutic peptide is 102-1300414 modified with maleimide and reacted with human ash albumin prepared in a physiological saline solution. Once the therapeutic peptide reacts with the blood knife to form a therapeutic victory-protein composition, the conjugate can be supplied to the patient. Furthermore, the improved therapeutic peptide can be supplied directly to the patient such that a covalent bond can be formed between the modified therapeutic peptide and the blood component in vivo. In addition, when the therapeutic delivery of the therapeutic peptide is ideal, a variety of delivery methods can be used: Α · Open surgical range lavage (Lavage) There are various indications for topical treatment of compounds, which are concomitant therapeutic The compound acts as an additive to be administered to an open surgery. In this example, the therapeutic compound can be perfused to the site of the surgical procedure and (or a portion of the brick location) prior to suturing, or the therapeutic compound can be placed in a restricted area for a period of time (ie, in the artery) The endometrial ablation operates one of the internal arteries after the private sequence is worn or within a portion of the gastrointestinal tract during resection, and then the excess fluid is expelled. Β· Tissue transplanted tissue transplantation, such as autologous and xenogeneic venous/arterial and valvular transplantation, and organ transplantation, can be treated with a prior treatment of the compound, which has been modified to allow The covalent bond is formed by culturing in a therapeutic solution and/or soaking it in a solution. A 103-, 1300414 c. catheter delivery guide can be used as part of an internal diagnostic procedure to deliver the therapeutic peptide to the interior of an organ (gp, gallbladder, digestive tract, vagina/uterus), or to an cardiovascular The procedure for the catheter, such as balloon angl0plasty. Standard catheters such as newer drug delivery and iontophoresis (iont〇ph〇retic) catheters can be used. D· Direct injection Yes. In areas of vascularization where the sickle is poor, such as intra-articular space, direct injection of a therapeutic compound can be biologically conjugated to the surface tissue and achieve the desired drug action. Other applications include intra-bone/primary intratumoral injections, intravaginal injections, intrauterine injections, enteral injections, intra- otpharyngeal injections, intracapsular injections, subcutaneous injections, intra-articular injections, and intra-abdominal work. Injection or intraocular injection, as well as surgery via bronchoscopy, via the nasogastric tube, and via the renal stoma. 6. The monitoring of the presence of the modified therapeutic stimulating derivative is further directed to determining the therapeutic peptide and/or guanidine analog, or derivatives thereof in biological samples such as blood, and Embellished. Method of object/length and method of determining the stability of the peptidase of the improved therapeutic peptide. The blood of a mammalian host can monitor the presence of the improved therapeutic challenge one or more times. By taking a blood or blood sample of a portion of the host, it can be determined whether the therapeutic peptide binds to the long-lived blood component at a level sufficient for the therapeutic activity, and then determines -104 ~ 1300414 in the blood. The amount of peptide compound treated. If desired, it may also be determined why the blood component is bound to the therapeutic peptide-derived molecule. This is especially important when using a non-waiting cure. The specific cis-butanin-pro-imine-treated peptide is relatively simple to calculate the half-life of serum albumin and IgG. One of the methods of determining the concentration Q of the therapeutic peptide, analog, derivative, and conjugate is to use the therapeutic peptide, or a therapeutic peptide analog, or a derivative thereof, and The conjugates have specific antibodies and are used as treatments that may be associated with the toxicity of such therapeutic peptides, analogs, and/or derivatives and conjugates thereof. This antibody has this advantage because the increased stability and duration of action of this therapeutically successful in vivo may cause new problems during treatment, including the possibility of increased toxicity. It must be mentioned, however, that in some instances, the conventional antibody: does not recognize the difference between the cleaved and uncut therapeutic peptides. In these examples, other detection techniques can be applied, such as lc/ms (Liquid Chromatography/Mass Spectrometry). The use of a specific problem-determining therapeutic substance < immunogenic peptide having a high-potential therapeutic peptide, an analog, or a derivative thereof, or a plurality of antibodies, can facilitate mediation any. The antibody can be produced or obtained from a host which is immunized with the peptide, the analog, or the organism thereof, or the immunological fragment, or relative to the substance. The antigenic determinant of the combination is immune. Preferably, the anti-suppression to s I4 - group has a specificity and affinity for the natural form of the therapeutic peptide or the analog of the treatment, the type of the drug, the type of the product, and the type of the conjugation. This 、,.. This specific antibody can also be labeled with an enzyme, 璧-105-1300414 pigment, or radiation. An antibody specific for the derived therapeutic peptide can be produced by using a purified therapeutic plate to induce a therapeutically specific antibody to the derivatization. By the induction of the antibody, it is not only intended to obtain an immune response stimulus by injecting it into an animal body, but also to obtain a similar step of the production of a synthetic antibody or other specific binding molecule, such as Xuexue recombinant immunization. Protein library. Both the single plant and the plurality of antibodies can be produced by a process known to those skilled in the art. In some instances, the use of monoclonal antibodies is preferred for the use of multiple antibodies, such as when degradation occurs in more than one non-antigenic determinant/antibody recognized region. The antibody can be used to treat toxicity caused by administration of a derivative of the therapeutic peptide, analog, or the like, and can be used in vitro or in vivo. Methods of in vitro treatment may include toxic immuno-dialysis treatments which immobilize the antibody to a solid support. The method of in vivo treatment may comprise administering an antibody effective to cause clearance of the antibody-substance complex. The antibody may be used to remove the therapeutic peptide from the blood of a patient in vitro. Conjugates, derivatives, and the like, which are carried out by contacting blood with the antibody in the absence of sputum. For example, the antibody can be immobilized or immobilized in a column matrix... the patient's blood can be removed from the patient and passed through the matrix. The therapeutic peptide, analog, organism, or conjugate will bind to the antibody, and then the blood containing a small amount of therapeutic peptide, analog 1 organism, or conjugate can be returned to the disease The amount of therapeutic peptide compound that is removed from the circulatory pedigree, the sputum, and the sputum can be adjusted by pressure and flow rate.泫Priority from the blood of a patient. 106 - 13〇〇414

The therapeutic peptide, analog, derivative, or conjugate removed therein is affected by, for example, the use of a half-permeable membrane, or the method known to those skilled in the art from the cell first. The plasma component separated from the component and the gray component is affected by a matrix containing the anti-therapeutic superiority. In addition, the preferentially removed therapeutically-enhanced blood cells, including red blood cells, are collected and concentrated in the blood cells of the patient's blood and the anti-therapeutic superiority of the distant cells with a fixed The antibody is contacted to affect the removal of serum components in the blood of the patient. The antibody can be administered parenterally to a patient having the therapeutic susceptibility, analog, derivative, or composition for therapeutic use. The anti-system binds to the therapeutic peptide compound and conjugate. If the activity is not completely blocked, once the therapeutic peptide is combined, it can block the activity to thereby reduce the bioavailable concentration of the therapeutic peptide compound in the bloodstream of the patient and reduce the nociceptive side effects. . In addition, the combined antibody-therapeutic superior ruthenium complex contributes to the therapeutic peptide compound and conjugate derived from the bloodstream of the patient. The invention, which has been fully described in detail herein, is exemplified by the following non-limiting examples. -107- 1300414 Example A. General Method for Synthesizing the Improved Therapeutic Phenomenon The improved peptide is synthesized on a 〇〇μιπο 1 e grade solid phase peptide synthesis system in a Symphony peptide synthesizer In the medium, it uses protective Rink Amide MB HA resin, Fmoc protective amino acid, and is prepared in Λ/,Λ/-dimercaptocaramine s (DMF) solution. Alkyl-1-yl', W,, tetradecyl-urea cation hexafluorophosphate (Hbtu) and activated with methylmorpholine (NMM), and N_hexahydroacridinyl group of the Fm〇c group ( Piperidine) deprotection (step). The deprotection of the Fmoc group at the edge uses 2〇% N-hexahydro. Bipyridyl (step 2) and then 3-cis-2-imimide The conversion of citric acid (3-ΜΡ A), the light combination of the aryl group, or one or more of the Fmo 〇AEEA after the 3-MPA is combined (step 3). Resection of the resin and The separation of the product was carried out using 86% TFA/5% TIS/50/.H2〇/20/〇 phenylthiopyrene and 2% test, and then killed by dry-cold Et20 (step 4). The product is by pre- Purified by reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a protective module (guard modu丨e) equipped with Dynamax C18, 6〇A, 8 μιτι Dynamax C18, 6〇A, 8 μΓη, 21 mm x 25 cm column, 21 mm x 25 cm column, and human 214 and 254 nm UV detector (Varian Dynamax UVD ll). This product must have RP-HPLC The mass spectrometer determines the purity of >95%. The mass spectrometer uses a continuous spectrometer of Hew丨ett Pa cka "d LC M S- 414 11 00 with a two-dimensional array detector and uses Electrospray ionization method B. Naturally smashing bond change In order to facilitate the improvement of the peptide, one or more amino acid residues may be added to the winning plates described in Examples 1 to 5, and/or The one or more amino acid residues may also be substituted with other amino acid residues. This change may aid in the attachment of reactive groups. Immune full L1 - Lys is added to the C-terminus of KRINGLE-5 Preparation of NAc_Pr〇_Arg-Lys_Leu-Tyr-Asp-Tyr-Lys_NH2.3TFA using an automated peptide: synthesis method, the following protective amine The acid is added to the Rink Amide MBHA resin in sequence: 卬〇〇1^(6〇外〇H, Fmoc-Tyr(tBu)〇H, Fmoc-Asp(OtBu)-〇H, Fmoc_ Ty“(tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Pro-〇H. In the deblocking of the Fmoc group, the N-terminal of the resin-bound amino acid was treated with 2% by weight of N-hexahydropyridyl prepared in DMF for about 15-2 Torr. The coupling of acetic acid is carried out under conditions similar to those of coupling with an amine group. The final step of resizing from the resin is carried out using the excision mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to obtain the desired product, i.e., a white solid after lyophilization. 1300414 jt-based iLl-Lys was added to the C-terminal NAc-Arg-Lys-Leu_Tyr-Asp-Tyr-Lys_NH2.2TFA.3TFA of KRINGLE-5 using the automated peptide synthesis method, the following protection The amino acid is added to the Rink Amide MBHA resin in sequence: "〇!〇〇1^3(8〇€;)-〇H, Fmoc-Ty"(tBu)〇H, Fmoc-Asp(〇tBu) -〇H, Fmoc-Tyr(tBu)〇H, FmooLeu_〇H, Fmoc-Lys(Boc)-〇H,

FmooA "g(Pbf)-〇H. In the deblocking of the Fmoc group, the N-terminal of the resin-bound amino acid is treated with 20% N-hexahydropyridyl prepared in DMF by about 15 -20 minutes. The hydrazine acetate is carried out under similar conditions to the coupling of the amino acid. The final step of resizing from the resin is carried out using the excision mixture as described above - the product is separated by precipitation and The preparative HPLC was purified to obtain the desired product, that is, the white solid after lyophilization. Rabbit Example 3 - Lys was added to the N-terminal N Ac-Ty r-Thr-Th r of kringle-5 -Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-

Preparation of Lys_NH2.3TFA Using an automated peptide synthesis method, the following protective amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-〇H, Fmoc-Tyr(tBu)〇H , FmooAsp(〇tBu)-〇H, Fmoc-Tyr(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, 1300414

Fm〇oA"g(Pbf)-〇H, Fmoc-P"o-〇H, Fmoc-Asn(T"t)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Thr(tBu)- 〇H, Fmoc-

Tyr(tBu)〇H. In the deblocking of the Fmoc group, the N-terminal of the amino acid bound to the tree is treated with 20% N-hexahydropyridyl prepared in DMF - for about 15-20 minutes. The coupling of acetic acid is carried out under a similar strip of coupling with the amino acid. The final step of resizing from the resin is carried out using the ablation mixture as described above. The product was isolated by precipitation and purified by preparative O HPLC to give the desired product, i.e., lyophilized white solid. Example 4 - Lys was added to the N-terminus of kringle-5, and Cys NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-GIy-Pro- at position 524 was substituted with Ala Preparation of Trp-AIa524-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH2.4TFA

For the method of synthesizing the peptide, the following protective amino acid is sequentially added to the Rink Amide MBHA resin: corpse 171〇〇1^5(巳〇0)-〇H, Fmoc-Tyr(tBu) 〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ty"(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-A"g(Pbf)- 〇H, Fmoc-Pro-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Tyr(tBu)〇H, Fmoc -Ala-〇H, Fmoc-Trp-〇H, Fmoc-Pro- 〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Va 〇H, -111- 1300414

Fm〇c-Asp(〇tBu)-〇H, Fmoc-Asp(〇tBu)-〇H, Fm〇cP“〇-〇H, Fm〇oAsn(Trt)-OH, FmooA“g(Pbf)-〇 H. in Fm〇c

In the deblocking of the group, the N-terminal of the resin-bound amino acid is treated with 20% N-hexahydroacridinyl in DMF for about 15-20 minutes. The coupling of acetic acid is carried out under similar conditions to the coupling of the amino acid. The final step of resizing from the resin is carried out using the excision mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to give the desired product, i.e., lyophilized white solid. f Example 5 · Lys added to the N-terminus of kringle-5 NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-GIy-Pro-Trp-

Preparation of Lys-NH2.2TFA Using an automated peptide synthesis method, the following protective amino acids were sequentially added to Rink Amide MBHA resin: "111〇〇1^5 (〇(:)-〇H , Fmoc-Trp-〇H, Fmoc-Pro-〇H, FmooGly-〇H, Fmoc-Gly-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Va H, Fmoc-Asp(〇tBu)-〇H, Fmoc-P "〇-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-A"g(Pbf)-〇H. On the Fmoc basis In blocking, the N-terminal of the resin-bound amino acid is treated with 20% N-hexanitrogen in d MF for about 15 - 20 minutes. The combination of acetic acid and The amino acid coupling is carried out under similar conditions. The final step of resizing from the resin is carried out using the excision mixture as described above. The product is separated by a shovel and purified by preparative ΗPLC to obtain the desired product. -112- 1300414 '', lyophilized white solid. - D-Ala2 GLP-1 (7-36) 醯 的 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙 僙Solid phase synthesis and a Symphony Synthetic Synthesizer It is carried out using Fmoc-protective Rink Amide MBHA resin, Fmoc-protected amino acid, and ruthenium-stupyl-azide-azide prepared in Λ/,Ν-dimethylamidamine (DMF) solution. 1-yl-Λ/,/V,W,,/V·-tetradecyl-urea cation hexafluorophosphate (HBTU) and activated with Λ/-mercapto porphyrin (ΝΜΜ) and Fmoc group The deprotection of the piperidine (step 1). The removal of the resin and the separation of the product used 85% TFA / 5% TIS / 5% phenylthio decane and 5% phenol, and This was followed by precipitation by dry-cold Et2(R) (step '2). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) prepared double effect Η P LC system: Use a flow rate of 9 · 5 m L / mi η and can use - more than 180 min of Phenomen ex Luna 10 μ phenyl-hexyl - 3 〇 -55% B (prepared in water 0.045% TFA (A) Gradient dilution with 0.045% TFA (B) prepared in CH3CN, 21 mm x 25 cm column* and UV damper at λ214 and 254 nm (Varian Dynamax UVD(R)) to provide this >95% Ideal peptide of purity Rp-HPLC system to which the decision to. These steps are illustrated in the following chart. — 113- 1300414

Fmoc-Rink Amide MBHA Resin

Step 1 SPPS

H.N-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-PS Pro 2 I ] 85% TFA/5% TIS/5. /. Phenylthiophene / 5% phenol

TFA

TFA TFA

hL N-HaEGTFTSDVSSYLEGQAAKEFlAWLVKGR-NHL

TFA D-Ala^GLP-1 (7-36VNH. c. Preparation of improved peptide from the cysteine-free peptide

The preparation of the maleimide-based peptide from a therapeutic peptide containing a plurality of protective functional groups and no cysteic acid can be exemplified by the synthesis of the following peptides. The peptide is modified at the N-terminus, the C-terminus, or the amino acid between the N-terminus and the C-terminus. The modified peptide is synthesized by delinking the N-terminus of the natural peptide sequence or by delinking the C-terminus of the natural peptide sequence. One or more additional amino acids can be added to the therapeutic peptide to facilitate attachment of the reactive groups. 1. Improvement at the C-terminus of the therapeutic peptide Example 7 - Improvement of the ε-amine group of the added C-terminal lysine residue on the RSV peptide

Val-lIe-Thr-IIe-G!u-Leu-Ser-Asn-lle-Lys-Glu-Asn-Lys- 1300414

Met-Asn-Gly-Ala-Lys-VahLys-Leu-lle-Lys-GIn-Glu-Leu-Asp-Lys-Tyr-Lys-Asn-Ala-Val-Lys-(N8-MPA) 63⁄4 ^ Borrow o

The D AC analog was carried out using a solid solid phase synthesis method, a Symphony peptide synthesizer, and an Fmoc protective Rink Amide MBHA on a solid phase synthesis of 1 〇 0 μ mole. The following protective amino acid is sequentially added to the resin · Fmoc-Lys(Aloc)-〇H, Fmoc-Va N〇H, Fmoc-Ala-〇H, Fmoc-Asn(Trt)-〇 H, Fmoc-Lys(Boc)-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Asp(tBu)-〇H, Fmoc-Leu-〇H, Fmoc -Glu(tBu)-〇H, Fmoc-Gln(T"t)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc_lle-〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)- 〇H, Fmoc-Va 〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Ala-〇H, Fmoc-Gly-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Met-〇H , Fmoc-Lys(Boc)-OH, Fmoc-Asn(Trt)-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-lle-〇H, Fmoc-Asn (Trt)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Leu-〇H, Fmoc-Glu(tBu)-〇H, F moc -11 e -〇H, F m ο ο T h" ( t B u)-〇H, F moc - Π e -〇H, Fmoc-Val-OH. These are sequentially dissolved in N,N-dimercaptoamine (DMF)' and use 〇- Benzopyridinyl-1-yl-N, N, Ν', N,-tetradecyl _ urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) are activated. Fmoc The removal of the protective group is done by dissolving N, 20% (V/V) N-hexahydroacridinyl solution in N-dimethylammonium (DMF)-115-1300414 is achieved by immersing for 20 minutes (step 1). The Lys (Aloe) The selective deprotection of the group is carried out manually by treatment with a solution of 3 eq of Pd(PPh3)4 dissolved in 5 mL of CHC丨3·· NMM : HOAc (18:1:0_5) The resin was completed in 2 hours (Step 2). The resin was then CHCI3 (6 X 5 mL), 20% HOAc (6 x 5 mL) dissolved in dcM, DCM (6)

x 5 mL), and DMf (6 x 5 mL) for cleaning. The synthesis is then re-automated to add 3-methyleneimine propionic acid (step 3). Between each coupling, the resin was washed three times with hydrazine, hydrazine-dimethylformamide (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA/5% TIS/5% phenylthiodecane and 5% phenol, and then reprecipitated as dry-cold (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex Luna 10 μ base with a flow rate of 9.5 mL/min and over 180 min. - 30-55% of hexyl Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm column and λ214 and 254 nm A UV detector (Varian Dynamax UVD II) was provided to provide the desired peptide of >95% purity, which was determined by Rp_HPLC. -116- 1300414 8 -Dyn A1_13 Addition of c-terminal ε-amino group of amine acid residue -Dyn Α 1-13(Νε-ΜΡΑ)-ΝΗ2 synthesis Tyr-Gly-GIy-Phe -Leu-Arg-Arg-IIe-Arg-Pro-Lys-Leu-Lys-(Ns-MPA)-NH2

The modified Dyn A 1-13 solid phase peptide synthesis method on the 100 μ mole scale was carried out using artificial solid phase synthesis, a Symphony peptide synthesizer, and Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin: FmooLys(Aloc)-〇H, Fmoc-Leu_OH, Fmoc-Lys(Boc)-〇H, Fmoc-Pro-〇H, Fmoc-Arg ( Pbf)-〇H, Fmoolle-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-A"g(Pbf)-〇H, Fmoc-Leu-OH, Fmoc_Phe-〇H, Fmoc-Gly-〇H , Fmoc-Gly-〇H, Fmoc-Ty "(tBu)-〇H. These systems are sequentially dissolved in N,N-dimercaptocarbamamine (DMF), and azeo-branched azide is used. Alkyl-1-yl-N,N,Ν',Ν'-tetramethyl-urea cation hexamethylene sulfate (HBTU) and diisopropylethylamino group (DIE oxime) are activated. Fmoc protective group The removal of the group was achieved by using a solution of 20% (v/v) N-hexahydroacridinyl group dissolved in N,N-dimercaptoamine (DMF) for 20 minutes (step 1). The selective deprotection of the Lys (Aloe) group is carried out manually, and by dissolving in a 1 1111 (1: latch (3丨3: called 1^11\/1: [-1〇) 3 eq of Pd(PPh3)4> trough solution in gossip (18:1:〇.5) was completed by treating the resin for 2 hours (step 2). Then, the resin was CHC13 (6 X 5 mL). ), 2〇% H〇Ac (6 X 5 mL), DCM (dissolved in DCM) 6 X 5 mL), and DMF (6 χ 5 mL) were used for cleaning. The synthesis was then re-automated to add 3-butene 117-! 1300414 quinone imine citrate (step 3). Between each coupling, the resin was washed three times with N,N-dimercaptononylamine (DMF) and three times with isopropanol. Using 85% TFA/5% TIS/5% thioanisole The resin was removed from the resin with 5% phenol and then reprecipitated by dry-cold cooling (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) Prepared double-effect HPLC system: use a flow rate of 9.5]111^/111丨11 and use more than 18〇111丨11 of 1!6110111€11 to 1^111^10 μphenyl-hexyl Gradient dilution of 30-55 % B (0.045 % TFA (A) prepared in water and 0.045% TFA (Β) prepared in CH3CN), 21 mm x 25 cm column and UV4 spectrometry at λ214 and 254 nm (Varian Dy n am ax UVD II) to provide the desired peptide of >95% purity, which was determined by RP-HPLC. The structure of the product is

Hi N-Tyr-Giy-Giy-Phe-Leu-Arg-Aro-Ile-Arg-Pro-Lys-Leu-Lys-NH2 CCM008 Example 9 - C_terminal deaminating acid residue added on DynA2-13 Improvement of ε_ Amino Group-DynA2-13(Ns-MPA)-NH2 Synthesis Gly-GIy-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-(Νε-ΜΡΑ)- ΝΗ2 _11R_ 1300414 Using the automatic leaping synthesizer, the following protective bases were added to Rink Amide MBHA resin: FmooLys(Mtt)-〇H, Fm〇c-Leu-〇H, Fm〇c-Lys (Boc)-〇H, Fmoc-Pro-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-lle-〇H, Fmoc-A “g(Pbf)-〇H, Fmoc-Arg(Pbf)- 〇H, Fmoc-Leu-〇H, Fmoc-Phe-〇H,

FmooGly-〇H, and Boc-G丨y-〇H. The subsequent step is the use of a synthetic method in which the Mtt group is selectively removed and coupled to MPA by the activation of HBTU/H〇Bt/DIEA in DMF. The dynorphin-labeled analog is removed from the resin and the product is isolated by precipitation and purified by preparative HPLC to obtain the desired product in a yield of 35%, ie, freeze-dried. White solid afterwards. Anal. HPLC showed the product to have >95% purity, and Rt = 30.42 min. The EShMS m/z is C73H123N25〇15 (MH + ), the calculated value is '1590.0, and the actual value is MH3 + 53H - Dyn A 1-13. The added C-terminal ε-amino group of the amino acid residue Improved · Synthesis of Dyn A 1-13(AEA3-MPA)-NH2 Tyr-Gly-GIy-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-

Lys-(AEA3-MPA)-NH2 Using an automated peptide synthesizer, the following protective groups were added sequentially to Rink Amide MBHA resin: Fmoc-Lys(Mtt)-〇H, Fmoc-Leu-OH, Fmoc-Lys(Boc)-〇H, Fmoc-P“o-OH, — 119- 1300414

Fmoc-A "g(Pbf)-〇H, Fmoc-lle_〇H, Fmoc-Arg(Pbf)-OH, Fm〇c_A"g(Pbf)-〇H, Fm〇c-Leu-〇H, Fmoc -Phe-〇H, Fmoc-Gly-〇H, FmooGly-〇H, and Boc-Tyr(Boc)-〇H.

The subsequent step is the two artificial synthesis: selective removal of the Mtt group using the activation of HBTU/H〇Bt/DIEA in DMF, and the three-Fmoc-ΑΕΑ-ΟΗ group (AEA) = Amine ethoxyacetic acid) is combined with hydrazine PA and Fmoc is removed between each coupling. The dynorphin-labeled analog is removed from the resin and the product is isolated by hydration and purified by preparative HPLC to obtain the desired product in a yield of 29% 'ie, freeze-dried White solid afterwards. Anal·H PLC showed the product with >95% purity and Rt = 33.06 min. ES Bu MS m/z is C94H154N29〇23 (MH+), calculated as 2057.2, actual value is MH4 + 515.4, MH3+ 686.9, MH2+ 1029.7 〇

yFA TFATFA TFA TFA

H2^Tyr^-Gly-Phe-Leu-Arg-Ar〇-lie-Arg-Pro4.y»-Lei>.Lys-NH CCI-1009 Ai cover J 11 A Dyn A 2-13 added c Synthesis of modified Dyn A 2-13{AEA3-MPA)-NH2 with ε-amino group of amino acid residue

Gly-Gly.Phe-Leu-Arg.Arg.lle.Arg.Pro.Lys-Leu.Lys. (AEA3-MPA)-NH2 Using an automatic smashing synthesizer, the following protective groups are sequentially 120 - 1300414

Add to Rink Amide MBHA resin: Fmoc-Lys(Mtt)-〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Pro-〇H, Fmoc-A“g(Pbf) -〇H, Fmoc-lle-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Leu-〇H, Fmoc-Phe-〇H, Fm〇c-Gly - 〇H, and Fmoc-Gly-〇H. The subsequent step is to use an artificial synthesis method to selectively remove the Mtt group, three Fmoc- using activation of HBTU/H〇Bt/DIEA in DMF. The ΑΕΑ-ΟΗ group is coupled to the MPA and the Fmoc is removed between each coupling. The analog of the dynorphin is removed from the resin and the product is isolated by sinking and purified by preparative HPLC. The desired product, i.e., the white solid after lyophilization, was obtained in a yield of 29%. Anal. H PLC showed product with >95% purity, and Rt = 31.88 min. ESI-MS γπ/ ζ is C85H145N25〇21 (ΜΗ + ), the calculated value is 1894.3, the actual value is ΜΗ4 + 474.6, ΜΗ3+ 632.4, ΜΗ2+ 948.10.

HtN-Gly-Gly-Phft-Lea-Afy-Arg-lte-Arj-Pro-Lys-Leu-Lys -NH2 CCM010

TFA Example 12 - Improvement of the ε-amine group of the C-terminal amide acid residue added to the neuropeptide Y

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Lys- (N-£MPA)-NH2 System 121-1300414

The modified neural version Y analog was subjected to a solid phase synthesis method of 100 μηιole grade using artificial solid phase synthesis, a Symphony S±^ synthesizer, and Fmoc protective Rink Amide MBHA. The following protective amino acid is sequentially added to the resin: "^10〇Lys(Aloc)-OH, Fmoc-Leu-〇H, Fmoc-Ala-〇H, Fmoc-Ser(tBu)-〇 H, Fmoc-Tyr(tBu)-〇H, Fmoc-Tyr(tBu)-OH, Fmoc-Arg(Pbf)-〇H, Fmoc-Ala-〇H, Fmoc-Met-〇H, Fmoc-Asp(tBii )-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Ala-〇H, Fmoc-Pro-〇H, Fmoc_Ala_〇H, FmooAsp(tBu)_〇H, Fmoc-Glu(tBu)-〇 H, Fmoc-Gly-〇H, Fmoc-Pro_〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Asp(tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Lys(Boc)- 〇H, Fmoc_Ser(tBu)-〇H, Fmoc_Pro_〇H, Fmo〇Tyr(tBu)-〇H. These systems are sequentially dissolved in N,N-dimercaptoamine group (DMF) and used 〇-Benzoquinone azide small group -N, hydrazine, hydrazine, N,-tetradecyl-urea cation hexafluorocarbonate (HBTU) and diisopropylethylamine (DIE oxime) are activated. Fmoc The removal of the protective group was achieved by using a solution of 20% (v/v) N-hexahydrogen in N,N-dimethylammoniumamine (DMF) for 20 minutes. (Step 1). The selective deprotection of the Lys (Aloe) group is performed manually and by The resin was dissolved in 5 m L of CHCI3:M:MM:H〇Ac (18:1:0.5) in 3 eq of Pd(PPh3)4 solution to complete the treatment for 2 hours (Step 2). The resin was washed with CHC13 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 x 5 mL), and DMF (6 x 5 mL). The δ mystery system was re-automated to add 3-butane di-imine-imine-acrylic acid (step-1 2Ζ- 1300414)

Step 3). Between each coupling, the resin was washed three times with N,N-dimethylmethine (DMF) and three times with isopropanol. The 闬 85% TFA / 5% TIS / 5% phenylthio group was calcined with 5% phenol and the sputum was removed from the resin, and then re-precipitated by dry-ice cooling [Step 4]. The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system: using a flow rate of 9.5 mL/mm and using more than 18〇11^11? }^11〇11^11 is 1^111^1〇4 phenyl-hexyl 30- 55% B (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN) Gradient dilutions, 21 mm x 25 cm column and 1 214 and 254 detectors in humans 214 and 254, such as 11〇71^11^1^0 II) to provide the ideal victory of 95% purity Peptide, which is determined by rp-HPLC. f Example 1 3 - GLP-1 (7-36) C: Modified arginine GLP-1 (Preparation of 7-36J-EDA-MPA) The modified GLP-1 analog was applied manually on a 1 μμ mole scale solid phase peptide synthesis system and on a Symphony Synthesizer SAS R1N (super acid sensitive resin). The protective amino acid is added to the resin in sequence: FmooAΓg(Pbf)-〇H, Fmoc-

Gly-〇H, Fmoc-Lys(Boc)-〇H, Fmoc_Va 〇H, Fmoc-Leu-〇H, Fmoc-Trp(Boc)-〇H, Fmoc-Ala-OH, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Glu(〇tBu), 〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Ala-〇H, Fmoc-Ala-OH, Fmoc--123- 1300414, poor Brother Ming < ;

Gln(T"t)-〇H, Fmoc-Gly-〇H, Fmco-Glu(〇tBu)-〇H, Fm〇c-Leu-〇H, Fmoc-Ty"(tBu)-〇H, Fmoc- Ser(tBu)-〇H, Fm〇c-Ser(t巳u)-〇H, Fmoc-Va〇H, Fmoc-Asp(tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc -Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr(tBu)-OH-Fmoc-Gly-OH &gt; Fmoc-Glu(OtBu)-〇H, Fmoc-Ala_〇H, Boc -His(T"t)-〇H. These are sequentially dissolved in N,N-dimercaptononylamino (DMF), and 〇-benzoquinone azide-1-yl-oxime is used. Ν,Ν,Ν, tetradecyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) are activated. The removal of Fmoc protective group is dissolved in N, N. - 20% (v/v) N-hexahydro in dimercaptoamine (DMF), which is achieved by a solution of the pyridine group for 20 minutes (step 1). The complete protective peptide is borrowed. It is removed from the trunk by treatment with 1% TFA / DCM (step 2). Then, ethyldiamine and 3-methyleneimine propionate are added sequentially to the free C- End (step 3). The protective group is then cleaved and the product is 85% TFA / 5% TIS / 5% Η 2 〇 / 5 % of this thiol smoldering was separated from 5% by age, followed by precipitation by dry-ice 巳丨 2 〇 (Step 4). The product was prepared by reverse phase HPLC. Purified, the HPLC uses a Varian (Rainin) prepared double-effect Η PLC system using an Oynamax C18 equipped with a guard module of dynama XC彳8, 6〇A, 8 μηι, 6 〇 A, 8 μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors (Varian Dynamax UVD II) at λ 214 and 254 nm to obtain an ideal DAC of &gt; 95% purity determined by RP-HpLc. These steps are described in the following chart: -m 1300414 • SASRIN resin

Step S 1 I SPPS • v

Boc-HAEGITTSDVSSYLEGQAAKEF丨AWLVKGR- Although the steps 2 _ j 1% TFA/ DCM

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-OH Step 3

K-extension ethyldiamine 2. 3-cis-butadienylamine

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-0

〇 〇 Step 4 85% TFA/5% TlS/5% H20/5% phenylthioformamidine/5% phenol H2N-HAEGTFTSDVSSYLEGQAAKEF!AWLVKGR-0

〇 〇

GLF-1 (7-36)-EDA-MPA

Example 1 4 - Improved Essen ingot-4 (1-39)-EDA-MPA of C-terminal silk cavity acid on Exendin-4 The modified Essen ingot-4 analog The solid phase peptide synthesis method on the 100 μ mole scale was performed manually on a Symphony Synthesizer SASRIN (super acid sensitive resin). The following protective amino acid is sequentially added to the resin: 卩1110〇36巾81〇-〇^^"1110〇-Pr〇-〇H, Fmoc-Pro-〇H, Fmoc-P"o -〇H, Fm〇c-Ala-〇H, Fmoc-Gly-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Ser(tBu)-〇H, -125- 1300414

Fm〇cP "〇-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn(T"t)-〇H, Fmoc-Lys(Boc)-〇H, FmooLeu-〇H, Fmoc-Trp(Boc)-〇H, Fmoc-Glu(〇tBu)-OH, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu-〇H, Fmoc-Arg(Pbf)-〇H , Fm〇c-Va 〇H, Fmoc-Ala-〇H, Fmoc-Glu(〇tBu)-OH, Fmoc-Glu(OtBu)-OH - Fmoc-Glu(OtBu)-OH &gt; Fmoc-Met- 〇H, Fm〇c-Gln(Trt)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Leu-〇H, Fmoc-Asp(〇tBu)- 〇H, Fmoc-_Se"(tBu)'〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Th"(tBu)-〇H, Fmoc-Gly-〇H, Fmoc -Glu(〇tBu)-〇H, Fmoc-Gly-〇H, Boc-His(Trt)-〇H, which are sequentially dissolved in N,N-dimercaptononylamine (DMF), and Activated with hydrazine-benzazole with azido-1-yl-N, N, fT, N1-tetradecyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (dieA) The removal of the Fnnoc protective group was carried out using a solution of 20% (v/v) N-hexahydropyridyl group dissolved in hydrazine, hydrazine-dimercaptoamine amide (DM F) for 20 minutes. Achieved. (Step 1). The complete protection The winning plate is cut from the tree trunk by treatment with 1% TFA / DCM (step 2). Then, the ethyldiamine group and the 3-m-butyleneimine propionic acid are sequentially added to The free end (step 3). The protective group is then cleaved and the product is isolated using 86% TFA/5% TIS/5% H2 〇/20/0 phenylthio decane and 2% phenol. The product was precipitated by dry-cold cooling (step 4). The product was purified by preparative reverse phase HPLC using one

Va "ian (Rainin) prepared double-effect HPLC system using 0-113 - 1300414 equipped with Dynamax C18, 6〇A, 8 μηι protective module (guard module) 0丫113!113/(318 , 60 people, 8 mouth 〇 1, 21 〇 1! 1 [1 乂 25 〇 171 column, 21 [1111! x 25 cm column, and UV detectors at λ214 and 254 nm (Varian 0 〇 3〇 13义1]\/0 11), to obtain the ideal DAC by the ruler ^卩1_(3 determines the purity &gt; 95%. 〇SASRIN resin

Step 1 1 SPPS

Boc-HGEGTFTSDLSKQMEEEAVRLF Old WLKNGGPSSGAPPPS·Resin Step 2

1% TFA/DCM

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-OH 1. &quot; 申 乙基 ethyl diamine t 2. 3- maleimide imine propionate

Boc-HGEGTFTSDLSKQMEEEAVRLFEWLKNGGPSSGAPPPS-Os.

Step 4 j 85% TFA/5% TIS/5% H20/5% phenylthioformamidine / 5% phenol

H2N-HGEGTHSDLSK〇MEEEAVRLFIEWLKNGGPSSGAPPPS-CK

Aisen ingot · 4 · (l-39)-EDA-MPA a 127- 1300414 f application - improvement of the epsilon-amine group of the c-terminal deaminating acid residue added on the small endogenous hormone

His-Ser-Asp-GIy-Thr-Phe-Thr-Ser-GIu-Leu-Ser-Arg-

Leu-Arg-GIu-Gly-Ala-Arg-Leu-Glu-Arg-Leu-Leu-GIn- 61乂-1^ to -\/3卜1^5-(to-1\/!?8)_ ~1-12 loan

The modified enterocollagen analog is subjected to a solid phase synthesis method of 100 μ mole grade using artificial solid phase synthesis, a Symphony peptide synthesizer, and Fmoc protective Rink Amide MBHA. . The following protective amino acid is sequentially added to the resin: "〇!〇〇Lys(Aloc)-〇H, FmooVahOH, Fmoc-Leu-〇H, Fmoc-Gly_〇H, Fmoc-Gln ( Trt)-〇H, Fmoc-Leu-〇H, Fmoc-Leu-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Glu(tBu)-〇H,

V

Fmoc-Leu-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Ala-〇H, Fmoc-Gly-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Ser(tBu)-OH, Fmoc-Leu-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Ser(tBu)- 〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Gly-OH, Fmoc-Asp(tBu)-OH, Fmoc-Se"( tBu)-〇H, Fmoc-His(Boc)-〇H. These systems are sequentially dissolved in N,N-dimercaptononylamine (DMF), and 〇-benzoquinone azide-1 is used. -Based-N, hydrazine, hydrazine 1, Ν'-tetradecyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate. Removal of Fmoc protective group is used 20% (V/V) N-hexahydropyridyl-(and S-1300414) dissolved in hydrazine, hydrazine-dimercaptoamine (DMF)

The solution was allowed to act for 20 minutes (step 1). The selective deprotection of the Lys (Aloe) group was carried out manually and by dissolving in a solution of 5 mL (^(313,[\/^:^1〇八〇(18:1:0.5)) The 卩6(卩卩^13)4 solution of 3 69 was treated to treat the resin for 2 hours (step 2). Then, the resin was CHC13 (6 X 5 mL), 20% H dissolved in DCM. 〇Ac (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) were cleaned. The synthesis was then re-automated to add 3-m-butylene imidate Acid (Step 3). Between each coupling, the resin was washed three times with N,N-dimercaptononylamine (DMF) and three times with isopropanol. Using 85% TFA/5% TIS/ The peptide was excised from the resin with 5% thioanisole and 5% phenol, and then reprecipitated with dry-cold Et2(R) (Step 4). The product was purified by preparative reverse phase HPLC. A Varian (Rainin) preparative double-effect HPLC system was used: 30-55% B of Phenomenex LunalOy Phenylhexyl group with a flow rate of 9.5 mL/min and over 180 min (0.045% TFA prepared in water) (A) with 0.045% TFA (B) prepared in CH3CN Dilutions, 21 mm X 25 cm columns, and U&quot;\M detectors (Varian Dynamax UVD II) at λ 214 and 254 nm to provide the ideal peptide of &gt;95% purity, which is RP -HPLC. Example 16 - Modified N Ac-Pro-Arg-Lys-Leu-Tyr- of the ε-amine group of the C-terminal deaminating acid residue added to kringle-5 Preparation of Asp-Tyr-Lys-(N8-MP(R)-D-FA-129-1300414 The modified kringle-5-peptide is used in the solid phase peptide synthesis method of 1 〇〇μπιοΐθ grade. The phase synthesis method, the Symphony flash synthesizer, and the Fmoc protective Rink Amide Μ Β Η A. The following protective amino acids are sequentially added to the tree.

Asp(tBu)-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc, Arg(Pbf)-〇H, Fmoc-Pro-〇 H. It is sequentially dissolved in N,N-dimercaptononylamine (DMF), and 〇-笨甲醯醯醯-1-yl-N,N,Ν',Ν'-tetramethyl is used. - Urea cation hexafluoro sulphate (HBTU) and monoisopropylethylamine (DIEA) to activate. The removal of the Fmoc protective group was achieved by using a solution of 20% (v/v) N-hexahydropyridyl group dissolved in hydrazine, hydrazine-dimercaptoamine (DMF) for 20 minutes. (step 1). At the end of the synthesis, an &lt;acid&gt; needle was added to acetate the N-terminus. &gt;·· The selective deprotection of the Lys (Aloe) group was carried out manually and by using 3 eq of Pd dissolved in 5 mL of CHCl3:NMM··H〇Ac (18:1:0.5) The (PPh3)4 solution was treated to treat the resin for 2 hours (step 2).

The resin was then washed with CHCI3 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 x 5 mL). . The synthesis is then re-automated to add 3-p-succinimide propionate (step 3). Between each coupling, the resin was washed three times with N,N-dimethylanilinoyl (D M F) and three times with isopropanol. The resin was excised from the resin using 85% TFA / 5% TIS / 5% phenylthio decane and 5% phenol, and then re-sinked with dry-cold Et2 ( (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a flow rate of 9 · 5 m L/m iη and more than 1 80 m iη Phemen omenex Luna 10 μl-hexyl 30-55% 巳 (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm An X 25 cm column and a UV detector at λ 214 and 254 nm (Varian Dynamax U VD 11) were provided to provide the ideal peptide of &gt;95% purity, which was determined by Rp-HPLC. Example 17 _ modified NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lhr-Teu-Tyr-Asp of the epsilon-amine group of the amino acid residue added to the kringle-5 Preparation of -Tyr-Lys-(Ns-MPA)-NH2.2TFA Using an automated peptide synthesizer, the following protective amino acid was added sequentially to Rink Amide MBHA resin: "^1〇〇1^ 5(Bagua)-〇H, Fmoc-Ty"(tBu)〇H, Fmoc-Asp(〇tBu)-OH, Fmoc-Tyr(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc_Pro_〇H, FmooAsn(Trt)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-

Tyr(t3u)〇H (step 1). In the deblocking of the Fmoc group, the N-terminus of the amino acid bound to the tree is prepared as 20% N-hexahydrogen in DMF. It is treated for about 1 5-20 minutes. The final step of resizing from the resin is carried out using the excision mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to give the desired product. </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; The selective deprotection of the Lys (Aloe) group was carried out manually, and by 3 dQ of Pd (PPh3) in a 5 mL CHCl3:NMM:H〇Ac (18:1:0.5) The solution was treated with 4 solutions for 2 hours (step 2). The resin was then washed with CHC13 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 X 5 mL). . The synthesis is then re-automated to add maleimide propionic acid (step 3). Between each coupling, the resin was washed three times with N,N-dimercaptomeric amine (DMF) and three-persons with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% of this thiol oxime and 5%, and then reprecipitated by dry-cold 玢 2 ( (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex Luna 10 μ phenyl with a flow rate of 9.5 mL/min and over 180 min. - 30-55% of hexyl B (prepared in water, 〇·〇 45% TFA (A) and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm column and λ A 214 and 254 nm UV detector (Varian Dynamax UVD II) was provided to provide the desired peptide of &gt;95% purity, which was determined by RP-HPLC. Example 1 8 - Improvement of the ε-amine group of the C-terminally deaminated amino acid residue added to kringle-5 - NAc-Arg-Asn-Pro-Asp-GIy-Asp-Val-Gly- Gly-Pro-T rp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Ty r-Asp- A 132- 1300414

Preparation of Tyr-Lys-(Ns-MPA)-NH2.3TFA

The following protective amino acids were sequentially added to Rink Amide MBHA resin using an automatic peptide synthesizer: Fmoc-Lys(Aloc)-〇H, Fmoc-Ty((tBu)〇H, FmooAsp(〇 tBu)-〇H, Fmoc-Tyr(tBu)OH, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fm〇c-Arg(Pbf)-〇H, Fmoc-Pro-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Tyr(tBu)〇H, Fmoc-Ala-〇H, Fmoc-Trp- 〇H, FmooPro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Va 〇H, Fmoc-Asp(OtBu)-〇H, Fmoc-Gly-〇H, Fmoc-Asp( 〇tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Asn(T"t)-〇H, Fmoc-A"g(Pbf)-〇H (Step 1). Deblocking of Fmoc group The N-terminus of the resin-bound amino acid is 20% N-hexahydrogen prepared in bMF, which is about 15 to 20 minutes longer than the bite base. The coupling of acetic acid is similar to that of the amino acid. The final step from the resin removal is carried out using the excision mixture as described above. The product is isolated by precipitation and purified by preparative HPLC to obtain the desired product, ie, after lyophilization. White The selective deprotection of the Lys (Aloe) group was carried out manually and by using 3 eq of Pd dissolved in 5 mL of CHCI3:NMM:H〇Ac (18:1:0.5) The (PPh3)4 solution was treated to treat the resin for 2 hours (step 2). Then, the resin was CHCi3 (6 χ 5 mL), 2% by weight of HOAc (6 X 5 mL) dissolved in DCM, DCM. (6 X 5 mL), and DK4F (6 x 5 address) - 133 - 1300414 for cleaning. Then the synthesis was re-automated to add 3 · cis-butyl diimine propionic acid (step 3). Between each hydration, the resin was washed three times with hydrazine, hydrazine-dimethylformamide (DMF) and three times with isopropanol. Using 85% TFA / 5% TIS / 5% stupyl The decane was cleaved from the resin with 5% phenol and then reprecipitated by dry-cold Et2 hydrazine. Step 4) The product was purified by preparative reverse phase HPLC. Use a Varian (Rainin) preparative double-effect HPLC system: use a 30-55% B of Phenomenex Luna 10 μ phenyl-hexyl which can be used at a flow rate of 9.5 mL/min and can be used for more than 180 min (prepared in water) 045% TF A (A) and A gradient dilution of 0.045% TFA (B) in CH3CN, a 21 mm X 25 cm column, and a UV detector at λ 214 and 254 nm (Varian Dynamax UVD II) to provide this &gt;95% The ideal peptide for purity, which is determined by RP-HPLC. Fjfe Example 19 - Modified C-terminal acyl-amino acid of the C-terminal amino acid residue on the kringle-5 - NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly- Gly-Pro-Trp-- Lys-(Ns-MPA)-NH2.TFA was prepared using an automatic peptide synthesizer, and the following protective amino acids were sequentially added to Rink Amide MBHA resin: "1 ^〇〇1^5(八丨〇〇)-〇H, Fmoc-Trp-OH, Fmoc-P“o-〇H, Fmoc-Gly-〇H, Fm〇c-Gly-〇H, Fmoc-Va OH, Fmoc-Asp(〇tBu)-〇H,

Fmoc-Gly-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Pro_〇H, one 134- 1300414

Fmoc-Asn(T"t)-〇H, Fmoc-Arg(Pbf)-〇H (Step 1) The selective deprotection of the Lys (Aloe) group is carried out manually, and is dissolved in one by one. 5 mL of CHCI3: NMM: 3 eq of H〇Ac (18:1:0.5)

The Pd(PPh3)4 solution was treated to treat the resin for 2 hours (step 2). After that, the resin was CHC13 (6 X 5 mL), 20% H〇Ac - (6 x 5 mL) dissolved in DCM, DCM (6 x 5 mL), and DMF (6 x 5 mL). To clean it. The synthesis is then re-automated to add 3-methyleneimine hydrazine to propionate (step 3). Between each coupling, the resin was washed three times with n,N-dimercaptocarbamimidyl (DMF) and three times with isopropanol. The resin was excised from the resin using 85 % TFA / 5% TIS / 5% thiol and 5%, and then killed by dry-cold Et2 ( (Step 4). The product was purified by preparative reverse phase HPLC using one

Varian (Rainin) Prepared Double-Effect HPLC System: Use a 30-55% P of Phenomenex Luna 10 μ Phenyl-Hexyl group with a flow rate of 9.5 mL/min and over 180 min (0.045% TFA prepared in water ( Α) with a gradient dilution of 0.045% TFA (B) prepared in CH3CN, a 21 mm x 25-cm column, and a UV detector (Varian . Dynamax UVD II) at λ 214 and 254 nm. This &apos;95% pure ideal peptide is provided which is determined by RP-HPLC. Example 20 - ε-by-group modification of the C-terminal amidoxime residue added to kringle-5 - NAc-Arg-Lys-Leu-T y r-As p-Ty r- Preparation of Ly s - (Νε-Μ PA)-NH2.2TFA A 13 5 - 1300414 The following protective amino acid was sequentially added to Rink Amide MBHA resin using an automatic sputum synthesizer: corpse! 〇〇1^5(八一〇(:)-〇H, Fm〇c-Ty“(tBu)〇H, Fmoc-Asp(〇tBu)-〇H, Fm〇c-Tyr(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, -Fm〇cA"g(Pbf)-OH (Step 1). In the deblocking of the Fmoc group, the resin-bound amino acid The N-terminal is treated with 20% N-rhodium hexahydro σ prepared in DMF for about 15-20 minutes. The light of acetic acid is carried out under conditions similar to those of the amino acid coupling. The resin ablation step was carried out using the excision mixture as described above. The product was isolated by thawing and purified by preparative HPLC to obtain the desired product, i.e., a white solid after cooling. The selective deprotection of the Lys (Aloe) group is carried out manually and by dissolving in 1 mL CHCI3: NMM: HOAc (18:1: 〇.5)*2 3 eq of Pd(PPh; 3)4 solution to treat the resin for 2 hours to complete (step; ^ 2). Then, the resin is ( :1^13(6 15 1^), soluble in 2% of 〇〇1^. H〇Ac (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 χ 5 mL·) • to clean it. The synthesis is then re-automated to add 3·cis-butyl diimine propionic acid (step 3). Between each coupling, the resin is Ν,Ν-dimethyl The guanamine group (DMF) was washed three times and washed three times with isopropyl alcohol. 甩 85% TFA / 5% butyl IS / 5% thiosulfanyl decane and 5% phenol were used to remove the resin from the resin, and then The dry-cold EtA is re-precipitated (step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system: using a flow rate of 1300414 9·5 mL/min and can use more than 180 min of Phenomenex Luna 10 μ of stupyl-hexyl 30-55% B (0.045% TFA U prepared in water) and 0.045% TFA (B) prepared in CH3CN) Gradient dilution, 21 mm x 25 cm column and detector at λ214 and 254 nm (Vari An Dynamax UVD II) to provide the ideal peptide of &gt;95% purity, which is determined by RP-HPLC. Example 21 - ε-based modification of the added C-terminal deaminating acid residue at the Kringle-5-NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(N8- The MPA)-NH2.2TFA was prepared using an automatic peptide synthesizer, and the following protective amino acid was sequentially added to Rink Amide MBHA resin': Fmoc_Lys(Aloc)-

〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ty"(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-A"g(Pbf)- 〇H,

Fmoc-Pro-OH (step 1). In the deblocking of the Fmoc group, the N-terminal of the resin-bound amino acid is treated with a 2% by weight of N_hexa-argon in DMF for about 15 to 20 minutes. The coupling of Gj3 into Gk is carried out under conditions similar to the coupling of the amino acid. The most self-extracting step of excision only from the mystery is performed using the excision mixture as described above. The thrift is separated from the precipitate by a predetermined product, and purified by P P C to obtain the product of the slave, that is, the white solid after lyophilization. Manually, the selective deprotection of the Lys (Aloe) group is performed as a 137-1300414 and by dissolving in a 〇11_〇3^~^1\/|:| The 3 eq Pd(PPh3)4 solution of -1〇8 (:18:1:0.5) was used to treat the resin for 2 hours (step 2). Then, the resin was CHC丨3 (6 X). 5 m L), 20% H〇Ac (6x5mL) dissolved in DC oxime, DCM (6x5mL), w&amp; DMF (6 x 5 mL) for cleaning. The synthesis is then re-automated to add 3- ^ Maleimide propionic acid (step 3). Between each coupling, the resin is washed three times with hydrazine, fluorenyl-dimercaptoamine (DM F) and bismuth isopropoxide Wash three times. Use 85% TFA/5% TlS/5% thioanisole and 5% aging to remove the sputum from the resin and then reprecipitate with dry-cold Et2(Step 4) The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex with a flow rate of 9.5 17117111丨11 and over 18〇111||1 Luna 10 μ phenyl-hexyl 30-55% Β (prepared in water 0.045 Gradient dilution of % TFA (A) with 0.045% TFA (B) prepared in CH3CN, 21 mm x 25 cm column and UV detector at λ214 and ^ 2 5 4 nm (V a "ian D ynama XUVDI i), to provide the ideal peptide of 95% purity, which is determined by rp-HPLC. f Example 22 - Kringle - 5 added C-terminal lysine Improvement of the ε-amino group of the residue NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Ns-AEEA-IVIPA)-NH2.2TFA using an automatic scoring synthesizer The protective amino acid is added to Rink Amide MBHA resin in the order of -138 - 1300414: 卩! 71〇〇1^3(八一〇〇)-〇H, Fmoc-Ty"(tBu)〇H, Fmoc-Asp(OtBu)-〇H, Fmoc-Ty"(tBu)OH, Fm〇c_Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Pro- 〇H (Step 1). In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid is treated with 20% N-hexahydropyridyl prepared in DMF for about 15-20 minutes. The acetic acid is carried out under conditions similar to those of the amino acid. The selective deprotection of the Lys (Aloe) group is carried out manually, and by dissolving in one of 5 1111 (3^1〇丨3^1\41^汨〇8. (18:1:0.5) The 3 eq Pd(PPh3)4 solution was used to treat the resin for 2 hours (step 2). The resin was then dissolved in 20% H〇Ac in DCM with CHC13 (6 X 5 mL). 6 X 5 mL), DCM (6 X 5 mL), and DMF (6 χ 5 mL) were cleaned. The synthesis was then re-automated. The synthesis was then re-automated to add AEEA (Amine B Oxyethoxyacetic acid) group and 3-m-butylenediamine propionic acid (MPA) (step 3). Resection of the resin and separation of the product make 甩85% TFA/5./.T1S/ 5% phenylthio brothel and 5% phenol, and then precipitated by dry-ice-cold hydrazine (step 4). The product is purified by preparative reverse hplc, which uses a Varian (Rainin) prepared double-effect HPLC system: using a Phenomenex Luna 10 μ stupid-hexyl 3〇·55% b with a flow rate of 9.5 mL/min and over 180 min (prepared in water 〇〇45 〇 /. TFA (Α) and prepared in CH3CN 0. A gradient dilution of 045% TFA (Β), a 21 mm x 25 cm column, and a UV detector at λ 214 and 254 nm (Varian Dynamax UVD II) - 139-1300414 1300414 (Step 4). Prepared by reversed HP LC for purification using a Varian (Rainin) preparative double-effect HPLC system: using a flow rate of 9.5 mL/min and over 180 min of use

Phenomenex Luna 10 μ phenyl-hexyl 30-55% B (0.045% octopus eight (eight) prepared in water and prepared in (31 &quot;13〇~中0.04 5〇/〇丁"八(Β)) Gradient dilution, 21 mm X 25 cm column and UV detector at λ 214 and 254 nm (Varian Dynamax UVD 11) f. Example 24 - Added C-terminal separation on GLP-1 Improvement of ε-amine group of acid residue GLP-1 (1-36)-Lys37(Ns-MPA)-NH2_5TFA#;

His-Asp-GIu-Phe-GIu-Arg-His-Ala-Glu-GIy-Thr-Phe-Thr-

Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-GIy-GIn-Ala-AIa-Lys-

Glu.Phe-IIe-Ala-Trp-Leu-Va|.Lys-Gly.Arg-Lys(N8-MPA)-

NH2.5TFA

The following protective amino acid was sequentially added to Rink Amide MBHA resin using an automatic peptide synthesizer: "171〇〇1^3(八丨〇〇)-〇H, FmooArg(Pbf)-〇 H, Fmoc-Gly-〇H, Fmoc-Lys(tB〇c)_〇H, Fmoc-Va, H, Fmoc-Leu-〇H, Fmoc-T “p-〇H, FmooAla-OH, Fmoc- lle-〇H, Fmoc-Phe-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Lys(tBoc)-〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc-Gln (T"t)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(OtBu)-〇H, Fmoc-Leu-〇H, Fmoc-Tyr(Pbf)- 1300414 〇H, Fmoc-Se"(tBu )-〇H, Fmoc-Se "(tBu)-〇H, Fmoc-Va 〇H, Fm〇c-Asp(〇tBu)-〇H, Fmoc-Se"(tBu)-〇H, Fmoc-Thr (tBu)-〇H, Fmoc-Phe-〇H, Fm〇c_Thr(tBu)-〇H, Fm〇c-Gly-〇H, Fmoc-Glu(〇tBu)-〇H, FmooAla-〇H,

Boc-His(N-Trt)-OH - Fmoc-Arg(Pbf)-OH - Fmoc-

Glu(OtBu)-〇H, Fmoc-Phe-〇H, Fmoc-Glu(〇tBu)-〇H,

Fmoc-Asp(〇tBu)-OH, Boc-His(N-Trt)_〇H (step 1). The selective deprotection of the Lys (Aloe) group is carried out manually, and by dissolving in a solution of 5 1! 11^ 〇 ^ 10 丨 3: 1 1/1[\1/1^〇八〇 The 3 eq [Pd(PPh3)4 solution in (18:1: 〇.5) was completed by treating the resin for 2 hours (step 2). The resin was then washed with CHC13 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 x 5 mL). . The synthesis is then re-automated to add 3-cis-butadiene and diimide-acrylic acid (step 3). The resection of the resin and the separation of the product were carried out using 85 % TFA/5% T1S/5% thiol oxime and 5% hop, and then precipitated by dry-cold EtsO (Step 4). . The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system: using a flow rate of 9.5 mL/min and using more than 18 〇 171 丨 11? (16 〇[116[16乂1&gt;11113 1〇4 stupid-hexyl 30 55% B (0.045% TFA (A) prepared in water and 0.04 5 % TFA (B) prepared in CH3CN) Gradient dilution, 21 mm X 25 cm column and UV detectors at λ214 and 254 nm (va "jan"

Dynamax UVD II). The product must have a purity of &gt;95% as determined by an RP-HPLC mass spectrometer using a continuous spectrometer with a Hewlett Packard LCMS-11 00 prepared with a secondary body - 142 1300414 array detector. And using an electrospray ionization method. These steps are described in the chart below.

Fmoc-Rink Amide MBHA Resin

Step carbonyl SPPS

Boc-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys(A!oc)-PS

Step 2j ^d(PPh.)./NMM/HOAc/CHCL

Boc-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-PS Step 3 3- Maleimide

〇

Boc-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-N Η〇 Step 4 W 85. /. TFA / 5% TlS / 5% thioanisole / 5 ° /. phenol

TFA

TFA

〇

TFA

H. N-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR- N H〇

TFA GLP-1 f1-36VLvs^fE-MPAVNH„

Example 25 The addition of the C-terminus on the GLP-1 to the ε-amino group of the acid residue. Preparation of GLP-1 (1-36)-Lys37 (Ns-AEEA-AEEA-MPA)-NH2.5TFA;

His-Asp-Glu-Phe-GIu-Arg-His-Ala-GIu-Gly-Thr-Phe-Thr-

Ser-Asp-Val-Ser-Ser-Tyr-Leu-Giu-Gly-GIn-Ala-AIa-Lys- -1 Λλ- 1300414 GIu-Phe-Ile-AIa-Trp-Leu-Va!-Lys-Gly- Arg-Lys (N8-AEEA-

AEEA-MPA)-NH2.5TFA Using an automatic peptide synthesizer, the following protective amino acid was added to Rink Amide MBHA resin: FmooLys(Aloc)- - 〇H, Fmoc-A"g (Pbf)-〇H, Fmoc-Gly-〇H, Fmoc-

Lys(tBoc)_〇H, Fmoc-Va 〇H, Fmoc-Leu-〇H, Fmoc-o Trp-〇H, Fmoc-Ala-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H , Fmoc-Glu(〇tBu)-〇H, Fmoc-Lys(tBoc)-〇H, Fmoc_Ala-〇H, Fnioc-Ala-OH, Fmoc-Gln(Trt)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc_Leu-〇H, Fmoc-Tyr(Pbf)·〇H, Fmoc_Ser(tBu)_〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Va〇H , Fmoc-Asp(〇tBu)-OH, FmooSer(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Gly- 〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Ala-〇H, 〇B〇c-His(N-Trt)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc- • Glu (〇tBu)-〇H, Fmoc-Phe-〇H, FmooGlu(〇tBu)-〇H, - Fmoc-Asp(〇tBu)-〇H, Boc-His(N-Trt)-〇H (Step 1 ). The selective deprotection of the Lys (Aloe) group is carried out manually, and by dissolving in a solution of 5 11^(^(313:~[\/^旧0八〇(18:1:〇.5) 3 eq of Pd(PPh3)4 solution was used to treat the resin for 2 hours (step 2). Then, the resin was CHC13 (6 X 5 mL), 20% H〇Ac dissolved in DCM. (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) were cleaned. The synthesis was then re-automation to add two aeea -144- 1300414 (amine ethoxylate B) Oxyacetic acid) group and the 3·cis-butyl diimide propionic acid (step 3). Resin removal and product separation using 85% tfa/5% TIS/5% thioanisole and 5 % phenol, and then by dry-cold Et2 沉 to kill (Step 4). The product was prepared by preparative reverse-phase HPLC to 'pure', the HPLC system uses an x/arian (Rainin) Prepare double effect. HPLC system: use a flow rate of 9·5 mL / min and make 甩 more than 1 80 ^ 11 door 卜 〇〇 〇〇 16 door to 1 ^ door 3 10 phenyl-hexyl 30-55. / 8. (Prepared in water, 〇 〇 45% TFA (A) and 0.045% TFA prepared in CH3CN (B)) Gradient dilution, 21 mm x 25 cm column and UV detector at λ 214 and 254 nm (va "jan Dynamax UVD II". This product must have a purity of > 95% determined by rP_HPLc mass spectrometer The mass spectrometer is a continuous spectrometer equipped with a Hewlett Packard LCMS-11 二级 with a two-dimensional array detector and an electrospray ionization method. The ESHMS m/z is C174H26, 5N44〇56 (MH + ), the calculated value is 3868, the actual value is [m + H2] 2 1934, [M + H3] 3 + 1 290, 〇 [M + H4] 4 + 967. These steps are described in the following chart. -145* 1300414

Fmoc-Rink Amide MBHA Resin

Step 琛 SP SPPS

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys(Aloc)-PS 2) vPd(PPh.)./NMM/HOAc/CHCl.

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-PS Step carbonyl 3l 1 · FmooAEEA-〇H (2 times) 2. 3-m-butylene-K-imine-propionic acid Hf

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-

〇 〇

〇 Step 4l 4 85% TFA/5% HS/5. /. Phenylthiol disease / 5%® 〇 〇

TFA TFA TFA H.N-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR- 〇

CCi-1051 TFA GLP-1 (7-36-Κ(ΑΕΕΛ,-ΜΡΑ))-ΝΗ.

Example 26 Improvement of the ε-Amine Group of the C-Terminal Amino Acid Residue Added on GLP_1

Preparation of GLP-1 (7-36)-Lys37(Ns-MPA)-NH2.4TFA His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-GIn-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys(Ns-MPA)-NH2.4TFA using an automatic peptide synthesizer, The following protective amino acids are added sequentially to Rink Amide MBHA resin: Fmoc-Lys(Aloc)- -146 1300414

〇H, Fmoc-A "g(Pbf)-〇H, Fmoc-Gly-〇H, Fmoc-Lys(tB〇c)-〇H, Fm〇c-Vah〇H, Fmoc-Leu-〇H, Fm 〇c-Trp-〇H, Fmoc-Ala-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, FmooGlu(〇tBu)-〇H, Fmoc-Lys(tBoc)-OH, Fmoc-Ala -〇H, Fmoc-Ala-〇H, Fmoc-Gln(T"t)-OH, Fmoc-Gly-〇H, Fmoc-Glu(OtBu)-OH &gt; Fmoc-Leu-OH &gt; Fmoc-Tyr( Pbf)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc_Ser(tBu)-OH, Fmoc-Va 〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H , Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Ala- 〇H, Boc-His(N-Trt)-〇H (Step 1). The selective deprotection of the Lys (Aloe) group is carried out manually, and by dissolving 1 mL of CHCl3:NMM: 3 eq of Pd(PPh3)4 solution in H〇Ac (18:1:0.5) was treated to treat the fat for 2 hours (Step 2). Then the resin was CHC13 (6 X 5 mL). It was dissolved in 20% H〇Ac (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) dissolved in DCM. The synthesis was then re-automated to add the cis. Ding Aminopropionic acid (step 3). Resin removal and product separation using 85 % TF A/5 % T丨S/5 % 笨 曱 与 与 5% 5% 以及 以及 以及 以及 以及 以及 以及 以及EhO is precipitated (step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect Η P LC system: using a flow rate of 9.5 m L /mi η and can use more than 18〇171丨9116 threshold [716[16乂1«11 door 3 1 mouth phenyl-hexyl 30-55% Β (prepared in water 〇〇45〇/〇 Gradient dilution of TFA (Aj with 0.045% DFA (B) prepared in -147 — 1300414 CH3CN), 21 mm x 25 〇yang column, and 11/detector at 214 and 254 thresholds (\/3"丨311

Dynamax UVD 1丨). The product must have a purity of &lt;95 % determined by an rp-HPLC mass spectrometer using a continuous spectrometer with a Hewlett Packard LCMS-11 00 prepared with a secondary body barrier detector. An electrospray ionization method is used.

Preparation of ε-amino group of C-terminal deaminating acid residue added to ±MM27 - GLP-1 Preparation of GLP-1 (7-36)-Lys37 (Ns-AEEA_AEEA-MPA}-NH2-4TFA

His-Ala-GIu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-

Leu-GIu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-

Val-Lys-Gly-Arg-Lys(N8-AEEA-AEEA-MPA)-NH2.4TFA The following protective amino acid was added to Rink Amide MBHA resin using an automatic peptide synthesizer: 11!〇〇1^5(八丨〇〇)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-〇H, Fmoc-Va〇H, Fmoc-Leu-〇H, Fmoc-Trp-〇H, Fmoc-Ala-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Lys( tBoc)-〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc- Leu-〇H, Fmoc-Tyr(Pbf)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc--148- 1300414

Va 〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fm〇c-Th“(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr( tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Ala-〇H,

Boc-His(NT"t)-〇H (Step 1). - The selective deprotection of the Lys (Aloe) group is preferably carried out manually, and by dissolving in a solution of 5 1^ [&quot;1(:丨3:~^^1\/1 3 eq of Pd(PPh3)4 solution in 〇8 (:(18:1:0.5)) to process the resin for 2 hours to complete (step Ό 2). Then the resin is CHC13 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 x 5) The synthesis is then re-automated to add two AEEA (amine ethoxyethoxyacetic acid) groups and the 3-cis-butane diimine propionic acid (step 3). The resection of the resin and the separation of the product were carried out using 85% TFA / 5% TIS / 5% thiosulfanyl decane and 5% phenol, and then by dry-cold Ets 〇 (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative ruthenium double-effect HPLC system: using a flow rate of 9.5 mL/mi η and using - over 1 80 min Phenomenex Luna 1 0 μ Phenyl-hexyl 30, 55% Β (0.045% TFA prepared in water (Α) Gradient dilution of 0.045% TFA (B) prepared in CH3CN, 21 mm X 25 cm column and 11/detector in 214 and 254 thresholds (\/3 "1311〇7 door 31113 Parent UVD 11). The product must have a purity of >95% determined by Rp_HPLC mass spectrometer. The mass spectrometer uses a continuous spectrometer with a Hewlett Packard LCMS-1100 equipped with a two-level array detector. Use electrospray ionization method. ·· 149- 1300414

Example 28 - E-Ala2 GLP-1 (7-36)-Lys37(NbMPA)-NH2.4TFA of the C-terminal deaminating acid residue added to D-Ala2 GLP-1 System

His-d-AIa-Glu-GIy-Thr-Phe-Thr-Ser-Asp-Val-

Ser-Ser-Tyr-Leu-Glu-Gly-Gln-AIa-Ala-Lys-Glu-

Phe-Ile-AIa-Trp-Leu-Val-Lys-Gly-Arg-

Lys(Ns-MPA)-NHh2.4TFA

The following protective amino acid was sequentially added to Rink Amide MBHA resin using an automatic peptide synthesizer: "17!〇〇1^5(八1〇€:)-〇H, FmooA"g( Pbf)-〇H, Fmoc-Gly-〇H, Fmoc-Lys(tBoc)-OH-Fmoc-Val-OH &gt; Fmoc-Leu-OH &gt; Fmoc-Trp-OH, Fmoc-Ala, 〇H, Fmoc -rle-〇H, Fmoc-Phe-〇H, Fmoc_Glu(〇tBu)-〇H, Fmoc-Lys(tBoc)-〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc_Gln(T" t)-〇H, Fmoc-Gly-〇H, Fmoc_Glu(〇tBu)-〇H, Fmoc-Leu-〇H, Fmoc-Tyr(Pbf)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc -Ser(tBu)-〇H, Fmoc-Va, 〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Se"(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc- Phe-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-d-Ala-〇H,

Boc-His(N-Trt)-〇H (step 1). The selective deprotection of the Lys (Aloe) group was carried out manually, and by dissolving one of 15 in CHC 3:NMM:H〇Ac (.18:1:0·5) The 1300414 3 eq Pd(PPh3)4 solution was used to treat the resin for 2 hours (step 2). The resin was then washed with CHC13 (6 X 5 mL), o〇9c H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 X 5 mL). It. The synthesis is then re-automated to add 3-maleimide propionic acid (step 3). The resection of the resin and the separation of the product were carried out using 85% TFA / 5% TIS / 5% phenylthio decane and 5% phenol, and then precipitated by dry-cold Eta oxime (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex LunalOp phenyl-hexyl group with a flow rate of 9.5 mL/min and over 180 min. 30-55% B (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mmx25 〇〇! column and 214 and 254 gates 111 1]\/detector (\/3 "丨3 Dynamax UVD II). The product must be determined by rP_hplc mass spectrometer > 9 5 % purity 'The mass spectrometer uses one prepared two The Hewlett Packard LCMS-11 〇〇 continuous spectrometer of the Array Array Detector and the electrospray ionization method are used. These steps are described in the following chart: 1 1 51 - 1300414

Fmoc-Rink Amide MBHA Resin SPPS Steps 1

Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys(Aloc)-PS 2 )]pd(PPhJ ,/NMM/HOAc/CHCL

Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-PS Step 3,

Boc-HaEGTRSDVSSYLEGQAAKEFlAWLVKGR- N • H 〇 3-m-butyleneimine-propionic acid

Step 4U 85°/. TFA/5% TIS/5% phenylthiocarbazone/5% phenol

TFA

TFA

TFA

〇 NH«

K N-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR- N H〇 TFA D-Ala^GLP-1 (7-36)-Lvs^fE-MPAVNH.

Example 29 - Modification of the ε-amine group of the C-terminal deaminating acid residue added to D-Ala2 GLP-1 - D-AIa2 GLP-1 (7-36)-Lys37 (Ns-AEEA- AEEA-MPA)-^ NH2.4TFA preparations His-D-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-GIn-Ala- Ala-Lys-Glu-Phe-lIe-AIa-Trp-Leu-Val-Lys-Gly-Arg-Lys (Νε-ΑΕΕΑ-ΑΕΕΑ-ΜΡΑ)-NH2.4TFA using an automatic peptide synthesizer, the following protection Amino acid system-I 52- 1300414 〇

Add to Rink Amide MBHA resin: "[71〇〇1^5(八一〇(:)-OH - Fmoc-Arg(Pbf)-OH ^ Fmoc-Gly-OH - Fmoc-Lys(tBoc)-OH - Fmoc-Val-OH - Fmoc-Leu-OH 'Fmoc-T"p-〇H, Fmoc-Ala-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, FmooGlu(〇tBu)-〇 H, Fmoc-Lys(tBoc)-〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc-Gln(T“t)-〇H, Fmoc-Gly-〇H, Fmoc-Glu(OtBu )-OH &gt; Fmoc-Leu-OH - Fmoc-Tyr(Pbf)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Va〇H, Fmoc- Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Gly- 〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-d-Ala-〇H, Boc-His(NT“t)-OH (Step 1). Selective deprotection of the Lys (Aloe) group The effect is carried out manually and is treated by a solution of 3 eq of Pd(PPh3)4 dissolved in 118(:(18:1:0.5) The resin was completed in 2 hours (Step 2). Then the resin was CHC13 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL) And DMF (6 X 5 mL)

To clean it. The synthesis is then re-automated to add two AeeA (amine ethoxyethoxyacetic acid) groups and the 3-methyleneimine propionate (step 3). Resin removal and product separation using 85% tfa/5%

TlS/50/. The stupid thiol smoldering is carried out with 5%, and then precipitated by dry-cold Et2 hydrazine (step 4). The product was purified by preparative reverse hpLC using a va "丨aη (rajηjpj) prepared double-effect Η P LC system using a flow rate of g · 5 m L / min and using more than ί 8〇一153 - 1300414

171 towel? [1011〇1110门六父1^1!3 1〇Phenyl-hexyl 3〇-55%8 (0.045% TFA prepared in water (A) and 0,045% TFA (B) prepared in CH3CN) Gradient dilutions, 21 mm x 25 cm column and UV detectors at λ214 and 254 nm (Varian Dynamax U VD I 丨). The product must have a purity of &gt;95% as determined by an RP-HPLC mass spectrometer using a continuous spectrometer of Hewlett Packard LCMS-1100 equipped with a two-level array detector and use of electricity Spray ionization method. These steps are described in the chart below. step 1

Fmoc-Rink Amide MBHA Resin SPPS

BooHaEGTFTSDVSSYLEGQAAKEFlAWLVKGR-Lys(A!)-PS

Step 2] JPd(PPK)./NMM/HOAc/CHQ

Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-

Boo 1. Fmoc-AEEA-〇H (2 times) 2. 3-cis-butyl quinone diimine propyl hydrazine

, PS 〇 4) I 85% TFA / 5% TIS / 5% phenylthiomethyl building / 5 ° /. phenol

TFA TFA

PS 〇 ΊΤΑ hi. N-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGRjl

TFA

D-AlaOLP-1 f7-36VLvs&quot;fE-AEEA.-MPAVNI-L-154- 1300414 f Example 30 _ Essen ingot-4 (1-39) added C-terminal amide acid residue Improvement of ε-amine group

Preparation of Essen ingot-4 (1-39)_Lys4Q(Ns-MPA)-NH2; His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-Met- Glu-Glu-GIu-AIa-Val-Arg-Leu-Phe-lIe-Giu-Trp-Leu-Lys-Asn-GIy-GIy-Pro-Ser-Ser-Gly-AIa-Pro-Pro-Pro-Ser- Lys (Ns-MPA)-NH2.5TFA

The following protective amino acid was sequentially added to Rink Amide MBHA resin using an automatic peptide synthesizer: "^1〇〇1^5, (八一〇〇:)-〇H, FmooSer(tBu )-〇H, Fmoc-Pro-〇H, Fmoc-P "o-〇H, Fmoc-Pro-〇H, Fmoc-Ala-〇H, Fmoc-Gly-OH, Fmoc-Se"-〇H, Fmoc -Ser(tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Glu(〇tBii)-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu-〇H, Fmoc-Arg(Bpf) -〇H, Fmoc-VahOH'Fmoc-Ala-〇H, FmooGlu(〇tBu)-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Met- QH, Fmoc-Gln(Trt)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Leu-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fm〇c-Thr(tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Glu( 〇tBu)-〇H, Fmoc-Gly-〇H, Boc-His(T"t)-〇H (Step 1). A 155-1300414 The selective deprotection of the Lys (Aloe) group is preferred. Manually and by dissolving in 5 mL CHCI3: NMM: 3 eq of Pd (PPh3) 4 solution in H〇Ac (18:1:0 5) to treat the fat for 2 hours (step 2). Then, the resin is CHCI3 (6) X 5 mL), 20% H〇Ac (6x5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) dissolved in DCM were washed. The synthesis was then re-automated to add two AEEA ( Amine ethoxyethoxyacetic acid) group and the 3 - cis-butyl iodide propan acid (step 3). Resin removal and product separation using 85% TFA / 5% TIS / 5% benzene The thiodecane is reacted with 5% phenol, and then by dry-cold Eh〇 (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) Preparative double-effect Η P LC system: use a 30-5% hydrazine of Phenomen ex Luna 10 μ phenyl-hexyl group with a flow rate of 9 · 5 m L/mi η and can be used for more than 180 min (prepared in water) 〇·〇450/: TFA (Α) with a gradient dilution of 0.045% TFA (B) prepared in CH3CN, a 21 mm χ 25 cm tube column, and a UV detector for humans 214 and 254 _ (Varian Dynamax * UVD丨丨). The product must have a purity of 95% by RP-HPLC mass spectrometer using a Hewlett Packard LCMS-11 00 continuous spectrometer with a two-dimensional array detector and use Electrospray ionization method. These steps are described in the chart below. -156- 1300414

Fmoc-Rink Amide MBHA Resin

Step 1 SPPS

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-Lys(Aloc)-PS

lvPd(PPhJ,/NMM/HOAc/CHCL

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-Lys-PS Steps

Boc-HGEGTFTSDLSKQMEEEAVRLF!EWLKNGGPSSGAPPPS-N Η〇 3-m-butyleneimine-propionic acid

PS ^4]] 85% TFA/5% TlS/5% phenylthioformamidine / 5% phenol

TFA

H. N-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS- N H〇

TFA

Exendin*4 (1-39VLvs...(Ε-ΜΡΑ)-ΝΗλ

PS

TFA

TFA Example 31 - Modified Eisen ingot-4 (1-39)-Lys4° (Ns) of the ε-amine group of the C-terminal deaminating acid residue added to Essen ingot-4 (1·39) -AEEA-AEEA-MPA)-NH2.5TFA preparation;

His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-

Met-Glu-Glu-Glu-AIa-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-

Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-

Lys(Ns-AEEA-AEEA-MPA)-NH2.5TFA -157- 1300414 using an automatic peptide synthesizer, the following protective amino acid system

Add to Rink Amide MBHA resin: "〇1〇〇1^5(八丨〇(:)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Pro-OH, Fmoc-Pro-〇H , Fmoc-Pro-OH ^ Fmoc-Aia-OH &gt; Fmoc-Gly-OH &gt; Fmoc-Ser-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇 H, Fmoc-Gly-〇H, Fmoc_Asn(Trt)-〇H, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Trp-〇H, Fmoc-G mountain(〇tBu)-〇H , Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu-OH ^ Fmoc-Arg(Bpf)-〇H &gt; Fmoc-Val-OH ^ Fmoc-Ala-〇H, Fmoc-Glu(OtBu )-〇H, Fmoc-Glu(〇tBu)-〇H, FmooGlu(〇tBu)-〇H, FmooMet_〇H, FmooGln(Trt)-〇H, Fmoc_Lys(Boc)_〇H, Fmoc_Ser(tBu) -OH, Fmoc-Leu-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc- Thr(tBu)-〇H, Fmoc-Gly-〇H, Fmoc_Glu(〇tBu)-〇H, Fmoc_Gly-〇H,

Boc, His (T "t) - 〇H (step 1). 'The selective deprotection of the Lys (Aloe) group is preferably carried out manually" and by dissolving CHCI3:NMM in 5 mL: 3 eq of Pd(PPh3)4 solution in H〇Ac (1 8:1:0.5) was used to treat the resin for 2 hours (step 2). Then the resin was CHCI3 (6 X 5 mL), It was washed in 20% H〇Ac (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 λ 5 mL) in DCM. The synthesis was then re-automated to add two AEEA (Amine ethoxyethoxyacetic acid) group and the 3-cis-butyl bis-imide propionic acid (step 3). Resection of the resin and separation of the product using 85 〇 / 〇 -1 S8 - 1300414 TFA /5% TIS / 5% phenylthio decane and 5% phenol, and then precipitated by dry ice-cold Ets ( (Step 4). The product is purified by preparative reverse Η P LC This ΗPLC system uses a Va ri an (Rai ni η) preparative double-effect HPLC system. · Use a Phenomenex Luna 1 0 μ • Stupid base with a flow rate of 9·5 mL/min and a enthalpy of more than 180 min. -35% of hexyl _ 55% Β (0.045% TFA (Α) prepared in water and Prepare a gradient dilution of 0.045% TFA (B)> in CH3CN, 21 mm X 25 cm tube branch, and enter the 214 and 254 gates! 11 11/detector (\/3 "丨311〇7 gates 3〇13父UVD II). The product must have a purity of &gt;95% determined by the rP_hplC mass spectrometer using a Hewlett Packard LCMS-11 00 prepared with a two-level array detector. Continuous spectrometers and electrospray ionization methods are used. These steps are described in the following chart: -159- 1300414

Fmoc-Rink Amide MBHA Tree 3

SPPS

Boc-HGEGTFTSDLSKQMEEEAVRLF!EWLKNGGPSSGAPPPSLys(Aloc)-PS Huimin? I ^PdfPPh^^/NMM/HOAc/CHCl^

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSLys-PS 1. Fmoc-AEEA-OH (2 times) 〇

〇 2. 3-butylene quinolate

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSf Light·g il j 85°/. ΤΡΑ/5% TIS/5% phenylthioformamidine/5% phenol

TFA

TFA

TFA

H^HGEGTTTSDLSKQMEEEAVRLF 丨 EWLKNGGPSSGAPPPSq TFA

〇 〇

Fyftndin-4 v.^〇rF-AFFA.-MPAVNH. Example 32 - Addition of C-terminal lysine residues on Eisen ingot-3 (1-39)

Improvement of ε-amine group of Eisen ingot-3 (1-39)-Lys4° (Nk-MPA}-NH2-5TFA;

His-Ser-Asp-GIy-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-

Met-Glu-Glu-GIu-AIa-Val-Arg-Leu-Phe-lle-Giu-Trp-Leu-

Lys-Asn-Giy-GIy-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-

Lys(Ns-MPA)-NH2.5TFA was added to Rink Amide MBHA resin using an automatic peptide synthesizer, Fmoc, Lys (Aloc) - 1 60 - 1300414

〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Pro-〇H, Fmoc-P “o-〇H, Fm〇c-Pro-〇H, Fmoc-Ala-〇H, Fmoc-Gly-〇 H, Fmoc-Se "-〇H, Fmoc-Ser(tBu)_〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn(Trt)-〇H , Fm〇c-Lys(B〇c)-〇H, Fmoc-Leu-〇H, Fmoc-Trp-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-lle-〇H, Fmoc-Phe -〇H, Fmoc-Leu-OH - Fmoc-Arg(Bpf)-OH ^ Fmoc-Val-OH &gt; Fmoc-Ala-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Glu(〇tBu )_〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Met-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Lys(Boc)-〇H, FmooSer(tBu)-〇H , Fmoc-Leu_〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr( tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(〇tBu)-〇H, Boc-His(Trt)-〇H (Step 1) / The The selective deprotection of the Lys (Aloe) group is preferably carried out manually and by using 3 eq of Pd (PPh) dissolved in 5 mL of CHCI3:NMM:H〇Ac (18:1:0.5) 4) The solution is treated to treat the resin for 2 hours (step 2). Then, the resin is CH C丨3 (6 X 5 m L), 20% H〇Ac (6x5mL) dissolved in DC 、, DCM (6x5mL), ai DMF (6 x 5 mL) for cleaning. Then, the synthetic system was re- Automated to add 3-m-butyleneimine propionic acid (step 3). Resin removal and product separation using 85% TFA / 5% TIS / 5% stupyl decane and 5 〇 / phenol And then by dry-cold Et2〇 to the temple (step 4). The product is purified by preparative reverse phase HPLC using a one-161-1300414

Va ri a η (R aini η) prepared double effect Η PLC system: use a flow rate of 9.5 ^) 1_ / 11 ^ door and can use more than 18 〇 [7 ^ 卩 ^ 1011 〇〇 10 door 6 father 1 ^113

30 μM of 10 μl-hexyl group B (0.045% TFA (Α) prepared in water and 0.045% TFA (Β) prepared in CH3CN), 21 mm×25 cm column and λ214 and 254 Nm UV detector (Varian Dynamax UVD II). The product must have a purity of &gt;95% as determined by RP-HPLC mass spectrometry using a continuous spectrometer with a Hewlett Packard LCMS-00 00 equipped with a two-level array detector and use of electricity Spray ionization method. These steps are described in the chart below.

Fmoc-Rink Amide ΜΒΗΑ Resin

Step carbonyl lj SPPS V

H.N-HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-PS Step Xue 2jv 85°/. TFA/5% TIS/5. /. Phenylthiophene / 5% phenol

TFA TFA TFA hLN-HSDGTFTSDLSKQMEEEAVRLF 丨 EWLKNGGPSSGAPPPS- mess

TFA

Exendin-3 (1-39)-NH. Example 33 - Modified Eisen ingot-3 of the ε-amine group of the C-terminal deaminating acid residue added to Essen ingot-3 (1-39) Preparation of (1-39)-Lys40(Ns-AEEA-AEEA-MPA)-NH2.5TFA; 162-1300414

His-Ser-Asp-GIy-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn- IVlet-Glu-Glu-Glu-Ala-VahArg-Leu-Phe-lle-Glu-Trp-Leu-

Lys-Asn-GIy-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-

Lys(Ns-AEEA-AEEA-MPA)-NH2.5TFA p makes a weekly peptide synthesizer, and the following protective amino acid is sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Aloe)- • μ, Ο 〇Η, Fmoc-Ser(tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Pro-〇H, Fmoc-Pro-〇H, Fmoc-Ala-〇H, Fmoc_Gly-〇H, Fmoo Ser-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Lys (Boc)-〇H, Fmoc-Leu-〇H, Fmoc-Trp-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu- OH ^ Fmoc-Arg(Bpf)-〇H &gt; Fmoc-Val-OH ^ Fmoc-Ala-〇H, Fmoc-Glu(〇tBu)-〇H, Fmoc-Glu(〇tBu)-〇H, )Fmoc -Glu(〇tBu)-〇H, Fmoc-Met-〇H, Fmoc-Gln(Trt)- - OH 'Fmoc-Lys(Boc)-OH &gt; Fmoc-Ser(tBu)-OH &gt; Fmoc- Leu-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-〇H &gt; Fmoc-Phe-OH &gt; Fmoc-Thr(tBu) -OH &gt; Fmoc-Gly-〇H, FmooAsp(〇tBu)_〇H, Fmoc-Se"(〇tBu)_〇H, Boc-His(Trt)-〇H (Step 1). The Lys (Aloe The selective deprotection of the group is preferred Manually performed 'and treated with 2 eq of Pd (PPh3) 4 solution dissolved in 5 mL of CHC丨3:NMM:H〇Ac (18:1:0.5) And complete (steps 1 163 - 1300414, step 2). Then the 'fef ticks are CH C1 :, ( 6 x 5 m L), dissolved in DC Μ 20% H〇Ac (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 xs mL) were alpha washed. The synthesis was then re-automated to add two AEEA (amine ethoxyethoxyacetic acid) groups and the cis-butane Di-imine propionate (step 3). Resin removal and product separation were performed using 85 〇/. TF A/5 % T丨S/5 % thioanisole was calcined with 5%, and then precipitated by dry ice-cold Et2〇 (Step 4). The product is prepared with a reverse latch (3 to purify the '^^匕0 system using a \/3" 13 [1 (Min 3丨11丨门) prepared double-effect ΗPLC system: using a flow rate It is 9·5 mL/miη and can be used for more than 180 min of Phenomenex Luna 10 μ phenyl-hexyl 3〇-55% 巳 (prepared in water 0.045% butyl "eight (eight) and prepared in (^3〇~ Gradient dilution of 0.045% TFA (Β)), 21 mm X 25 cm column, and UV detector (VarianDynamax UVD丨丨) at λ214 and 254 nm. The product must be determined by RP-HPLC mass spectrometer. &gt; 95% purity, the mass spectrometer uses a continuous spectrometer with a Hewlett Packard LC MS-1100 equipped with a two-dimensional array detector and an electrospray ionization method. Example 34 - H1V-1DP178 Modification of the improved HIV-1 DP 178 anti-snoring sputum on the C-terminus; Tyr-Thr-Ser-Leu-lie-His-Ser-Leu-Ile-GIu-Glu-Ser-GIn- Asn-GIu-Glu-Giu-Lys-Asn-Glu-GIu-GIu-Leu-Leu-Glu-Leu-Asp-Lys-Trp_Ala-Ser_Leu_Trp-Asn-Trp_Phe-Lys-( Νε_ ΜΡΑ)-ΝΗ2 一ι 6厶One 1300414

The following protective amino acid was sequentially added to Rink Amide MBHA resin using an automatic peptide synthesizer. Fmoc-Lys(Mtt)-〇H, Fm〇c-Phe-〇H, FmooTrp (Boc )-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-T"p(Boc)_〇H, Fmoc-Leu-〇H, Fmoc, Ser(tBu)-〇H, Fm〇c-Ala- 〇H, Fmoc-Trp(Boc)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Asp(tBu)-〇H, FmooLeu-〇H, Fmoc-Glu(tBu)-〇H, Fmoc- Leu-OH, Fmoc-Leu-〇H, Fmoc-Glu(Tbu)-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Asn(Trt)-OH, FmooLys(Boc)-〇H, Fmoc-Glu(tBu')-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Asn(T“t)_ 〇H , Fmoc-Gln(T"t)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Glu(tBu)-〇H, Fmoc_Glu(tBu)-〇H, Fmoc-lle-〇H, Fmoc- Leu-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-His(Trt)-〇H, Fmoc-lle-〇H, Fmoc-Leu-〇H, Fmoc-Ser(tBu)-〇H, Fmoc -Thr(tBu)-〇H and Boc-Tyr(tBu)-OH. The subsequent steps use artificial synthesis: selective removal of the Mtt group and use of ^^7^ in the DMF. /0 The activation of the old eight and the car Dimethyleneimine propionic acid (MPA). The target molecule is removed from the resin; the product is isolated by a sump and purified by preparative hydrazine P LC to obtain the desired product, ie, lyophilization </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt;

Asn-Asn-Leu-Leu-Arg-AIa-IIe-Glu-Ala-Glu-GIu-His-Leu-Leu-Glu-Leu-Thr-VahTrp-Glu-lle-Lys-Glu-Leu-Glu-Ala- Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-L^u-Lys-Asp-GIu-Lys-(Νε-ΜΡΑ)ΝΗ2

The following protective amino acid was sequentially added to Rink Amide resin using an automatic peptide synthesizer: "111〇〇Lys(Mtt)-〇H, Fmoc-Gln(Trt)-〇H, FmooAsp (tBu)-OH, Fmoc-Lys(Boc)_〇H, Fmoc-Leu-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Arg(Pbf)-〇H, FmooGlu(tBu)-OH, Fmoc-Va OH, Fmoc-Ala-〇H, Fmoc-Leu-〇H, Fmoc-lle-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Ala-〇H, Fmoc-Gln(Trt) -〇H, Fmoc-Leu-〇H, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-〇H, Fmoolle-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Trp(Boc )-〇H, Fmoc-Va^OH, Fmoc-Thr(tBii)-OH, Fmoc-Leu-〇H, Fmoc-Gln(Trt)_OH, Fmoc-Leu-〇H, Fmoc-Leu-〇H, Fm〇c_His(Trt)-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Gln(Trt)-〇H, Fmoc-Ala-〇H, Fmoc-Glu(t巳u)-〇H, Fmoc -lle-〇H, Fmoc-Ala-〇H, Fmoc-A"g(Pbf)-〇H, Fmoc-Leu-〇H, Fmoc-Leu-〇H, Fmoc, Asn(Trt)-〇H, FmooAsn (Trt)-〇H. The subsequent step is to use artificial synthesis: selective removal of the Mtt group and activation of HBTU/H〇Bt/DlEA in DMF to couple the maleicene Propionate (ΜPA). The standard class -166-1300414 is removed from the resin; the product is isolated by precipitation and purified by preparative [_1[3匕〇 to obtain the desired product , that is, a white solid after lyophilization. 2. Improvement on the end of therapeutic peptide

Exemption Example - Improvement on the amine group added to the amine residue on the RSV wins version (Ns-MPAI-Lys-VaMIe-Thr-Ile-Glu-Leu-Ser-Asn- lle-Lys-Glu-Asn-Lys-Met-Asn-GIy-Aia-Lys-Val-Lys-Leu-lIe-Lys-Gln-Glu-Leu-Asp-Lys-Tyr_Lys-Asn-Ala-Val The improved RSV is better than the 100 pmole grade solid phase synthesis method using artificial solid phase synthesis, the Symphony peptide synthesizer, and the Fmoc protective Rink Amide MBHA. The protective amino acid is added to the resin in sequence: Fmoc-Va^OH, Fmoc-Ala-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc- Tyr(tBu)-〇H, Fmoc-Lys(Boc)-OH, Fmoc-Asp(tBu)-OH-Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH - Fmoc-Lys(Boc)-OH - Fmoc-lle-OH ^ Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Va 〇H, Fmoc-Lys(B〇c)-OH, Fmoc-Ala-〇H, Fmoc-Gly-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Met-〇H, Fmoc-Lys(Boc)-〇H,

Fmoc-Asn(T"t)_〇H, Fmoc-Glii(tBLi)-〇H, Fmoc--167- 1300414

Lys(Boc)-〇H, Fmoc-lle-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Se“(tBu)-〇H, Fmoc-Leu-〇H, FmooGlu(tBu)-〇H , Fmoc-lle-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-lle-〇H, Fm〇c-Va, H, Fm〇c-Lys(Aloc)-〇H. Disperse in dimercaptomethylamine (DMF), and use 〇-曱醯曱醯 azide small group-N,N, NVN·-tetradecyl-urea cation hexafluorophosphate (HBTU) and diiso Activated by propylethylamino (DIEA). The removal of the Fmoc protective group uses 20% (V/V) N- dissolved in N,N-dimercaptononylamine (DMF). The solution of the hexahydroacridinyl group is effected for 20 minutes (step 1). The selective deprotection of the Lys (Aloe) group is carried out manually, and by dissolving in a 5 mL portion of CHCl3 : NMM : H〇 The 3 eq Pd(PPh3)4 solution in Ac (18:1:0.5) was treated with the resin for 2 hours (step 2). Then, the resin was dissolved in DCM with CHCl3 (6 X 5 mL). 20% H〇Ac (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) were used for cleaning. The synthesis was then re-automated to add maleicene. Aminopropionate Step 3). Between each coupling, the resin was washed three times with N,N•dimercaptoalkylamine (DMF) and three times with isopropanol. Using 85% TFA/5% TIS/5% The peptide is cleaved from the resin with 5% phenol and then reprecipitated by dry-ice cooling (step 4). The product is purified by preparative reverse phase HPLC. The HPLC system uses a Varian (Rainin) preparative double-effect HPLC system: a 30-55% hydrazine of Phenomenex Luna 10 μ phenyl-hexyl which can be used at a flow rate of 9·5 mL/min and can be used for more than 180 min. A gradient dilution of 45% TFA (Α) with 〇·〇 45% TFA (B) prepared in CH3CN, a 21 r-168-1300414 mmx25 cm column and UV detection at λ214 and 254 nm A Varian Dynamax UVD II was provided to provide the ideal version of the &gt;95% purity, which was determined by RP-HPLC. The N-terminal lysine residue added to the ridge MIZ-neuropeptide Improvement on the ε-amine group (N-BMPA)-Lys-Tyr-Pro-Ser-Lys-Pro-Glu-Asn-Pro-Gly-GIu-Asp-Ala-Pro-Ala-Glu-Asp-Met Preparation of -Ala-Arg-Tyr-Tyr-Ser-Ala-Leu The solid phase synthesis method of the 00 μm〇丨e grade was carried out using artificial solid phase synthesis, a Symphony Synthetic Synthesizer, and Fmoc Protective RinkAmide MBHA. The following protective amino acid is sequentially added to the resin · Fmoc-Leu-〇H,

Fmoc-Ala-〇H' Fmoc-Ser(tBu)-〇H, Fmoc-Tyr(tBu)-〇H,

FmooTyr(tBu)-〇H, Fmoc-A"g(Pbf)-〇H, Fmoc-Ala-〇H,

Fmoc-Met-〇H, Fmoc-Asp(tBu)-〇H, Fmoc-Glu(tBu)-〇H,

Fmoc-Ala-〇H, Fmoc-Pro-〇H, Fmoc-Ala-〇H, Fmoo

Asp(tBu)-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Gly-〇H,

Fmoc-Pro-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Glu(tBu)-〇H,

FmooPro-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Ser(tBu)-〇H,

Fmoc-Pro-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Lys(Aloc)-〇H. It is sequentially dissolved in N,N-dimercaptononylamino (DMF), and 〇-benzoquinone azide-1-yl-N,N,N1,N,-tetradecyl- The base cation hexafluoro-169-1300414 phosphate (HBTU) is activated with diisopropylethylamino (D1EA). The removal of the protective group of F m 〇c is carried out using a solution of 20% (V/V) N-hexahydronole in the n, n-dimethylhydrazineamine (DMF) 2 It is achieved in minutes (step 1). The selective deprotection of the Lys (Aloe) group is carried out as a 卩0 by dissolving in a 5 mL of CHCl3: NMM:H〇Ac (18:1:〇.5) The solution was treated with the solution of the resin for 2 hours (step 2). The resin was then washed with CHCI3 (6 X 5 mL 〇, 20% H〇Ac (6 x 5 mL) dissolved in DCM, DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated to add 3-m-butylenediamine propionate (step 3). The resin is N,N-didecylguanamine between each combination. The base (DMF) was washed three times and washed three times with isopropyl alcohol. The peptide was excised from the resin using 85% tfA / 5% TIS / 5% stupyl decane and 5% phenol, and then dried and chilled Et2 〇 沈 殿 ( (Step 4). The product was purified by preparative reverse hplc using a Varian (Rainin) preparative double-effect HPLC system using a flow rate of 9.5 mL/min. A gradient dilution of 30-55% B (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN) of Phenomenex Luna 10 μ stupyl-hexyl over 1 80 min, 21 mm X 25 cm column and UV concentrator (Varian Dynamax UVD II) at 214 and 254 nm: to provide the desired peptide of 95% purity, which is determined by RP-HPLC. :IH立-祌Modified 1300414 (N-8MPA)-Lys-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pr〇- on the ε-amino group of the N-terminally deaminated amino acid residue added on the peptide Y GIy-

Glu-Asp-Ala-Pro-AIa-Glu-Asp-Met-AIa-Arg-Tyr-Tyr-

Preparation of Ser-Ala-Leu

The modified neuropeptide 丫 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 Eight 1111 (^?\/16^1 eight is carried out. The following protective amino acids are sequentially added to the resin: Fmoc-Leii-〇H, Fmoc-Ala-〇H, Fmoc-Se" (tBu)_〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Ala-〇H, Fmoc_Met-〇H, Fmoc -Asp(tBu)-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Ala-OH &gt; Fmoc-Pro-OH &gt; Fmoc-Ala-OH - Fmoc-Asp(tBu)-〇H, Fmoc -Glu(tBu)-〇H, FmooGly-〇H, Fmoc-Pro-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Asp(tBu)_〇H, Fmoc-Pro-〇H, Fmoc- Lys(Boc)-〇H, Fmoc-Ser(tBu)_〇H, Fmoc-P"〇-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Lys(Aloc)-〇H. Soluble in n,N-dimercaptononylamine (dmf), and using 〇-benzoquinone S-nitro-1-yl-N,N,NVN1 tetradecyl-adenocation hexafluoroantate (HBTU) is activated with diisopropylethylamino (D丨EA). Removal of Fm〇c protective group This is achieved by using a solution of 20% (v/v) N-hexahydropyridyl in N,N_:mercaptoamine (DMF) for 2 minutes. (Step 1). The Lys (Aloe) The selective deprotection of the group was carried out manually and by using 3 eq of Pd (dissolved in 5 mL of CHCl3: NMM: H〇Ac -171-'· 1300414 (18:1:0·5) The PPh3)4 solution was treated to treat the resin for 2 hours (Step 2). The resin was then CHCl3 (6 X 5 mL 〇, 20% H〇Ac (6 x 5 mL) dissolved in DCM, DCM (6 χ 5 mL),

And DMF (6 x 5 mL) to clean it. The synthesis is then reactivated to add 3-methyleneimine propionic acid (step 3). The resin was washed three times with N,N-dimercaptoamined amine (D M F) and washed three times with isopropanol between each face. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% thiophenyl decane and 5% phenol, and then reprecipitated with dry-cold Et2 hydrazine (step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex Luna 1 0 μ with a flow rate of 9.5 mL/min and over 1 80 min. 30-55% phenyl-hexyl Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21mm x 25cm column and UV at λ214 and 254 nm A detector (Varian Dynamax UVD I®) was provided to provide the desired peptide of &gt;95% purity, which was determined by RP-HPLC. Example 39 - ε-based modification of the added N-terminal lysine residue on Dvn A 1-13-(Ns-IVIPA)-Dyn A 1-13-NH2 synthesis (Ns-MPA )-Lys-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu The modified Dyn A 1-13 is used in the solid phase of the 100 pmole grade. The phase synthesis method, the Symphony peptide 172-1300414 synthesizer' and the Fmoc protective Rink Amide MB Η A were carried out. The following protective amino acid is added to the resin in sequence: Fmoc-

Lys(Boc)-〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, FmooP"〇-〇H, Fmoc-A"g(Pbf)-〇H, Fmoc-lle-〇H , Fmoc-A "g(Pbf)-〇H, Fmoc-A"g(Pbf)-〇H, Fm〇c-Leu-〇H, Fmoc-Phe-〇H, Fmoc-Gly-〇H, Fmoc- Gly-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Lys(Aloc)-〇H. These systems are sequentially dissolved in N,N-dimercaptononylamine (DMF), and 〇 is used. - Benzene azide-1-yl-indole, N, Ν', N, tetradecyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate. Fmoc The removal of the protective group was achieved by using a solution of 20% (v/v) N-hexahydrogen in N,N-dimercaptononylamine (DMF) for 20 minutes. (Step 1). The selective deprotection of the Lys (Aloe) group is carried out manually and by dissolving in a 5 m L of CHCl3 : NMM : H〇Ac (18:1:0'5) The 3 eq Pd(PPh3)4 bath was used to treat the resin for 2 hours (step 2). Then, the resin was CHCI3 (6 X 5 mL), dissolved in DCM 20% Η〇Ac ( 6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) for cleaning. The synthesis was re-automated to add maleimide-acrylic acid (step 3). The resin was washed three times with n,N-dimercaptoamine group (DM F) between each coupling. And washed three times with isopropyl alcohol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% phenylthio decane and 5% phenol, and then re-precipitated by dry-ice cold 丨 2 〇 (Step 4). The product is purified by preparative reverse phase HPLC using one

Varian (Rainin) prepared double-effect system: the angle of the corner can be -173- 1300414

9.5 mL/min and can use more than 180 min of Phenomenex Luna 10 μ of stupyl-hexyl 30-55% B (0.045% TFA (A) prepared in water and %·〇 45% TFA (B prepared in CH3CN) )) a gradient dilution, a 21 mm X 25 cm column, and a UV detector at λ 214 and 254 nm ~3 "丨3[1〇711311!3 parent 1^0丨丨) to provide the &gt; The ideal peptide of 95% purity is determined by RP-HPLC.

Example 40 · Dyn A 2-1 7·ΝΗ2 is improved on the N-terminal glycan acid · Synthesis of MPA-AEA3-Dyn Α 2-17·ΝΗ2 (MPA-AEA-AEA-AEA)-Gly-Gly- Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-T rp-Asp-Asn-Glu using an automated peptide synthesizer, the following protective amino acids and cis-butane diterpenes The imine is added to the Rink Amide MBHA resin in sequence:

Fmoc-Gln(T"t)-〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Asp(〇iBu)-〇H, Fmoc-Trp(BOc)-〇H, Fmoc-Lys(Boc)- 〇H, Fmoc-Leu-〇H, FmooLys(Boc)-〇H, Fmoc-Pro-〇H, FmooA “g(Pbf)-〇H, Fmoc-Me-〇H, Fmoc-Arg(Pbf)-〇 H, Fmoc-Arg(Pbf)-〇H, Fmoc-Leu-〇H, Fmoc-Phe-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, FmooAEA-〇H, Fmoc_ AEA-OH, Fmoc-AEA-〇H, and MPA. The dynorphin-labeled analog is removed from the resin and the product is isolated by sinking and purified by preparative HPLC to yield 32%. The desired product, i.e., the lyophilized pale yellow solid was obtained. Anal. HPLC showed product - 174- 〆, 1300414 &gt; 95% purity, and Rt = 33.44 min. ES b MS m/z 〇109 Latch 172~35〇29 (ΜΗ), 5 ten nose value is 2436.8, and the actual value is MH3 + 813.6.

TFTFATFA TFA TFA TFA οα-ιοιι Example 42 - Improvement of the ε-cavity of the N-terminal lysine residue added on Kringle-5 (Ns-MPA)-Lys-Pro Preparation of -Arg-Lys-Leu-Tyr-Asp-Tyr-NH2-2TFA

The improved Kringle-5 wins the 1〇〇pmole grade solid phase synthesis method using artificial solid phase synthesis, Symphony Synthetic Synthesizer, and Fmoc Protective Rink Amide MBHA comes with it. The following protective amino acid is added to the resin in sequence: 卩阳〇〇-

Tyr(tBu)-〇H, Fmoc-Asp(tBu)-〇H, Fmoc-Tyr(tBu)-〇H, Fmoc-Leu_〇H, Fmoc-Lys(Boc)-〇H, Fmoc_Arg(Pbf)_ 〇H, Fmoc-Pro-〇H, Fmoc-Lys(Aloc)-〇H. The system is sequentially dissolved in N,N-monodecylamined amine (DMF), and 〇-benzoquinone is used to make agglomerated -1-yl-N, N, Ν', N1-tetradecyl- Urea cation hexafluorophosphate (HBTU) is activated with diisopropylethylamino (D1EA). The removal of the Fmoc protective group uses a solution of 175-1300414 dissolved in 20% (v/v) N-hexahydropyridinium in N,N-dimethylformammine (DMF). It takes 20 minutes to reach (step 1). At the end of the synthesis, B&lt;acid&gt; anhydride was added to aceticate the end. The selective deprotection of the Lys (A|〇c) group was carried out manually and by using 3 eq of Pd dissolved in 5 mL of CHCI3:NMM:H〇Ac (18:1:0.5) The (PPh3)4 solution was treated to treat the resin for 2 hours (step 2). The resin was then washed with CHCl3 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 x 5 mL), and DMF (6 x 5 mL). . The synthesis is then re-automated to add 3-methyleneimine propionic acid (step 3). The resin was washed three times with N,N-dimercaptoguanamine (DMF) and three times with isopropanol between each face. The peptide was excised from the resin using 85% TFA/5% TIS/5% thiophenyl oxime and 5%, and then reprecipitated by dry-cold 曰丨2〇 (Step 4). The product was purified by preparative reverse ΗPLC using a Va ri a η (Rainin) preparative double-effect HPLC system using a flow rate of 9.5 mL/min and over 1 80 min. a gradient dilution of Phenomenex Luna 10 μ stupyl-hexyl 30-55% Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm tube Columns and UV detectors (Varian Dynamax UVD II) at λ 214 and 254 nm were used to provide the desired peptide of &gt;95% purity, which was determined by RP-HPLC. f Example 43 - Kenning (the improvement of kringleV5 on the N-terminal proline (Μ P A-AEE A)-P ro-Arg-Lys-Leu-Ty r-Asp-Ty r-Ly s- - Preparation of 176- 1300414 NH2.2TFA

The following protective amino acid was sequentially added to RinkAmide MBHA resin using an automatic peptide synthesizer: Fmoc-Lys(Boc)_〇H, Fmoc-Ty((tBu)〇H, Fmoc-Asp(〇 tBu)-〇H, Fmoc-Tyr(tBu)〇H, Fmoc-Leu-〇H, FmooLys(Boc)-〇H, Fmoc-Arg(Pbf)_〇H, Fmoc-Pro-〇H (Step 1) The deprotection of the Fmoc group at the end is accomplished by coupling 20% N-hexahydroacridinyl (step 2) and then Fmoc-AEEA. The resulting 20% N-prepared in DMF. The hexahydroacridinyl deprotected Fmoc-AEEA-peptide allows for the addition of the next 3-MPA (step 3). Resin removal and product separation using 86% TFA/5% TIS/5% H2〇 /2% phenylthiodecane with 2%

Phenol, which is then precipitated by dry-cold Et2(R) (step 4). ^The product is purified by preparative reverse phase HPLC using a Varian (Rainin) prepared double-effect hplc system. The system uses a Dynamax C18, 6〇A ' 8 pm, 21 mm x 25 cm column, 21 mm x 25 cm tube equipped with a Dynamax C18, 60A, 8 μηι protection module (gUa "d module"). Column, and UV detector at λ214 and 254 nm (Varian Dynamax UVD II). The product must have a purity of >95% determined by RP-HPLC mass spectrometry. Hew|ett Packard [CMS-1 1 0 continuous spectrometer and electrospray ionization method for secondary body array detectors.) Example 44 - Kringle-5 on the end of the city Improvement - 177 - 1300414 (MPA) - Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH2.2TFA is prepared using an automatic peptide synthesizer, the following protective amino acid system Addition to RmkAmideMBHA resin: Fmoc-Lys(Boc)-〇H,

Fmoc-Tyr(tBiJ)〇H, Fmoc-Asp(〇tBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Arg(Pbf) - 〇H, Fmoc-Pro-〇H (step 1). Deprotection of the Fm o c group at the end is accomplished by coupling of a 20% N·hexahydroquine bite (step 2) followed by 3-MPA (step 3). The resection of the resin and the separation of the product were carried out using 86% TFA/5% TIS/5% H2〇/2% thiocarbazide and 2% phenol, followed by precipitation by dry-ice cold Et2〇 (steps) 4). The product was purified by preparative reverse phase HPLC, a dual-effect HPLC system prepared by Varian (Rainin) using a protective module equipped with Dynamax C18, 60A, 8 μηι. (gUard module) Dynamax C18, 6〇A, 8 μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors at λ 214 and 254 nm (Va “ian Dynamax UVD II” The product must have a purity of >957 as determined by an RP-HPLC mass spectrometer using a Hew丨ett P a cka rd LC M S prepared with a two-dimensional array detector. -1100 continuous spectrometer and electrospray ionization method. Capsule Example 4 5 &quot;kringle-5 on Ν-terminal tyrosine improvement (MPA-AEEA)-Tyr-Thr-Thr -Asn-Pro-Arg-Lys-Leu-Tyr- -178 — 1300414

The preparation of Asp-Tyr-NH2.2TFA was carried out using an automatic peptide synthesizer, and the following protective amino acid was sequentially added to Rink Amide MBHA resin: Fmoc-Lys(B〇c)-〇H, * Fmoc-Ty"(tBu)〇H, Fmoc-Asp(〇tBu)_〇H, Fmoc- - Tyr(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H,

Fmoc-Arg(Pbf)-〇H, Fmoc-Pro-〇H, Fmoc-Asn(T"t)-〇H, J Fmoc-Thr(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-

Tyr(tBu)〇H (step 1). Deprotection of the Fmoc group at the end is accomplished by coupling 20% N-hexahydropyridyl (step 2) followed by Fmoc-AEEA. The resulting Fmoc-AEEA-peptide deprotected with 20% N-hexahydropyridyl in DMF allowed for the subsequent addition of 3-MPA (step 3). Resin removal and product separation were carried out using 86% TFA/5% TlS/5% H2〇/20/0 stupid and 2% phenol, followed by precipitation by dry-ice cold Et2〇 ( Step 4). The product was purified by reverse phase HPLC of hydrazine prepared by a two-effect HPLC system prepared with a Varianmax C18, 60A, 8 μητι. Module (gUa"dm〇(juie)

Dynamax C18, 6 〇 A, 8 μιτι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors at λ 214 and 254 nm (Va "ian Dynamax UVD II". This product must be determined by rp_hplc mass spectrometer > 95% purity, the mass spectrometer uses a continuous spectrometer with a Hewlett Packard LCMS-11 备 equipped with a two-dimensional array detector and an electrospray ionization method. ·· -179- 1300414 41 &quot; Kringle-5 on the N-terminal tyrosine (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Ty r-Asp-

Preparation of Tyr-NH2.2TFA The following protective amino acid system was added to Rink Amide MBHA resin using an automatic peptide synthesizer: Fmoc-Lys(Boc)-〇H,

Fmoc-Tyr(tBu)〇H, Fmoc-Asp(〇tBij)-〇H, Fmoc-

Tyr(tBu)OH, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H,

Fmoc-A "g(Pbf)-〇H, Fmoc-Pro-〇H, Fmoc-Asn(T"t)-〇H,

Fmoc-Thr(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-

Tyr(tBu)〇H (step 1). Deprotection of the Fmoc group at the end is **

This is accomplished using the coupling of 20% N-hexahydropyridyl (step 2) followed by 3-MPA (step 3). The resection of the resin and the separation of the product were carried out using 86% TFA/5% TIS/5% H2〇/2% phenylthiodecane and 2% phenol, followed by precipitation by dry-ice cold Et2〇 (steps) 4). The product was purified by a preparative reverse phase ΗPLC using a V a "ia η (Rainin) preparative double-effect HPLC system using a device equipped with Dynamax C18, 60A, 8 μιτι Guard module Dynamax C18, 6〇A, 8 μπι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors at λ 214 and 254 nm (Varian

Dynamax UVD II). The product must have a purity of &lt;95 % determined by RP-HPLC mass spectrometer using a continuous spectroscopic Hewlett Packard LCMS-1100 equipped with a two-stage -180 - 1300414 array detector. And the use of electrospray ionization methods. Example 47 - Improvement of kringle-5 on the N-terminal arginine (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-GIy-Pro-Trp-Ala-Tyr- Thr-Th r-As η - P ro-Arg - Ly s -Le u -Ty r-As p -Ty r-NH2_3TFA is prepared using an automatic peptide synthesizer, the following protective amino acid system Addition to Rink Amide MBHA resin: Fmoc-Lys(Boc)-〇H, Fmoc-Tyr(tBu)〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Tyr(tBu)〇H, FmooLeu- 〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-P“o-pH, Fm〇c-Asn(T“t)-〇H, Fmoc-Thr(tBu )-〇H, Fmoc-Thr(tBu)-〇H, Fmoc_ Tyr(tBu)〇H'Fmoc-Ala-〇H, Fmoc-Trp-〇H, Fmoc-Pro-〇H-Fmoc-Gly-〇H &gt; Fmoc-Gly-OH ^ Fmoc-Val-OH -Fm〇C-ASp(〇tBU)-〇H, Fm〇C-Gly-〇H, Fm〇c-Asp(〇tBu)-〇H, FmooP "o-〇H, Fmoc-Asn(Trt)-〇H, Fmoc_ A"g(Pbf)-〇H (Step 1). The deprotection of the p:m〇c group at the end is by 20% N - hexahydro. Completion of coupling with pyridine group (step 2) and then Fm〇c-AEEA. The resulting Fmoc-AEEA-derived 20% N-hexahydropyranyl deprotected DMF in DMF The addition of the next 3-MPA can be allowed (step 3). Resin removal and product separation are performed using 86% 181 - 1300414 TFA / 5% T1S / 5% H20 / 2% thiolethane and 2 % phenol, which is then precipitated by dry-cold Et2 ;; the temple is carried out (less recorded 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparation. Double-effect HPLC system, the system is equipped with one

Dynamax C18, 60A, 8 μηι protective module (DynamaxC18, 6〇A, 8μηη, 21 mmx25cm column, 21 mm x 25 cm column, and UV detectors at λ 214 and 254 nm ( Varian Dynamax UVD II). The product must have a purity of &gt;95% as determined by RP-HPLC mass spectrometry using a continuous spectrometer with a Hewlett Packard LCMS-11 00 prepared with a two-dimensional array detector and using electricity. Spray ionization method. f Example 48 - Guining (KringleV5 modified on N-terminal proline (MPA)-Arg-Asn-Pro-Asp-GIy-Asp-Val-Gly-GIy-Pro-Trp-Ala-Tyr- The Thr-Thr-Asn-Pro-Arg-Lys-Leu-Ty r-Asp-Tyr-NH2-3TFA was prepared using an automatic peptide synthesizer, and the following protective amino acid was added to Rink Amide in sequence. On MBHA resin: Fmoc-Lys(Boc)-〇H, Fmoc-Tyr(tBu)〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Ty“(tBu)〇H, Fmoc-Leu-OH ' FmooLys(Boc)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-Pro-〇H, Fmoc-Asn(T“t)-〇H,

FmooThr(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc- -182 - 1300414

Ty "(tBu)〇H, Fmoc-Ala-〇H, Fmoc-Trp-〇H, Fmoc_P plant 〇H〇, Fmoc, Gly-〇H, Fmoc-Gly-〇H, Fmoc-Va 〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Asp(〇tBu〇H, Fmoc_Pro-〇H, Fmoc-Asn(Trt)-〇H, Fmoo A“g(Pbf) -0H (Step 1). Deprotection of the Fmoc group at the end is accomplished by the combination of 20% N-hexahydroacridinyl (Step 2) and then 3-MPA (Step 3). The excision and separation of the product were carried out using 86% TFA/5% TIS/5% H2〇/2% stupid thiomethane and 2% phenol, followed by precipitation by dry-cold 丨2〇 (steps) 4) The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a device equipped with Dynamax C18, 6〇A, 8 μπι Guard module Dynamax C18, 6〇A, 8 μιτΊ, 21 mm x 25 cm column, 21 mm 25 (^ tube column, and 1 214 detector with 214 and 254'111 (乂31^3 door

Dynamax UVD 11). The product must have a purity of &gt;95% as determined by an Rp-HPLC mass spectrometer using a continuous spectrometer with a Hewlett Packard LCMS-1100 equipped with a two-dimensional array detector and using electrospray Ionization method.实苑例49 A modification of kringle-5 at the N-terminal arginine (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp.Val-GIy-Gly-Pro-Trp -NH2.TFA was prepared using an automatic peptide synthesizer, and the following protected 4-amino acid was added to Rink Amide MBHA resin in the order of -183-1300414: Fmoc-Lys(Boc)-〇H, Fm〇 cT "p-〇H, Fmoc-P"o-〇H, Fmoc-Gly-〇H, Fm〇c-Gly-〇H, Fmoc-Va 〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Gly-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-P"〇-〇H, Fmoc-

Asn(Trt)-〇H, FmooArg(Pbf)-OH (step 1). Deprotection of the Fmoc group at the end is accomplished by the use of 20% N-hexahydro-beta than the bite group (step 2) and then the Fmoc-AEEA. The resulting Fmoc-AEEA-win version, which was prepared by denaturing 20% N-hexahydrogen in dmf, allowed the addition of 3-MPA (step 3). Resin removal and product separation were performed using 86% TFA/5% ΊΊS/5% H2 〇/20/〇 phenylthiocarbazone and 2% phenol, followed by dry-cold Ets〇 (Step 4). The product was purified by a preparative reverse phase ΗPLC using a Varian (Rainin) preparative double-effect HPLC system that was equipped with a Dynamax C18, 60A, 8 μηι Protection module (gua "d

Module) Dynamax C18, 6〇A, 8 μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors (Varian Dynamax UVD II) at λ 214 and 254 nm. The product must have a purity of &gt;95% as determined by an RP-HPLC mass spectrometer using a continuous spectrometer with a Hewlett Packard LCMS-1100 equipped with a two-dimensional array detector and using electrospray Ionization method. f Example 50 - Kenning 仏1^叩16)-5 on the arginine of the heart (MPA)-Arg-Asn-Pro-Asp.Gly-Asp-Val-Gly-GIy-Pro-

Preparation of Trp_NH2_TFA - 184-1300414 Using an automated peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-〇H, Fmoc-Trp-〇 H, FmooPr〇_〇H, Fmo〇Gly-〇H, Fmoc-

Gly-OH ^ Fmoc-Val-OH ^ Fmoc-Asp(〇tBu)-OH ^ Fmoc-Gly-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Pro-〇H, Fmoc-Asn(Trt )-〇H, FmooArg(Pbf)-〇H (Step 1). The deprotection of the Fmoc group at this end is by the use of 20% N-hexahydro. This is accomplished by the incorporation of a pyridine group (step 2) followed by a 3-MPA (step 3). The resection of the resin and the separation of the product were carried out using 86% TFA/5% TlS/5% H20/2% thiocarbazide and 2% phenol, followed by precipitation by dry-cold Et2 hydrazine (Step 4). ). The product was purified by reverse phase HPLC using a pre-commissioning system using a 3"3" ([^111丨门) prepared double effect}^1_ (3 system, the system uses one equipment Dynamax C*j8, 6〇A, 8 μιτι protection module (guard

Module) Dynamax C18, 6〇A, 8 μπΊ, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors at λ214 and 254 nm (Varian Dynamax UVD I丨). The product must have a purity of &gt;95% as determined by an RP-HPLC mass spectrometer using a Hew I e 11 P ackard LCMS -1 00 prepared with a first-order array. A continuous spectrometer and an electrospray ionization method. — 185 — 1300414 Example 51 - Modified by Guining 0^丨 Qiu 16)-5 on the terminal arginine (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH2.2TFA The preparation uses an automatic sputum synthesizer, and the following protective amino acid is sequentially added to RinkAmide MBHA resin: Fmoc-Lys(Boc)-〇H,

Fmoc-Tyr(tBu)〇H, Fmoc-Asp(〇tBu)-OH, Fmoc-Tyr(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-A“g (Pbf)-〇H (Step 1). Deprotection of the Fmoc group at the end is accomplished by coupling with 20% N-hexahydroacridinyl (Step 2) and then Fmoc-AEEA. The Fmoc-AEEA-peptide deprotected with 20% hexahydropyridyl in DMF allowed the addition of the next 3_MPA (step 3). Resection of the resin and separation of the product used 86% TFA/5 % TIS / 5% H2 〇 / 2% phenylthiomethane and 2% phenol, which is then precipitated by dry-cold Et2 hydrazine (step 4). The product is pre-bucked by reverse phase HPLC. Purified, the HPLC uses a Varian (Rainin) preparative double-effect HPLC system using a Dynamax C18, 6 equipped with a Dynamax C18, 60A, 8 μm protection module (gUa "d modu|e") 〇A, 8 pm, 21 mm x 25 cm column, 21 mm x 25 cm column, and uv detectors of λ2ΐ4 and 254叩 (Va “ian Dynamax UVD丨I). This product must have Rp_HpLC mass spectrometry The instrument determines the purity of &gt;95%, and the mass spectrometer uses a preparation Continuous splitting solution of Hewlett Packard LCMS-1100 with secondary body array detector and electrospray ionization method. . . -186- 1300414 Actual selection of I52 - Kringing-5 at the N-terminal spermine Acid-modified (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH2.2TFA was prepared using an automated peptide synthesizer, and the following protective amino acid system was added to Rink Amide. On MBHA resin: FmooLys(Boc)-〇H, • Fmoc-Ty((tBu)〇H, FmooAsp(〇tBu)-〇H, Fmoc-

Ty "(tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, O Fmoc-Arg(Pbf)-〇H (Step 1) Deprotection of the Fmoc group at the end This was accomplished by coupling 20% N-hexahydropyridyl (step 2) followed by 3-MPA (step 3). Resin removal and product separation using 86% TFA/5% TIS/5% H2〇 /2% thioanisole is calcined with 2%, and then precipitated by dry-cold chilling (step 4). The product is purified by preparative reverse phase HPLC. The system uses a Varian (Rainin) preparative double-effect HPLC system. The system uses an O Dynamax, 6〇Α, 8 μτη, 21 equipped with a Dynamax C18, 6〇A, 8 μιτι protective module (guard module). Mm χ 25 cm column, 21 mm vx 25 cm column, and UV accumulator at λ 214 and 254 nm (Varian

Dynamax UVD II). The product must have a purity of &gt;95% as determined by an rp-HPLC mass spectrometer. The mass spectrometer uses a continuous spectrometer with a Hewlett Packard LCMS-11 00 prepared with a two-dimensional array detector and uses electricity. Spray ionization method. jL SELECTION 53 - Improvement of kringle-5 on the N-terminal amino acid (MPA-AEEA}-Pro-Arg-Lys-Leu-Tyr-Asp4H2.2TFA 187 - 1300414 偾In an automatic peptide synthesizer, the following protective amino acid is sequentially added to Rink Amide MBHA resin: Fm〇C-LyS(B〇c)-〇H, Fmoc-Asp(〇tBu)-〇H , Fmoc-Ty "(tBu)〇H, Fmoc-Leu-〇H, Fmoc_Lys(Boc)-〇H, Fmoc-Arg(Pbf)-〇H, Fmoc-

Pro-OH (step 1). The end of the enthalpy (7) is called the deprotection of the group by using 20% N-hexahydro. This is done by combining the pyridine group (step 2) and then Fmoc-AEEA. The resulting Fmoc-AEEA-peptide, which was deprotected with 20% N-hexahydropyridyl in DMF, allowed the addition of the next 3-MPA (step 3). The resection of the resin and the separation of the product were carried out using 86% TFA/5% TlS/5% H2〇/2% phenylthio-f-sinter and 2% test, followed by precipitation by dry-ice-cooled Etz® (steps) 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect Η PLC system. The system was equipped with a device equipped with dyna γπ a X C18, 6〇A, 8 μηι The guard module has Dynamax C18, 6〇A, 8pm, 21 mmx25cm tubing, 21 mmx25cm tubing' and UV detectors (Varian Dynamax UVD II) at λ 214 and 254 nm. The product must have a purity of &gt;95% as determined by RP-HPLC mass spectrometry using a continuous spectrometer with a Hewlett Packard LCMS-11 00 prepared with a two-dimensional array detector and using electricity. Spray ionization method. 188-1300414 Example 54 - Improvement of kringle-5 on the N-terminal proline (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH2.2TFA

The following protective amino acids were sequentially added to Rink Amide MBHA resin using an automated peptide synthesizer: FmooLys(Boc)-〇H, Fmoc-Asp(〇tBu)-〇H, Fmoc-Tyr( tBu)〇H, Fmoc-Leu-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-A“g(Pbf)-〇H, Fmoc-P“o-〇H (step ride 1). The end The deprotection of the Fmoc group is accomplished by the use of 20% N-hexahydrogen, which is more than the surface of the bite base (step 2) and then 3-MPA (step 3). The removal of the resin and the separation of the product are used 86. % TFA / 5% TIS / 5% H2 〇 / 2% phenylthio decane and 2% phenol, and then precipitated by dry-ice cold ( 2 。 (Step 4). Purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a guard module equipped with Dynamax C18, 6〇A, 8 μητι Dynamax C18, 6〇A, 8 μηι, 21 mm x 25 cm columns, 21 mm x 25 cm columns, and UV detectors (Varian Dynamax UVD II) at λ214 and 254 nm. This product must have rp -HPLC mass spectrometer determined &gt; 95% purity 'the mass spectrometer A continuous spectrometer with a Hewlett Packard LCMS-1 100 prepared with a two-dimensional array detector and an electrospray ionization method were used. 3. Improvement on Intermediate Amino Acid - 189 - 1300414 Example 55 1^526(8-1\/^8) Synthesis of 61^-1(7-3 6)-^^2 The improved GLP-1 analogue is a solid phase peptide of 1 〇〇μm0|e grade The synthesis was carried out in a Symphony Synthetic Synthesizer using Fmoc Protective Rink Amide MB(R) A resin. The following protective amino acids were added to the resin in sequence: =:1710〇8"9(口匕1:)··〇H, Fmoc-Gly-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Va〇H,

Fmoc-Leu-〇H, Fmoc-Trp(Boc)-〇H, Fmoc-Ala-〇H,

Fmoc-lle-OH, FmooPhe-〇H, Fmoc-Glu(〇tBu)-〇H,

Fmo〇Lys(Aloc)-〇H, FmooAla-〇H, Fmoc-Ala-〇H,

Fmoc-Gln(Trt)-OH, FmooGly-〇H, FmooGlu(〇tBu)-〇H, Fmoc-Leu-〇H, FmooTy“(tBu)-〇H, Fmoc-

Ser(tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Va 〇H,

Fmoc-Asp(tBu)-〇H, Fmoc-Se"(tBu)-〇H, Fmoc- »·

Thr(tBu)-〇H, Fmoc-Phe-〇H, Fmoc-Thr(tBu)-〇H,

Fmoc-Gly-〇H, Fmoc, Glu(〇tBu)-〇H, FmooAla-〇H,

Boc-His(Trt)-〇H. It is sequentially dissolved in n,N-dimercaptononylamino group (DMF), and 〇-笨甲醯醯醯-1-yl-N,N,N·,N'·tetradecyl group is used. - Urea cation hexafluorophosphate (HBTU) and diisopropylethylamino (DIEA) to activate. The removal of the Fmoc protective group was achieved by using a solution of 20% (v/v) N-hexahydropyridyl group dissolved in n,N-dimercaptoamine (DMF) for 20 minutes. (Step 1). The selective deprotection of the Lys (Aloe) group was carried out manually, and by dissolving 3 eq of Pd (PPh3) in 5 mL of CHCI3: NMM ··H〇Ac (18:1:0.5) 4 The solution was treated to treat the resin for 2 hours (step 2). The resin was then washed with CHCl3 (6-190 - 1300414 x 5 mL), 20% HOAc (6 x 5 mL) dissolved in DCM, DCM (6 x 5 mL), and dMF (6 x 5 mL). The synthesis is then re-automated to add 3-methyleneimine propionic acid (step 3). Between each coupling, the resin was washed three times with hydrazine, hydrazine-dimethyl guanamine (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% thiosulfanyl and 5% phenol, and then precipitated as dry-cold Et2 〇S (step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex Luna 1 0 with a flow rate of 9·5 mL/min and over 180 min. 30 5 笨 - 己 己 30 30 Β 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备 制备The column and the UV detector (VarianDynamax UVD II) at λ214 and 254 nm are ideal for providing this &gt;95% purity, which is determined by Rp·HpLC. These steps are described in the following chart. One 191 one 1300414

Fmoc-Rink Amide MBHA Resin

Step 1 SPPS

...^ T

Boc-HAEGTFTSDVSSYLEGQAA-Lys(Aloc)-EFIAWLVKGR-PS I Pd(PPh3)4/NMM/HOAc/CHC!3 ▼

Boc-HAEGTFTSDVSSYLEGQAA-Lys-EFIAWLVKGR-PS

Step 4 1 I 85% TFA/5% TIS/5% H20/5% Phenylthiophene/5% Phenol

H2 N-HAEGTFTSDVSSYLEGQAA

Lys26(E-MPA)GLP-1 (7-36)-NH2-192- 1300414 D_Therapeutic peptides from a peptide containing a free half-proline are modified from a cysteine The preparation of the maleic imino-based peptide in the peptide can be exemplified by the synthesis of the peptide described below. The peptide is modified at the end, the C-terminus, or the amino acid between the ~-terminus and the c-terminus. a plurality of cysteine residues containing a plurality of protective functional groups and all having only one free cysteine D-amine (ie, other cysteine acids other than one cysteine are disulfide-bonded) The S-method is bound to the therapeutic peptide to prepare the maleimide group. Linked from an intermediate amino acid in a natural sequence, as in Example 5. The free cysteine can be capped or replaced with other amino acids (e.g., alanine, guanine, etc.). When the peptide contains a cysteine, the cysteine must be in a capped state after the addition of cis-butadiene diimine. False If the semi-deaminating acid is involved in the binding site, it must be estimated that the semi-proline is protected. How much potential activity is lost when the vine group is covered. The synthetic route is similar to the above-described embodiment if the cysteamine 4 I can be in a capped state. The therapeutic peptide containing a cysteine includes: Ga (the subunit of the G therapeutic peptide-binding protein), 724-739 fragment of the nitric oxide synthase blocking peptide in the brain of the rat, human [Ty "〇" 1-32 fragment of the a subunit of inhibin, 254-274 fragment of HIV envelope protein, and P34cdc2 kinase fragment. -193-1300414 1. Modified Example 56 at the N-terminus - Inhibin N-terminal ionwise modified (Ns-MPA)-Lys-Tyr-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-AIa -Leu-Arg-Leu-Leu-G!n-Arg-Pro-Pro-Glu-Glu-Pro_Ala-Ala-Ala-His-Ala-Asn-Cys-His-Arg The solid phase peptide synthesis of the analog on the 100 μηηοΐθ scale uses manual solid phase synthesis, a Symphony peptide synthesizer, and Fmoc protective Rink Amide MBHA. The following protective amino acid system Add to the resin sequentially: 卩! 7100八"9 (mouth-匕〇H, Fmoc-His(Boc)-〇H, Fmoc-Cys(Trt)-〇H, Fmoc-

Asn(Trt)_〇H, Fmoc-Ala-〇H, R.moc-His(Boc)-OH,

Fmoc-Ala-OH &gt; Fmoc-Ala-OH - Fmoc-Pro-OH, Fmoc-

Glu(tBu)-〇H, Fmoc-Glu(tBu)-〇H, Fmoc-Pro-〇H,

Fmoc-P "o-〇H, Fmoc_Arg(Pbf)-〇H, Fmoc-Gln(Trt)-〇H,

Fmoc-Leu-OH, Fmoc-Leu-〇H, FmooArg (Pbf>-〇H,

Fmoc-Leu-OH, Fmoc-Ala-〇H, Fmoc-Ser(tBu)-〇H,

Fmoc-Pro-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Trp(Boc)-〇H,

Fmoc-Pro-〇H, Fmoc-Trp(Boc)-〇H, Fmoc-Ser(tBu)-〇H,

Fmoc-Met-〇H, Fmoc-Leu-〇H, Fmoc-Pro-〇H, Fmoc-

Thr(tBu)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Tyr(tBu)-〇H,

Fmoc-Lys(Aloc)-OH. It is sequentially dissolved in N,N-..dimercaptoamine 194 1300414

Base (DMF), and using 〇-benzoquinone-azido-l-yl-indole, hydrazine, hydrazine 1, Ι\τι-tetramethyl·· urea cation hexafluorophosphate (HBTU) and diisopropyl B Amine (DIEA) to activate it. The removal of the Fmoc protective group is such that 20% of the solution of octadecyl N-hexahydroacridinyl is dissolved in N,N-dimercaptoamine (DMF) for 2 minutes. This is achieved (step 1). The selective deprotection of the Lys (Aloe) group is carried out manually and by dissolving in 5 mL of CHCl3 : NMM : H〇Ac (18:1:0.5) 3 eq of Pd(PPh3)4&gt; solution was used to treat the resin for 2 hours (step 2). The resin was then CHCl3 (6 X 5 mL), 20% HO Ac (6) dissolved in DCM. x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) were cleaned. Then, the synthesis was re-automated to add 3-methyleneimine propionic acid (steps) 3). Between each coupling, the resin was washed three times with N,N-dimercaptononylamine (DMF) and three times with isopropanol. Using 85% TFA/5% TIS/5% benzene The peptide is cleaved from the resin with thiodecane and 5 phenol, and then reprecipitated by dry-ice cooling (step 4). The product is purified by preparative reverse phase HPLC. Use a Varian (Rainin) preparative double-effect HPLC system: use a flowable It is 9.5 mL/min and can use more than 180 min of Phenomenex Luna 10 μ stupyl-hexyl 30-55% Β (prepared in water 〇·〇 45% TFA (Α) and 0.045% TFA prepared in CH3CN ( B)) a gradient dilution, a 21 mm X 25 cm column, and a UV detector at λ 214 and 254 nm (Varian Dynamax UVD II) to provide the ideal peptide of &gt;95% purity. Determined by RP-HPLC. -195- 1300414 Example 57 A modified RSV anti-stomnation (Antifusogenic) plate at the N-terminus, 3-(MPA)-VaI-He-Thr-lIe-Glu-Leu -Ser-Asn-lle-Lys-Glu-

Preparation of Asn-Lys-Cys-Asn-GIu-Aia-Lys-Vai-Lys-Leu-Ile-Lys-GIu-* Glu-Leu-Asp-Lys-Tyr-Lys-Asn-AIa-Val In the natural sequence, cysteine O (Cys) is substituted with methionine. The modified anti-RSV analog was synthesized on a 1 00 &quot;mole grade solid phase synthesizer in a Symphony Synthesizer using Fmoc Protective Rink Amide MBHA resin, Fmoc protection Amino acid, ruthenium azide-1-yl-hydrazine/, hydrazine/, hydrazine, tetramethyl-urea cation hexafluorophosphate prepared in dimercaptononylamine (DMF) solution (HBTU) and activated with decylmorpholine (ΝΜΜ), and

V

Deprotection of the hexahydro σ-piperidine of the Fmoc group (step 1). Deprotection of the edge Fmoc group is achieved using a 20% N-hexahydropyridinyl group (step 2) followed by a combination of 3-MPA (step 3). The removal of the resin and the separation of the product were carried out using 86% TFA/5% TIS/5% ★ H2O/2% of the thiol oxime and 2% s and then by dry-cold EhO precipitation ( Step 4). The reverse phase of the preparation

Purified by HPLC using a Varian (Rainin) prepared double-effect Η PLC system. This system uses a protection module equipped with Digital X C18, 6〇A, 8 μιτι (guard moduleW Dynamax C18, 6〇A, 8 μηι, 21 mm x 25 cm column '21 mm x 25 cm column, and 214 and 254 _1^ detector (\/3 "丨抓0" grab 3乂一1 96-1300414 UVD II). The product must have a purity of >95% determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-11 00 with a two-level array detector. Continuous spectrometers and electrospray ionization methods are used. These steps are described in the following chart.

FmooRink Amide MBHA Resin I Step 1 j SPPS .v

Fmoc-ViTIELSNIKENKMNGAKVKLIKQELDKYKNAV-PS Step Lin 2 jv20°/. N-hexidinyl h2n-vitielsnikenkmngakvklikqeldkyknavk-ps 3-m-butyleneimine propionic acid

Η

^VITIELSNIKENKMNGAKVKLIKQELDKYKNAV-PS Step 4 j 85% TFA/5% TIS/5. /. Phenylthiophene / 5% phenol

h TFA TFA TFA TFA

Y^^YKvmELSNIKENKMNGAKVKUKQELDK 丫KNAV-NH2 TFA TFA TFA 2. Modified at C-terminus 58 - Modified C-terminal lysine added to statin to improve the addition of statin peptide Improvement of N-terminal deionization (Ne-MPA)-Lys-Cys-Asn-Leu-Lys-Glu-Asp-Gly-lle-Ser-Ala-Ala-Lys-Asp-Va-Lys 197- 1300414 A modified statin peptide analog on the 100 μmol scale of solid phase synthesis using manual solid phase synthesis, a simpson (S ymph ο ny) peptide synthesizer, and Fmoc protection Sexual Rink Amide ΜΒΗΑ. The protective amino acid of the following iii is sequentially added to the resin: F ΠΊ Ο 〇

Lys(Boc)-〇H, Fmoc-Va 〇H, Fmoc-Asp(tBu)-〇H, Fmoc-Lys(Boc)-OH &gt; Fmoc-Ala-OH &gt; Fmoc-Ala-OH ^ FmooSer( tBu)-〇H, Fmoc-lle-OH, Fmoc-Gly-〇H, Fmoc-Asp(tBu)-〇H, FmooGlLi(tBu)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Leu - 〇H, Fmoc-Asn(Trt)_〇H, Fmoc-Cys(Trt)-〇H, Fmoc-Lys(Aloc)-〇H. It is sequentially dissolved in N,N-dimethylammonium (DMF), and the azide-stirsty azide-1-yl-indole, anthracene, NV Ν'-tetradecyl-urea The cationic hexa-phosphate (ΗΒ丁υ) and diisopropylethylamino (DIEΑ) are activated. Transfer of Fmoc protective group

^ V was achieved by using a solution of 20% (v/v) N-hexahydropyridyl group dissolved in N,N-dimercaptoamine (dmF) for 20 minutes (step 彳). The selective deprotection of the Lys (Aloe) group was carried out manually, and by dissolving 3 eq of P d (PP h3 in 5 mL of CHCI3 : NMM : H〇Ac (18:1:0.5) 4 &gt; Valley liquid to treat the resin for 2 hours to complete (Step 2). Then the resin was washed with CHCI3 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 X 5 mL). . The synthesis is then re-automated to add 3-p-succinimide propionate (step 3). Between each coupling, the resin was washed three times with N,N-dimercaptocarbamimidyl (DMF) and three times with isopropanol. A 198-1300414 peptide was excised from the resin using 85% TFA / 5% T丨S / 5% phenylthio decane and 5% phenol, and then reprecipitated with dry-cold Et2 ( (Step 4 ). The product was purified by preparative reverse phase HPLC using a Va "ian (Rainin) preparative double-effect HPLC system using a helium flow rate of 9. 5 mL/min and a use of more than 180 min. Phenomenex Luna 10 μ Stupid-Hexyl 30-55〇/〇Β (Prepared in #1水0.〇45%丁"八(八) and prepared in (^30中中〇.〇45%丁厂Eight (B)) gradient dilutions, 21 mm X 25 cm columns, and UV detectors (Varian Dynamax UVD®) at λ214 and 254 nm to provide the ideal peptide of &gt;95% purity, which is This was determined by rp-HPLC.Example 59 - Improvement of the V-end of the RSV shuttle (FUSOGENIC) peptide at the C-terminus Val-Ile-Thr-Ile-GIu-Leu-Ser-Asn-lle-Lys-GIu-Asn-Lys -Cys-Asn-GIy-Ala-Lys-Val-Lys-Leu- Me- Lys-Gln-Glu-Leu-Asp-Lys-Tyr-Asn-Ala-Val-(AEEA.MPA) Self-contained multiple protective The preparation of the maleimide-based peptide in the functional group and a peptide of cysteine can be exemplified by the synthesis of a modified RSV shuttle peptide. The improved RSV shuttle peptide is borrowed. Synthesized by adding an isolated amino acid residue to a natural sequence to detach from the C-terminus The following chart illustrates that in the case where half of the cysteine is included in the sequence of the peptide but is not important for the biological activity of the peptide, the residue must be other amino acids (ie, Substituted by alanine, guanidine thioglycol, etc. In the following synthesis, cysteine (cys) is substituted with hydrazine 1300414 (Met) in the natural RSV sequence. Amino-based RSV-spinning is a solid phase peptide synthesis system of 1 pmole grade using manual solid phase synthesis and a Symphony peptide synthesizer. The synthesizer makes weekly Fmoc protection. Rmk Arrnde MBHA, Fmoc protective amino acid, 〇-笨甲醯醯 azide y-yl·A/, W' prepared in λ/,λ/- bis-mercaptoamined amine (DM F) solution , Λ / '-tetradecyl _ urea cation hexafluorophosphate (hbtU) and activated by methyl whallin (NMM), and the deprotection of the N-hexahydroacridinyl group of the Fmoc group (step 彳The selective deprotection of the Lys (Al〇c) group was carried out manually and by using 3 eq of Pd dissolved in 5 mL of CHCI3 : NMM : H〇Ac (18:1:0.5) (P The Ph3)4 solution was used to treat the resin for 2 hours (step 2). The resin was then washed with CHCI3 (6 X 5 mL), 20% HOAc (6 X 5 rnL) dissolved in DCM, DCM (6 x 5 mL), and DMF (6 χ 5 mL). The synthesis is then re-automated to add 3-m-butylenediminopropionic acid (step 3). The resin was washed three times with dimethyl hydrazide (DMF) and three times with isopropanol between each hydration. Use 85% tfa / 5% TIS / 5% phenylthio decane with 5. /. The peptide is cleaved from the resin and reprecipitated by dry-cold Et2(R) (step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a flow rate of 9.5 17117!11_丨11 and using more than 180 171 丨? 611 〇〇 ^ 116 乂 1 « 1 ] door 3 10 mouth stupid - hexyl 30-55% B (prepared in water 0.045% TFA (A) and 0.045% TFA (B) prepared in CH3CN) Gradient dilutions, 21 -200-1300414 mm x 25 cm columns and UV detectors at λ 21 4 and 254 nm (Varian Dynamax UVD II) to provide the ideal peptide of >95% purity, It is determined by RP-HPLC. These steps are described in the chart below.

Fmoc-Rink Amide MBHA Resin ^

Step 1 J SFPS f,

Boc-ViTIELSNIKENKMNGAKVKLJKQELDKYKNAVK(A!doc)-PS Step Jun, 1 丨 vPd(PPh3)4/NM_OAc/cmCI3

Boc-VITlELSNiKENKMNGAKVKLIKQELDKYKNAVK-FPS

Step 3) 3-m-butyleneimine propionate

Step 4 | j 85% TFA/5% TIS/5% Phenylthiophene/5% Phenol

TFA

TFA

TFA

TFA

TFA TFA TFA TFA

3. Improvement on Intermediate Amino Acids Example 60 - Improvement of Gcx Sheng Edition -201 1300414

Cys-Asn-Leu-Lys-Glu-Asp-Gly.lle-Ser-Ala-Ala-Lys-Asp-

Val's self-contained multi-protective functional group and a cysteine acid-based version of the product can be exemplified by the synthesis of a modified Ga-Sheng version. The modified Ga 肷 合成 is synthesized by the linkage of an intermediate amino acid as described below. L In the case where half of the cysteine is contained in the sequence of the peptide but is not important for the biological activity of the peptide, the residue must be capped or with other amino acids (ie, alanine) , 曱 thiamine, etc.) replaced. The modified Ga peptide is a solid phase peptide synthesis system of 1 〇〇μm0|e grade using manual solid phase synthesis and a Symphony peptide synthesizer using Fmoc protective Rink Amide. MBHA, Fmoc protective amino acid, prepared in /V, dimercaptononylamine (DMF) solution 曱 曱 叠 叠 -1- -1- 基 基 基 基 A A -1- -1- -1- -1- Λ/'-tetradecyl-urea cation hexa-acidate (HBTU) and activated with TV-mercapto porphyrin (NMM), and

The N-hexahydrop of the Fmoc group is deprotected from the bite group (step 1). The selective deprotection of the LyS;, (Aloc) group was carried out manually and by dissolving 3 eq of P d in 5 mL of CHCI3: NMM: H〇Ac (18:1:0.5) PP h3) 4 &gt; trough solution was completed by treating the resin for 2 hours (step 2). Then, the resin was washed with CHCI3 (6 X 5 mL), 20% H〇Ac (6x5 mL) dissolved in DCM, DCM (6×5 mL), and DMF (6×5 mL). The synthesis is then re-automated to add 3-cis-butanediamine propionate (step 3). Between each coupling, the resin was rinsed three times with -207-1300414 N,N-dimercaptononylamine (DMF) and three times with isopropanol. Use 85% TFA / 5% T1S / 5% stupid base burn and 5%

The cockroach is cut off from the resin' and then sunk to the dry-cold Et2 〇 (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Phenomenex Luna 10 μ base with a flow rate of 9.5 mL/min and over 180 min. - 30-55% of hexyl Β (0. 045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm column and χ 214 An 254 nm UV detector (Varian Dynamax UVD I(R)) was provided to provide the desired peptide of &gt;95% purity, which was determined by rp-HPLC. E- Preparation of a modified peptide from a peptide containing two cysteic acids in a disulfide bridge. When the peptide contains two cysteines as a disulfide bridge, the peptide is Move up from the support resin before the maleimide is added. We must add a Lys protected with a Mtt group to selectively deprotect the lysine in the presence of other ϋi-Boc protective lysine. The protective group is present in the position other than the carboxy terminus (which is present in the unprotected state due to its self-removal of the support resin) and the position of the dicysteine After the resin is removed from the resin, it must be protected. Mild gas oxidation produces this disulfide bridge and the peptide can be purified in this step! -203-1300414. The liquid phase chemistry then activates the c-terminus in the presence of a disulfide bridge and adds the maleimide to the c-terminus (via an amino-alkyl-methyleneimine) When needed. The peptide is then completely deprotected. Examples of therapeutic peptides containing two cysteines as a disulfide bridge include human bone calcium factor 1-49, human diabetes, related peptides, and human/dog atrial sodium sulphate peptides. 5 - 28 fragments, bovine specific hormone, and human [TyrO] - cortical balance 29 . From the treatment of the two cysteines as a disulfide bridge, the oxime · · 烤 烤 一 一 一 一 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 可 。 。 。 。 。 The peptide can be modified at the N-terminus, the C-terminus, or on the amino acid at the N-terminus and the C-terminus. 1· Improvement on the N-end

f Example 61 - Improvement of the TH-1 wins on the N_ end (N8-MPA) NH2.Lys-Arg.G!y-Asp-Ala-Cys-G!u-Gly-Asp-Ser_Gly-Gly- Pro-Phe-Cys is manufactured from a multi-protective functional group and free of free cysteine residues (ie, all cysteine residues are bound by a disulfide bridge) The method for the preparation of a thio-cyclized maleimide-based peptide by a peptide is illustrated by the synthesis of a modified TH-1 peptide. The improved TH-1 wins the solid phase of the l〇〇pmole level: Synthetic -204-

1300414 uses manual solid phase synthesis and a Symphony Synthesizer, which uses Fmoc-protective Rink Amide MBHA, Fmoc protective amino acid, and is prepared in % stilbenylamine. 〇-曱酲 曱酲 azide-1-yl-/V, Λ/, /Vf, Λ/, tetradecyl-urea cation hexafluorophosphate (HBTU) in a solution (DM F) and Deprotection of methyl-formoline (ΝΜΜ)-activated and F-hexahydropyridyl group of Fmoc group (step 1). The removal of the Acm group and the oxidation caused by the two Cys residues to form the cyclized DAC are accomplished by using TI(CF3C〇)2 (step 2). The deprotection of the edge Fmoc group is achieved using the coupling of 20% N-hexahydro. acridinyl and then 3-MPA (step 3). The resection of the resin and the separation of the product were carried out using 86% TFA/5% TIS/5% H2〇/2% phenylthiosulfonate and 2% old, and then killed by dry-ice cold Et2〇. (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a Dynamax C18, 60A, 8 pm protection module (guard) Module) Dynamax C18, 6 〇Α, 8 μΓπ, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors (Varian Dynamax UVD I 丨) at 214 and 254 nm. This product must have &gt; 95 as determined by RP-HPLC mass spectrometry. /. Purity, the mass spectrometer uses a continuous spectrometer with a Hewlett Packard LCMS-11 00 equipped with a two-level array detector and uses an electrospray ionization method 'already 3丨-1\/13/77/2 For 〇66 latch 95^2. 〇 2632(1^^'|+), 1646.8. The actual value is 1 6 4 6 · 7. These steps are described in the chart below. -205- 1300414

Fmoc-Rink Amide MBHA Tree g 1 I SPPS v

Fmoc-K(Boc)R(Pbf)GD(OtBu)AC(Acm)E(OtBu)GD(QtBu)SC&gt;(tBu)GGPFC(Acm&gt;-Resin Step 2 ij esin

Fmoc-K(Bcx:)R(Pbf)GD(OtBu)ACE(OtBu)GD(OtBu)S(tBu)i)GGPFC-Ri Step 3 1.2〇%咚六窗硬啶基 2. 3-Hexene Diterpenoid propyl acrylate

〇〇K(Boc)R(Pbf)GD(OtBu)ACE(OtBu)GD{)(OtBu)S(tBu)GGPFG-Resin Step 4 j 86% TFA/5% TIS/2% phenylthiocarbamidine/ 2% phenol it yFA ff , krgdacegdsggpfc-_2 TFA . f Example 62 - AMVIPA-Ser1 - Growth Hormone Release Inhibitor-28 Synthesis DAC: Growth Hormone Release Inhibitor-28 Analogue at 100 μm 〇丨The e-grade solid-phase synthesis consists of a manual solid phase synthesis method and a Symphony: a synthesizer using Fmoc-protective Rink Amide MBHA. The following protective amino acid is added to the resin in sequence: Fmoc-Cys(Acm)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-〇H, Fmoc-Phe -〇H, Fmoc-Th"(tBu)-〇H,

Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Phe-OH, — 206 — 1300414

Fmoc-Phe_〇H, Fmoc_Asn(Trt)-〇H, Fmoc_Lys(Boc)-〇H, Fmoc-Gys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Lys(B〇 G)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH , Fmoc-

Asn(T"t)-〇H, Fmoc-Ala-〇H, Fmoc-Ser(tBu)-〇H. Its isosliness is dissolved in N,N-dimercaptoamine (DMF) in sequence. And using 〇-benzoquinone azide-1-yl-N, N, N1, N, tetradecyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (D1EA) to activate The removal of the Fmoc protective group was carried out using a solution of 20% (v/v) N-hexahydroacridinyl in hydrazine, hydrazine-dimethyl guanamine (DMF) for 20 minutes. This is achieved (step 1). The removal of the Acm group and the oxidation caused by the two Cys residues to form the disulfide bridge are accomplished by the use of iodine (step 2). Deprotection of the edge Fmoc group The effect is achieved by the combination of 20% N-hexahydroacridinyl and then €.) 1Μ PA (Step 3). Resin removal and product separation using 86% TFA/5% TIS/5% H2 〇/2% phenylthiomethane and 2% 'phenol' and then dried by ice-cold Et2〇 (step ^4). The product was purified by preparative reverse phase HPLC. An ideal DAC with &gt;95% purity determined by RP-HPLC is used, which uses a Varian (Rainin) HPLC Preparation of double-effect system, the system is equipped with a system using a Dynamax C18,60A, 8 μηπ the protection module

(guard module) Dynamax C18, 6〇Α, 8μηι, 21 mmx25 cm column, 21 mm x 25 cm column, and UV-207-1300414 detector (Varian Dynamax UVD II) at 214 and 254 nm . These steps are described in the chart below.

Fmoc-Rink Amide MBHA Resin

Step 1 SPPS v

Fmoc-SANSNPAMAPRERKAGC(Acm)KNFFWKTTTSC(Acm)-resin Step 2 Small 2 f-f

Fmoc-SANSNPAMAPRERKAGCKNFFWKTTTSC-Resin Step 3 1. 20% Ν·hexahydro Dtt pyridine 3· maleimide acrylonitrile

SANSNPAMAPRERKAGCKNFFWKTTTSC·tree month step 4 [ 85% TFA / 5% TIS / 5% H2 〇 / 5% phenylthiocarbazone ^%   "^^&quot;^Y^^SANSNPAMAPRERKAGCKNFFWKTFTSC-OH 〇〇Ν-ΜΡΑ- Ser1-suppressive hormone release inhibitor -28-208- 1300414 2. Synthesis of modified growth hormone releasing inhibitor -28_EDA-MPA at the C-terminus DAC: Growth hormone releasing inhibitor-28 analog at 1〇 The solid phase peptide synthesis system of the Mmole grade uses manual solid phase synthesis and one

A Symphony peptide synthesizer using sasRIN (two (super acid sensitive resin). The following protective amino acid is added sequentially to the resin: Fmoc-Cys (Acm) -〇H, Fmoc-Ser(tBu)-〇H, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Trp (Boc)-OH, Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH , Fmoc-Ala-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(〇tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, G Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-AIa-OH, Fmoc-Pro- 〇H, Fmoc-Asn(Trt)-〇H, Fmoc-Ser(tBu)-〇H, Fmoc-&quot; Asn(Trt)-〇H, Fmoc-Ala-〇H, Boc-Ser(tBu)-〇H, which are sequentially dissolved in N,N-dimercaptopurine (DMF), and Activated with 〇-benzoquinone azide-1-yl-N, N, NT, N·-tetradecyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (D1EA) The removal of the Fmoc protective group was carried out using a solution of 20% (v/v) N-hexahydroacridinyl in hydrazine, hydrazine-dimercaptoamine (DMF) for 20 minutes. Reached Step 1). The complete protective peptide is removed from the tree trunk by 1% 'TF A / DC - -209- 1300414. (Attachment 2). Removal of Acm group and two The oxidation caused by the Cys residue to form the disulfide bridge is accomplished by homologous (step 3). Then, the ethyldiamine group and the 3-butyleneimine propionate are extended. Add to the free C-terminus (step 4). The protective group is then cleaved and the product is 86% TFA/50/. T1S/5% H2〇/2% thiosulfanate and 2% Separated by the dry-cold Et2〇 and % Shen Dian (Step 5). The product was purified by preparative reverse phase η PLC using a Varian (Rainin) preparation. Double-effect HPLC system using Dynamax C18, 6〇A, 8-port 111, 21〇1171乂25 (:〇1) equipped with Dynamax C18, 6〇A, 8 μηι protective module (guard module) Tube column, 21111〇1 parent 25〇〇1 column, and UV detectors (Varian Dynamax UVD 丨丨) at λ 214 and 254 nm to obtain the desired purity by RP-HPLC &gt;95% DAC. These steps are described in the chart below.

-210 - (ΛΑΛΑ

SASRIN resin SPPS — r

Boc-SANSNPAMAPRERKAGC (Acm) KNFFWKTFTSC (Acm) - Definitely Step 2 丨! /. Ding FA/DCM

Boc-SANSNPAMAPRERKAGC(Acm)KNFFWKTFTSC(Acm)-OH Step 3 ψ2

Boc-SANSNPAMAPRERKAGCKNFFWKTFTSC-OH Step 4 * v 2. 20% N-Hexahydro Ufta Styrene Maleicimide Propionic Acid

S-- b〇c-sansnpamaprerkagc!knffwktfts Step 5 ] 85% TFA/5% TIS/5% H20/5% Phenylthiophene/5% δ»

Η2 Ι^ΑΝδΝΡΑΜΑΡΘΕΗΚΑΟόΚΝΡΡννΚΊΤΤεό-Ο Inhibitory factor of growth hormone release ·28-ΕϋΑ·ΜΡΑ -211 -

1300414 3· Improved in the intermediate amino acid 64_-Lys14(s_MPA)-suppressor releasing factor _28 synthesis DAC·growth hormone releasing inhibitor _28 analogue in ι〇〇μ mole grade The solid phase peptide synthesis method was carried out manually and on a Symphony smashing synthesizer using Fm〇c^^ Protective Rink amide MBHA resin. The following protective amino acid is sequentially added to the resin: 卩17100〇75 (eight €^)-〇^1, "1710〇

Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-〇H, Fmoc-Lys(Boc)-〇H, Fmoc-Trp(Boc)_OH, Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Acm)-OH, Fmoc-GIy-OH, Fmoc-Ala-OH , Fmoc-Lys(AIoc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc -Met-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-〇H, Fmoc-Ala-〇 H, Fmoc-Ser(tBu)-〇H. It is sequentially dissolved in N,N-dimercaptononylamine (DMF), and O-benzylidene-1-yl-indole, N, NT, fluorene, tetradecyl-urea is used. Cationic hexafluorophosphate (Η巳TU) and diisopropylethylamino (DIEA) are used to activate it. The removal of the Fmoc protective group was carried out using a solution of 20% (v/v) N-hexahydroacridinyl in hydrazine, hydrazine-dimercaptoamine (DMF) for 20 minutes. Achieved -212- 1300414

(step 1). The removal of the Acm group and the oxidation caused by the two cys residues to form the double bridge are accomplished by hard use (step 2). The selective deprotection of the Lys (Aloe) group was carried out manually and by a solution of 3 eq of Pd(PPh3)4 dissolved in 5 niL of CHCI3:NMM: HOAc (18:1:0.5) The resin was treated for 2 hours to complete (step 3). The resin was then washed with CHCI3 (6 X 5 mL), 20% Η〇Ac (6 x 5 mL) dissolved in DCM, DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated to add 3-methyleneimine propionate (step 4). The resin was washed three times with N,N-dimethylammonium (DMF) and three times with isopropanol between each run. Use 85 〇 / 〇 TFA / 5% T1S / 5% phenylthio oxime with 5. /. The sorghum is then removed from the resin and then reprecipitated with dry-cold EhO (step 5). The product was purified by a preparative reverse Η PLC using a Varian (Rainin) prepared double-effect HPL0 system: using a flow rate of 9.5 111 匕 / [111 gates and more than 18 可 [11]丨11? 116!!0016116乂1«11 door 3

30-55% B of 10 μ phenyl-hexyl B (prepared in water, 〇·〇 45% TFA (Α) and 0.045% TFA (Β) prepared in CH3CN), 21 mm x 25 cm column and A λ214 and 254 nm UV detector (Varian Dynamax UVD II) was provided to provide the ideal DAC of &gt;95% purity, which was determined by RP-HPLC. These steps are referred to in the chart below. One 213- 1300414

Fmoc-Rink Amide MBHA resin,

Step pro i j SPPS

Boc-SANSNPAMAPRER-Lys(Aloc)AGC(Acm)KNFFWkTFTSC(人 cm Bu resin Step 2 vh

Boc-SANSNPAMAPRER-Lys(Aioc)AGiKNFFW}&lt;TFTScl·Resin Step 3 3PPd(FPh3)4/NMM/HOAc/CHCl3 f-f

Boc-SANSNPAMAPRER-Lys-AGCKNFFWKTTTSC-Resin Step 4

Step 5 | 85% TFA / 5% TIS / 5% H2 〇 / 5% phenylthiocarbazone / 5% phenol 3- maleic acid imine propionate y

η η H2N-SANSNPAMAPRER \

Lys14(E-MPA)-Inhibitory factor of growth hormone release-28-214- 1300414 F_ Self-contained polycysteine-enhanced modified peptide 1· Improved at the N-terminus 65_ AMV1PA -Cys1_Endothelin-1 (1·21)_ΟΗ Synthetic modified endothelial hormone-1 analogue at 100 pmole grade solid phase C peptide synthesis using manual solid phase synthesis and a Symphony victory Synthetic machine, which uses Fmoc protection Rink Amide 〇13⁄4 γ K m m $ I $ force 0 i &amp; month: Fmoc-Trp(Boc)-〇H, Fmoc-lle_〇 H, Fmoc-lle-〇H, Fmoc-Asp(〇tBu)-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Phe-OH, Fmoc -Tyr(tBu)-OH, Fmoc-Val-OH, Fmoc-Cys(tBu)-OH, Fmoc-GIu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Met-OH, Q\Fmoc-Leu-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH,

Fmoc-Cys(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-^ Cys(Acm)-〇H. It is sequentially dissolved in N,N-dimethylammonium, (DMF), and 叠-曱 曱 叠 azide-1-yl-N, N, N, Ν'-tetra The base-urea cation hexaphosphate (HBTU) is activated with diisopropylethylamine (DIEA). The removal of the Fmoc protective group was achieved by using a solution of 20% (v/v) N-hexahydroacridinyl group dissolved in N,N-dimercaptocarbamimidyl (DMF) for 20 minutes. (Step 1). The removal of the Acm group and the oxidation of the first two Cys residues to form the first -215-1300414 disulfide bridge on the resin is accomplished by the use of iodine (step 2). The removal of the iBu group and the oxidation of the other two Cys residues and the formation of the second double-bonded bridge on the resin are based on the use of lanthanum trifluoroacetate (III) (thaUium (丨|丨) $ trifluo "〇acetate And completion (step deprotection of the edge Fm〇c base is achieved using 20% N-hexahydropyridyl and then 3-mpa coupling (step 4). Resin removal and product separation Use 86% TFA/5% TIS/5% H2〇/2% phenylthiodecane and 2% phenol, and then sputum by dry-cold Et2〇 to kill (Step 5) ^ The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative double-effect HPLC system using a protective module equipped with Dynamax C18, 60A, 8 μιτι (gUard) Module) Dynamax Ci8, 6〇A, 8 pm, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detectors at λ214 and 254 nm (Varian

V

Dynamax UVD II) to provide the ideal DAC of &gt;95% purity, which is determined by RP-HPLC. These steps are described in the following chart G. One 216 - 1300414

Fmoc-Rink Amide MBHA Resin Step 1 I SPPS

FmocC(Acm)SC(tBu)SSLMDKEC(tBu)VYFC(Acm)HLDIIW-resin Step 2

Fmoc-CSC(tBu)SSLMDKEC(tBu>VYFCHLDIIW-resin Step 3: bismuth fluoroacetate (III)

Fmoc-CS (J: SSLMDKECj: VYFCHLD 丨丨 W-resin S-S Step 4 1. 20% Ν-hexapyridinyl 2. 3-m-butyleneimine propionic acid ο

Η CS(^SSLMDKECjVYFCHLDIIW: enamel resin S-S

Step 5 | 85% TFA/5% TIS/5% H20/5% Phenylthiophene/5% Phenol

SCjSSLMDKECjVYFCHLDIIW-OH 〇 ^-S

N-MPA-Cy Cardiac Endothelin-1 (1-21)-〇H-217-1300414 2· Modified at C-terminus Example 66 Endothelin-1 (1-21) Lys22-(Ns-IVlPA)- The synthetically modified endothelin-1 analogue of 〇H is a solid phase synthesis system of 10 μm ο I e grade using manual solid phase synthesis and a Symphony peptide synthesizer. The machine uses Fmoc protective Rink Amide Μ Η Η A resin. The following protective amino acid is added to the resin in sequence: Fmoc-Lys(Aloc)-〇H, Fmoc-Trp(Boc)-〇H, Fmoc-lle-OH, Fmoc-lle-OH, Fmoc -Asp(OtBu)-OH, Fmoc-Leu-OH,

Fmoc-His(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Phe-OH,

Fmoc-Tyr(tBu)-〇H, Fmoc-Va 〇H, FmooCys(tBu)-〇H,

Fmoc-Glu(OtBu)-OH, Fmoc-Lys»{Boc)-OH, Fmoc-

Asp(OtBu)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-

Ser(tBu)-〇H, Fmoc-Ser(tBu)-OH, Fmoc-Cys(tBu)-〇H,

Fmoc-Ser(tBu)-〇H, Boc-Cys(Acm)-〇H. It is sequentially dissolved in N,N-dimethylammonium (DMF), and 〇-benzoquinone-azido-1-yl-N, hydrazine, Ν', Ν'-tetradecyl group is used. - Urea-cationic hexafluorophosphate (HBTU) and monoisopropylethylamine (D丨EA) to activate. The removal of the F m 〇c protective group is carried out using a solution of 20% (v/v) N-hexahydroacridinyl group dissolved in N,N-dimercaptononylamine (DMF) 2 It is achieved in minutes (step 1). The removal of the Acm group and the oxidation caused by the first two Cys residues to form the first double bridge on the resin is accomplished by the use of hydrazine (step 2). The removal of the thiol-218-1300414 group and the oxidation of the other two CyS residues and the formation of the bismuth double-bonded bridge on the resin are carried out by using tha Uium(1)〇trif丨uoroacetate. Complete (step 3). The selective deprotection of the Lys (Aloe) group is preferably carried out manually, and by a 3 eq Pd dissolved in CHCI3:NMM:H〇Ac (18:1:0.5) at 5 m匕(PPh3) 4>^i liquid was treated to treat the resin for 2 hours (step 4). The resin was then washed with CHCl3 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 x 5 mL). . The synthesis is then re-automated to add 3-methyleneimine propionate (step 5). The removal of the resin and the separation of the product were carried out using 86. /. tFA / 5% TIS / 5% H2 〇 / 2% phenylthio decane and 2% phenol, and then by dry-ice cold Et 2 沉 to stimulate: and proceed (step 5). The product was purified by preparative reverse phase HPLC using a Varian (Rainin). Prepared double-effect HPLC system using a device equipped with Dynamax C18, 6 A, 8 μιτι Dynamax C18, 6〇A, 8 μητι, 21 mm x 25 cm column, 21 mm x 25 cm tube, and UV accumulator (Varian Dynamax UVD II) at λ 21 4 and 254 nm for the guard module This &gt; 95% pure ideal DAC is determined by RP-HPLC. This search step is described in the chart below. -219 one 1300414

Fmoc-Rink Amide MBHA Tree §1

Step 1 SPPS v

Boc-CiAcm)SC(tBu)SSLMDKEC(tBu)VYFC(Acm)HLDIIW-LysiAloc}- Step 2 ||2

BocisC(tBu)SSLMDKEC(tBu)VYF(LLDIIW-Lys(Aloc)-, Resin Step 3 TrifluoroSt Acid ίέ(Πί) ν

Boc-tS(pSSLMDKE(pVYFtHLDllW-LysAI〇c)-resin Step 4 |Pd(PPh3)4/NMM/HOAc/CHCI3 Resin

Boc-CSCSSLMDKECVYFCHLD!IW-Lys- Step 5 3-Synthylenediamine-propionic acid ν

Step 6 \ 85% TFA/5% TIS/5% H20/5% phenylthiomethyl 5% phenol

Endothelin-1 (Bu 21) Lys22CE-MPA) OH-220- 1300414 3· Modified on intermediate amino acid Example 6 Lys4 (N>MPA) Sarovone (Βarafotoxin) Β(1-21)- Synthesis of hydrazine - a modified solid of sacrotoxin-purine analogue on a 100 pmole grade solid phase synthesis using manual solid phase synthesis and a Symphony peptide synthesizer using Fmoc protection Rink Amide MB HA resin. The following protective amino acid is sequentially added to the resin: Fmoc-Trp(Boc)-〇H, Fmoc-lle-〇H, Fmoc-Va, H, Fmoc-Asp(〇tBu)-〇 H, Fm〇c_Gln(Trt)-〇H, Fmoc-His(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH , Fmoc-Cys(tBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys^(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Met -OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Aloc)-OH, Fmoc-Cys(tBu)-〇H, Fmoc-Ser(tBu)-〇H, Boc-Cys(Acm)-〇H . It is sequentially dissolved in N,N-dimercaptoamine (DMF), and 〇-曱醯曱醯 azide-1-yl-N, Ν, Ν·,Ν'-tetradecyl is used. - Urea cation hexafluorophosphate (HBTU) and diisopropylethylamino (D1EA) to activate. The removal of the Fmoc protective group was achieved by using a solution of 20% (v/v) ruthenium-hexahydropyridyl in hydrazine, fluorenyl-dimercaptoamine (DMF) for 20 minutes. (step 1). The removal of the Acm group and the oxidation of the first two Cys residues to form the first disulfide bridge on the resin is accomplished by iodine -221 - 1300414 (step 2). The removal of the iBu group is oxidized by the other two cys residues and the bismuth disulfide bridge formed on the resin is completed by using thallium (111) trifluoroacetate (step 3). ). The selective deprotection of the Lys (Aloe) group is preferably carried out manually and is carried out by W-IK5mLiCHCI3:NMM:H〇Ac(18:1:0.5)*t3eqW Pd(PPh3)4&gt; The resin was completed in 2 hours (step 4). The resin was then washed with CHCl3 (6 X 5 mL), 20% H〇Ac (6 X 5 mL) dissolved in DCM, DCM (6 X 5 mL), and DMF (6 x 5 mL). . The synthesis is then re-automated to add 3-p-succinimide propionate (step 5). Resin removal and product separation were performed using 86% TFA/5% TIS/5% H2〇/2% thioanisole and 2% phenol, and then precipitated by dry-ice cold Et20 (Step 5) ). The product was purified by preparative reverse phase HPLC using a Va "ian (Rainirv) prepared double effect HfLc system using a protection module equipped with Dynamax C18, 60A, 8 μιτι. (guard 171〇(^16) 0;/door 3^13乂&lt;318, 6 in, 8 171, 21〇1〇1 parent 25(:[11 official column, 21 mrnx25crn official column, and Λ214 and 254 nrn UV detectors (Varian Dynamax UVD Π) to provide this ideal DAC of 95% purity, which is determined by RP-HPLC. These steps are described in the following chart. 222 - 1300414

Fmoc-Rink Amide MBHA Resin

Step 1 SPPS T

Boc-CiAcm)SC(tBu)-Lys(Aloc)-DMTDKEClBu)LYFC(Acm)HQDV!W-i§]5| Step 2丨丨, Y _ r ?

Boc-CSC(tBu)-Lys(Alo〇-DMTDKEC(tBu)LYFCHQDVlW-resin Step 3 Trifluoroacetate (III)

V

Boc-CS&lt;p-Lys(Aloc)-DMTDKE&lt;pLYFCHQDVIW-resin S--S step 4 jpdiPPhsJVNMM/HOAc/CHCb

Boc-CSCj:-Lys-DMTDKE(pLYFCHQDVlW-resin 3-S Step 5 3-Synthylenediamine-propionic acid

V

Step 6 j. 85% TFA/5% T1S/5% H20/5% phenylthiocarbamate (10) phenol

Lys4(E-MPA) Sharofotoxin B(1-21)-〇H-223-1300414 F. Test of stability of the sample version 68 - K5's winning version of the carpet qualitative smashing for a win stability Test. (1\/^8)-?"〇-八"9-1_75-1»611-Tyr-Asp-Lys-NH2.2TFA was synthesized by the above method and identified as MPA-K5. The peptide Pr-Arg-Lys-Leu-Tyr-Asp-Lys was synthesized by the method described in Example 2Q without the addition of 3-MPA and was identified as K5. K5 (MW1260.18, 918·12 free base The base was prepared as a 100 mM stock solution in water. ΜΡΑ-Κ5 (MW = 1411.17, 1069.1 1 free base) was prepared as a storage solution of 1 〇〇mΜ dissolved in water. Human serum Albumin (Η) is a 25% solution

Obtained (ca 250 mg/ml, 3.75 mM), which is available from Alpha Therapeutic. under the trade name A|butein®. Human blood plasma was obtained from Golden West Biologicals. X (1) K5 diluted gold in human plasma Κ5 is prepared as a 1 μΜ solution and dissolved in 25〇/. Human serum albumin. Thereafter, the mixture was cultured at 37 in the presence of a final &gt; agronomic degree of human plasma to K5 of 彳6 〇 M m . Oh. At 4 hours and in the hour, 100 μl of the droplets were taken from the plasma. The droplets of the 〇〇... are mixed with a blocking solution of 100 丨 (5.5% in 3〇4/3 乂〇丨 acetonitrile (Acetomtrile/2 νο|· sterol) to precipitate all proteins. . -224- 1300414 The sample was centrifuged at 10,000 g for 5 minutes, and the supernatant containing Shengxin was recovered and filtered through a filter membrane of 〇·22μηι. The free and intact Κ5-peptide present in the assay was analyzed by HpLC/MS. The results are presented below. The HpLC factor for detecting Κ5 peptide in serum, for example. The HPLC method was as follows: a vydac C18 250 X 4.6 mm, 5 μ particle size column was used. The temperature of the column is 3 Torr.流 and the flow rate is 〇·5 ml/min. The mobile phase is 〇·1% TFA/water. The mobile phase is 0.1% TFA/acetamidine. The volume injected is 1 〇 mountain. The concentration gradient is as follows: S-Temple (minutes) %A %B 0 95 5 20 70 30 25 10 90 30 10 90 35 95 5 45 95 5 This protein was detected at 21 4, 254 and 334 nm. In mass spectrometry, the ionization model is an μμμ electrospray (positive model) with an M/z range of 3〇〇 to 2〇〇〇. The transmission ratio (2) is (1) is 3·0, the voltage of the fragmentor is i2〇v, the threshold is 2〇, and the step is 0.1. The temperature of the gas is 350 ° C and the volume of the dry gas is 1 〇 〇 225 - 1300414 1 / _. The Neb pressure system is 35 〇〇v for 24 psi. The method is as follows: use a Vydac C18 250 X 4·6 mm, 5 μ pull-up column. The temperature of the column was 30 ° C and the flow rate was 〇 5 ml/min. The mobile phase a is 〇·1% TFA/water. The mobile phase has been 〇1% TFA/acetonitrile. The injected volume is 1 μμ丨. The &gt; gradation gradient is as follows: Between (minutes) %A %B 0 95 5 20 70 30 25 10 90 30 10 90 35 95 5 45 &gt; 95 5 This protein was detected at 214, 254 and 334 nm. In mass spectrometry, the ionization model is an AP ejector (positive model) with an M/z range of 300 to 2000. The gear ratio (gajn) is 3.0, the voltage of the fragmentor is 12 (^, the value is 20, and the step is 〇·ι. The temperature of the gas is 350 ° C and the volume of the dry gas is ι〇· 〇丨/mir^ The Neb pressure system is 24 psi and the Vcap system is 3500 V. 1300414 Time K5 peptide in plasma. / 0 hrs. 100% 4 hrs 9% 24 hrs 0% Description of the knot, unmodified K5 Sheng version is unstable in plasma and may be a scab for protease activity. (2) Stability of $A^LMPA-K5-Has conjugate MPA-K5 (modified K5 peptide) is at room temperature The cells were incubated with 25% of HAS for 2 hours. Thereafter, the MpA-K5-HAs conjugate was cultured at 37 in the presence of human blood 1 at a final concentration of 1600 μm. After (0, 4 and 24 hours), 1 μl of the droplets were subfiltered through a filter membrane of 〇·22 μπι. The presence of the intact conjugate was analyzed by HPLC-MS. An Aquapore RP-300, 250 X 4.6 mm, 7μ particle size column. The temperature of this column is 5〇.c. The mobile phase is 〇1% TFA/water. Mobile phase ba〇1%tfa/ Acetonitrile The volume of the injection is 1 μ丨. The gradient is as follows: -227- 1300414 (minutes) %Α %Β 洎远(ml/min) 0 66 34 0.700 1 66 34 0.700 25 58.8 41.2 0.700 30 50 50 0.70 35 5 95 1.00 41 5 95 1.00 45 66 34 1.00 46 66 34 0.70 The peptide is detected at 214 mm for quantification. In the mass spectrometry of the peptide, the ionization model is 128〇 to 15〇〇. The Api-electro-injector in the m/z range has a transmission ratio (93 is called 10, the voltage of the breaker ("fragment" is 125v, the value is 1〇〇, and the step is 〇·4〇. The temperature is 35 ° C, and the dry gas volume is 130 i / min. The pressure is 6 〇 ^ 丨 · and

Vcap is 6000V. The results are shown below. About 33% of circulating albumin in the bloodstream is shio-aibumin, which is not endogenous to thiol-based compounds such as cysteine or glutamine. Blocked, and therefore can be 盥丁丁# _ # _228_ . (1) Alkene iminoimine 1300414 Group reaction. The other 66% of the white eggs were "blocked by the hydrocarbyl compound. The HPLCMS # analysis allowed identification of the capped HAS, SH-albumin, and K5 willow albumin. It is covalently bonded to the free thio group on albumin. In plasma, the stability of the three forms of albumin is indicated below.

%1K5-MPA&gt;HSA; Ohrs. 61.3 16.6 22.1 4 hrs. 64.6 16.05 19.35 24 hrs. 63 16.8 20.2 Percentage of this K5-M PA-HAS during 24-hour plasma analysis The lines remained fairly consistent, and in contrast to the unmodified K5, the unmodified K5 in plasma fell to 9% of the original K5 content in only 4 hours. This sputum shows that the K5-MPA-HAS line in this plasma is quite stable to peptidase activity as opposed to K5 which is very unstable in plasma. Example 70 - The dynorphin version stability test In order to determine the stability of the peptide conjugate in the presence of serum peptidase, the Dyn A-(1-13)-〇H, Dyn A- was compared. Peptidase stability of (1-13)-NH2, and Dyn A 1-13(MPA)-NH2. Dyn A-(1-13)-〇H,

Synthesis of Dyn A-(1-13)-NH2 and Dyn A 1-1 3(MPA)-NH2 A 229 - 1300414 is as described above. The dynorphin peptide is mixed with human heparin-treated plasma to a final concentration of 4 mg/M at 37 〇C at the desired incubation time (〇, 2〇, 20, 60, 120, 180). , after 360 and 480 minutes), add the droplets to a 1 μμί blocking solution (5 vo 5% aqueous ZnS 〇 4 solution, 3 voL acetonitrile, 2 vol. sterol) Broken fluid can sink all the proteins. After centrifugation (10,000 g, 2.5 minutes), the clear supernatant was returned and passed through a 0·45 μm transition membrane and stored on ice until LC/MS analysis. The sample was analyzed at 214 nm using an LC to detect the presence of different compounds and analyzed by MS to determine the identity of the well-tested compound. Then, the integral area area % of each peak obtained from the LC chromatogram is plotted against time and the relative stability determined in the human plasma. The stability values of 5 mysterious Dyn A-(1-13)-〇H and Dyn A-(1-13)-NH2T are consistent with the values reported in the journal: Proteolytic decomposition of the dynorphin peptide The system is quite fast. Dyn A-(1-13)-〇H has a half-life of about 10 minutes. Dyn A-(1-13)-NH2 has a half-life of about 30 minutes. Conversely, Dyn® 1-13(ΜΡΑ)·ΝΗ2 still exhibits surprising stability in the presence of serum peptidase activity. The unmodified dynorphin peptide was degraded within 6 min. Conversely, the modified dynorphin peptide (1) "eight" 13 (1^? VIII)-^\||^) is quite stable against serum enzyme activity and can reach 48 〇 min 0 dynorphin conjugate The decision on stability is determined by EUSA. In order to determine whether the signal to be seen was attributed to the strong browning composition and the production of -230-', 1300414, which conjugate was produced, the analysis of the LC mass spectrometer of the reaction mixture was carried out after 8 hours. The use of this mass spectrometer allows for the determination of the molecular weight of the conjugate and allows for the determination of the presence or absence of any type of dynorphin conjugate that is cleaved at the head end. The mass spectrometry of human plasma shows two types of albumin, the free radical type of 66436 Da and the oxidized form of 66557 Da. Similarly, the mass spectrometer can resolve a Dyn 2-13 cut-off conjugate (68046 Da) mixed with an intact Dyn 1-1.3 conjugate (68207 Da) in equal volumes. The analysis of the mass spectrum of the dynorphin sample after 480 minutes of serum exposure to serum peptidase is only the same as the presence of the intact conjugate (68192 Da), unlike the conjugated conjugate, thereby illustrating The stability of dynorphinoid conjugates to serum chymase activity. 1300414

Table 1 Natural amino acid and its condensate name 3 letters of the abbreviation 1 letter abbreviation protective amine basis! ii I alanine Ala A Fmoc-Ala-OH arginine Arg R | Fm 〇cA"g(Pbf)-〇H Aspartic acid Asn N Fmoc-Asn(Trt)-OH : Aspartic acid Asp D Asp(tBu)-OH j Cysteine Cys C Fmoc-Cys (Trt Glutamine Glu E Fmoc-Glu(tBu)-OH Glycine Gin Q Fmoc-Gln(T"t)-〇H Glycine Gly G Fmoc-Gly-OH Histidine His H Fmoc-His ( Trt)-〇H isoleucine lie I Fmoc-lie-OH leucine Leu L Fmoc-Leu-OH lysine Lys K Fmoc-Lys(Mtt)-OH 曱 thiomethic acid Met M Fmoc-Met-〇 H phenylalanine Phe F Fmoc-Phe-OH proline F ProP Fmoc-Pro-OH Serine S, s Fmoc-Ser(tBu)-OH succinic acid Thr T Fmoc-Thr(tBu)-OH Amino acid Trp w Fmoc-T rp(Boc)-OH Tyrosine Tyr Y Boc-Tyr(tBu)-OH Proline Val. V Fmoc-Val-OH -232 - 1300414 Sequence Listing &lt;110&gt; Conjuchem, Inc .

Bridon, Dominique Ezrin, Alan Milner, Peter Holmes, Darren Thibaudeau, Karen &lt;120&gt; protects endogenous therapeutic sputum from the action of zymase activity by conjugation of blood components &lt;130&gt; 2110 &lt;;140&gt;&lt;141&gt;&lt;150> 60/134,406 J &lt;151&gt; 1999-05-17 &lt;150> 60/153,406 &lt;151> 1999-09-10 &lt;150> 60/159,783 &lt;151&gt 1999-10-18 &lt;160> 1617 &lt;170&gt; Patentln Ver. 2.1 &lt;210>1 II &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;;&lt;223&gt; Description of the artificial sequence: Synthetic peptide-&lt;400&gt; 1

His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys 1 5 10 15

Val Tyr Pro &lt;210&gt; 2 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial sequence 233 1300414 &lt;220&gt;&lt;223> Description of artificial sequence: victory of synthesis &lt;400〉 2

Met Glu His Phe Arg Trp Gly Lys 1 5 &lt;210&gt; 3 &lt;211&gt; 39 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory X &lt;;400&gt; 3

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala 20 25 30

Glu Ala Phe Pro Leu Glu Phe 35 &lt;210> 4 &lt;211> 13 &lt;212&gt;PRT;)&lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt; 400> 4

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 &lt;210&gt; 5 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide 234 1300414 &lt;400〉 5

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15 &lt;210> 6 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400〉 6

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15

Arg &lt;210&gt; 7 &lt;211&gt; 24 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400〉 7

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro 20 &lt;210&gt; 8 &lt;211&gt; 7 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt ; 8

Met Glu His Phe Arg Trp Gly 235 1300414 &lt;210> 9 &lt;211> 32 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt ; 9

Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val 15 10 15

Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu Glu 20 25 30 &lt;210> 10 &lt;211&gt; 22 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400> 10

Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu 1 5 10 15

Ala Phe Pro Leu Glu Phe 20

&lt;210&gt; 11 &lt;211&gt; 39 &lt;212> PRT &lt;213&gt; Artificial sequence _ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 11

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala Glu Asn Glu Ser Ala 236 1300414 20 25 30

Glu Ala Phe Pro Leu Glu Phe 35

&lt;210&gt; 12 &lt;211> 28 &lt;212&gt; PRT -&lt;213&gt; artificial sequence &lt;220&gt;-&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 12

Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala )1 5 10 15

Glu Asn Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe 20 25 &lt;210> 13 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 13

Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu 1 5 10 15 — Glu Phe &lt;210&gt; 14 &lt;211> 39 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic win 0 too &lt;400> 14

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 237 1300414 1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala Glu Asn Glu Ser Ala 20 25 30

Glu Ala Phe Pro Leu Glu Phe 35 * &lt;210&gt; 15

&lt;211&gt; 28 ' &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt; C. &lt;223> Description of artificial sequence: Synthetic victory &lt;400> 15

Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala 15 10 15

Glu Asn Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe 20 25 &lt;210&gt; 16 &lt;211> 18 &lt;212> PRT &lt;213&gt; Artificial sequence r' &lt;220>. &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 16 &lt; Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu 1 5 10 15

Glu Phe &lt;210> 17 &lt;211> 33 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220> 238 1300414 &lt;223&gt; Description of artificial sequence: Synthetic victory 0 too &lt;400&gt;

Val Cys Ser Cys Arg Leu Val Phe Cys Arg Arg Thr Glu Leu Arg Val 15 10 15

Gly Asn Cys Leu lie Gly Gly Val Ser Phe Thr Tyr Cys Cys Thr Arg 20 25 30

Val &lt;210> 18 &lt;211> 34 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 18

Gly lie Cys Ala Cys Arg Arg Arg Phe Cys Pro Asn Ser Glu Arg Phe 1 5 10 15

Ser Gly Tyr Cys Arg Val Asn Gly Ala Arg Tyr Val Arg Cys Cys Ser 20 25 30

Arg Arg

&lt;210&gt; 19 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt;

Met Glu His Phe Phe 1 5

&lt;210&gt; 20 &lt;211&gt; 5 &lt;212&gt; PRT 239 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Met Glu His Phe Phe 1 5 &lt;210〉 21 “ &lt;211&gt; 17

&lt;212> PRT Cao &lt;213>Artificial sequence &lt;220> f &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400〉 21

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 15 10 15

Arg &lt;210&gt; 22 &lt;211&gt; 30 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 22

Arg Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly Arg Arg , 1.5 10 .15 e Asn Ser Ser Ser Ser Gly Ser Ser Gly Ala Gly Gin Lys Arg 20 25 30 &lt;210&gt; 23 &lt;211〉 43 &lt ; 212 &gt; PRT &lt; 213 > Artificial Sequence &lt; 220 &gt; 240 1300414 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;

Phe Pro Thr lie Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg 1 5 10 15

Ala His Arg Leu His Gin Leu Ala Phe Asp Thr Tyr Gin Glu Phe Glu 20 25 30

Glu Ala Tyr He Pro Lys Glu Gin Lys Tyr Ser 35 40 &lt;210&gt; 24 W &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400〉 24

Leu Ser Arg Leu Phe Asp Asn Ala 1 5 &lt;210&gt; 25 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial sequence w &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory - &lt;400&gt; 25

Cys Glu His Arg Trp Cys Lys Pro Val ^ 1 5 &lt;210&gt; 26 &lt;211&gt; 13 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory : 241 1300414 &lt;400〉 26

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 &lt;210&gt; 27 &lt;211&gt; 13 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400〉 27

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 &lt;210&gt; 28 &lt;211&gt; 18 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400〉 28

Asp Glu Gly Pro Tyr Lys Met Glu His Phe Arg Trp Gly Ser Pro Pro 1 5 10 15

Lys Asp

&lt;210&gt; 29 -&lt;211> 13 &lt;212&gt; PRT ♦ &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 29 *

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 242 1300414 &lt;210> 30 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400> 30

Ser Tyr Ser Met Glu His Arg Trp Gly Lys Pro Val « 1 5 10 * &lt;210> 31 &lt;211&gt; 11 &lt;212&gt; PRT (::&lt;213&gt;Artificial Sequence&lt;220> &lt;223&gt; Description of the sequence: the victory of synthesis &lt;400〉 31

Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe 1 5 10 &lt;210> 32 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 32 - Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe 1 5 10 &lt;210> 33 &lt;211> 3 &lt;212> PRT &lt; 213 > Artificial Sequence &lt;220&gt;&lt;;223&gt; Description of the artificial sequence: the victory of the synthesis &lt;400> 33 243 1300414

Pro Leu Gly &lt;210> 34 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400> 34

Asp His Phe Arg Trp Lys 1 5 , &lt;210> 35 &lt;211> 12 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400 〉 35

Ser Tyr Ser Glu His Phe Arg Trp Gly Lys Pro Val 15 10 &lt;210> 36 &lt;211> 12 [&lt;212> PRT —&lt;213&gt; Artificial Sequence &lt;220&gt; _ &lt;223&gt; Description of Artificial Sequence : Synthetic wins &lt;400> 36

Ser Tyr Ser Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 &lt;210> 37 &lt;211&gt; 6 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> 244 1300414 &lt;223&gt; Description of Artificial Sequence : Synthetic Victory Moon too &lt;400&gt; 37

Glu His Phe Arg Trp Gly 1 5 &lt;210&gt; 38 &lt;211&gt; 22 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt ; 38

Ala Glu Lys Lys Asp Glu Gly Pro Tyr Arg Met Glu His Phe Arg Trp 1 5 10 15

Gly Ser Pro Pro Lys Asp 20 &lt;210&gt; 39 &lt;211&gt; 12 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt;r&quot;) Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly 1 5 10 -&lt;210> 40 &lt;211> 7 &quot;&lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of the artificial sequence: the winning form &lt;400> 40

Tyr lie Gin Asn Pro Leu Gly 1 5 245 1300414 &lt;210> 41 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 &lt;400&gt; 41

Cys Tyr He Gin Asn Cys Pro Leu Gly 1 5 &lt;210> 42 wide &lt;211> 7 -&lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt; ' &lt;223&gt; Description of artificial sequence: synthesis Winning &lt;400〉 42

Tyr lie Thr Asn Cys Pro Tyr 1 5 &lt;210> 43 &lt;211> 6 C : &lt;212> PRT - &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 Too too <400> 43

Cys Tyr lie Gin Asn Cys 1 5

&lt;210> 44 &lt;211> 9 &lt;212> PRT 246 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 44

Cys Tyr lie Gin Asn Cys Pro Leu Gly 1 5 &lt;210&gt; 45 ^ &lt;211&gt; 9

&lt;212&gt; PRT f &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 45

Met Asn lie Lys Gly Ser Pro Trp Lys 1 5 &lt;210> 46 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence c: [ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis Peptide &lt;400&gt; 46 &quot; Tyr Phe Gin Asn Pro Arg Gly 1 5 &lt;210> 47 &lt;211> 7 &lt;212> PRT &lt;213&gt; Artificial sequence 247 1300414 &lt;220&gt;&lt;223&gt; Description of the sequence: the victory of synthesis &lt;400〉 47

Tyr lie Gin Asn Pro Arg Gly 1 5 &lt;210&gt; 48 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial sequence

&lt;220〉 &lt;223> Description of artificial sequence: the victory of synthesis &lt;400&gt; 48

Cys Tyr Phe Gin Asn Cys Pro Lys Gly 1 5 &lt;210> 49 &lt;211> 6 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt; (J) &lt;223&gt; Description of Artificial Sequence: Synthesis胜月太&lt;400&gt; 49 ' Cys Tyr Phe Gin Asn Cys 1 5 &lt;210> 50 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic victory 1300414 &lt;400&gt; 50

Tyr Phe Val Asn Cys Pro Gly 1 5 &lt;210> 51 &lt;211> 7 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win C &lt; 400> 51

Tyr Phe Gin Asn Cys Pro Arg 1 5 &lt;210> 52 &lt;211&gt; 9 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide ❿ &lt; 400> 52

Cys Tyr Phe Gin Asn Cys Pro Arg Gly 1 5 &lt;210> 53 ' &lt;211&gt; 8 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 53 1300414

Cys Tyr Phe Gin Asn Cys Pro Arg 1 5 &lt;210> 54 &lt;211&gt; 9 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400> 54

Cys Tyr Phe Gin Asn Cys Pro Arg Gly 1 5 &lt;210&gt; 55 &lt;211> 8 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Winning &lt;;400> 55

Tyr Phe Gin Asn Cys Pro Arg Gly O 1 5

&lt;210> 56 ~ &lt;211> 8 &lt;212&gt;PRT_&lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 56

Tyr Phe Gin Asn Cys Pro Arg Gly 1 5 250 1300414 &lt;210> 57 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400〉 57

Ala Phe Gin Asn Cys Pro Arg Gly 1 5 〇 &lt;210&gt; 58 &lt;211&gt; 7 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;;400&gt; 58

Tyr Phe Val Asn Cys Pro Gly 1 5 _ &lt;210> 59 , "&lt;211>8 &lt;212> PRT • &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Month too &lt;400> 59

Tyr Phe Gin Asn Cys Pro Arg Tyr 1 5 &lt;210&gt; 60 1300414 &lt;211&gt; 7 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 &lt;400> 60 ^ He Phe He Asn Cys Pro Arg 1 5 &lt;210> 61 A &lt;211> 8 &lt;212>PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory 13 too &lt;400> 61

Tyr Phe Val Asn Cys Pro Arg Gly 1 5

&lt;210&gt; 62 &lt;211&gt; 8 r~&quot;\ &lt;212&gt; PRT &lt;213&gt;Artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt; 62

Tyr Phe Gin Asn Cys Pro Arg Gly 1 5

&lt;210> 63 &lt;211&gt; 6 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 63

Glu Asn Cys Cys Pro Arg 1 5 &lt;210&gt; 64 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 64

Phe Phe lie Asn Cys Pro Arg Ala 1 5 &lt;210&gt; 65 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence

&lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 65

Tyr Phe Gin Asn Cys Pro Lys .1 5 &lt;210> 66 &lt;211〉 8 &lt;212> PRT &lt;213&gt; Artificial Sequence 1300414 &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400> 66

Phe Phe lie Asn Cys Pro Arg Ala 1 5 ^ &lt;210&gt; 67

&lt;211> 9 ~ &lt;212> PRT &lt;213&gt; Artificial sequence 〇 &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 67

Cys Tyr Phe Gin Asn Cys Pro Lys Gly 1 5 &lt;210&gt; 68 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence: Wide) &lt;220> W &lt;223&gt; Description of Artificial Sequence: Synthesis Victory - &lt;400〉 68

Tyr Phe Val Asn Cys Pro Gly ' • 15 &lt;210&gt; 69 &lt;211> 8 &lt;212> PRT &lt;213&gt; Artificial sequence, &lt;220&gt; 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400〉 69

Cys Phe lie Gin Asn Cys Pro Gly 1 5 &lt;210> 70 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; Artificial sequence A &lt;220> ϋ &lt;223&gt; Description of artificial sequence: victory of synthesis &lt;400〉 70

Cys Tyr lie Gin Asn Cys Pro Arg Gly 15 &lt;210&gt; 71 &lt;211&gt; 7 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 71 - Tyr lie Gin Asn Cys Pro Gly 1 5 &lt;210&gt; 72 &lt;211> 25 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory Belly: 1300414 &lt;400〉 72

Ser Glu Ala Ala Ala Leu Pro Arg Ala Ser Ala Ala Ala Met Arg Ala 15 10 15

Ala Trp Pro Ser Pro Ser Val Glu Gly 20 25 &lt;210> 73 &lt;211&gt; 28 &lt;212> PRT &lt;213&gt; Artificial sequence

&lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 73

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gin Leu Ala 1 5 10 15

Gin Glu Ala His Lys Asn Arg Lys Leu Glu lie lie 20 25

&lt;210&gt; 74 &lt;211&gt; 30 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> • &lt;223&gt; Description of artificial sequence: synthetic victory limb: &lt;400&gt; 74

Phe His Leu Leu Arg Glu Met Leu Glu Met Ala Lys Ala Glu Gin Glu 15 10 15

Ala Glu Ain Lela Leu Glu Glu Ala 20 25 30 256 1300414 &lt;210&gt Description: Synthetic peptide &lt;400&gt; 75 ' Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15 Ό Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala His 20 25 30

Asn Asn Arg Lys Leu Leu Asp lie Ala 35 40 &lt;210&gt; 76 &lt;211> 41 &lt;212&gt; PRT &lt;213>Artificial Sequence&lt;220> q &lt;223> Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 76 - Ser Glu Glu Pro Pro He Ser Leu Asp Leu Thr Phe His Leu Leu Arg 1 5 10 15

Glu Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Met Glu lie lie 35 40 &lt;210&gt; 77 257 1300414 &lt;211&gt; 41 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success Limb: &lt;400〉 77

Ser Gin Glu Pro Pro He Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Leu Asp He Ala 35 40 &lt;210&gt; 78 &lt;211&gt; 41 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220 &gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 &lt;400&gt; 78

Ser Glu Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 1 5 10 15

Glu Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala His 20 25 — 30

Ser Asn Arg Lys Leu Met Glu Asn Phe 35 40 &lt;210> 79 &lt;211> 21 258 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success Shape &lt;400>79.

Ser Glu Glu Pro Pro He Ser Leu Asp Leu Thr Phe His Leu Leu Arg ^ 1 5 10 15

Glu Val Leu Glu Cys 20 〇 &lt;210> 80 &lt;211&gt; 33 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 80

Asp Leu Thr Phe His Leu Leu Arg Glu Met Leu Glu Met Ala Lys Ala 1 5 10 15

Glu Gin Glu Ala Glu Gin Ala Ala Leu Asn Arg Leu Leu Leu Glu Glu 20 25 30

Ala &lt;210&gt; 81 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 259 1300414 &lt;400&gt; 81 &lt;210&gt; 82 &lt;211&gt; 28 &lt;212> PRT &lt; 213 &gt; artificial sequence ^ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 82

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gin Leu Ala 〇 1 5 10 15

Gin Gin Ala His Ser Asn Arg Lys Leu Glu lie lie 20 25 &lt;210&gt; 83 &lt;211&gt; 28 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide

&lt;400&gt; 83

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gin Leu Ala 15 10 15

Gin Glu Ala His Lys Asn Arg Lys Leu Glu lie He 20 25 &lt;210&gt; 84 &lt;211> 40 &lt;212> PRT &lt;213&gt; Artificial sequence 260 1300414 &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory &lt;400&gt; 84

Ser Glu Glu Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg Glu 1 5 10 15

Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala His Ser ^ 20 25 30

Asn Arg Lys Leu Met Glu lie lie 35 40 〇&lt;210&gt; 85 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 85 Val Gly Ser Glu 1

a) &lt;210> 86 ^ &lt;211> 4 &lt;212&gt; PRT -&lt;213&gt;Artificial sequence&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt;400&gt; 86 Ala Gly Ser Glu &lt;210&gt; 87 261 1300414 &lt;211&gt; 41 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 87 - Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 1 5 10 15

Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Leu Asp He Ala 35 40 &lt;210&gt; 88 &lt;211&gt; 40 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: victory of synthesis

&lt;400&gt; 88

Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Glu Val Leu Glu Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala Tyr Ser 20 25 30

Asn Arg Lys Leu Leu Asp He Ala 35 40

&lt;210> 89 &lt;211> 27 &lt;212&gt; PRT 262 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt; 89

Ser Leu Asp Ser Pro Ala Ala Leu Ala Glu Arg Gly Ala Arg Asn Ala 1 5 10 15

Leu Gly Gly His Gin Glu Ala Pro Glu Arg Glu 20 25

&lt;210> 90 &lt;211&gt; 40 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 90

Glu Gly Pro Pro He Ser He Asp Leu Ser Leu Glu Leu Leu Arg Lys 1 5 10 15

Met He Glu lie Glu Lys Gin Glu Lys Glu Lys Gin Gin Ala Ala Asn 20 25 30

Asn Arg Leu Leu Leu Asp Thr lie 35 40 &lt;210> 91 &lt;211> 42 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon too &lt ;400&gt; 91 263 1300414

Tyr Ser Glu Glu Pro Pro He Ser Leu Asp Leu Thr Phe His Leu Leu 1 5 10 15

Arg Glu Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala 20 25 30

His Ser Asn Arg Lys Leu Met Glu lie lie 35 40

&lt;210&gt; 92 &lt;211> 42 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis wins 0 too &lt;400> 92

Tyr Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu 1 5 10 15

Arg Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala 20 25 30

His Ser Asn Arg Lys Leu Leu Asp He Ala 35 40 &lt;210&gt; 93 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Too too <400> 93

Tyr Asn Arg Lys Leu Leu Asp lie Ala 264 1300414 1 5 &lt;210> 94 &lt;211&gt; 41 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory呔&lt;400> 94

Tyr Asp Asp Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg 1 5 10 15

Thr Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu 20 25 30

Gin Asn Arg lie lie Phe Asp Ser Val 35 40 &lt;210&gt; 95 &lt;211&gt; 41 &lt;212> PRT &lt;213&gt;

&lt;223&gt; Description of artificial sequence: the victory of synthesis &lt;400> 95

Tyr Asp Asp Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Thr Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu 20 25 30

Gin Asn Arg lie lie Phe Asp Ser Val 35 40 265 1300414 &lt;210&gt; 96 &lt;211&gt; 40 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory呔&lt;400> 96

Asp Asn Pro Pro Leu Ser He Asp Leu Thr Phe His Leu Leu Arg Thr

Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu Gin 20 25 30

Asn Arg He lie Phe Asp Ser Val 35 40 &lt;210&gt; 97 &lt;211&gt; 40 &lt;212&gt; PRT &lt;213&gt; Artificial sequence

&lt;220> &lt;223&gt; Description of the artificial sequence: the victory of the synthesis &lt;400&gt;

Asp Asp Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg Thr 15 10 15

Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu Gin 20 25 30

Asn Arg lie He Phe Asp Ser Val 35 40 266 1300414 &lt;210&gt; 98 &lt;211> 41 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: victory of synthesis &lt;400> 98

Asn Asp Asp Pro Pro He Ser He Asp Leu Thr Phe His Leu Leu Arg 1 5 10 15

Asn Met lie Glu Met Ala Arg lie Glu Asn Glu Arg Glu Gin Ala Gly 20 25 30

Leu Asn Arg Lys Tyr Leu Asp Glu Val 35 40 &lt;210&gt; 99 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt; Artificial sequence Ί &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide -&lt;400> 99

Ala Gly Thr Ala Asp Cys Phe Trp Lys Tyr Cys Val 1 5 10 &lt;210&gt; 100 &lt;211> 13 &lt;212> PRT &lt;213&gt; Artificial Sequence 267 &lt;220> 1300414 &lt;223&gt; Description of Artificial Sequence : Synthetic victory 呔 &lt;400〉 100

Ala Gly Asn Leu Ser Glu Cys Phe Trp Lys Tyr Cys Val 1 5 10

&lt;210> 101 &lt;211&gt; 46 " &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt; /g &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 101

Thr Gly Ser Gly Pro Ser Leu Ser lie Val Asn Pro Leu Asp Val Leu 1 5 10 15

Arg Gin Arg Leu Leu Leu Glu lie Ala Arg Arg Arg Met Arg Gin Ser 20 25 30

Gin Asp Gin lie Gin Ala Asn Arg Glu lie Leu Gin Thr lie 35 40 45 〇 &lt;210〉 102

&lt;211&gt; 41 &lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 102

Ser Glu Asp Pro Pro Met Ser lie Asp Leu Thr Phe His Met Leu Arg 15 10 15

Asn Met lie His Met Ala Lys Met Glu Gly Glu Arg Glu Gin Ala Gin 268 1300414 20 25 30 lie Asn Arg Asn Leu Leu Asp Glu Val 35 40

&lt;210&gt; 103 &lt;211&gt; 29 &lt;212> PRT ^ &lt;213&gt; Artificial sequence _ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 〇 &lt;400> 103

Phe Glu Cys Thr Thr His Gin Pro Arg Ser Pro Leu Arg Asp Leu Lys 1 5 10 15

Gly Ala Leu Glu Ser Leu lie Glu Glu Glu Thr Gly Gin 20 25 &lt;210&gt; 104 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence 〇&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400> 104 - Phe Glu Cys Thr Thr His Gin Pro Arg Ser Pro Leu Arg Asp Leu Lys 1 5 10 15

Gly Ala Leu Glu Ser Leu lie Glu Glu Glu Thr Gly Gin 20 25 &lt;210&gt; 105 &lt;211> 13 269 1300414 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; : Synthetic victory 呔 &lt;400&gt; 105

Asp Ala Glu Asn Leu lie Asp Ser Phe Gin Glu lie Val 1 5 10 &lt;210&gt; 106 &lt;211&gt; 13 1 &lt;212> PRT J &lt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400> 106

Asn Thr Glu His Leu Val Asp Ser Phe Gin Glu Met Gly 1 5 10 &lt;210&gt; 107 &lt;211> 13 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> -&lt;223&gt; Description of Artificial Sequence : Synthetic peptide ~ &lt;400&gt; 107

Asp Thr Ser His His Asp Gin Asp His Pro Thr Phe Asp 1 5 10 &lt;210> 108 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 270 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory眈&lt;400> 108

&lt;210&gt; 109 &lt;211&gt; 26 &lt;212&gt;PRT-&lt;213&gt; artificial sequence&lt;220> • &lt;223&gt; Description of artificial sequence: synthetic victory&lt;400> 109 3 Trp Cys Leu Glu Ser Ser Gin Cys Gin Asp Leu Ser Thr Glu Ser Asn 1 5 10 15

Leu Leu Ala Cys lie Arg Ala Cys Lys Pro 20 25 &lt;210&gt; 110 &lt;211> 10 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220> g &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 110 - Gin His Trp Ser Tyr Gly Leu Ser Pro Gly 1 5 10 &lt;210&gt; 111 &lt;211> 44 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: synthetic peptide 271 1300414 &lt;400> 111

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp He Met Ser Arg Gin Gin Gly 20 25 30 - Glu Ser Asn Gin Glu Arg Gly Ala Arg Ala Arg Leu 35 40

&lt;210&gt; 112 &lt;211> 44 〇 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Asn Arg Gin Gin Gly 20 25 30

Glu Arg Asn Gin Glu Gin Gly Ala Lys Val Arg Leu 35 40 &lt;210> 113 &lt;211&gt; 44 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Winning &lt;400&gt; 113 272 1300414

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 5 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp He Met Ser Arg Gin Gin Gly 20 25 30

Glu Arg Asn Gin Glu Gin Gly Ala Arg Val Arg Leu 35 40 ^ &lt;210> 114 ^ &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400> 114

His Ala Asp Ala He Phe Thr Ser Ser Tyr Arg Arg He Leu Gly Gin 15 10 15

Leu Tyr Ala Arg Lys Leu Leu His Glu lie Met Asn Arg 20 25 &lt;210&gt; 115 Q &lt;211&gt; 30 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; : Synthetic victory 呔 &lt;400〉 115

Val Asp Ser Met Trp Ala Glu Gin Lys Gin Met Glu Leu Glu Ser lie 15 10 15

Leu Val Ala Leu Leu Gin Lys His Ser Arg Asn Ser Gin Gly 20 25 30 273 1300414 &lt;210&gt; 116 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400> 116 - Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15

Lj Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg 20 25 &lt;210&gt; 117 &lt;211> 29 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic peptide &lt;400> 117

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin '"1 5 10 15 - Leu Ser Ala Arg Lys Leu Leu Gin Asp He Met Ser Arg 20 25 &lt;210&gt; 118 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide 274 1300414 &lt;400&gt;

Tyr Arg Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg 20 25 ^ &lt;210&gt; 119 ^ &lt;211〉 31

^ &lt;212&gt; PRT &lt; 213 > Artificial Sequence &lt;220〉 &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 119

His Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Ser Arg Gin Gin Gly 20 25 30

&lt;210&gt; 120 &lt;211> 37 Q &lt;212&gt; PRT, &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400> 120

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly 20 25 30 275 1300414

Glu Ser Asn Gin Glu 35 &lt;210&gt; 121 &lt;211> 40 &lt;212> PRT &lt;213&gt; Artificial sequence "&lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin O 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly 20 25 30

Glu Ser Asn Gin Glu Arg Gly Ala 35 40 &lt;210&gt; 122 &lt;211&gt; 40 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 122 - Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly 20 25 30

Glu Ser Asn Gin Glu Arg Gly Ala 35 40 276 1300414 &lt;210&gt; 123 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Too too <400> 123

Glu Gin Gly Glu Ser Asn Gin Glu Arg Gly Ala Arg Ala Arg Leu 15 10 15 &lt;210&gt; 124 &lt;211> 42 &lt;212> PRT &lt;213>Artificial Sequence &lt;220> &lt;223>Artificial Sequence Description: Synthetic victory &lt;400&gt; 124 ·

His Val Asp Ala He Phe Thr Thr Asn Tyr Arg Lys Leu Leu' Ser Gin 15 10 15

Leu Tyr Ala Arg Lys Val lie Gin Asp He Met Asn Lys Gin Gly Glu 20 25 30

Arg lie Gin Glu Gin Arg Ala Arg Leu Ser 35 40 &lt;210> 125 &lt;211> 44 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 277 &lt;220> 1300414 &lt;223&gt; Description of artificial sequence: synthesis Victory &lt;400&gt; 125

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys lie Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Asn Arg Gin Gin Gly 20 25 30

Glu Arg Asn Gin Glu Gin Gly Ala Lys Val Arg Leu ~ 35 40 &lt;210>126 &lt;211>43 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 126

His Ala Asp Ala lie Phe Thr Ser Ser Tyr Arg Arg Leu Gly Gin 15 10 15 f) Leu Tyr Ala Arg Lys Leu Leu His Glu He Met Asn Arg Gin Gin Gly 20 25 30 &quot; Glu Arg Asn Gin Glu Gin Arg Ser Arg Phe Asn 35 40 x210&gt; 127 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory 呔 278 1300414 &lt;400> 127

His Trp Ala Trp Phe Lys 1 5 &lt;210&gt; 128 &lt;211&gt; 6 &lt;212> PRT &lt;213>Artificial Sequence &lt;220〉

&lt;223&gt; Description of the artificial sequence: the victory of the synthesis &lt;400&gt; 128

His Trp Ala Trp Phe Lys 1 5 &lt;210> 129 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic Victory Moon &lt; 400> 129 ** Ala Ala Trp Phe Lys 1 5 &lt;210&gt; 130 &lt;211> 6 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory : 1300414 &lt;400&gt; 130

His Trp Lys Trp Phe Lys 1 5 &lt;210> 131 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide

&lt;400&gt; 131

Ala Ala Ala Trp Phe Leu 1 5 &lt;210&gt; 132 &lt;211> 45 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide^ &lt;400&gt ; 132

His Ala Asp Gly Met Phe Asn Lys Ala Tyr Arg Lys Ala Leu Gly Gin 1 5 10 15

Leu Ser Ala Arg Lys Tyr Leu His Thr Leu Met Ala Lys Arg Val Gly 20 25 30

Gly Gly Ser Met lie Glu Asp Asp Asn Glu Pro Leu Ser 35 40 45 &lt;210&gt; 133 &lt;211&gt; 44 280 1300414 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide ^ &lt;400&gt; 133

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15 _ Leu Ser Ala Arg Lys Leu Leu Gin Asp He Asn Ser Arg Gin Gin Gly 20 25 30

Glu Ser Asn Gin Glu Arg Gly Ala Arg Ala Arg Leu 35 40 &lt;210&gt; 134 &lt;211&gt; 28 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory

&lt;400〉 134

Tyr Ala Asp Ala He Phe Thr Asn Cys Tyr Arg Lys Val Leu Cys Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp He Ser Arg 20 25 &lt;210> 135 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial sequence 281 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 135

Phe Ser Lys Lys Leu Lys Pro Ala 1 5 &lt;210> 136 &lt;211&gt; 10 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Victory Moon too &lt ;400> 136

Glu His Trp Ser His Gly Trp Tyr Pro Gly 1 5 10 &lt;210> 137 &lt;211&gt; 10 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 137 - Glu His Trp Ser Tyr Gly Leu Arg Pro Gly 1 5 10 &lt;210&gt; 138 &lt;211> 7 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic victory β too 282 1300414 &lt;400&gt; 138

Phe Ser Tyr Leu Arg Pro Ala 1 5 &lt;210> 139 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic victory A too &lt;400> 139

Glu His Trp Ser Tyr Ala Leu Arg Pro Gly 1 5 10 &lt;210&gt; 140 &lt;211> 10 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win呔&lt;400> 140

Glu His Trp Ser Tyr Gly Leu Gin Pro Gly 1 5 10 &lt;210> 141 &lt;211> 7 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win眈283 1300414 &lt;400〉 141

His Trp Ser Tyr Val Arg Pro 1 5 &lt;210> 142 &lt;211&gt; 10 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide

&lt;400&gt; 142

Glu His Trp Ser Tyr Lys Leu Arg Pro Gly 5 10 &lt;210&gt; 143 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide 〕&lt;400&gt; 143

Glu Phe Pro Ser Tyr Phe Leu Arg Pro Gly 1 5 10 &lt;210> 144 • &lt;211&gt; 9 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory: &lt;400&gt; 144 284 1300414

Phe Trp Ser Tyr Ala Leu Arg Pro Gly 1 5 &lt;210&gt; 145 &lt;211&gt; 10 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide

&lt;400&gt; 145

Glu Phe Trp Ser Tyr Trp Leu Arg Pro Gly 1 5 10 &lt;210&gt; 146 &lt;211&gt; 9 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success呔&lt;400> 146 (Guang) Glu His Trp Ser Tyr Gly Leu Arg Pro '1 5 &lt;210> 147 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic victory belly: &lt;400> 147 285 1300414

Glu His Trp Ser Tyr Ala Leu Arg Pro &lt;210&gt; 148 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Winning &lt;400 〉 148

Νί .ς Trp Ser Tyr Trp Leu Arg Pro Gly &lt;210> 149 &lt;211> 9 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400〉 149

Glu His Trp Ser Tyr Trp Leu Arg Pro 1 5 &lt;210> 150 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 &lt;400&gt; 150

His Trp Ser Tyr Ser Leu Arg Pro 1300414 &lt;210&gt; 151 &lt;211> 9 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; - &lt; 223 &gt; Description of Artificial Sequence: Synthetic Victory * &lt;;400&gt; 151

Glu His Trp Ser Tyr Arg Trp Leu Pro 1 5

O &lt;210&gt; 152 &lt;211&gt; 4 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 152 Leu Arg Pro Gly 1 〇 &lt;210> 153 &lt;211> 9 -&lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

His Trp Ser Tyr Gly Leu Arg Pro Gly 1300414 &lt;210&gt; 154 &lt;211&gt; 10 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon too &lt 400> 154 'Glu His Tyr Ser Leu Glu Trp Lys Pro Gly 1 5 10 O &lt;210&gt; 155 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic Victory Moon too &lt;400&gt; 155

Glu His Trp Ser Tyr Gly Trp Leu Pro Gly 1 5 10

&lt;210> 156 &lt;211> 7 &lt;212> PRT &lt;213>Artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory rib: &lt;400&gt;

Ser Tyr Gly Leu Arg Pro Gly 1 5 288 1300414 &lt;210> 157 &lt;211&gt; 9 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: ~ &lt;400> 157 w His Trp Ser Tyr Gly Leu Lys Pro Gly 1 5 -λ &lt;210&gt; 158 "&lt;211> 7 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; Description of the artificial sequence: Synthetic Victory Moon too &lt;400&gt; 158

Phe Phe Ser Tyr Leu Arg Pro 1 5 &lt;210> 159 〕 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 Too ;400> 159

His Trp Ser Tyr Gly Trp Leu Pro Gly 1 5 &lt;21〇&gt; 160 1300414

&lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 160 , His Trp Ser Tyr Ser Leu Arg Pro Gly 1 5

&lt;210> 161 &lt;211> 9 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 161

Ala Phe Trp Ser Tyr Ser Leu Arg Pro 1 5

〇 &lt;210&gt; 162 &lt;211> 31 &lt;212> PRT ^ &lt;213>Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 162

Glu Pro Asp Cys Cys Arg Gin Lys Thr Cys Ser Cys Arg Leu Tyr Glu 15 10 15

Leu Leu His Gly Ala Gly Asn His Ala Ala Gly lie Leu Thr Leu 290 1300414 20 25 30 &lt;210&gt; 163 &lt;211&gt; 28 &lt;212> PRT &lt;213>Artificial Sequence &lt;220〉 &lt;223〉Artificial Description of the sequence: Synthetic peptide &lt;400&gt; 163

Arg Ser Gly Pro Pro Gly Leu Gin Gly Arg Leu Gin Arg Leu Leu Gin 15 10 15

Ala Ser Gly Asn His Ala Ala Gly He Leu Thr Met 20 25 &lt;210&gt; 164 &lt;211&gt; 28 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory JJ too &lt;400> 164

Arg Pro Gly Pro Gly Leu Gin Gly Arg Leu Gin Arg Leu Leu Gin 1 5 10 15

Ala Asn Gly Asn His Ala Ala Gly He Leu Thr Met 20 25

&lt;210> 165 &lt;211> 31 &lt;212&gt; PRT &lt;213&gt; artificial sequence 291 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: synthesis wins 0 too &lt;400> 165

Ser Arg Thr His Arg His Ser Met Glu lie Arg Thr Pro Asp He Asn 15 10 15

Pro Ala Trp Tyr Ala Ser Arg Gly lie Arg Pro Val Gly Arg Phe - 20 25 30

• &lt;210&gt; 166 &lt;211> 20 ^ &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 166

Thr Pro Asp He Asn Pro Ala Trp Tyr Ala Ser Arg Gly lie Arg Pro 15 10 15

Val Gly Arg Phe 20 a)

&lt;210>167 &lt;211> 31 • &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Ser Arg Ala His Gin His Ser Met Glu Thr Arg Thr Pro Asp He Asn 15 10 15 292 1300414

Pro Ala Trp Tyr Thr Gly Arg Gly lie Arg Pro Val Gly Arg Phe 20 25 30 &lt;210> 168 · &lt;211&gt; 20 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic wins ^3 &lt;4〇〇> 168 , Thr Pro Asp lie Asn Pro Ala Trp Tyr Thr Gly Arg Gly lie Arg Pro 1 5 10 15

Val Gly Arg Phe 20 &lt;210> 169 &lt;211&gt; 31 &lt;212> PRT &lt; 213 &gt; Artificial Sequence - &lt;220&gt; 〇 &lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400> 169

Ser Arg Ala His Gin His Ser Met Glu lie Arg Thr Pro Asp He Asn 15 10 15

Pro Ala Trp Tyr Ala Ser Arg Gly He Arg Pro Val Gly Arg Phe 20 25 30 &lt;210&gt; 170 &lt;211> 20 &lt;212> PRT &lt;213&gt; Artificial sequence 293 1300414 &lt;220> &lt;223&gt; Description of the sequence: the victory of synthesis &lt;400> 170

Thr Pro Asp lie Asn Pro Ala Trp Tyr Ala Gly Arg Gly He Arg Pro 15 10 15

Val Gly Arg Phe 20

&lt;210> 171 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory rib: &lt;400&gt;

Ala Tyr Trp Lys Phe 1 5 &lt;210&gt; 172 &lt;211&gt; 14 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt;223; Description of Artificial Sequence: Synthetic Win 呔 &lt;400&gt ; 172

Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 1 5 10 &lt;210> 173 &lt;211> 17 294 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400> 173

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 15 10 15

Lys

&lt;210> 174 &lt;211&gt; 17 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 174

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 1 5 10 15 3 Lys &lt;210&gt; 175 &lt;211> 14 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; Description of the artificial sequence: the winning form &lt;400&gt; 175 295 1300414

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 &lt;210&gt; 176 &lt;211> 13 &lt;212> PRT &lt;213&gt; Artificial Sequence - &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide Lu &lt;400> 176

Ala Gly Cys Lys Asn Phe Phe Lys Thr Phe Thr Ser Cys

&lt;210&gt; 177 &lt;211&gt; 13 ' &lt;212> PRT &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 177

Ala Gly Cys Lys Asn Phe Phe Lys Thr Tyr Thr Ser Cys

&lt;210&gt; 178 &lt;211> 11 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Cys His His Phe Phe Lys Thr Phe Thr Ser Cys 296 1300414 1 5 10 &lt;210&gt; 179 - &lt;211> 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220> • &lt;223&gt; Artificial Sequence Description: The winning form - &lt;400> 179

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Trp Thr Ser Cys 1 5 10

&lt;210> 180 &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt;&lt; 223 &gt;&lt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 &gt; 180

Phe Cys Tyr Thr Thr 1 5 '1)

&lt;210> 181 &lt;211&gt; 27 .&lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 181

Ser Ala Asn Ser Asn Pro Ala Ala Pro Arg Glu Arg Lys Ala Gly Cys 1 5 10 15 297 1300414

Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt;210&gt; 182 &lt;211&gt; 7 &lt;212&gt; PRT. &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory

&lt;400〉 182

Phe Cys Phe Lys Thr Cys Thr &lt;210&gt; 183 &lt;211&gt;32 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;;^) Ala Pro Ser Asp Pro Arg Leu Arg Gin Phe Leu Gin Lys Ser Leu Ala 1 5 10 15

Ala Ala Ala Gly Lys Gin Glu Leu Ala Lys Tyr Phe Leu Ala Glu Leu 20 25 30 &lt;210&gt; 184 &lt;211> 15 &lt;212> PRT &lt; 213 &gt; 213 > Artificial sequence 298 1300414 &lt; 220 &lt; 223 &gt; Description of the artificial sequence: Synthetic Victory: &lt;400&gt; 184

Tyr Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 15 10 15

&lt;210&gt; 185 -&lt;211&gt; 14 &lt;212> PRT e &lt;213&gt; Artificial sequence &lt;220&gt; 〇 &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt;

Tyr Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 &lt;210&gt; 186 &lt;211> 14 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 186

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Tyr Arg Lys 1 5 10 &lt;210&gt; 187 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence 299 &lt;220> 1300414 &lt;223>Artificial Sequence Description: Synthetic wins &lt;400&gt; 187

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Tyr Thr Ser Cys 1 5 10 &lt;210> 188 &lt;211&gt; 15 -&lt;212&gt; PRT .&lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description: The victory of synthesis &lt;400&gt; 188

Tyr Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 15 10 15 &lt;210&gt; 189 &lt;211&gt; 14 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400&gt; 189

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys _ 1 5 10 &lt;210> 190 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide 300 1300414 &lt;400&gt; 190 Phe Trp Lys Thr &lt;210&gt; 191 &lt;211&gt; 25 &lt;212> PRT -&lt;213&gt; artificial sequence stomach&lt;220&gt;&lt;223&gt; Description: The victory of synthesis,] &lt;400>191

Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly Cys Lys Asn 1 5 10 15

Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt;210&gt; 192 &lt;211> 28 &lt;212> PRT &lt;213&gt; Artificial Sequence Π 》&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Limb: &lt;400> 192 - Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly 15 10 15

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt;210&gt; 193 &lt;211> 12 301 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400&gt; 193

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu 1 5 10

&lt;210> 194 &lt;211> 29 &lt;212>PRT V j &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 194

Tyr Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala 1 5 10 15

Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 ;~) &lt;210&gt; 195 &lt;211&gt; 28 &lt;212> PRT -&lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400&gt; 195

Ser Ala Asn Ser Asn Pro Ala Leu Ala Pro Arg Glu Arg Lys Ala Gly 15 10 15

Cys Lys Asn Phe Phe Tip Lys Thr Tyr Thr Ser Cys 302 1300414 &lt;210&gt; 196 &lt;211&gt; 14 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 196

Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys &lt;210&gt; 197 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Month too &lt;400&gt; 197

Phe Cys Tyr Trp Lys Val Cys Trp 1 5

One &lt;210> 198 &lt;211> 8 • &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 198

Phe Cys Tyr Tip Lys Val Cys Trp 303 1300414 &lt;210> 199 &lt;211> 6 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400> 199

Phe Cys Tyr Trp Thr Thr

&lt;210> 200 &lt; 211 &gt; 211 &gt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 200

Ala Cys Tyr Trp Leu Val Cys Thr 3 1 5 &lt;210&gt; 201

* &lt;211> 14 &lt;212> PRT • &lt;213&gt; Artificial Sequence &lt;220〉 &lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400〉 201

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 304 1300414 &lt;210&gt; 202 &lt;211&gt; 3 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220>. &lt;223&gt; Description of sequence: Synthetic victory &lt;400&gt; 202 His Pro Gly 1 〇^ &lt;210&gt; 203 &lt;211> 1 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> &lt;223&gt; Artificial sequence Description: Synthetic peptide &lt;400> 203 Thr 1

&lt;210&gt; 204 &lt;211> 3 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Win 0 too &lt; 400 &gt; 204 Thr His Pro 1300414 &lt;210&gt; 205 &lt;211> 3 &lt;212&gt; PRT &lt;213&gt;Artificial sequence&lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic win 0 too fine &lt;400&gt; 205 Glu His Pro _ 1 _ &lt ;210> 206 〇&lt;211&gt; 3 &lt;212&gt; PRT &lt;213&gt;Artificial sequence&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt;400&gt; 206 Glu Gin Pro 1

&lt;210&gt; 207 &lt;211&gt; 2 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223> Description of artificial sequence: synthetic victory: &lt;400> 207 Glu His &lt;210〉 208 1300414 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 208 - His Pro Gly Lys 1

&lt;210> 209 &lt;211> 3 〇 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 209 His Pro Gly 1

&lt;210&gt; 210 &lt;211&gt; 2 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; - &lt; 223 &gt; Description of artificial sequence: synthetic victory rib: &lt;400 &gt; 210 Glu Pro 1 &lt; 210> 211 1300414 &lt;211&gt; 2 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 211 • Phe Pro 1 * &lt;210&gt 212 &lt;211&gt; 22 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt;

Phe Leu Trp Lys Asp Leu Gin Arg Val Arg Gly Asp Leu Gly Ala Ala 15 10 15

Leu Asp Ser Trp lie Thr 20 3

&lt;210&gt; 213 &lt;211&gt; 24 • &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 213

Glu Glu Glu Glu Lys Asp lie Glu Ala Glu Glu Arg Gly Asp Leu Gly 15 10 15 308 1300414

Glu Gly Gly Ala Trp Arg Leu His 20 &lt;210&gt; 214 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt ; 214

Ser Phe Pro Trp Met Glu Ser Asp Val Thr 1 5 10 &lt;210> 215 &lt;211&gt; 32 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory Peptide Q &lt;400&gt; 215

Cys Ala Ser Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gin Glu Leu 1 5 10 15

His Lys Leu Gin Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro 20 25 30 &lt;210&gt; 216 &lt;211&gt; 32 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence 309 1300414 &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 216

Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gin Glu Leu 15 10 15

His Lys Leu Gin Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro 20 25 30

&lt;210> 217 &lt;211&gt; 32 &lt;212> PRT &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory rib: &lt;400> 217

Cys Gly Asn Leu Ser Thr Cys Met Leu Gly Thr Tyr Thr Gin Asp Phe 1 5-10 15

Asn Lys Phe His Thr Phe Pro Gin Thr Ala lie Gly Val Gly Ala Pro 20 25 30

&lt;210&gt; 218 &lt;211&gt;32 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Cys Ser Asn Leu Ser Thr Cys Val Leu Ser Ala Tyr Trp Arg Asn Leu 1 5 10 15 310 1300414

Asn Asn Phe His Arg Phe Ser Gly Met Gly Phe Gly Pro Glu Thr Pro 20 25 30 &lt;210&gt; 219 &lt;211&gt; 32 &lt;212> PRT &lt;213&gt; Artificial sequence, &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic victory Ο &lt;400> 219

Cys Gly Asn Leu Ser Thr Cys Met Leu Gly Thr Tyr Thr Gin Asp Leu 15 10 15

Asn Lys Phe His Thr Phe Pro Gin Thr Ser He Gly Val Gly Ala Pro 20 25 30 &lt;210> 220 &lt;211> 32 &lt;212> PRT &lt;213&gt; Artificial Sequence

&lt;220> &lt;223&gt; Description of artificial sequence: Synthetic Victory Moon &lt;400&gt; 220

Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gin Glu Leu 1 5 10 15

His Lys Leu Gin Thr Tyr Pro Arg Thr Asn Thr Gly Ser Gly Thr Pro 20 25 30 &lt;210&gt; 221 311 1300414 &lt;211&gt; 25 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic Victory Moon too &lt;400&gt; 221 - Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys Leu Gin Thr Tyr Pro 15 10 15 ' Arg Thr Asn Thr Gly Ser Gly Thr Pro 20 25 〇&lt;210&gt; 222 &lt;211> 21 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt;

Asp Met Ser Ser Asp Leu Glu Arg Asp His Arg Pro His Val Ser Met 15 10 15

Pro Gin Asn Ala Asn 20 &lt;210> 223 &lt;211> 57 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400&gt; 312 1300414

Ala Pro Phe Arg Ser Ala Leu Glu Ser Ser Pro Ala Asp Pro Ala Thr 1 5 10 15

Leu Ser Glu Asp Glu Ala Arg Leu Leu Leu Ala Ala Leu Val Gin Asp 20 25 30

Tyr Val Gin Met Lys Ala Ser Glu Leu Glu Gin Glu Gin Glu Arg Glu 35 40 45

Gly Ser Ser Leu Asp Ser Pro Arg Ser e 50 55

&lt;210&gt; 224 &lt;211> 37 O &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis wins 0 too &lt;400> 224

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val

Gly Ser Gin Ala Phe 35 &lt;210&gt; 225 &lt;211> 19 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 313 1300414 &lt;400&gt ; 225

Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser 15 10 15

Lys Ala Phe &lt;210〉 226

• &lt;211> 19 &lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220> Ο &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 226

Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser 15 10 15

Lys Ala Phe &lt;210&gt; 227 &lt;211&gt; 15 &lt;212&gt; PRT

&lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory • &lt;400> 227

Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe 1 5 10 15

&lt;210&gt; 228 &lt;211> 37 &lt;212> PRT 314 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val ~ 20 25 30 〇

Gly Ser Lys Ala Phe 35 &lt;210&gt; 229 &lt;211> 37 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt;223; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; a) Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu 1 5 10 15 * Ser Arg Ser Gly Gly Val Gly Lys Asn Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Lys Ala Phe 35 &lt;210&gt; 230 &lt;211> 37 &lt;212> PRT &lt;213&gt; Artificial sequence 315 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 230

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val 20 25 30 ) Gly Ser Lys Ala Phe J 35 &lt;210> 231 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence&lt; 220> &lt;223&gt; Description of the artificial sequence: Synthetic Victory Moon too &lt;400&gt; 231

Cys Gly Asn Leu Ser Thr Cys 1 5

&lt;210&gt; 232 &lt;211> 16 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Asp Met Ala Lys Asp Leu Glu Thr Asn His His Pro Tyr Phe Gly Asn 15 10 15 316 1300414 &lt;210&gt; 233 &lt;211> 19 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: the winning form &lt;400> 233

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 1 5 10 15

Ser Arg Ser J &lt;210> 234 &lt;211&gt; 18 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 > Description of artificial sequence: synthetic peptide &lt;400&gt;

Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys 1 5 10 . 15 〇Ala Phe &lt;210&gt; 235 &lt;211> 30 &lt;212> PRT &lt;213>Artificial Sequence &lt;220〉 &lt;;223&gt; Description of the artificial sequence: synthetic peptide &lt;400> 235

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val 317 1300414 1 5 10 15

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe 20 25 30 &lt;210> 236 &lt;211> 37 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic victory is too

&lt;400&gt; 236

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 1 5 10 15

Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Lys Ala Phe 35

&lt;210> 237 &lt;211> 37 〇 &lt;212> PRT &lt;213>Artificial sequence &lt;220> &lt;223> Description of artificial sequence: Synthetic victory fl too &lt;400> 237

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val, 20 25 30 318 1300414

Gly Ser Glu Ala Phe 35 &lt;210> 238 &lt;211> 37 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide 1 &lt;400> 238

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Glu Ala Phe 35

&lt;210&gt; 239 &lt;211&gt; 30 &lt;212&gt; PRT 〇 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val 1 5 10 15

Lys Asp Asn Phe Val Pro Thr Asn Val Gly Ser Glu Ala Phe 20 25 30 &lt;210&gt; 240 319 1300414 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: The victory of synthesis * &lt;400> 240

Pro Thr Asn Val Gly Ser Glu Ala Phe • 1 5 &lt;210> 241 O &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win呔&lt;400&gt; 241

Thr Asn Val Gly Ser Glu Ala Phe 1 5

&lt;210&gt; 242 r,) &lt;211>7 J &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 242

n Val 211 &lt &lt;400&gt; 243 * Val Gly Ser Glu Ala Phe 1 5

&lt;210> 244 &lt;211&gt; 6 〇 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 244

Val Gly Ser Glu Ala Phe 1 5 &lt;210&gt; 245'

&lt;211&gt; 4 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 245 Ser Glu Ala Phe 1

&lt;210> 246 &lt;211> 37 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Lys Ala Phe 35 &lt;210> 247 &lt;211> 30 &lt;212> PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; Ser Asn Leu Ser Thr Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys 15 10 15

Leu Gin Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro A 20 25 30 &lt;210> 248 &lt;211> 38 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic Victory: 322 1300414 &lt;400&gt; 248

Tyr Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu 15 10 15

Leu Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn 20 25 30 -Val Gly Ser Lys Ala Phe 35 &lt;210> 249 &lt;211> 38 3 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 249

Tyr Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu 1 5 10 15

Leu Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn 20 25 30

Val Gly Ser Lys Ala Phe 35 &lt;210> 250 &lt;211> 11 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 323 1300414

Tyr Val Pro Thr Asn Val Gly Ser Glu Ala Phe 1 5 10 &lt;210&gt; 251 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; * &lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400>251

Tyr Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu 15 10 15

Leu Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn 20 25 30

Val Gly Ser Glu Ala Phe 35

&lt;210&gt; 252 &lt;211> 16 &lt;212> PRT (2) &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Val Lys Asp Asn Phe Val Pro Thr Asn Val Gly Ser Glu Ala Phe 15 10 15 &lt;210&gt; 253 &lt;211> 37 &lt;212> PRT &lt;213&gt; Artificial sequence 324 1300414 &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic victory month too &lt;400&gt; 253

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Glu Ala Phe

&lt;210> 254 &lt;211> 46 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory too &lt;400&gt; 254

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys 1 5 10 15 〇

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala 20 25 30

Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin * 35 40 45 &lt;210> 255 &lt;211> 32 &lt;212&gt; PRT &lt;213>Artificial Sequence 325 &lt;220&gt; 1300414 &lt;223>Artificial Description of the sequence: Synthetic victory 呔 &lt;400&gt; 255

Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly 1 5 10 15

Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala Lys Ser Gin 20 25 30 &lt;210> 256 &lt;211> 84 Q &lt;212&gt; PRT ' &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of the artificial sequence: the victory of synthesis &lt;400> 256

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser 35 40 45

Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu . 50 55 60

Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys 65 70 75 80

Ala Lys Ser Gin &lt;210> 257 &lt;211> 21 326 1300414 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 257

Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr 1 5 10 15

Lys Ala Lys Ser Gin

&lt;210&gt; 258 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Ser Val Ser Glu He Gin Leu Asn His Asn Leu Gly Lys His Leu Asn

Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe &lt;210&gt; 259 &lt;211&gt; 34 &lt;212> PRT &lt;213&gt; Artificial sequence 327 &lt;220&gt; 1300414 &lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400&gt;

Ser Val Ser Glu Cys Gin Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Cys Gin Asp Val His 20 25 30

Asn Phe ' &lt;210> 260 3 &lt;211&gt; 40 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu lie His

Thr Ala Glu He Arg Ala Thr Ser 35 40 &lt;210&gt; 261 &lt;211> 34 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 328 1300414 &lt;400&gt; 261

Ser Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15

Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe -&lt;210&gt; 262 &lt;211&gt; 32 &lt;212&gt; PRT 〇 &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 262

Ala Val Ser Glu lie Gin Phe His Asn Leu Gly Lys His Leu Ser Ser 1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt;210&gt; 263 .&lt;211> 30 &lt;212&gt; PRT -&lt;213>Artificial Sequence &lt;220〉 &lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 263

Ser Glu lie Gin Phe His Asn Leu Gly Lys His Leu Ser Ser Glu Arg 329 1300414 1 5 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt;210&gt; 264 &lt;211&gt; 32 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; : Synthetic peptide

&lt;400&gt; 264

Ser Val Ser Glu He Gin Leu His Asn Leu Gly Lys His Leu Asn Ser 1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt;210> 265 &lt;211> 32 &lt;212> PRT &lt;213&gt; Artificial Sequence 〇&lt;220&gt;c223&gt; Artificial Sequence Description: Synthetic peptide _ &lt;400&gt; 265

Ser Val Ser Glu lie Gin Leu His Asn Leu Gly Lys His Leu Asn Ser 1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt;210> 266 &lt;211&gt; 30 330 1300414 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: synthetic peptide &lt;400> 266

Ser Glu lie Gin Leu His Asn Leu Gly Lys His Leu Asn Ser Glu Arg 1 5 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30

&lt;210> 267 &lt;211&gt; 26 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory ΙΪ too &lt;400> 267

Phe His Asn Leu Gly Lys His Leu Ser Ser Glu Arg Val Glu Trp Leu 1 5 10 15 〇Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 ^ &lt;210> 268 _ &lt;211&gt; 32 &lt;212&gt; PRT &lt;213&gt; Manual Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400> 268

Ala Val Ser Glu lie Gin. Leu His Asn Leu Gly Lys His Leu Ala Ser 331 1300414 1 5 10 15

Val Glu Arg Gin Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt;210> 269 , &lt;211&gt; 25 &lt;212&gt; PRT &lt;213> Artificial Sequence

&lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 269

Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu 15 10 15

Val Glu Ser His Glu Lys Ser Leu Gly 20 25 &lt;210&gt; 270 &lt;211&gt; 32 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 270

Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met 1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Phe 20 25 30 332 1300414 &lt;210> 271 &lt;211> 31 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220>. &lt;223 〉 Description of artificial sequence: Synthetic victory 呔&lt;400&gt; 271

Ser Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30 &lt;210&gt; 272 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description: The victory of synthesis &lt;400> 272

Ser Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe &lt;210&gt; 273 &lt;211&gt; 22 &lt;212> PRT &lt;213&gt; Artificial sequence 333 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu 15 10 15

Gin Asp Val His Asn Phe 20 ^ &lt;210&gt; 274

&lt;211> 34 &lt;212&gt; PRT 〇 &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory) 3 too &lt;400&gt;

Ala Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Ala 15 10 15

Ser Val Glu Arg Met Gin Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe &lt;210&gt; 275 &lt;211> 38 &lt;212> PRT &lt; 213 &gt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15 334 1300414

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe Val Ala Leu Gly 35 &lt;210&gt; 276 &lt;211> 44 &lt;212&gt; PRT &lt;213&gt; Artificial sequence

&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 276

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg 35 40

〇 &lt;210> 277 &lt;211&gt; 21 &lt;212> PRT a &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt; 277

Leu Gin Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro 15 10 15

Arg Asp Ala Gly Ser 335 20 1300414 &lt;210&gt; 278 &lt;211&gt; 30 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt ; 278 ΓΛ Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys 1 5 10 15

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly 20 25 30 &lt;210> 279 &lt;211&gt; 46 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : The victory of synthesis呔

&lt;400〉 279

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys 15 10 15

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala 20 25 30

Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin 35 40 45 &lt;210&gt; 280 &lt;211&gt; 32 336 1300414 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic Victory Moon too &lt;400&gt; 280

Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly - 1 5 10 15

Alu Lys Ser Gin 20 25 30 o. &lt;210&gt; 281 &lt;211&gt; Description of the artificial sequence: the victory of the synthesis &lt;400&gt; 281

Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin 1 5 10 15

&lt;210&gt; 282 &lt;211&gt; 15 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin 1 5 10 15 337 1300414 &lt;210&gt; 283 &lt;211&gt; 36 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 283

Tyr Pro lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15 3

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30

Arg Pro Arg Tyr 35 &lt;210&gt; 284 &lt;211&gt; 41 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: victory of synthesis

&lt;400&gt; 284

Tyr Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser He 1 5 10 15

Gin Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu He 20 25 30

His Thr Ala Glu He Arg Ala Thr Ser 35 . 40 &lt;210&gt; 285 338 1300414 &lt;211&gt; 45 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 285

Tyr Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu 15 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30

His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg 35 40 45 &lt;210&gt; 286 &lt;211&gt; 35 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 286

Tyr Ser Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu 1 5 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30

His Asn Phe 35 &lt;210> 287 &lt;211> 34 339 1300414 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30,] Asn Phe &lt;210&gt; 288 &lt;211&gt; 22 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 288

Tyr Leu Gin Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala 15 10 15

Pro Arg Asp Ala Gly Ser 20 &lt;210&gt; 289 &lt;211&gt; 28 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 0 Too &lt;400&gt; 289 340 1300414

Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met Glu Arg Val Glu 15 10 15

Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 &lt;210> 290 &lt;211&gt; 26 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 290

Tyr Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys Glu Asp Asn Val 1 5 10 15

Leu Val Glu Ser His Glu Lys Ser Leu Gly 20 25

&lt;210&gt; 291 &lt;211> 33 &lt;212> PRT )&lt;213&gt; Artificial sequence ^ &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory rib: &lt;400&gt;

Tyr Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu 15 10 15

Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser 20 25 30

Gin 341 1300414 &lt;210&gt; 292 &lt;211&gt; 22 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu 1 5 10 15 )Thr Lys Ala Lys Ser Gin 20 &lt;210&gt; 293 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400> 293 _ Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser He Gin 〇1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu He His &quot; 20 25 30

Thr Ala &lt;210> 294 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence 342 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory limb: &lt;400> 294

Ala Arg Ser Ala Trp 1 5 &lt;210&gt; 295 one &lt;211> 34

^ &lt;212> PRT &lt;213&gt; Artificial Sequence /) &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 295

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu lie His 20 25 30

Thr Ala Q &lt;210&gt; 296 &lt;211&gt; 33 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin Asp 1 5 10 15

Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu lie His Thr 343 1300414 20 25 30

Ala &lt;210&gt; 297 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;-&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 297 〇Tyr Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser He 1 5 10 15

Gin Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu He 20 25 30

His Thr Ala 35 &lt;210> 298 &lt;211> 34 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;-&lt;223&gt; 223 Description of artificial sequence: synthetic peptide • &lt;400&gt;

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu lie His 20 25 30

Thr Tyr 344 1300414 &lt;210&gt; 299 &lt;211&gt; 37 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 299

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu He His 20 25 30

Thr Ala Glu lie Arg 35 &lt;210> 300 &lt;211> 28 &lt;212> PRT &lt;213&gt; Artificial sequence Ο &lt;220> • &lt;223> Description of artificial sequence: Synthetic victory. &lt;400 〉 300

Leu Leu His Asp Lys Gly Lys Ser He Gin Asp Leu Arg Arg Arg Phe 15 10 15

Phe Leu His His Leu lie Ala Glu He His Thr Ala 20 25 &lt;210> 301 &lt;211&gt; 27 345 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 301

Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys 15 10 15

Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu

&lt;210&gt; 302 &lt;211&gt; 20 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400&gt; 302

Tyr Leu Thr Gin Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gin Pro 〇 1 5 10 15

Leu Lys Thr Pro - 20 &lt;210&gt; 303 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 346 1300414 &lt;400&gt ; 303

Thr Arg Ser Ala Trp 1 5 &lt;210&gt; 304 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;, &lt;223&gt; Description of artificial sequence: synthetic victory month too ^ &lt; 400> 304 Ό Thr Arg Ser Ala Trp 1 5

&lt;210> 305 &lt;211> 32 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400> 305

Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu

Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser 20 25 30 &lt;210&gt; 306 &lt;211> 33 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory 眈 347 1400414 &lt;400&gt; 306

Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp 15 10 15

His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg 20 25 30

His &lt;210&gt; 307 &lt;211&gt; 34 丫 212&gt; PRT j &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Thr Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Glu Asn Asn Arg Arg 1 5 10 15

Thr His His Met Gin Leu Met lie Ser Leu Phe Lys Ser Pro Leu Leu 20 25 30 〇Leu Leu &lt;210&gt; 308 &lt;211&gt; 31 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt Description of artificial sequence: synthetic victory &lt;400> 308

Met lie Pro Ala Lys Asp Met Ala Lys Val Met lie Val Met Leu Ala 348 1300414 1 5 10 15 lie Arg Phe Leu Thr Lys Ser Asp Gly Lys Ser Val Lys Lys Arg 20 25 30

&lt;210> 309 &lt;211&gt; 27 ‘ &lt;212&gt; PRT &lt; 213> artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: synthetic peptide &lt;400>309

Thr Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Gly Lys Gin Gin Lys 1 5 10 15

Asn Thr Ser Tyr Ala Thr Asn Asp Leu lie He 20 25 &lt;210> 310 &lt;211> 30 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Win Limb: &lt;400> 310

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe 15 10 15

Gly Ala He Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30

&lt;210&gt; 311 &lt;211> 30 &lt;212&gt; PRT 349 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory limb: &lt;400&gt;

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 15 10 15 • Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30

, &lt;210> 312 &lt;211&gt; 25 &lt;212&gt; PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 312

Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys Leu Gin Thr Tyr Pro 15 10 15

Arg Thr Asn Thr Gly Ser Asn Thr Tyr

&lt;210&gt; 313 &lt;211> 24 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory rib: &lt;400> 313

Leu Gly Arg Leu Ser Gin Glu Leu His Arg Leu Gin Thr Tyr Pro Arg 15 10 15 350 1300414

Thr Asn Thr Gly Ser Asn Thr Tyr 20 &lt;210> 314 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide 〇 &lt; 400> 314

Ala Thr Gin Arg Leu Ala Asn Glu Leu Val Arg Leu Gin Thr Tyr Pro 15 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr 20 25 &lt;210&gt; 315 &lt;211> 29 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400> 315

Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe Gly 15 10 15

Ala lie Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 &lt;210&gt; 316 &lt;211> 37 351 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 316

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu ^ 15 10 15 lie Arg Ser Ser Asn Asn Leu Gly Ala lie Leu Ser Pro Thr Asn Val 20 25 30 〇

Gly Ser Asn Thr Tyr 35 &lt;210> 317 &lt;211&gt; 37 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 317 ( J Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala lie Leu Ser Ser Thr Asn Val . 20 25 30

Gly Ser Asn Thr Tyr 35 &lt;210&gt; 318 &lt;211&gt; 37 &lt;212> PRT &lt;213&gt; Artificial sequence 352 1300414 &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: Synthetic victory &lt;400&gt; 318

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala lie Leu Ser Ser Thr Asn Val , 20 25 30

Gly Ser Asn Thr Tyr 35 c &lt;210&gt; 319 &lt;211> 13 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala 1 5 10 c

&lt;210&gt; 320 &lt;211&gt; 10 ~ &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 320

Ser Asn Asn Phe Gly Ala lie Leu Ser Ser 1 5 10 353 1300414 &lt;210&gt; 321 &lt;211&gt; 37 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 321

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val 20 25 30

Gly Ser Asn Thr Tyr 35 &lt;210&gt; 322 &lt;211> 30 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide 〇&lt;4〇〇 &gt; 322

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu . 1 5 10 15 • Gly Pro Val Leu Pro Pro As As Val Gly Ser Asn Thr Tyr 20 25 30 &lt;210> 323 &lt;211&gt; 30 &lt ;212> PRT &lt; 213 > artificial sequence 354 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 323

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe 1 5 10 15

Gly Ala He Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30

&lt;210> 324 &lt;211&gt; 30 ^ &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 324

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 15 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30

&lt;210> 325 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys Leu Gin Thr Tyr Pro 15 10 15 355 1300414

Arg Thr Asn Thr Gly Ser Asn Thr Tyr 20 25 &lt;210&gt; 326 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213>Artificial Sequence^ &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning C; &lt;400&gt; 326

Leu Gly Arg Leu Ser Gin Glu Leu His Arg Leu Gin Thr Tyr Pro Arg 1 5 10 15

Thr Asn Thr Gly Ser Asn Thr Tyr 20 &lt;210&gt; 327 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence

&lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 327

Ala Thr Gin Arg Leu Ala Asn Glu Leu Val Arg Leu Gin Thr Tyr Pro 15 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr 20 25

&lt;210> 328 &lt;211> 29 &lt;212&gt; PRT 356 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe Gly 1 5 10 15

Ala lie Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr * 20 25 &lt;210&gt; 329 〇&lt;211&gt; 37 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 329

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15 lie Arg Ser Ser Asn Asn Leu Gly Ala lie Leu Ser Pro Thr Asn Val

Gly Ser Asn Thr Tyr 35 &lt;210> 330 &lt;211> 37 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning 357 1300414 &lt;400&gt; 330

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala He Leu Ser Ser Thr Asn Val 20 25 30 &quot; Gly Ser Asn Thr Tyr 35 &lt;210&gt; 331 p, &lt;211&gt; 37 匕! &lt;212>PRT &lt;213&gt; Artificial sequence &lt;220> &lt;223> Description of artificial sequence: Synthetic victory &lt;400&gt; 331

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala He Leu Ser Ser Thr Asn Val 20 25 30 〇

Gly Ser Asn Thr Tyr 35 ^ &lt;210&gt; 332 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Victory: &lt;400&gt; 332 358 1300414

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala 1 5 10

&lt;210> 333 &lt;211> 10 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 333

Ser Asn Asn Phe Gly Ala He Leu Ser Ser 1 5 10 &lt;210> 334 &lt;211> 37 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Win呔&lt;400> 334

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val 20 25 30

Gly Ser Asn Thr Tyr 35 &lt;210> 335 &lt;211&gt; 30 &lt;212&gt; PRT &lt;213&gt; artificial sequence 359 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 0 too &lt;400&gt ; 335

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 15 10 15

Gly Pro Val· Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30 &lt;210&gt; 336 * &lt;211&gt; 28 &lt;212&gt; PRT ^ . &lt;213&gt;Artificial Sequence &lt;220〉 &lt;223&gt; Description of the artificial sequence: Synthetic victory &lt;400&gt; 336

Ser Gin Gly Thr Phe Thr Ser Glu Tyr Ser Lys Tyr Leu Asp Ser Arg 15 10 15

Arg Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 20 25 0 &lt;210&gt; 337 ' &lt;211&gt; 35 &lt;212&gt; PRT, &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence : Synthetic peptide &lt;400> 337

His Gly Glu Gly Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Ala Arg 15 10 15

Leu Phe He Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro 360 1300414 20 25 30

Pro Pro Ser 35 &lt;210&gt; 338 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory C &lt;400> 338

His Ser Gin Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15

Arg Arg Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 20 25 &lt;210> 339 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt; Artificial sequence (1, &lt;220> a &lt;223&gt; artificial sequence Description: The victory of synthesis - &lt;400&gt; 339

Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr • 1 5 10 &lt;210&gt; 340 &lt;211> 8 &lt;212&gt; PRT &lt;213>Artificial Sequence 361 &lt;220&gt; 1300414 &lt;223> Description of Artificial Sequence : Synthetic wins &lt;4〇〇&gt; 340

Phe Val Gin Trp Leu Met Asn Thr 1 5 &lt;210> 341 * &lt;211&gt; 28

^ &lt;212> PRT &lt;213&gt; Artificial Sequence "丨 &lt;220> l &lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400> 341

Ser Gin Gly Thr Phe Thr Ser Glu Tyr Ser Lys Tyr Leu Asp Ser Arg 1 5 10 15

Arg Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 20 25 &lt;210&gt; 342 &lt;211&gt; 36 -&lt;212&gt; PRT Q &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 342

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 15 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu 20 25 30

Val Lys Gly Arg 362 35 1300414 &lt;210> 343 &lt;211> 37 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400&gt; 343

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 15 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe He Ala Trp Leu 20 25 30

Val Lys Gly Arg Gly 35 &lt;210&gt; 344 &lt;211> 30 &lt;212> PRT &lt;213&gt; Artificial sequence

&lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 344

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 15 10 15

Gin Ala Ala Lys Glu Phe lie Ala Trp Leu Val Lys Gly Arg 20 25 30 &lt;210> 345 &lt;211> 33 363 1300414

&lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 345

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr He Leu Asp Asn 1 5 10 15

Leu Ala Thr Arg Asp Phe lie Asn Trp Leu He Gin Thr Lys lie Thr 20 25 30

C AsP &lt;210> 346 &lt;211&gt; 34 &lt;212> PRT &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 346

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr He Leu Asp Asn 15 10 15

Leu Ala Ala Arg Asp Phe lie Asn Trp Leu He Gin Thr Lys He Thr 20 25 30

Asp Arg &lt;210> 347 &lt;211&gt; 37 &lt;212> PRT &lt;213&gt; Artificial sequence 364 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory belly: &lt;400> 347

His Ser Glu Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15

Arg Arg Ala Glu Asp Phe Val Glu Trp Leu Met Asn Thr Lys Arg Asn 20 25 30

Lys Asn Asn He Ala 35 &lt;210&gt; 348 &lt;211> 37 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;

His Ser Glu Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15

Arg Arg Ala Glu Asp Phe Val Glu Trp Leu Met Asn Thr Lys Arg Asn 20 25 30

Lys Asn Asn He Ala 35 &lt;210> 349 &lt;211&gt; 39 &lt;212> PRT &lt;213&gt; Artificial sequence 365 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory limb: &lt;400 〉 349

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser 35 &lt;210&gt; 350 C &lt;211&gt; 34 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 223 &lt; 223 &gt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Victory &lt;400&gt ; 350

His Ala Asp Gly Thr Leu Thr Ser Asp He Ser Ser Phe Leu Glu Lys 1 5 10 15

Gin Ala Thr Lys Glu Phe lie Ala Trp Leu Val Ser Gly Arg Gly Arg

Arg Gin &lt;210> 351 &lt;211> 29 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory belly: 366 1300414 &lt;400> 351

His Ser Gin Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 15 10 15

Lys Lys Ala Gin Glu Phe Val Gin Trp Leu Met Asn Thr 20 25 &lt;210> 352 &lt;211&gt; 39 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis Victory &lt;400> 352

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 1 5 10 15

Glu Ala Val Arg Leu Phe He Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser 35 &lt;210>353 &lt;211&gt; 33 &lt;212&gt; PRT -&lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt ; 353

His Ala Asp Gly Ser Phe Thr Ser Asp lie Asn Lys Val Leu Asp Thr 15 10 15

He Ala Ala Lys Glu Phe Leu Asn Trp Leu lie Ser Thr Lys Val Thr 20 25 30 367 1300414

Glu &lt;210&gt; 354 &lt;211> 36 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 354 〇

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 15 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu 20 25 30

Val Lys Gly Arg 35 &lt;210&gt; 355 &lt;211> 30 Q &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt;

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 15 10 15

Gin Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg 20 25 30 368 1300414 &lt;210> 356 &lt;211&gt; 19 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: The victory of synthesis &lt;400> 356

Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu Val 1 5 10 15

Xaa Gly Arg

&lt;210> 357 &lt;211> 4 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 357 Ser Asp Val Ser

&lt;210&gt; 358 -&lt;211&gt; 5 &lt;212&gt; PRT '&lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Thr Ser Asp Val Ser 1 5 369 1300414 &lt;210> 359 &lt;211> 6 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400 〉 359

Phe Thr Ser Asp Val Ser 1 5 (, a &lt;210>360 &lt;211> 7 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 223 > Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 360

Thr Phe Thr Ser Asp Val Ser 1 5

&lt;210&gt; 361 &lt;211&gt; 8 &lt;212> PRT -&lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 361

Gly Thr Phe Thr Ser Asp Val Ser 1 5 &lt;210&gt; 362 1300414 &lt;211&gt; 9 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 362

Glu Gly Thr Phe Thr Ser Asp Val Ser 1 5 &lt;210&gt; 363

&lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 363

Ala Glu Gly Thr Phe Thr Ser Asp Val Ser 1 5 10

&lt;210&gt; 364 &lt;211&gt; 39 〇 &lt;212&gt; PRT &lt;213&gt; artificial sequence ' &lt;220> .&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 364

His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 37] 1300414

Ser Gly Ala Pro Pro Pro Ser 35 &lt;210> 365 &lt;211&gt; 39 &lt;212&gt; PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &gt; • &lt;223 &gt; Description of Artificial Sequence: Synthetic Win &lt; 400 〉 365

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser 35 &lt;210> 366 &lt;211> 31 &lt;212&gt; PRT &lt;213&gt; artificial sequence, &lt;220&gt; lj &lt;223&gt; Description of artificial sequence: synthetic peptide &lt; 400> 366 .His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 1 5 10 15

Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Tyr 20 25 30 &lt;210&gt; 367 &lt;211&gt; 31 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 372 1300414 &lt;220&gt;&lt;223&gt; Description of the sequence: the winning form &lt;400> 367

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Tyr 20 25 30

-&lt;210> 368 &lt;211> 31 ^ &lt;212> PRT &lt;213&gt; artificial sequence &lt;220&gt; t5 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Met lie Glu 1 5 10 15

Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro 20 20 30

&lt;210&gt; 369 &lt;211> 37 &lt;212> PRT &lt; 213 &gt; 213 > Artificial sequence &lt;220 &lt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400> 369

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 1 5 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu 20 25 30

Val Lys Gly Arg Lys 35 &lt;210> 370 373 1300414 &lt;211&gt; 31 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 370

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15

Gin Ala Ala Lys Glu Phe lie Ala Trp Leu Val Lys Gly Arg Lys 20 25 30

&lt;210> 371 &lt;211> 40 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 371

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 f '丨Ser Gly Ala Pro Pro Pro Ser Lys One 35 40 * &lt;210&gt; 372 &lt;211> 40 • &lt;212> PRT &lt;213>Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 372

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15 374 1300414

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser Lys 35 40 &lt;210> 373 &lt;211> 40 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 373

His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser Lys 35 40

&lt;210> 374 &lt;211&gt; 31 &lt;212> PRT (1 &lt; 213> artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &quot;&lt;400&gt;

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Met Glu Glu A 15 10 15

Glu Val Arg Leu Phe He Glu Trp Leu Lys Asn Gly Gly Pro Tyr 20 25 30

&lt;210> 375 &lt;211> 30 &lt;212&gt; PRT 375 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 375

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Met Glu Glu 1 5 10 15

Glu Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Tyr 20 25 30

&lt;210> 376 &lt;211> 29 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 376

Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe lie Glu 1.5 10 15

Trp Leu Lys Gly Gly Pro Ser Ser Gly Pro Pro Pro 20 20 &lt;210> 377 &lt;211> 31 〇&lt;212> PRT-&lt;213>Artificial Sequence&lt;220&gt; ^ &lt;223&gt; Artificial Sequence Description: Synthetic victory month too &lt;400> 377

Glu Ala Glu Asp Leu Gin Val Gly Gin Val Glu Leu Gly Gly Gly Pro 1 5 10 15

Gly Ala Gly Ser Leu Gin Pro Leu Ala Leu Glu Gly Ser Leu Gin 20 25 30 &lt;210&gt; 378 376 1300414 &lt;211&gt; 32 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400&gt; 378

Tyr Glu Ala Glu Asp Leu Gin Val Gly Gin Val Glu Leu Gly Gly Gly 15 10 15

Pro Gly Ala Gly Ser Leu Gin Pro Leu Ala Leu Glu Gly Ser Leu Gin 20 25 30 c &lt;210> 379 &lt;211> 51 &lt;212> PRT &lt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: the victory of synthesis &lt;400&gt; 379

Gly lie Val Glu Gin Cys Cys Thr Ser He Cys Ser Leu Tyr Gin Leu 1 5 10 15

Glu Asn Tyr Cys Asn Phe Val Asn Gin His Leu Cys Gly Ser His Leu

20 25 30

Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr 35 40 45

Pro Lys Thr 50 &lt;210&gt; 380 &lt;211> 16 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt; 377 1300414 &lt;223&gt; Description of artificial sequence: Synthetic victory rib: &lt;400&gt;

Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg Tyr 1 5 10 15

&lt;210&gt; 381 &lt;211> 35 &lt;212> PRT ^ &lt;213> artificial sequence. &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Arg Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg

Cl 5 10 15

Tyr Pro Val Gly Lys Phe Phe Gin Tyr Asp Thr Trp Lys Gin Ser Thr 20 25 30

Gin Arg Leu 35 &lt;210&gt; 382 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt; u &lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 382 * Gly Leu Pro Ala Leu Leu Arg Ala Arg Arg Gly His Val Leu Ala Lys 15 10 15

Glu Leu Glu Ala Phe Arg Glu Ala 20 &lt;210&gt; 383 &lt;211&gt; 361 1300 414 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400> 383

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp 1 5 10 15

Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr He Asn Leu Leu Thr 20 25 30

Arg Pro Arg Tyr

&lt;210> 384 &lt;211&gt; 39 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Pro Asp Lys Asp Phe He Val Asn Pro Ser Asp Leu Val Leu Asp Asn 15 10 15

Lys Ala Ala Leu Arg Asp Tyr Leu Arg Gin lie Asn Glu Tyr Phe Ala

He lie Gly Arg Pro Arg Phe 35 &lt;210&gt; 385 &lt;211&gt; 3 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 385

Phe Met Arg 379 1300414 &lt;210> 386 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide - &lt;400&gt;

Cys Trp Arg Tyr Cys Trp Arg Tyr ' 1 5 &lt;210&gt; 387 〇&lt;211> 36 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400〉 387

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp 15 10 15

Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr lie Asn Leu lie Thr 20 25 30

Arg Gin Arg Tyr 35 &lt;210&gt; 388 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 388

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp 15 10 15 380 1300414

Met Ala Arg Tyr Tyr Ser Ala Leu 20 &lt;210> 389 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400> 389 lie Gly Pro Tyr Arg Leu Arg Tyr 1 5 〇&lt;210> 390 &lt;211> 36 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis Victory &lt;400&gt; 390

Gly Pro Ser Gin Pro Thr Tyr Pro Gly Asp Asp Ala Pro Val Glu Asp 1 5 10 15

Leu He Arg Phe Tyr Asp Asn Leu Gin Gin Tyr Leu Asn Val Val Thr 20 20 30, one..

Arg His Arg Tyr * 35 &lt;210&gt; 391 &lt;211&gt; 36 &lt;212> PRT , &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 391

Ala Pro Leu Glu Pro Val Tyr Pro Gly Asp Asn Ala Thr Pro Glu Gin 381 1300414 1 5 10 15

Met Ala Gin Tyr Ala Ala Asp Leu Arg Arg Tyr lie Asn Met Leu Thr 20 25 30

Arg Pro Arg Tyr 35

-&lt;210> 392 &lt;211&gt; 6 ^ &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> (l· &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 392

Leu Thr Arg Pro Arg Tyr 1 5 &lt;210> 393 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;. &lt;223&gt;223 Description of Artificial Sequence: Synthetic Peptide &lt;400&gt ; 393

Leu Thr Arg Pro Arg Tyr &lt;210> 394 -&lt;211> 36 &lt;212&gt; PRT * &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 394

Ala Pro Ser Glu Pro His His Pro Gly Asp Gin Ala Thr Gin Asp Gin 15 10 15

Leu Ala Gin Tyr Tyr Ser Asp Leu Tyr Gin Tyr lie Thr Phe Val Thr 382 1300414 20 25 30

Arg Pro Arg Phe 35

&lt;210&gt; 395 &lt;211> 36 &lt;212&gt; PRT • &lt;213&gt;Artificial Sequence&lt;220&gt; • &lt;223&gt; Description of Artificial Sequence: Synthetic Victory·&lt;400> 395 Wide Ala Pro Leu Glu Pro Met Tyr Pro Gly Asp Tyr Ala Thr His Glu Gin. 1 5 10 15

Arg Ala Gin Tyr Glu Thr Gin Leu Arg Arg Tyr lie Asn Thr Leu Thr 20 25 30

Arg Pro Arg Tyr 35 &lt;210> 396 &lt;211> 36 &lt;212> PRT &lt;213&gt; artificial sequence f) &lt;220> &lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt; 396 -Tyr Pro Pro Lys Pro Glu Asn Pro Gly Glu Asp Ala Pro Pro Glu Glu 15 10 15

Leu Ala Lys Tyr Tyr Thr Ala Leu Arg His Tyr He Asn Leu He Thr 20 25 30

Arg Gin Arg Tyr 35 &lt;210> 397 383 1300414 &lt;211> 36 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory. &lt;400&gt; 397

Tyr Pro He Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30

Arg Gin Arg Tyr 35 &lt;210> 398 &lt;211&gt; 34 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 398 lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn 15 10 15 (^) Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gin A 20 25 30

Arg Tyr &lt;210&gt; 399 &lt;211&gt; 36 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis wins 0 too &lt;400> 399 384 1300414

Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30

Arg Gin Arg Tyr 35 &lt;210> 400 &lt;211&gt; 36 -&lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> 〇 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 400

Tyr Pro He Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Thr 20 25 30

Arg Pro Arg Tyr 35

&lt;210&gt; 401 _ &lt;211&gt; 10 (, &lt;212>PRT &lt; 213> artificial sequence . &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide 1 &lt;400> 401

Glu Gin Asp Tyr Thr Gly Trp Met Asp Phe 1 5 10 &lt;210&gt; 402 &lt;211> 33 &lt;212> PRT &lt;213&gt; Artificial Sequence 385 1300414 &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 402

Lys Ala Pro Ser Gly Arg Met Ser lie Val Lys Asn Leu Gin Asn Leu 15 10 15

Asp Pro Ser His Arg lie Ser Asp Arg Asp Tyr Met Gly Trp Met Asp 20 25 30

Phe

&lt;210> 403 r' &lt;211&gt; 4 I &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 &gt; 403 Asp Tyr Met Gly 1 &lt;210&gt; 404 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; 213 > artificial sequence 0 &lt; 220 &gt; ^ &lt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 404 &quot ; Asp Tyr Met Gly Trp Met Asp Phe 1 5 &lt;210> 405 &lt;211> 8 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 405 386 1300414

Asp Tyr Met Gly Trp Met Asp Phe 1 5 &lt;210> 406 &lt;211> 7 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win-&lt ;400&gt; 406

Tyr Met Gly Trp Met Asp Phe * 1 5 broad &lt;210> 407 I &lt;211> 4 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: synthetic peptide &lt;400> 407 Trp Met Asp Phe 1 &lt;210&gt; 408 &lt;211&gt; 33 &lt;212> PRT &lt; 213 &gt; 213 &gt; </ RTI> artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt; 400> 408

Lys Ala Pro Ser Gly Arg Val Ser Met lie Lys Asn Leu Gin Ser Leu 15 10 15

Asp Pro Ser His Arg lie Ser Asp Arg Asp Tyr Met Gly Trp Met Asp 20 25 30 387 1300414

Phe &lt;210&gt; 409 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;-&lt;223&gt; Description of artificial sequence: synthetic victory &^ &lt;400&gt; 409 &lt;210&gt; 410 v ' &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; artificial sequence. &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 410

Ser Ala Glu Glu Tyr Glu Tyr Pro Ser 1 5 &lt;210> 411 〇&lt;211> 5 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory呔&lt;400&gt; 411

Asp Tyr Met Gly Trp 1 5 &lt;210&gt; 412 1300414 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Success &lt;400&gt; 412

Asp Tyr Met Gly Trp Met • 15 &lt;210> 413 &lt;211&gt; 9 Q &lt;212&gt; PRT &lt;&lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 413

Val Pro Val Glu Ala Val Asp Pro Met 1 5

&lt;210&gt; 414 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt; _ &lt;223&gt; Description of Artificial Sequence: Synthetic Win S---400> 414 &lt;210&gt; 415 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Asp Tyr Met Gly Trp Met Asp Phe 1 5 &lt;210> 416 &lt;211&gt; 23 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;〇&lt;223&gt; Description of artificial sequence: synthetic victory&lt;;400> 416

Met Lys Val Ala He lie Phe Leu Leu Ser Ala Leu Ala Leu Leu Asn 15 10 15

Leu Ala Gly Asn Thr Thr Ala 20

&lt;210&gt; 417 &lt;211&gt; 27 &lt;212&gt; PRT f &lt; 213 &gt; artificial sequence &lt;220&gt; - &lt;223&gt; Description of artificial sequence: synthetic peptide % &lt;400&gt;

Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro 15 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met 20 25 390 1300414 &lt;210&gt; 418 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis Victory &^ &lt;400> 418

Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro ^ 15 10 15 &lt;210> 419 〇&lt;211> 27 &lt;212> PRT &lt; 213> Artificial Sequence &lt;220> &lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 419

Ala Pro Val Ser Val Gly Gly Gly Thr Val Leu Ala Lys Met Tyr Pro 1 5 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met r 20 25 , one..

&lt;210&gt; 420 -&lt;211> 14 &lt;212> PRT « &lt;213&gt; Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;4〇0&gt; 420

Met Tyr Pro Arg Gly Asn His Trp Ala Val Gly His Leu Met 391 1300414 1 5 10 &lt;210> 421 &lt;211> 36 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic victory 呔 &lt;400> 421 - Phe Leu Pro His Val Phe Ala Glu Leu Ser Asp Arg Lys Gly Phe Val 15 10 15 () Gin Gly Asn Gly Ala Val Glu Ala Leu His Asp His Phe Tyr Pro Asp 20 25 30

Tip Met Asp Phe 35 &lt;210> 422 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide (J &lt; 4〇〇 &gt; 422

Glu Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp — 1 5 10 15 , Phe &lt;210&gt; 423 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 392 1300414 &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory &lt;400&gt; 423

Glu Leu Gly Pro Gin Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys 1 5 10 15

Lys Gin Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met 20 25 30

Asp Phe C &lt;210> 424 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Glu Arg Pro Pro Met Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp 1 5 10 15

Phe &lt;210> 425 &lt;211> 5 &lt;212&gt; PRT &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 425 393 1300414

Ala Trp Met Asp Phe 1 5 &lt;210> 426 &lt;211> 42 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Ala Glu Gly Thr Phe He Ser Asp Tyr Ser He Ala Met Asp Lys

Lie His Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys Gly Lys 20 25 30

Lys Asn Asp Trp Lys His Asn He Thr Gin 35 40 &lt;210> 427 &lt;211&gt; 42 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence 〇&lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthesis胜呔&lt;400> 427 ^ Tyr Ala Glu Gly Thr Phe lie Ser Asp Tyr Ser lie Ala Met Asp Lys 15 10 15

He Arg Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys Gly Lys 20 25 30

Lys Ser Asp Trp Lys His Asn He Thr Gin 35 40 394 1300414 &lt;210&gt; 428 &lt;211&gt; 30 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 428 • Tyr Ala Glu Gly Thr Phe lie Ser Asp Tyr Ser He Ala Met Asp Lys 1 5 10 15

Qj lie Arg Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys 20 25 30 &lt;210&gt; 429 &lt;211&gt; 30 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400&gt; 429

Tyr Ala Glu Gly Thr Phe lie Ser Asp Tyr Ser lie Ala Met Asp Lys 15 10 15

He Arg Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys • 20 25 30 &quot;&lt;210> 430 &lt;211> 22 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic Victory Moon 395 1300414 &lt;400&gt; 430

Phe Val Pro He Phe Thr His Ser Glu Leu Gin Lys lie Arg Glu Lys 1 5 10 15

Glu Arg Asn Lys Gly Gin 20 &lt;210〉 431 ^ &lt;211〉 22

^ &lt;212> PRT -&lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 431

Phe Val Pro He Phe Thr Tyr Gly Glu Leu Gin Arg Met Gin Glu Lys 15 10 15

Glu Arg Asn Lys Gly Gin 20

&lt;210&gt; 432 &lt;211&gt; 22 &lt;212&gt; PRT G &lt;213&gt; Artificial sequence ^ &lt;220> ^ &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Phe Val Pro lie Phe Thr Tyr Gly Glu Leu Gin Arg Leu Gin Glu Lys 15 10 15

Glu Arg Asn Lys Gly Gin 20 396 1300414 &lt;210> 433 &lt;211> 21 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide, &lt;400&gt; 433

Phe Val Pro He Phe Thr Tyr Gly Glu Leu Arg Leu Gin Glu Lys Glu 1 5 10 15

Arg Asn Lys Gly Gin 20 &lt;210> 434 &lt;211> 9 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;4〇〇&gt ; 434

He Ala Arg Arg His Pro Tyr Phe Leu 1 5

-&lt;210&gt; 435 &lt;211&gt; 27 ^ &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Glu Ser 397 1300414 15 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25 &lt;210&gt; 436 &lt;211> 27 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win呔

&lt;400〉 436

His Ser Asp Gly Leu Phe Thr Ser Glu Tyr Ser Lys Met Arg Gly Asn 1 5 10 15

Ala Gin Val Gin Lys Phe lie Gin Asn Leu Met 20 25 &lt;210> 437 &lt;211〉 27

&lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide Rabbit &lt;400&gt;

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Glu Gly 1 5 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25 &lt;210> 438 398 1300414 &lt;211&gt; 27 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis Victory &lt;4〇〇&gt; 438

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Asp Ser 1 5 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25 c . &lt;210> 439 * &lt;211> 27 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic peptide &lt;400> 439

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Gin Asp Ser

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val A 20 25 ^ &lt;210&gt; 440 &lt;211&gt; 26 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory 399 1300414 &lt;400> 440

Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Asp Ser Ala 15 10 15

Arg Leu Gin Arg Leu Leu Gly Gly Leu Val 20 25

&lt;210&gt; 441 &lt;211&gt; 32 , &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning One &lt;400> 441

Ala Ala Met Leu Ala Ser Gin Thr Glu Ala Phe Val Pro He Phe Thr 15 10 15

Tyr Gly Glu Leu Gin Arg Met Gin Glu Lys Glu Arg Asn Lys Gly Gin 20 25 30

&lt;210&gt; 442 &lt;211&gt; 28 &lt;212> PRT wide &lt;213> artificial sequence Γ) ν- &lt;220> Qin&lt;223&gt; Description of artificial sequence: synthetic victory brick &lt;400> 442

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Arg Gin 1 5 10 15

u la 20 210 210 210 210 210 210 210 210 : Synthetic peptide &lt;400&gt; 443 : His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Arg Gin I 1 /., 5 10 15

Leu Ala Val Arg Arg Tyr Leu Asn Ser lie Leu Asn Gly Lys Arg 20 25 30

&lt;2i〇&gt; 444 &lt;211&gt; 12 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> % t &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 444

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 1. 5 10

(, &lt;210> 445 &lt;211&gt; 27 j &lt;212&gt; PRT &lt;2.13&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 445

His Ala Asp Gly Val Phe Thr Ser Asp Phe Ser Arg Leu Leu Gly Gin 1 5 10 15 401 1300414

Leu Ser Ala Lys Lys Tyr Leu Glu Ser Leu lie 20 25

&lt;210> 446 &lt;211&gt; 27 &lt;212&gt; PRT (&lt;213&gt; artificial sequence ^ &lt;220&gt;&lt;223&gt; Human J: Description of sequence: synthetic peptide &lt;400&gt;

His Ala Asp Gly Val Phe Thr Ser Asp Tyr Ser Arg Leu Leu Gly Gin

Lie Ser Ala Lys Lys Tyr Leu Glu Ser Leu lie 20 25 &lt;210&gt; 447 &lt;211&gt; 27 # &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Winning &lt;4〇〇&gt; 447

His Ala Asp Gly Val Phe Thr Ser Asp Phe Ser Lys Leu Leu Gly Gin 15 10 15

Leu Ser Ala Lys Lys Tyr Leu Glu Ser Leu Met 20 25 &lt;210&gt; 448 &lt;211&gt; 42 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence 402 1300414 &lt;220&gt;&lt;2.23&gt; Description of Artificial Sequence: Synthetic victory: &lt;400&gt; 448

His Ala Asp Gly Val Phe Thr Ser Asp Phe Ser Lys Leu Leu Gly Gin 15 10 15

Leu Ser Ala Lys Lys Tyr Leu Glu Ser Leu Met Gly Lys Arg Val Ser 20 25 30

Ser Asn He Ser Glu Asp Pro Val Pro Val 35 40

&lt;210&gt; 449 &lt;211> 12 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of human procedure ill: synthetic victory &lt;4〇〇&gt; 449

Val Ser Ser As As He Ser G 。 。 。 。 。 。 : Synthetic victory fl too &lt;400> 450

Ser Ser Glu Gly Glu Ser Pro Asp Phe Pro Glu Glu Leu Glu Lys 1 5 10 15 403 1300414 &lt;210&gt; 451 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of the artificial sequence: synthetic peptide &lt;400> 451

Cys Ser Cys Asn Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp lie lie Trp 20 &lt;210&gt; 452 &lt;211&gt; 28 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Ser Arg Phe Arg Lys Gin

Met Ala Val Lys Lys Tyr Leu Asn Ser Val Leu Thr 20 25 &lt;210&gt; 453 &lt;211&gt; 28 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory: 404 1300414 &lt;400> 453

His Ser Asp Ala Leu Phe Thr Asp Thr Tyr Thr Arg Leu Arg Lys Gin 1 5 10 15

Met Ala Met Lys Lys Tyr Leu Asn Ser Val Leu Asn 20 25 &lt;210&gt; 454 &lt;211&gt; 28 &lt;212> PRT &lt; 213 > Artificial Sequence r; &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic victory &lt;4〇〇&gt; 454

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 20 25

&lt;210> 455 &lt;211&gt; 28 C &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220> -&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser He Leu Asn 20 25 405 1300414 &lt;210&gt; 456 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 456

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg 1 5 10 Q &lt;210&gt; 457 &lt;211> 19

&lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide

&lt;400&gt; 457 Tyr Thr Arg Leu Arg Lys Gin Met Ala Val Lys Lys Tyr Leu Asn Ser

He Leu Asn &lt;210> 458 &lt;211> 18 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 406 1300414 &lt;400&gt;

Thr Arg Leu Arg Lys Gin Met Ala Val Lys Lys Tyr Leu Asn Ser lie 1 5 10 15

Leu Asn &lt;210&gt; 459 &lt;211&gt; 27 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; artificial sequence C &lt; 220 &gt;&lt; 223 &gt; 223 > Description of artificial sequence: synthetic victory &lt;400> 459

His Ser Asp Ala Val Phe Thr Asp Asn Ser Arg Phe Arg Lys Gin Met 1 5 10 15

Ala Ala Lys Lys Tyr Leu Asn Ser Val Leu Ala 20 25

&lt;210&gt; 460 &lt;211&gt; 23 C &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 460

Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin Met Ala Val Lys Lys 1 5 10 15

Tyr Leu Asn Ser He Leu Asn 20 407 1300414 &lt;210&gt; 461 &lt;211&gt; 28 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt;400&gt; 461

Lys Pro Arg Arg Pro Tyr Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 1 ' 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 20 25 &lt;210> 462 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis胜呔&lt;400&gt; 462^ Tyr Phe Asp Ala He Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 〇1 5 10 15 t Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg 20 25 &lt;210&gt;&lt;211&gt; 28 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 眈 408 1300414 &lt;400> 463

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 1 5 10 15

Leu Ala Val Lys Lys Tyr Leu Asn Se.r lie Leu Asn 20 25 &lt;210> 464 &lt;211〉 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence (&lt;220> &lt;223&gt; artificial sequence Description: Synthetic peptide &lt;400> 464

Leu Met Tyr Pro Thr Tyr Leu Lys 1 5 &lt;210&gt; 465 &lt;211> 29 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> G : &lt;223&gt; Description of Artificial Sequence: Synthetic Winning , &lt;400&gt; 465

Met Met Arg Asp Ser Gly Cys Phe Gly Arg Arg He Asp Arg lie Gly , 15 10 15

Ser Leu Ser Gly Met Gly Cys Asn Gly Ser Arg Lys Asn 20 25

&lt;210> 466 &lt;211> 15 &lt;212&gt; PRT 409 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 466

Gly Phe lie Trp Gly Asn lie Phe Gly His Tyr Ser Gly Asp Phe 15 10 15 &lt;210&gt; 467 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213>Artificial sequence Ο &lt;220> &lt;223&gt; Artificial sequence Description: Synthetic peptide &lt;400> 467

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg 1 5 10 &lt;210&gt; 468 &lt;211> 24 &lt;212> PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthesis Peptide v &lt;400> 468 - Ser Ser Asp Cys Phe Gly Ser Arg lie Asp Arg He Gly Ala Gin Ser 15 10 15

Gly Met Gly Cys Gly Arg Arg Phe 20 &lt;210&gt; 469 &lt;211> 20 410 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400> 469

Cys Phe Gly Ser Arg lie Asp Arg lie Gly Ala Gin Ser Gly Met Gly 1 5 10 15

Cys Gly Arg Phe 20

&lt;210&gt; 470 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Cys Phe Gly Ser Arg lie Asp Arg lie Gly Ala Gin Ser Gly Met'Gly 15 10 15 〇Cys Gly Arg Arg Phe 20 -3⁄4.. &lt;210&gt; 471 ^ &lt;211> 24 &lt;212> PRT &lt;213&gt Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 471 411 1300414

Ser Ser Asp Cys Phe Gly Ser Arg He Asp Arg lie Gly Ala Gin Ser 1 5 10 15

Gly Met Gly Cys Gly Arg Arg Phe 20 &lt;210&gt; 472 &lt;211&gt; 30 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt; f &lt; 223 &gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 472

Ala Pro Arg Ser Met Arg Arg Ser Ser Asp Cys Phe Gly Ser Arg lie 1 5 10 15

Asp Arg He Gly Ala Gin Ser Gly Met Gly Cys Gly Arg Phe 20 25 30 &lt;210&gt; 473 &lt;211&gt; 24 &lt;212> PRT &lt;213&gt; Artificial sequence C &lt;220&gt;&lt;223:&gt; Description of the sequence: Synthetic peptide &lt;400> 473 - Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin Ser Gly 1 5 10 15

Leu Gly Cys Asn Ser Phe Arg Tyr 20 &lt;210&gt; 474 &lt;211&gt; 17 412 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; 223 Description of Artificial Sequence: Synthetic Peptide &lt;;400> 474

Cys Phe Gly Gly Arg Met Asp Arg lie Gly Ala Gin Ser Gly Leu Gly 1 5 10 15

Cys &lt;210> 475 (...&lt;211>22 '&lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: synthetic peptide &lt;400&gt; 475

Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin Ser Gly Leu Gly 15 10 15

Cys Asn Ser Phe Arg Tyr 20 o &lt;210> 476 . &lt;211> 28 &lt;212> PRT * &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: synthetic peptide &lt;400&gt; 476

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly 15 10 15 413 1300414

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt;210&gt; 477 &lt;211> 11 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;4〇〇&gt; 477 (' Arg Cys Gly Gly Arg lie Asp Arg lie Arg Cys &lt;210> 478 &lt;211&gt; 26 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 478

Arg Arg Ser Ser Cys Phe Gly Gly Arg He Asp Arg He Gly Ala Gin O 1 5 10 15 , Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt;210&gt; 479 &lt;211&gt; 26 &lt;212&gt; PRT &lt;;213&gt;Artificialsequence&lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic Victory Moon 414 1300414 &lt;400> 479

Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly Ala Gin 1 5 10 15

Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt;210&gt; 480 &lt;211&gt; 25 &lt;212&gt; PRT : &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; B too &lt;400> 480

Arg Ser Ser Cys Phe Gly.Gly Arg Met Asp Arg lie Gly Ala Gin Ser 1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt;210&gt; 481 C, &lt;211>23 &lt;212&gt; PRT .&lt;213&gt; Artificial Sequence Dream &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 481

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin Ser Gly 1 5 10 15

Leu Gly Cys Asn Ser Phe Arg 415 20 1300414 &lt;210&gt; 482 &lt;211&gt; 27 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt; 400> 482

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Lys Leu Asp Arg lie Gly 15 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys 20 25 &lt;210&gt; 483 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success呔&lt;400> 483 (3 Ser Ser Cys Phe Gly Gly.Arg lie Asp Arg He Gly Ala Gin Ser Gly 1 5 10 15

Leu Gly Cys Asn Ser » 20 &lt;210&gt; 484 &lt;211> 23 &lt;212> PRT &lt;213&gt; Artificial sequence 416 &lt;220> 1300414 &lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400&gt ; 484

Ser Ser Cys Phe Gly Gly Arg lie Asp Arg He Gly Ala Gin Ser Gly 1 5 10 15

Leu Gly Cys Asn Ser Phe Arg 20 &lt;210&gt; 485 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt;Artificial sequence C &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400&gt;; 485

Ser Ser Cys Phe Gly Gly Arg lie Asp Arg He Gly Ala Gin Ser Gly 1 5 10 15

Leu Gly Cys Asn Ser Phe Arg Tyr 20

&lt;210&gt; 486 &lt;211&gt; 28 &lt;212> PRT G) &lt;213&gt; Artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 486

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg lie Asp Arg He Gly 1 5 10 15

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 417 1300414 &lt;210&gt; 487 &lt;211> 24 &lt;212&gt; PRT &lt;213&gt; Manual Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 487

Arg Ser Ser Cys Phe Gly Gly Arg He Asp Arg He Gly Ala Gin Ser 15 10 15

Gly Leu Gly Cys Asn Ser Phe Arg 20 &lt;210&gt; 488 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;; 488

Arg Ser Ser Cys Phe Gly Gly Arg lie Asp Arg He Gly Ala Gin Ser 1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt;210> 489 &lt;211> 56 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory 418 1300414 &lt;4〇〇&gt; 489

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly 15 10 15

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Ser Leu Arg Arg 20 25 30

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly Ala Gin Ser Gly 35 40 45

Leu Gly Cys Asn Ser Phe Arg Tyr 50 55

&lt;210> 490 C &lt;211> 32 &lt;212&gt; PRT &lt;213>Artificial sequence ' &lt;220> &lt;223> Description of artificial sequence: Synthetic victory &lt;400> 490

Ala Gly Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg He 15 10 15

Asp Arg He Gly Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 30

e &lt;210&gt; 491 &lt;211&gt; 27 ^ &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 491

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Lys Leu Asp Arg lie Gly 419 1300414 15 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys 20 25 &lt;210&gt; 492 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win呔&lt;400&gt; 492

Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys 15 10 15 &lt;210> 493 &lt;211&gt; 15 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic win C' &lt;400> 493

Arg Ser Ser Cys Phe Gly Gly Arg lie Asp Arg lie Gly Ala Cys « 15 10 15 &lt;210> 494 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223>Artificial Sequence Description: The winning form: 420 1300414 &lt;4〇〇&gt; 494

Ser Phe Gly Gly Arg lie Asp Arg lie Gly Ala Gin Ser Gly Leu Gly 15 10 15

Asn Ser Phe Arg Tyr 20 &lt;210> 495 &lt;211&gt; 28 &lt;212&gt; PRT &lt;213&gt; Artificial sequence C: &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 495

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly 1 5 10 15

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25

&lt;210> 496 &lt;211&gt; 21 〇 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 496

Phe Ala Gly Arg He Asp Arg He Gly Ala Gin Ser Gly Leu Gly Cys 15 10 15

Asn Ser Phe Arg Tyr 20 1300414

&lt;210> 497 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 497

Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg 1 5 10

&lt;210&gt; 498 &lt;211&gt; 30 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 498

Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys 15 10 15 〇Asn Leu Leu Asp His Leu Glu Glu Lys Met Pro Leu Glu Asp 20 25 30 &lt;210> 499 “ &lt;211> 37 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 499 422 1300414

Glu Val Val Pro Pro Gin Val Leu Ser Glu Pro Asn Glu Glu Ala Gly 1 5 10 15

Ala Ala Leu Ser Pro Leu Pro Glu Val Pro Pro Trp Thr Gly Glu Val 20 25 30

Ser Pro Ala Gin Arg 35 &lt;210> 500 &lt;211&gt; 20 ' &lt;212> PRT 〇 &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 500

Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu 15 10 15

Thr Ala Pro Arg 20 &lt;210&gt; 501 〇 &lt;211&gt; 27 &lt;212&gt; PRT, &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 501

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Lys Leu Asp Arg He Gly 15 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys 423 1300414 20 25 &lt;210> 502 &lt;211> 24 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 502

Tyr Ser Ser Cys Phe Gly Gly Arg lie Asp Arg lie Gly Ala Gin Ser 15 10 15

Gly Leu Gly Cys Asn Ser Phe Arg 20 &lt;210> 503 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide (:&lt;;4〇〇&gt; 503

Tyr Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu 1 5 10 15 - Leu Thr Ala Pro Arg 20 &lt;210> 504 &lt;211&gt; 32 &lt;212> PRT &lt;213>Artificial Sequence 424 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt; 504

Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met 1 5 10 15

Asp Arg lie Gly Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 30 &lt;210> 505 &lt;211&gt; 24 C &lt;212> PRT ~ &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic victory S too &lt;400> 505

Tyr Ser Ser Cys Phe Gly Gly Arg lie Asp Arg lie Gly Ala Gin Ser 1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg 20

C &lt; 210 > 506 &lt; 211 > 35 , &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt; 400 > 506

Ser Phe Asn Ser Cys Phe Gly Asn Arg He Glu Arg He Gly Ser Trp 15 10 15 425 1300414

Ser Gly Leu Gly Cys Asn Asn Val Lys Thr Gly Asn Lys Lys Arg lie 20 25 30

Phe Gly Asn 35 &lt;210> 507 &lt;211&gt; 32 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 507

Ser Pro Lys Met Met His Lys Ser Gly Cys Phe Gly Arg Arg Leu Asp 15 10 15

Arg He Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Lys Tyr 20 25 30

&lt;210&gt; 508 &lt;211> 22 &lt;212&gt; PRT G) &lt;213&gt; Artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Gly Trp Asn Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg He Gly Ser 15 10 15

Leu Ser Gly Leu Gly Cys 20 426 1300414 &lt;210> 509 &lt;211&gt; 32 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400 〉 509

Ser Pro Lys Met Val Gin Gly Ser Gly Cys Phe Gly Arg Lys Met Asp 15 10 15

Arg lie Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His 20 25 30 &lt;210&gt; 510 &lt;211&gt; 45 &lt;212&gt; PRT &lt; 213 〆 artificial sequence &lt;220> &lt;223&gt; Description: Synthetic peptide &lt;400&gt; 510

Ser Gin Gly Ser Thr Leu Arg Val Gin Gin Arg Pro Gin Asn Ser Lys

Val Thr His He Ser Ser Cys Phe Gly His Lys lie Asp Arg lie Gly 20 25 30

Ser Val Ser Arg Leu Gly Cys Asn Ala Leu Lys Leu Leu 35 40 45 &lt;210> 511 &lt;211〉 26

&lt;212&gt; PRT 427 1300414 &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 511

Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp Arg He Gly Ser Leu Ser 1 5 10 15

Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr 20 25 &lt;210> 512 (a &lt;211>32 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 512

Ser Pro Lys Thr Met Arg Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp 15 10 15

Arg He Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr 20 25 30 c

.&lt;210&gt; 513 &lt;211&gt; 32 ^ &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Asn Ser Lys Met Ala His Ser Ser Ser Cys Phe Gly Gin Lys lie Asp 428 1300414 1 5 10 15

Arg He Gly Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe 20 25 30 &lt;210&gt; 514 &lt;211> 45 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory 呔〇 &lt;400&gt; 514

Ser Gin Asp Ser Ala Phe Arg lie Gin Glu Arg Leu Arg Asn Ser Lys 15 10 15

Met Ala His Ser Ser Ser Cys Phe Gly Gin Lys lie Asp Arg lie Gly 20 25 30

Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe 35 40 45

&lt;210&gt; 515 &lt;211&gt; 33 〇 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 515

Tyr Ser Pro Lys Met Val Gin Gly Ser Gly Cys Phe Gly Arg Lys Met 1 5 10 15

Asp Arg Leu Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg 20 25 30 429 1300414

His &lt;210> 516 &lt;211> 32 &lt;212> PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 516

Ser Pro Lys Met Val Gin Gly Ser Gly Cys Phe Gly Arg Lys Met Asp 15 10 15

Arg lie Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His 20 25 30 &lt;210> 517 &lt;211&gt; 22 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptide C'. &lt;400&gt; 517, Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg lie Gly Ser 1 5 10 15

</ RTI> <RTIgt; ; 518

Gly Leu Ser Arg Ser Cys Phe Gly Val Lys Leu Asp Arg He Gly Ser 1 5 10 15

Met Ser Gly Leu Gly Cys 20 &lt;210> 519 &lt;211> 53 (, &lt;212> PRT - '213> Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400> 519

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 15 10 15

Gin Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly 20 25 30

Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg lie Gly Ser Met 35 40 45

Ser Gly Leu Gly Cys - 50 &lt;210&gt; 520 &lt;211&gt; 53 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 431 1300414 &lt;400 〉 520

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 1 5 10 15

His Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Gly Asn Lys Lys Gly 20 25 30

Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg lie Gly Ser Met 35 40 45

Ser Gly Leu Gly Cys 50 &lt;210> 521 [&lt;211> 27 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Success &lt;400&gt; 521

Lys Pro Gly Thr Pro Pro Lys Val Pro Arg Thr Pro Pro Gly Glu Glu 1 5 10 15

Leu Ala Glu Pro Gin Ala Ala Gly Gly Asn Gin 20 25 &lt;210&gt; 522 C ; &lt;211&gt; 21 &lt;212&gt; PRT, &lt;213&gt; Artificial Sequence &lt;220&gt; ^ &lt;223&gt; Description of Artificial Sequence : Synthetic wins &lt;400> 522

Gly Asp Lys Thr Pro Gly Gly Gly Gly Ala Asn Leu Lys Gly Asp Arg 15 10 15

Ser Arg Leu Leu Arg 20 432 1300414

&lt;210> 523 &lt;211> 27 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 523

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg He Gly Ser 15 10 15

Met Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt;210&gt; 524 Q &lt;211&gt; 23 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 524

Tyr Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg He Gly 15 10 15

Ser Met Ser Gly Leu Gly Cys 20 &lt;210> 525 O &lt;211> 7 &lt;212&gt; PRT .&lt;213&gt; Artificial Sequence &lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt ;400&gt; 525

Asp Ala Phe Val Ala Leu Met 1 5

&lt;210&gt; 526 &lt;211&gt; 7 &lt;212> PRT 433 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Asp Ala Phe Val Ala Leu Met 1 5 &lt;210&gt; 527 &lt;211> 11 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400 〉 527

Glu Pro Ser Lys Asp Ala Phe He Gly Leu Met &lt;210&gt; 528 &lt;211> 9 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 528

Gly Pro Ser Gly Phe Tyr Gly Val Arg 1 5 C &lt;210> 529 &lt;211&gt; 10 .&lt;212&gt; PRT &lt;213&gt; Artificial Sequence^ &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 529

Ala Pro Leu Ser Gly Phe Tyr Gly Val Arg 1 5 10 &lt;210&gt; 530 &lt;211> 7 434 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 530

Asp Ser Phe Val Gly Leu Met 1 5 &lt;210> 531 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 〇 &lt;220&gt;&&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 531

His Lys Thr Asp Ser Phe Val Gly Leu Met 1 5 10 &lt;210&gt; 532 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Shape &lt;400> 532 C His Lys He Asn Ser Phe Val Gly Leu Met 1 5 10

, &lt;210&gt; 533 &lt;211&gt; 11 ^ &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;

Tyr His Lys Thr Asp Ser Phe Val Gly Leu Met 1 5 10 435 1300414 &lt;210> 534 &lt;211&gt; 10 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400> 534

His Lys Thr Asp Ser Tyr Val Gly Leu Met 1 5 10 (: &lt;210>535 &lt;211&gt; 7 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 535

Lys Asp Ser Phe Val Gly Met 1 5

C &lt; 210 &gt; 536 &lt; 211 &gt; 6 - &lt; 212 > PRT &lt; 213 &gt; Artificial Sequence - &lt; 220 &lt; 223 &gt; Description of Artificial Sequence: Synthetic Win &lt; 400 > 536

Arg Ala Trp Phe Pro Pro 1 5 &lt;210> 537 436 1300414 &lt;211> 6 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 537

Ala Ala Trp Phe Pro Pro 1 5 &lt;210&gt; 538 &lt;211> 6 (; &lt;212>PRT ' &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 538

Ala Ala Trp Phe Pro Pro 1 5 &lt;210> 539 &lt;211&gt; 7 &lt;212> PRT &lt; 213 > Artificial Sequence 〇 &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 呔 &lt;400 〉 539 Asp Ser Phe Val Ala Leu Met 1 5 &lt;210> 540 &lt;211&gt; 6 &lt;212> PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory Shape &lt;400> 540

Asp Ser Phe Val Gly Leu 1 5 &lt;210&gt; 541 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 541 (;Asp Ser Phe Trp Ala Leu Met,...1 5 &lt;210> 542 &lt;211> 7 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis Peptide &lt;400&gt; 542

Asp Tyr Trp Val Trp Trp Arg 1 5

C] &lt;210&gt; 543 &lt;211> 7 , &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 &gt; 543

Asp Tyr Trp Val Trp Trp Lys 1 5 &lt;210&gt; 544 &lt;211> 10 1300414 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;4〇〇&gt; 544

Asp Met His Asp Phe Phe Val Gly Leu Met 1 5 10 &lt;210> 545 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> . &lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;4〇〇&gt; 545

Asp Met His Asp Phe Phe Gly Leu Met 1 5 &lt;210&gt; 546 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400> 546

Asp Met His Asp Phe Phe Pro Gly Leu Met

&lt;210&gt; 547 &lt;211&gt; 11 &lt;212> PRT '&lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Asp Met His Asp Phe Phe Val Gly Leu Met 1 5 10 439 1300414 &lt;210&gt; 548 &lt;211> 9 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: The victory of synthesis &lt;400>548

Asp Pro His Asp Phe Trp Val Trp Leu 1 5 &lt;210> 549 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 549

Gly Asn Leu Trp Ala Thr Gly His Phe Met 1 5 10 &lt;210> 550 &lt;211> 30 &lt;212> PRT &lt;213>Artificial Sequence ' &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory C &lt;400&gt; 550

Leu Ser Trp Asp Leu Pro Glu Pro Arg Ser Arg Ala Gly Lys lie Arg - 1 5 10 15 - Val His Pro Arg Gly Asn Leu Trp Ala Thr Gly His Phe Met 20 25 30 &lt;210&gt; 551 &lt;211&gt; 32 &lt ;212> PRT &lt;213&gt;Artificial sequence&lt;220> 440 1300414 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Ala Pro Leu Ser Trp Asp Leu Pro Glu Pro Arg Ser Arg Ala Gly Lys 1 5 10 15

He Arg Val His Pro Arg Gly Asn Leu Trp Ala Thr Gly His Phe Met 20 25 30 &lt;210> 552 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence Γ &lt;220&gt; ^ &lt;223&gt; Description of the artificial sequence: the winning form &lt;400&gt; 552

Cys Tyr Trp Val Cys 15 &lt;210&gt; 553 &lt;211&gt; 10 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 553 〇 Gly Asn His Trp Ala Val Gly His Leu Met 1 5 10 &lt;210> 554 ^ &lt;211> 6 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory 8 too &lt;400&gt; 554

Lys lie Pro Tyr lie Leu 1 5 441 1300414 &lt;210&gt; 555 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt; 400> 555

Tyr Phe Leu Phe Arg Pro Arg Asn 1 5 &lt;210&gt; 556 &lt;211&gt; 25 Q &lt;212&gt; PRT W &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 556

Phe Lys Val Asp Glu Glu Phe Gin Gly Pro lie Val Ser Gin Asn Arg 1 5 10 15

Arg Tyr Phe Leu Phe Arg Pro Arg Asn 20 25

-&lt;210&gt; 557 ("&lt;211>23 &lt;212> PRT - &lt;213&gt; artificial sequence &lt;220&gt;, &lt;223&gt; Description of artificial sequence: synthetic victory &, &lt;400> 557

Tyr Lys Val Asn Glu Tyr Gin Gly Pro Val Ala Pro Ser Gly Gly Phe 1 5 10 15

Phe Leu Phe Arg Pro Arg Asn 20 442 1300414 &lt;210&gt; 558 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 558

Asp Ala Gly His Gly Gin lie Ser His Lys Arg His Lys Thr Asp Ser 1 5 10 15

Phe Val Gly Leu Met 20 (-&lt;210> 559 &lt;211&gt; 10 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 559

Pro Asn Pro Asp Glu Phe Val Gly Leu Met 15 10

&lt;210&gt; 560 &lt;211> 9 &lt;212&gt; PRT 〇&lt;213&gt;Artificial sequence&lt;220>, &lt;223&gt; Description of artificial sequence: synthetic victory&lt;400> 560 -Glu Leu Trp Ala Val Gly Ser Phe Met . 1 5 &lt;210&gt; 561 &lt;211> 9 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220> 443 1300414 &lt;223> Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 561

Glu Leu Trp Ala Val Gly Ser Leu Met 1 5 &lt;210&gt; 562 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Peptide &lt;;400> 562

Glu Ala Asp Pro Asn Lys Phe Tyr Gly Leu Met 1 5 10 &lt;210&gt; 563 &lt;211> 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 563

Glu Ala Asp Pro Asn Lys Phe Tyr 1 5

〇 &lt;210&gt; 564 &lt;211> 18 -· &lt;212&gt; PRT &lt;213>Artificial sequence, &lt;220>, &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ser Pro Ser Asn Ser Lys Cys Pro Asp Gly Pro Asp Cys Phe Val Gly 1 5 10 15

Leu Met 444 1300414 &lt;210> 565 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Asp Phe Gly Leu Met 1 5

&lt;210> 566 &lt;211>6 &lt;212&gt; PRT f. &lt;213&gt; Artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Asp Asp Phe Gly Leu Met 1 5 &lt;210> 567 &lt;211> 10 · &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt; 400> 567

Gly Ser His Trp Ala Val Gly His Leu Met . 1 5 10 , &lt;210> 568 Φ &lt;211&gt; 23 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 568

Gly Lys Arg Asp Ala Asp Ser Ser lie Glu Lys Gin Val Ala Leu Leu 445 1300414 15 10 15

Lys Ala Leu Tyr Gly His Gly 20 &lt;210&gt; 569 &lt;211> 19 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Success &lt;400&gt; 569 C . Ala Leu Asn Ser Val Ala Tyr Glu Arg Ser Ala Met Gin Asn Tyr Glu 1 5 10 15

Arg Arg Arg &lt;210> 570 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly lie Cys Tyr Arg Arg Cys 1 5 10 15

Arg &lt;210&gt; 571 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 446 1300414 &lt;400> 571

Glu Gly Lys Arg Pro Trp He Leu 1 5 &lt;210&gt; 572 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 572

Met Leu Thr Lys Phe Glu Thr Lys Ser Ala Arg Val Lys Gly Leu Ser O 15 10 15

Phe His Pro Lys Arg Pro Trp lie Leu 20 25 &lt;210&gt; 573 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Skin &lt;;400> 573 Ο- Asp Met His Asp Phe Phe Val Gly Leu Met 1 5 10

&lt;210> 574, &lt;211> 10 Hyun &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 574

His Lys Thr Asp Ser Phe Val Gly Leu Met 1 5 10 447 1300414 &lt;210&gt; 575 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 575

Asp Ala Asp Ser Ser lie Glu Lys Gin Val Ala Leu Leu Lys Ala Leu 15 10 15

Tyr Gly His Gly Gin He Ser His 20

O &lt;210&gt; 576 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 576

Glu Gin Trp Phe Trp Trp Met 1 5 &lt;210> 577 &lt;211> 5 C &lt;212> PRT &lt;213&gt; Artificial sequence. &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide, &lt;400> 577 , Arg Phe Phe Leu Met 1 5 &lt;210&gt; 578 &lt; 211 &gt; 11 &lt;212&gt; PRT &lt; 213 &gt; Artificial sequence 448 1300414 &lt; 220 &lt; 223 &gt; 223 > Description of artificial sequence: Synthesis Victory &lt;400&gt; 578

Arg Pro Arg Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt;210&gt; 579 &lt;211&gt; 6 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Winning &lt;400> 579 (/: Arg Trp Phe Trp Leu Met 1 5 &lt;210> 580 &lt;211&gt; 2 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400> 580 Trp Met 1

Ο &lt;210> 581 &lt;211&gt; 5 -&lt;212> PRT &lt;213&gt; artificial sequence, &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 581

Arg Phe Phe Leu Met 1 5 &lt;210&gt; 582 449 1300414 &lt;211> 6 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Win 呔 &lt;400 〉 582

Arg Trp Phe Trp Leu Met 1 5 &lt;210&gt; 583 &lt;211&gt; 8 &lt;212> PRT &lt; 213 &gt; 213 > Artificial sequence " &lt; 220 > = &lt; 223 > Description of artificial sequence: synthetic victory &lt;400&gt; 583

Ala Gin Gin Phe Phe Gly Leu Met 1 5 &lt;210&gt; 584 &lt;211&gt; 6 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 584

Qj Tyr Phe Phe His Leu Met 1 5 &lt;210&gt; 585 .&lt;211> 11 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Victory Moon too &lt ;400&gt; 585

Arg Pro Lys Pro Gin Gin Phe Tyr Gly Leu Met 1 5 10 450 1300414 &lt;210&gt; 586 &lt;211> 10 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;, &lt;223&gt; Description of Artificial Sequence : Synthetic victory 呔 &lt;400&gt; 586

Arg Pro Lys Pro Gin Gin Phe Phe Leu Met 1 5 10 &lt;210&gt; 587 &lt;211&gt; 11 &lt;212&gt; PRT (; &lt;213>Artificial Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 587

Arg Pro Lys Pro Gin Gin Phe Phe His Leu Met 1 5 10 &lt;210&gt; 588 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 588

Arg Pro Lys Pro Gin Gin Phe Phe Trp Leu Met 1 5 10 &lt;210&gt; 589 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Winning &lt;400&gt; 589 451 1300414

Arg Pro Lys Pro Gin Gin Trp Phe Trp Leu Met 1 5 10 &lt;210&gt; 590 &lt;211> 11 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 590

Arg Pro Lys Pro Phe Gin Trp Phe Trp Leu Leu 1 5 10 (a &lt;210>591 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400> 591

Arg Pro Lys Pro Gin Gin Phe Phe Pro Leu Met 1 5 10 &lt;210> 592 &lt;211> 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 592 , Pro Gin Gin Phe Phe Gly Leu Met 1 5 &lt;210> 593 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt; 452 1300414 &lt;223&gt; Description of the artificial sequence: the winning form &lt;400> 593

Gin Phe Phe Leu Met 1 5 &lt;210> 594 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Gin Phe Phe Leu Met (::1 5 &lt;210&gt; 595 &lt;211> 6 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400> 595

Gin Phe Phe Gly Leu Met 1 5 &lt;210&gt; 596 O &lt;211&gt; 7 &lt;212> PRT -&lt;213>Artificial sequence &lt;220>. • &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 596

Gin Gin Phe Phe Gly Leu Met 1 5

&lt;210> 597 &lt;211> 6 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory limb: &lt;400> 597

Gin Phe Phe Gly Leu Met 1 5 &lt;210&gt; 598 &lt;211> 10 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 呔f &lt;400 〉 598 — Arg Pro Lys Pro Gin Gin Phe Phe Leu Met 1 5 10 &lt;210> 599 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400> 599

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu 1 5 10 〇&lt;210> 600 .&lt;211〉 8 &lt;212&gt; PRT - &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400> 600

Pro Gin Gin Phe Phe Gly Leu Met 1 5 &lt;210> 601 454 1300414 &lt;211> 6 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Too &lt;400&gt; 601

Glu Phe Phe Gly Leu Met 1 5 &lt;210> 602 &lt;211&gt; 6 &lt;212> PRT &lt;213&gt; Artificial Sequence 〇&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 602

Glu Phe Phe Pro Leu Met 1 5 &lt;210> 603 &lt;211&gt; 10 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 603 G Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu 1 5 10 &lt;210> 604, &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic win 0 too &lt;400> 604

Phe Phe Gly Leu Met 1 5 455 1300414 &lt;210&gt; 605 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400 〉 605

Arg Pro Lys Pro Gin Gin Phe Phe Pro Leu Met 15 10

&lt;210&gt; 606 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> Synthetic peptide &lt;223> Description of artificial sequence &lt;400> 606

Phe Phe Pro Leu Met &lt;210> 607 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; G) &lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 607 .Gin Gin Phe Phe Gly Leu Met 1 5 &lt;210> 608 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory)} too &lt;40〇&gt; 608 456 1300414

Arg Pro Lys Pro Gin Gin Phe Phe Leu Met 1 5 10

&lt;210&gt; 609 &lt;211> 6 &lt;212&gt; PRT - &lt;213&gt; Artificial sequence &lt;220> - &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 609

Glu Phe Phe Pro Leu Met 1 5 Q &lt;210&gt; 610 &lt;211> 11 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;; 610

Arg Pro Lys Pro Gin Gin Trp Phe Trp Leu Leu 15 10

&lt;210&gt; 611 &lt;211> 9 &lt;212> PRT O &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 611 , Lys Pro Pro Phe Asn Trp Phe Trp Leu 1 5 &lt;210&gt; 612 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt;Artificial sequence&lt;220&gt; 457 1300414 &lt;223&gt; 223> Description of artificial sequence: Synthetic victory month too &lt;400&gt; 612

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt;210&gt; 613 - &lt;211&gt; 11

&lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 613

Lys Pro Arg Pro Gin Gin Phe lie Gly Leu Met C 1 5 10 &lt;210> 614 &lt;211> 11 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 614

Lys Pro Arg Pro His Gin Phe Phe Gly Leu Met 1 5 10 &lt;210&gt; 615 ("&lt;211>3 &lt;212&gt; PRT -&lt;213&gt;Artificial Sequence&lt;220&gt;, &lt;223&gt; Artificial Sequence Description: Included in the victory of Ji too &lt;400> 615 Gin Trp Phe 1

&lt;210> 616 &lt;211> 14 &lt;212> PRT 458 1300414 &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 616

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met Gly Lys Arg 1 5 10 &lt;210> 617 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence : Synthetic peptide [&lt;400> 617

Arg Pro Lys Pro 1 &lt;210> 618 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 618

Arg Pro Lys Pro Gin Gin 1 5 c

&lt;210&gt; 619 .&lt;211&gt; 7 &lt;212&gt; PRT ~ &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 619

Arg Pro Lys Pro Gin Gin Phe 1 5 &lt;210&gt; 620 459 1300414 &lt;211> 9 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 620

Arg Pro Lys Pro Gin Gin Phe Phe Gly &lt;210> 621 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial sequence (' &lt;220> t &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 621

Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt;210&gt; 622 &lt;211&gt; 9 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &一&lt;400> 622 C. Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 &lt;210&gt; 623 ' &lt;211> 4 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; Description of the artificial sequence: Synthetic Victory Moon too &lt;400&gt; 623

Phe Gly Leu Met 460 1300414 &lt;210&gt; 624 &lt;211&gt; 3 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 624 Gly Leu Met &lt; 210 &gt; 625 &lt; 211 &gt; 211 &gt; 11 P) &lt;212 &gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt;223; Description of Artificial Sequence: Synthetic Peptide &lt;400 &gt; 625

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt;210> 626 &lt;211> 11 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220> G) &lt;223&gt; Description of Artificial Sequence: Synthetic win &lt;400&gt; 626 Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt;210&gt; 627 &lt;211> 10 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;;223&gt; Description of the artificial sequence: the winning form &lt;400> 627 46] 1300414

Arg Pro Lys Pro Gin Gin Phe Tyr Gly Leu 1 5 10

&lt;210&gt; 628 &lt;211> 7 &lt;212> PRT - &lt;213>Artificial sequence &lt;220> • &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt;

Asp Arg Val Tyr lie His Ala 1 5 Γ &lt;21〇&gt; 629 &lt;211> 11 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 629

Ala Pro Gly Asp Arg He Tyr Val His Pro Phe 1 5 10 &lt;210> 630 &lt;211> 7 _ &lt;212&gt; PRT ◦ &lt;213>Artificial Sequence &lt;220> -&lt;223&gt; Description of Artificial Sequence : The victory of synthesis ' &lt;400> 630

Gly Val Tyr Val His Pro Val 1 5 &lt;210&gt; 631 &lt;211> 15 &lt;212> PRT &lt;213&gt; Artificial sequence 462 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory &lt;;400> 631

Glu Asn Gly Leu Pro Val His Leu Asp Gin Ser lie Phe Arg Arg 1 5 10 15 &lt;210&gt; 632 &lt;211> 15 &lt;212> PRT &lt;213>Artificial Sequence &lt;220> &lt;223>Artificial Sequence Description: Synthetic peptide &lt;400&gt; 632 'Glu Asn Gly Leu Pro Val His Leu Asp Gin Ser lie Phe Arg Arg -1 5 10 15 &lt;210> 633 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Gly Leu Pro Pro Arg Pro Lys He Pro Pro 1 5 10

〇 &lt;210> 634 &lt;211> 10 _ &lt;212> PRT &lt;213&gt; Artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 634

Gly Leu Pro Pro Gly Pro Pro Pro Pro Pro 1 5 10 &lt;210> 635 &lt;211&gt; 8 463 1300414 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 635

Arg Pro Gly Phe Ser Pro Phe Arg 1 5 &lt;210> 636 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 636

Arg Pro Gly Phe Ser Pro Phe Arg 1 5 &lt;210> 637 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 637, Asp Arg Val Tyr lie His Pro Phe His Leu C 1 5 10

-&lt;210&gt; 638 &lt;211> 3 - &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 638 Gly Gly Gly 1 464 1300414 &lt;210&gt; 639 &lt;211> 7 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt; 400 > 639

Asp Arg Val Tyr lie His Pro 1 5 &lt;210> 640 &lt;211> 7 &lt;212> PRT [, &lt;213> artificial sequence 'one &lt; 220> &lt; 223> Description of artificial sequence: synthetic victory Peptide &lt;400&gt; 640

Cys Tyr Trp Lys Val Cys Thr 1 5 &lt;210&gt; 641 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt; 400> 641

Asp Arg Val Tyr He His Pro Phe . 1 5 . &lt;210> 642 &lt; 211 &gt; 8 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 642

Glu Gly Val Tyr Val His Pro Val 1300414 1 5 &lt;210&gt; 643 &lt;211> 4 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400> 643

Asp Arg Val Tyr &lt;210&gt; 644 r' &lt;211> 6 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;4〇〇 &gt; 644

Val Tyr lie His Pro Phe 1 5 &lt;210> 645 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence C &lt;220&gt;-&lt;223&gt; Description of artificial sequence: synthetic victory „ &lt;;400&gt; 645

Tyr He His Pro Phe ^ 1 5 &lt;210&gt; 646 &lt;211> 4 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Skin 1300414 &lt;400 〉 646 He His Pro Phe 1 &lt;210> 647 &lt;211&gt; 7 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt;

Arg Val Tyr He His Pro Phe 1 5 &lt;210&gt; 648 &lt;211&gt; 7 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt ; 648

Arg Val Tyr lie His Pro He 1 5

&lt;210&gt; 649 -&lt;211> 8 C &lt;212&gt; PRT &lt;213&gt; Artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide κ &lt;400&gt;

Pro Thr His lie Lys Trp Gly Asp 1 5 &lt;210> 650 &lt;211> 9 &lt;212> PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;;400&gt; 650

Glu Trp Pro Arg Pro Gin He Pro Pro 1 5 &lt;210> 651 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic S Too &lt;400> 651 (Asn Arg Val Tyr Val His Pro Phe His Leu 1 5 10 &lt;210&gt; 652 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: the winning form &lt;400> 652

Asn Arg Val Tyr Val His Pro Phe Asn Leu 1 5 10 l &lt;210〉 653

&lt;211> 10 * &lt;212> PRT &lt;213&gt; Artificial sequence ' &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 653

Asn Arg Val Tyr Val His Pro Phe Gly Leu 1 5 10 &lt;210&gt; 654 &lt;211&gt; 7 468 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 654

Asn Arg Val Tyr Val His Pro 1 5 &lt;210&gt; 655 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220&gt; G &lt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 655

Asn Arg Val Tyr Val His Pro Phe 1 5 &lt;210&gt; 656 &lt;211&gt; 9 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 656

Arg Val Tyr He His Pro Phe His Leu 1 5 &lt;210> 657 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400> 657

Tyr Lys Arg His Pro lie 1 5 469 1300414 &lt;210&gt; 658 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 658

Asp Arg Val Tyr lie Phe Pro Phe 1 5

&lt;210&gt; 659 &lt;211&gt; 13 [&lt;212> PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 659

Asp Arg Val Tyr He His Pro Phe His Leu Val lie His 1 5 10 &lt;210&gt; 660 &lt;211> 14 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence One &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic Victory &lt;400&gt; 660 - Asp Arg Val Tyr He His Pro Phe His Leu Val lie His Asn 1 5 10 &lt;210> 661 &lt;211> 14 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;;220〉c223&gt; Description of artificial sequence: synthetic peptide &lt;400> 661 470 1300414

Asp Arg Val Tyr lie His Pro Phe His Leu Leu Val Tyr Ser &lt;210&gt; 662 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory I too &lt;400> 662

Arg Val Tyr lie His Pro Phe 1 5 〇 &lt;210&gt; 663 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 663

Arg Val Tyr He His Pro 1 5 &lt;210> 664 &lt;211〉 7

&lt;212> PRT I &lt; 213 &gt; Artificial Sequence &lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 664 ^ Arg Val Tyr He His Pro Ala 1 5 &lt;210> 665 &lt;211&gt; 7 &lt;212> PRT &lt;213>Artificial sequence &lt;220> 471 1300414 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 665

Arg Val Tyr lie His Pro lie 1 5 &lt;210> 666 &lt;211>7 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400 〉 666

Arg Val Tyr He His Pro Thr &lt;210&gt; 667 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Arg Val Tyr lie His Pro Phe 1 5 &lt;210> 668 C &lt;211〉 7 &lt;212&gt; PRT .&lt;213&gt;Artificial sequence &lt;220> -&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 668

Arg Val Tyr Val His Pro Ala 1 5

&lt;210> 669 &lt;211> 6 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 669

Val Tyr lie His Pro lie 1 5 «210&gt; 67 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide C &lt;400&gt; 670

Asp Arg Val Tyr lie His Pro Phe His Leu Val lie His Ser 1 5 10 &lt;210&gt; 671 &lt;211> 7 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223:&gt; Artificial Sequence Description: Synthetic peptide &lt;400> 671

Arg Val Tyr Val His Pro Phe

&lt;210&gt; 672 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 672

Asp Arg Val Tyr Val His Pro Phe 1 5 &lt;210&gt; 673 473 1300414 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; Description of the artificial sequence: the victory of the synthesis &lt;400〉 673

Asp Arg Val Tyr Val His Pro Phe 1 5 &lt;210&gt; 674 &lt;211&gt; 10 &lt;212> PRT &lt;213>Artificial sequence &lt;220> i &lt;223&gt; Description of artificial sequence: synthetic victory &lt;4〇〇&gt; 674

Asp Arg Val Tyr Val His Pro Phe His Leu 1 5 10 &lt;210&gt; 675 &lt;211> 10 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400> 675 G"Asp Arg Val Tyr Val His Pro Phe Asn Leu 1 5 10 &lt;210&gt; 676 -&lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 676

Asp Arg Val Tyr Val His Pro Phe Ser Leu 1 5 10 474 1300414 &lt;210&gt; 677 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 677

Asp Arg Val Tyr Val His Pro Phe His Leu 1 5 10 &lt;210> 678 , &lt;211> 14 0 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 678

Asp Arg Val Tyr He His Pro Phe His Leu Val lie His Asn 1 5 10 &lt;210&gt; 679 &lt;211> 14 &lt;212> PRT &lt;213&gt; Artificial sequence " &lt;220> 1 &lt;223&gt; Artificial sequence Description: Synthetic peptide &lt;400> 679 - Asp Arg Val Tyr lie His Pro Phe His Leu Leu Val Tyr Ser 1 5 10 &lt;210&gt; 680 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213&gt; Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400> 68〇475 1300414

Pro His Pro Phe His Phe Phe Val Tyr Lys 1 5 10 &lt;210> 681 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400&gt; 681

Asp Arg Val Tyr lie His Pro Phe His Leu Leu Tyr Tyr Ser 1 5 10 [&lt;210> 682 &lt;211&gt; 14 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Artificial Sequence Description: Synthetic victory 呔 &lt;400&gt; 682

Asp Arg Val Tyr He His Pro Cys His Leu Leu Tyr Tyr Ser 1 5 10 &lt;210> 683 &lt;211> 14 &lt;212&gt; PRT G &lt;213&gt; Artificial Sequence &lt;220> -&lt;223&gt; Artificial Sequence Description: Synthetic Victory: &lt;400&gt; 683 • Asp Arg Val Tyr He His Pro Leu His Leu Leu Tyr Tyr Ser 1 5 10 &lt;210> 684 &lt;211> 14 &lt;212> PRT &lt;213〉 Artificial sequence &lt;220&gt; 476 1300414 &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 684

Asp Arg Val Tyr lie His Pro Val His Leu Leu Tyr Tyr Ser ' 1 5 10 &lt;210> 685 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400&gt; 685

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His C 15 10 15

Leu Asp He lie Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Arg Ser 35 &lt;210&gt; 686 &lt;211> 20 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence Width &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 686 lie Asn Thr Pro Glu Gin Thr Val Pro Tyr Gly Leu Ser Asn Tyr Arg 15 10 15

Gly Ser Phe Arg 20 &lt;210&gt; 687 &lt;211&gt; 18 &lt;212> PRT &lt;213&gt; Artificial sequence 477 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: synthetic skin &lt;400> 687

Val Asn Thr Pro Glu Arg Val Val Pro Tyr Gly Leu Gly Ser Pro Ser 1 5 10 15

Arg Ser &lt;210> 688 &lt;211> 39 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt; CJ &lt;223> Description of artificial sequence: Synthetic victory &lt;400&gt; 688

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 1 5 10 15

Leu Asp He He Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Ser Arg Ser 35 &lt;210&gt; 689 " &lt;211> 18 &lt;212> PRT &lt; 213 > Artificial Sequence '&lt;220> &gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Shape ^ &lt;400&gt; 689

Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Ser 1 5 10 15

Arg Ser &lt;210&gt; 690 &lt;211> 20 478 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 690

He He Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly 15 10 15

Ser Pro Arg Ser 20

&lt;210&gt; 691 &lt;211> 17 Q &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400> 691

Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Arg 15 10 15

Ser &lt;210&gt; 692 &lt;211&gt; 37 &lt;212&gt; PRT d) &lt;213>Artificial sequence &lt;220> -&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 692 * Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp He lie Trp Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly 20 25 30

Leu Gly Asn Pro Pro 35 479 1300414 &lt;210> 693 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400 〉 693

Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly Leu Gly Asn Pro Pro 15 10 15 &lt;210> 694 C &lt;211&gt; 41 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400> 694

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp lie lie Trp He Asn Thr Pro Glu Gin Thr Val Pro Tyr Gly 20 25 30 Factory Leu Ser Asn Tyr Arg Gly Ser Phe Arg 35 40

&lt;210&gt; 695 &lt;211&gt; 39 ^ &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 695

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15 480 1300414

Leu Asp lie He Trp Val Asn Thr Pro Glu His He Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Ser Arg Ser 35 &lt;210&gt; 696 &lt;211&gt; 18 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 696

Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Ser a 15 10 15

Arg Ser &lt;210&gt; 697 &lt;211&gt; 39 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 697

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His

Leu Asp He lie Tip Val Asn Thr Pro Glu Arg Val Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Ser Arg Ser 35 &lt;210&gt; 698 &lt;211&gt; 38 &lt;212> PRT &lt;213&gt; Artificial Sequence 48] 1300414 &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 698

Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp He lie Trp Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly 20 25 30

Leu Gly Asn Pro Pro Arg 35 _ &lt;210> 699 C &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400 〉 699

Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly Leu Gly Asn Pro Pro . 15 10 15

Arg

&lt;210&gt; 700 &lt;211>41 ^ &lt;212&gt; PRT &lt;213&gt; Artificial sequence - &lt;220> _ &lt;223&gt; Description of artificial sequence: synthetic victory)|Too ^ &lt;400&gt; 700

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp He lie Trp He Asn Thr Pro Glu Gin Thr Val Pro Tyr Gly 20 25 30

Leu Ser Asn His Arg Gly Ser Leu Arg 482 1300414 35 40 &lt;210&gt; 701 &lt;211> 20 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win呔&lt;400> 701

Cys Gin Cys Ala Ser Gin Lys Asp Lys Lys Trp Ser Tyr Cys Gin Ala 15 10 15

Gly Lys Glu lie 20 &lt;210&gt; 702 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 702

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp lie lie Trp 20 &lt;210&gt; 703 &lt;211> 15 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 703

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys 15 10 15 483 1300414 &lt;210> 704 &lt;211> 15 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; Description of the sequence: the victory of the synthesis &lt;4〇〇&gt; 704

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys 15 10 15 &lt;210&gt; 705 &lt;211&gt; 6 〇&lt;212> PRT / &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of the sequence: synthetic peptide &lt;400> 705

Trp Leu Asp He He Trp 1 5 &lt;210> 706 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt; G) &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 706 , Cys Ser Ala Ser Ser Leu Met Asp Lys Glu Ala Val Tyr Phe Cys His 1 5 10 15

Leu Asp He He Trp 20 &lt;210> 707 &lt;211> 20 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 484 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 707

Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Asp His Leu, 1 5 10 15

Asp lie lie Trp 20 &lt;210&gt; 708 &lt;211&gt; 21 &lt;212> PRT &lt; 213 &gt; 213 > artificial sequence ) &lt; 220 &lt; 223 &gt; 223 > Description of artificial sequence: synthetic victory &lt;400&gt; 708

Ala Ser Ala Ser Ser Leu Met Asp Lys Glu Ala Val Tyr Phe Ala His 1 5 10 15

Leu Asp He He Trp 20 &lt;210> 709 &lt;211> 16 &lt;212&gt; PRT &lt;213>Artificial Sequence) &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 709

Leu Met Asp Lys Glu Ala Val Tyr Phe Ala His Leu Asp He He Trp 1 5 10 15 &lt;210> 710 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic victory rib: 485 1300414 &lt;400&gt; 710

Cys Ala Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp lie He Trp 20 &lt;210> 711 &lt;211> 20 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic victory: C &lt;400&gt ; 711

Cys Ser Ala Ser Ser Leu Asp Lys Glu Ala Val Tyr Phe Cys His Leu 15 10 15

Ala He He Trp 20 &lt;210&gt; 712 &lt;211> 21 &lt;212> PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 > Description of the artificial sequence: the victory of the synthesis L &lt; 400 > 712

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His , 15 10 15

Leu Asn lie lie Trp 20 &lt;210&gt; 713 &lt;211&gt; 15 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt; 486 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 713

Asn Trp His Gly Thr Ala Pro Asp Trp Phe Phe Asn Tyr Tyr Trp 1 5 1.0 15 &lt;210&gt; 714 &lt;211> 14 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400&gt; 714

Asp Glu Glu Ala Val Tyr Phe Ala His Leu Asp lie lie Trp 1 5 10 &lt;210&gt; 715 &lt;211> 6 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic Victory Moon too &lt;400> 715

His Leu Asp lie lie Trp 1 5 &lt;210> 716 &lt;211&gt; 23 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 716

His Leu Asp lie He Trp Val Asn Thr Pro Glu His Val Val Pro Tyr 15 10 15

Gly Leu Gly Ser Pro Arg Ser 20 487 1300414 &lt;210> 717 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Peptide&lt;400&gt; 717

Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 1 5 10 15

Leu Asp lie He Trp 20 〇&lt;21〇&gt; 718 &lt;211&gt; 21 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400 〉 718

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 1 5 10 15

Leu Asp lie lie Trp 20 c &lt;210&gt; 719 -&lt;211> 16 &lt;212> PRT, &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic peptide &lt;400&gt ; 719

Ser Leu Lys Asp Leu Phe Pro Ala Lys Ala Ala Asp Arg Arg Asp Arg 15 10 15 &lt;210> 72〇488 1300414 &lt;211> 3 &lt;212&gt; PRT &lt;213>Artificial Sequence&lt;220&gt;&lt;223&gt Description of the artificial sequence: the victory of the synthesis &lt;400> 720 Leu Trp Trp 1 &lt;210> 721 &lt;211> 4 &lt;212> PRT &lt; 213 &gt; 213 &gt; 213 > artificial sequence 〇 &lt; 220 &gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 721 Met Leu Met Trp 1 &lt;210&gt; 722 &lt;211&gt; 1 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description: Synthetic wins &lt;400> 722 丨Arg 1 -&lt;210&gt; 723 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic Victory: &lt;400&gt; 723

Asp Pro lie Leu Trp 5 1300414 &lt;210> 724 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 724

Ser Pro Val Leu Trp 1 5 &lt;210&gt; 725 f : &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt ; 725

Leu Asp lie He Trp 1 5 &lt;210&gt; 726 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence C &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide » &lt;400&gt ; 726

Leu Asp He lie Trp - 1 5 &lt;210&gt; 727 &lt;211> 21 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 Description of Artificial Sequence: Synthetic Victory Moon 1300414 &lt; 400> 727

Cys Ser Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Asn Phe Cys His 15 10 15

Gin Asp Val lie Trp 20 &lt;210> 728 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory f j &lt;400&gt;

Cys Ser Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Tyr Phe Cys His 15 10 15

Gin Asp Val He Trp 20 &lt;210&gt; 729 &lt;211&gt; 21 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide C &lt; 400 &gt; 729

Cys Thr Cys Asn Asp Met Thr Asp Glu Glu Cys Leu Asn Phe Cys His - 15 10 15 , Gin Asp Val He Trp 20 &lt;210> 730 &lt;211> 16 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence&lt;220&gt; 49] 1300414 &lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 730

Gly Asn Trp His Gly Thr Ala Pro Asp Trp Phe Phe Asn Tyr Tyr Trp 1 5 10 15 &lt;210&gt; 731 . &lt;211〉 6

&lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 731

&lt;210&gt; 732

Thr Leu Asp Glu Glu Asp Leu Val Asp Ser Leu Ser Glu Gly Asp Ala 15 10 15 L. Tyr Thr Asn Gly Leu Gin Val Asn Phe His Ser Pro Arg Ser Gly Gin 20 25 30

Arg Cys Trp Ala Ala Arg Thr Gin Val Glu Lys Arg Leu 35 40 45 &lt;210&gt; 733 &lt;211> 16 &lt;212> PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 492 1300414 &lt;400&gt; 733

Cys Pro Pro Gly Ser Pro Met Asn Pro His His Lys Cys Glu Val Trp 15 10 15 &lt;210> 734 &lt;211> 5 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory rib: &lt;400> 734

Asp Pro Val Leu Trp &lt;210> 735 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt;

Glu Ala lie Trp Leu 1 5 &lt;210> 736 &lt;211&gt; 4 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 736

Ala Val Leu Trp &lt;210> 737 &lt;211> 3 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 493 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic Victory too &lt;400&gt; Leu Trp Trp 1 &lt;210&gt; 738 &lt;211&gt; 2 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 738 Leu Trp &lt 210> 739 &lt;211> 3 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 739 Leu Trp Tyr 1 &lt;210&gt; 740 C &lt; 211 &gt; 6 &lt; 212 &gt; PRT - &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of the artificial sequence: synthetic victory &lt; 400 > 740

Leu Trp Ala Ala Tyr Phe 1 5

&lt;210&gt; 741 &lt;211> 16 &lt;212&gt; PRT 1300414 &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 741

Gly Asn Trp His Gly Thr Ser Pro Asp Trp Phe Phe Asn Tyr Tyr Trp 15 10 15 &lt;210&gt; 742 &lt;211&gt; 14 &lt;212> PRT &lt;213>Artificial Sequence &lt;220> &lt;223>Artificial Sequence Description: Synthetic wins Q &lt;400&gt; 742

Asp Lys Glu Ala Val Tyr Phe Ala His Leu Asp He lie Trp 1 5 10 &lt;210&gt; 743 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; : Synthetic victory 呔 &lt;400&gt; 743

Cys Thr Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Tyr Phe Cys His 1 5 10 15 〇

Gin Asp He lie Trp - 20 -&lt;210> 744 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇 〇&gt; 744

Cys Thr Cys Lys Asp Met Thr Asp Glu Glu Cys Leu Asn Phe Cys His 495 1300414

Gin Asp Val lie Trp 20 &lt;210&gt; 745 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory &lt;400> 745

Tyr Pro Phe Val Glu Pro lie 1 5 &lt;210> 746 &lt;211> 3 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 746 Tyr Pro Phe &lt;21Ό&gt; 747 &lt;211&gt; 3 U &lt;212&gt; PRT &lt;213&gt;Artificial Sequence-&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide • &lt;4〇 〇&gt; 747

Tyr Pro Phe 1 &lt;210&gt; 748 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Pro Phe Pro Gly Pro lie 1 5 &lt;210&gt; 749 &lt;211> 4 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;22G&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt 749 Q ) Tyr Pro Phe Pro &lt;210> 750 &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400 〉 750

Tyr Pro Phe Pro Gly 1 5 C &lt;210&gt; 751 &lt;211&gt; 5 -&lt;212&gt; PRT &lt;213&gt;Artificial Sequence* &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 751

Tyr Pro Phe Pro Gly 1 5 &lt;210> 752 &lt;211> 5 1300414 &lt;212&gt; PRT • &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt ; 752

Tyr Pro Phe Pro Gly 1 5 &lt;210> 753 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; Q &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 753

Tyr Pro Phe Val Glu Pro He 1 5 &lt;210> 754 &lt;211> 2 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;

&lt;223&gt; Description of the artificial sequence: the victory of synthesis &lt;400> 754 Tyr Phe

-&lt;210&gt; 755 &lt;211> 3 ^ &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 755 Tyr Phe Tyr 1300414 &lt;; 210> 756 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;&lt; 223 &gt; Description of Artificial Sequence: Synthetic Win &lt;400 &gt; 756 Tyr Phe Tyr 1 &lt;210&gt; 757 &lt;211&gt; 4 &lt;212> PRT Q &lt; 213 &gt; 213 &gt; artificial sequence &lt;22G&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 757 Tyr Phe Pro Tyr 1 &lt;210&gt;&lt;211> 3 &lt;212> PRT &lt; 213 &gt; 213 &gt; artificial sequence &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic victory C' &lt;400>758 Tyr Phe Pro &lt;210&gt; 759 &lt;;211&gt; 3 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt;400&gt; 759 Tyr Phe Pro 1300414 1 &lt;210> 760 &lt;211 〉 3 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 760 Tyr Phe Pro 1 &lt;210> 761 〇 &lt;211&gt; 4 &lt;212> PRT &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Phe Pro Gly &lt;210> 762 &lt;211> 4 &lt;212&gt; PRT 〇 &lt;213>Artificial sequence ^ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide ' &lt;400> 762

Tyr Phe Pro Gly 1 &lt;210> 763 &lt;211&gt; 4 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 1300414 &lt;400> 763 Tyr Phe Pro Gly 1 &lt;210&gt; 764 &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 764

Tyr Phe Pro Gly Pro 1 5

&lt;210&gt; 765 &lt;211>.3 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 765 Tyr Phe Pro 1

&lt;210> 766 &lt;211&gt; 6 U &lt;212&gt; PRT &lt;213&gt; Artificial sequence .&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory - &lt;400&gt;

Pro Phe Pro Gly Pro He 1 5 &lt;210&gt; 767 * &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220> 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory fl too &lt ;400> 767

Pro Phe Pro Gly Pro lie 1 5 &lt;210> 768 &lt;211> 4 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 768

Tyr Pro Val Pro

&lt;210> 769 &lt;211> 4 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory fl too &lt;400> 769 Tyr Pro Phe Pro 1

Plant &lt;210> 770, &lt;211> 4 &lt;212&gt; PRT • &lt;213&gt; Artificial Sequence &lt;220&gt; * &lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400> 770

Tyr Pro Phe Pro 1

&lt;210&gt; 771 &lt;211&gt; 3 &lt;212&gt; PRT 1300414 &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 771 Tyr Pro Pro 1 &lt;210&gt; 772 &lt;211> 7 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide

&lt;400〉 772

Tyr Ala Phe Gly Tyr Pro Ser 1 5 &lt;210> 773 &lt;211> 3 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt ; 773 Tyr Arg Phe 1 &lt;210> 774 &lt;211> 32 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400> 774

Tyr Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15 503 1300414

Gin Lys Arg Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr 20 25 30 &lt;210> 775 &lt;211&gt; 17 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400> 775 _ Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn C l 5 10 15

Gin &lt;210&gt; 776 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 776

Tyr Gly Phe Leu Arg lie Arg Pro Lys Leu Lys 1 5 10 &lt;210&gt; 111 &lt;211> 17 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 777

Tyr Ala Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15 504 1300414

Gin &lt;210&gt; 778 &lt;211> 17 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Ala Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15 C) Gin &lt;210&gt; 779 &lt;211&gt; 17 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt Description of artificial sequence: synthetic peptide &lt;400> 779

Tyr Ala Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn 1 5 10 15 O Gin

-&lt;210&gt; 780 &lt;211&gt; 12 ^ &lt;212> PRT &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 780

Tyr Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys 1 5 10 505 1300414 &lt;210> 781 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 781

Tyr Gly Phe Leu Arg Arg He Arg 1 5 &lt;210&gt; 782 &lt;211&gt; 12 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 782

Tyr Gly Gly Phe Leu Arg lie Arg Pro Lys Leu Lys 1 5 10 &lt;210&gt; 783 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 783

Tyr Gly Gly Phe Leu Arg Arg Arg Pro Lys Leu Lys - 1 5 10 -&lt;210> 784 &lt;211&gt; 7 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; : Synthetic wins &lt;400> 784

Gly Gly Phe Leu Arg Arg He 506 1300414 1 5 &lt;210&gt; 785 &lt;211> 12 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;;400&gt; 785

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu 1 5 10 &lt;210&gt; 786 〇&lt;211&gt; 13 &lt;212> PRT - &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence : Synthetic victory 呔 &lt;400&gt; 786

Tyr Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys 1 5 10 &lt;210&gt; 787 &lt;211&gt; 13 &lt;212&gt; PRT r' &lt;213>Artificial sequence U &lt;220> &lt;223&gt; Artificial sequence Description: The victory of synthesis & ^ &lt;400〉 787

Tyr Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys * 1 5 10 &lt;210&gt; 788 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic victory 507 1300414 &lt;400&gt; 788

Tyr Gly Gly Phe Leu Arg Arg He Arg Pro 1 5 10 &lt;210&gt; 789 1 &lt;211〉 14

&lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 789

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Arg Leu Arg Gly &lt;210&gt; 790 &lt;211> 16 &lt;212> PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 790

Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 10 15 &lt;210&gt; 791

&lt;211> 16 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 791

Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt;210> 792 &lt;211> 11 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 508 1300414 &lt;220> &lt;223&gt; Description of the artificial sequence: Synthetic victory month too &lt;400> 792

Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu 1 5 10 &lt;210> 793 &lt;211> 15 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis Peptide &lt;400〉 793

Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 10 15 &lt;210> 794 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400> 794

Gly Phe Leu Arg Arg He 1 5

&lt;210> 795 &lt;211> 11 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 795

Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys 1 5 10 &lt;210&gt; 796 &lt;211> 15 509 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400> 796

Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt;210&gt; 797 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220> f ) &lt;223&gt; Description of the sequence: Synthetic victory 呔 &lt;400&gt; 797

Arg He Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 10 &lt;210> 798 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;, &lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 798 lie Arg Pro Lys Leu Lys Trp Asp Asn Gin G 1 5 10 -&lt;210> 799 &lt;211&gt; 12 -&lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;;223&gt; Description of the artificial sequence: the winning form &lt;400&gt; 799

Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 10 510 1300414 &lt;210&gt; 800 &lt;211> 16 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 800

Tyr Pro Phe Pro Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt;210&gt; 801 &lt;211&gt; 9 &lt;212&gt; PRT G) &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of the artificial sequence: synthetic peptide &lt;400> 801

Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 &lt;210> 802 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220>, 223&gt; Description of Artificial Sequence: Synthetic Winning. &lt;400> 802

Lys Trp Asp Asn Gin - 1 5 * &lt;210&gt; 803 &lt;211> 17 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;; 803

Tyr Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn 511 1300414 1 5 10 15

Gin &lt;210&gt; 804 &lt;211&gt; 13 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr 1 5 10 Γ &lt;210> 805 &lt;211> 9 &lt;212> PRT &lt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence : Synthetic Victory Moon too &lt;400> 805

Tyr Gly Gly Phe Leu Arg Arg Gin Phe 1 5

&lt;210> 806 &lt;211> 29 &lt;212&gt; PRT C &lt; 213 > artificial sequence &lt; 220 &gt;&lt; 223 > Description of artificial sequence: synthetic victory fl too &lt; 400 > 806 - Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr Arg Ser Gin 1 5 10 15

Glu Asp Pro Asn Ala Tyr Ser Gly Glu Leu Phe Asp Ala 20 25 &lt;210&gt; 807 &lt;211> 10 512 1300414 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence : Synthetic victory 呔 &lt;400&gt; 807

TG Lys Tyr Pro Lys 1 5 10 &lt;210&gt; Winning &lt;400&gt; 808

Tyr Gly Gly Phe Leu Arg Lys Tyr Pro 1 5 &lt;210&gt; 809 &lt;211> 13 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400> 809

A Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys &lt;210&gt; 810 &lt;211&gt; 7 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt;呔&lt;400&gt; 810

Tyr Gly Gly Phe Leu Arg Phe 1 5 513 1300414 &lt;210&gt; 811 &lt;211&gt; 7 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt;;400&gt; 811

Tyr Gly Gly Phe Leu Arg Phe 1 5

&lt;210> 812 &lt;211〉 29 &lt;212&gt; PRT

&lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 812

Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr Arg Ser Gin 15 10 15

Glu Asp Pro Asn Ala Tyr Tyr Glu Glu Leu Phe Asp Val 20 25

&lt;210> 813 &lt;211&gt; 31 (j &lt;212>PRT &lt;213&gt; artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory ^ &lt;400&gt; 813

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala He He Lys Asn Ala His Lys Lys Gly Gin 20 25 30 &lt;210&gt; 814 514 1300414 &lt;211&gt; 27 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400&gt; 814

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His 20 25 &lt;210&gt; 815 Q &lt;211&gt; 31 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 815

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala He ly Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 30 wide &lt;210> 816 U &lt;211> 26 &lt;212&gt; PRT -&lt;213&gt;Artificial sequence&lt;220&gt; ^ &lt;223&gt Description of artificial sequence: synthetic peptide &lt;400&gt; 816

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie He Lys Asn Ala 20 25 515 1300414 &lt;210&gt; 817 &lt;211> 27 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthesis Peptide &lt;400〉 817

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr 20 25 &lt;210&gt; 818 Q &lt;211&gt; 17 &lt;212&gt; PRT_ &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthesis Victory) 3 too &lt;400> 818

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu &lt;210&gt; 819 〇 &lt;211> 16 &lt;212&gt; PRT -&lt;213> artificial sequence &lt;220> • &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 819

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

&lt;210&gt; 820 &lt;211&gt; 16 &lt;212&gt; PRT 516 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15 &lt;210&gt; 821 &lt;211> 11 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: the winning form of synthesis &lt;400> 821

Tyr Gly Gly Phe Leu Arg Lys Tyr Arg Pro Lys 1 5 10 &lt;210> 822 &lt;211&gt; 7 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 822

Tyr Gly Gly Phe Leu Arg Lys 1 5 〇&lt;210> 823 -&lt;211&gt; 8 &lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400〉 823

Tyr Gly Gly Phe Leu Arg Lys Arg 1 5 &lt;210> 824 517 1300414 &lt;211> 31 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400〉 824

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie ly Lys Asn Ala His Lys Lys Gly Gin 20 25 30 〇&lt;21〇&gt; 825 &lt;211&gt; 27 &lt;212> PRT &lt; 213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 825

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His 20 25 O &lt;210&gt; 826 &lt;211&gt; 31 -&lt;212> PRT &lt;213&gt; Artificial Sequence • &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400> 826

Tyr Gly Gly Phe Met Ser Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala He lie Lys Asn Ala His Lys Lys Gly Gin 20 25 30 518 1300414 &lt;210&gt; 827 &lt;211&gt; 31 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic victory 呔 &lt;400&gt; 827

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15 -Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 30 o &lt;210&gt; 828 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Gly Gly Phe Met Thr Leu Phe Lys Asn Ala lie lie Lys Asn Ala 1 5 10 15

Tyr Lys Lys Gly Glu 20 c &lt;210&gt; 829 -&lt;211&gt; 26 &lt;212> PRT ▲ &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;; 829

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15 519 1300414

Leu Phe Lys Asn Ala lie lie Lys Asn Ala 20 25 &lt;210> 830 &lt;211&gt; 27 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: victory of synthesis &lt;400&gt; 830

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15 〇Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr 20 25 &lt;210〉 831 &lt;211> 26 &lt;212&gt; PRT &lt;;213>Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 831

Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr Leu Phe Lys Asn Ala 15 10 15 r lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 &lt;210&gt; 832 &lt;211&gt; 14 &lt;212> PRT &lt;213&gt Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 1 5 10 520 1300414 &lt;210&gt; 833 &lt;211&gt; 31 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400> 833

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie Val Lys Asn Ala His Lys Lys Gly Gin 20 25 30 c &lt;210&gt; 834 &lt;211> 31 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400> 834

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala lie He Lys Asn Val His Lys Lys Gly Gin

-&lt;210> 835 &lt;211> 10 -&lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Glu Leu Ala Gly Ala Pro Pro Glu Pro Ala 15 10 521 1300414 &lt;210&gt; 836 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 836 Tyr Gly Gly Phe 1 &lt;210&gt; 837 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400&gt; 837

Tyr Gly Gly Phe Met Thr Ser Glu Lys 1 5 &lt;210&gt; 838 &lt;211&gt; 4 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 838 Lys Lys Gly Glu 1 &lt;210&gt; 839 &lt;211&gt; 31 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400 〉 839

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15 522 1300414

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 30 &lt;210> 840 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description: Synthetic victory fl too &lt;400> 840

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15 Θ

Leu &lt;210&gt; 841 &lt;211&gt; 1 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr

〇 &lt;210&gt; 842 &lt;211&gt; 8 ^ &lt;212> PRT &lt;213&gt; artificial sequence ^ &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory B too &lt;400> 842

Tyr Gly Phe Met Thr Ser Glu Lys 1 5 &lt;210&gt; 843 &lt;211&gt; 8 523 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 843

Tyr Gly Phe Met Thr Ser Glu Lys 15 &lt;210&gt; 844 &lt;211> 16 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; CJ &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt;4〇〇&gt; 844

Tyr Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr Leu 1 5 10 15 &lt;210&gt; 845 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of the sequence: Synthetic peptide &lt;400&gt; 845

Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr Leu - 1 5 10 15 as &lt;210> 846 _ &lt;211&gt; 31 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 846

Tyr Gly Gly Phe Leu Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15 524 1300414

Leu Phe Lys Asn Ala He He Lys Asn Ala His Lys Lys Gly Gin 20 25 30

&lt;210&gt; 847 &lt;211&gt; 6 &lt;212&gt; PRT . &lt;213&gt; Artificial sequence &lt;220> • &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 847

Tyr Gly Gly Phe Met Lys 1 5 Q &lt;210&gt; 848 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;; 848

Tyr Gly Gly Phe Met Lys Lys 1 5 &lt;210&gt; 849 &lt;211&gt; 7 &lt;212&gt; PRT G &lt; 213 > Artificial Sequence &lt;220&gt; - &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 849 w Tyr Gly Gly Phe Met Lys Arg 1 5 &lt;210&gt; 850 &lt;211> 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt; 525 1300414 &lt;223&gt; Description of artificial sequence: Synthetic peptide &lt;400&gt; 850

Tyr Gly Gly Phe Met Arg Arg Val 1 5 &lt;210&gt; 851 . &lt;211&gt; 8

&lt;212&gt; PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic S-form: &lt;400> 851

Ala Ala Ala Tyr Gly Gly Phe Met

&lt;210&gt; 852 &lt;211> 26 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val 1 5 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu 20 25 &lt;210&gt; 853 &lt;211&gt; 26 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 853

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val 15 10 15 526 1300414

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu 20 25 &lt;210&gt; 854 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 854

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu 1 5 10 C &lt;21〇&gt; 855 &lt;211&gt; 12 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory 呔 &lt;400&gt; 855

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu 1 5 10 &lt;210> 856 &lt;211&gt; 22 &lt;212>PRT-&lt;213&gt;Artificial Sequence&lt;220&gt;"&lt;223&gt; Description of Artificial Sequence : The victory of synthesis • &lt;400> 856

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp 15 10 15

Tyr Gin Lys Arg Tyr Gly 20 &lt;210&gt; 857 &lt;211&gt; 3 527 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Peptide &lt;400&gt 857 Phe Ala Arg 1 &lt;210&gt; 858 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt; (3 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 858

Tyr Ala Gly Phe Gly 1 5 &lt;210&gt; 859 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Ala Gly Phe Leu L 1 5

-&lt;210&gt; 860 &lt;211&gt; 5 • &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 860

Tyr Ala Gly Phe Met 1300414 &lt;210&gt; 861 &lt;211&gt; 4 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 861 Tyr Gly Phe Leu 1

&lt;210&gt; 862 _ &lt;211&gt; 5 ◦ &lt;212> PRT &lt; 213> artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: synthetic victory &lt;400&gt; 862

Tyr Gly Phe Leu Arg 1 5 &lt;210&gt; 863 &lt;211&gt; 2 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220 &gt; 220 &lt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 863 Gly Phe &lt;210> 864 &lt;211&gt; 2 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 > Description of artificial sequence: synthetic victory month too &lt; gt 864 414414

Gly Phe &lt;210&gt; 865 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 865

Gly Gly Phe Leu &lt;210> 866 &lt;211&gt; 3 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Victory &lt;400> 866 Tyr Gly Phe 1

&lt;210&gt; 867 &lt;211&gt; 3 &lt;212&gt; PRT (!) &lt;213&gt;Artificial sequence &lt;220&gt;-&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 867 ' Tyr Gly Phe 1 &lt;210&gt; 868 &lt;211&gt; 3 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt; 1300414 &lt;223&gt; 223> Description of artificial sequence: synthetic victory &lt;400&gt; 868 Phe Leu Arg 1 &lt;210&gt; 869 &lt;211&gt; 3 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 &gt; 869 Tyr Gly Phe

&lt;210> 870 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 870

Tyr Gly Gly Phe Leu 1 5 &lt;210&gt; 871 C &lt;211> 5 &lt;212&gt; PRT, &lt;213&gt; Artificial Sequence &lt;220&gt; / &lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 871

Tyr Gly Gly Phe Leu 1 5

&lt;210&gt; 872 &lt;211> 5 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Gly Gly Phe Leu 1 5 &lt;210> 873 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide Q &lt;400> 873

Tyr Ala Gly Phe Leu 1 5 &lt;210&gt; 874 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Ser Gly Phe Leu Thr 1 5

&lt;210> 875 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 875

Tyr Thr Gly Phe Leu Thr 1 5 &lt;210> 876 1300414 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400 〉 876

Tyr Gly Gly Phe Leu Lys 1 5 &lt;210> 877 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt ; 877

Tyr Gly Gly Phe Met Arg 1 5 &lt;210> 878 &lt;211> 7 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Winning

&lt;400&gt; 878

Tyr Gly Gly Phe Met Arg Arg 5 &lt;210&gt; 879 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 879

Tyr Gly Gly Phe Met. Arg Arg Val Gly 1300414 &lt;210&gt; 880 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400&gt; 880

Tyr Gly Gly Phe Met Arg Gly Leu 1 5

&lt;210&gt; 881 &lt;211&gt; 7 &lt;212> PRT C &lt; 213 &gt; 213 > Artificial sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Gly Gly Phe Met Arg Phe 1 5 &lt;210&gt; 882 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt;Artificial sequence&lt;220&gt; Synthetic victory&lt;223&gt; Description of artificial sequence &lt;400&gt; 882

Tyr Gly Gly Phe Met 15 &lt;210&gt; 883 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 1300414 &lt;400&gt; 883

Tyr Gly Gly Phe Met 1 5 &lt;210> 884 . &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 884

Tyr Ala Gly Phe Met 1 5

&lt;212> PRT &lt;210> 885 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Ala Gly Phe Met 1 5 &lt;210&gt; 886 &lt;211&gt; 7 &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 886

Tyr Gly Gly Phe Met Arg Phe 1 &lt;210&gt; 887 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 5 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory&lt; 400> 887

Tyr Gly Gly Phe Met 1 5 &lt;210&gt; 888 &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt;G; Tyr Ala Gly Phe Met, a 1 5 &lt; 210 > 889 &lt; 211 &gt; 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;&lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;;400&gt; 889 Tyr Gly Phe Pro 1

U &lt; 210 &gt; 890 &lt; 211 &gt; 211 &gt; 211 &gt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence β &lt; 220 &gt;&lt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt; 400 &gt; 890 Tyr Gly Phe Met 1 &lt;210&gt; 891 &lt;211&gt; 8 1300414 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Gly Gly Phe Met Arg Arg Val 1 5 &lt;210&gt; 892 &lt;211> 31 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt; (3 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 892

Phe Ala Glu Pro Leu Pro Ser Glu Glu Glu Gly Glu Ser Tyr Ser Lys 15 10 15

Glu Val Pro Glu Met Glu Lys Arg Tyr Gly Gly Phe Met Arg Phe 20 25 30 &lt;210> 893 &lt;211&gt; 25 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt; _ &lt;223&gt; Artificial Sequence Description: Synthetic peptide L · &lt;400&gt; 893

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp - 15 10 15

Tyr Gin Lys Arg Tyr Gly Gly Phe Leu 20 25 &lt;210&gt; 894 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 537 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory呔&lt;400&gt; 894

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val 1 5 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu Gly Lys Arg Tyr Gly Gly 20 25 30

Phe Met &lt;210&gt; 895 &lt;211> 19 〇 &lt;212> PRT ~ &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 895

Ser Ser Glu Val Ala Gly Glu Gly Asp Gly Asp Ser Met Gly His Glu 1 5 10 15

Asp Leu Tyr &lt;210> 896 p &lt;211> 6 &lt;212>PRT &lt;213&gt; Artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory ‘ &lt;400&gt; 896

Leu Val Val Tyr Pro Trp 1 5 &lt;210&gt; 897 &lt;211&gt; 2 &lt;212&gt; PRT &lt;213&gt; artificial sequence 538 1300414 &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic victory&lt; 400> 897 Pro Gly &lt;210&gt; 898 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 898 (^ Tyr Pro Phe Pro - 1 &lt;210&gt; 899 &lt;211> 5 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 899

Tyr Pro Phe Pro Pro 1 5 &lt;210&gt; 900, I, 'U &lt;211&gt; 4 &lt;212&gt; PRT • &lt;213&gt;Artificial Sequence&lt;220> One &lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400〉 900 Tyr Pro Pro Pro 1

&lt;210&gt; 901 &lt;211&gt; 6 &lt;212> PRT 1300414 &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 901

Arg Tyr Leu Gly Tyr Leu 1 5 &lt;210> 902 &lt;211〉 8 &lt;212> PRT &lt;213&gt;Artificial sequence&lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt ; 902

Ala Ala Ala Tyr Gly Gly Phe Leu 1 5 &lt;210> 903 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 903

Ala Ala Ala Tyr Gly Gly Phe Leu

&lt;210&gt; 904 &lt;211> 18 &lt;212> PRT &lt; 213 &gt; 213 > Artificial sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400> 904

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp 1 5 10 15

Tyr Gin 540 1300414 &lt;210> 905 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 905

Tyr Pro Phe Pro Pro Leu 1 5 &lt;210> 906 Π &lt;211&gt; 7 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400> 906

Tyr Val Pro Phe Pro Pro Phe 1 5 &lt;210> 907 &lt;211&gt; 2 &lt;212&gt;PRT-&lt;213>Artificial sequence U &lt;220&gt;'&lt;223&gt; Description of artificial sequence: synthetic victory ^ &lt;400〉 907

Trp Gly Λ 1 &lt;210&gt; 908 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon 1300414 &lt;400&gt; 908 Tyr Arg Phe Lys 1 &lt;210&gt; 909 &lt;211&gt; 7 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;400> 909

Tyr Met Phe His Leu Met Asp 1 5

&lt;210> 910 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 910

Tyr Ala Phe Asp Val Val Gly 1 5

&lt;210&gt; 911 &lt;211>7^;&lt;212&gt; PRT &lt;213&gt;Artificial sequence &quot;&lt;220&gt; &&lt;223&gt; Description of artificial sequence: synthetic peptide ' &lt;400> 911

Tyr Ala Phe Glu Val Val Gly 1 5 &lt;210> 912 &lt;211> 4 &lt;212> PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt; 400> 912

Tyr Pro Trp Phe &lt;210&gt; 913 &lt;211&gt; 5 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 &gt; 913 ") Tyr Pro Trp Phe Phe - 1 5 &lt; 210 > 914 &lt; 211 &gt; 2 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;&lt; 223 &gt; Description of Artificial Sequence: Synthetic Win &lt; 400 &gt; 914 Tyr Arg 1 Ο &lt;210> 915 &lt;211> 1 -&lt;212> PRT &lt;213&gt; Artificial sequence • &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 915

Tyr &lt;210&gt; 916 &lt;211&gt; 2 1300414 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Win: &lt;400> 916 Leu Gly &lt; 210> 917 &lt;211> 4 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 917 Pro Gin Arg Phe 1 &lt;210&gt; 918 &lt; 211 &gt; 18 &lt;212> PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; Description of the artificial sequence: synthetic victory &lt;400 &gt; 918

Ala Gly Glu Gly Leu Ser Ser Pro Phe Trp Ser Leu Ala Ala Pro Gin

Arg Phe &lt;210> 919 &lt;211&gt; 17 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory limb: 544 1300414 &lt;400> 919

Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn 1 5 10 15

Gin &lt;210&gt; 920 &lt;211&gt; 3 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; 223 Description of artificial sequence: synthetic peptide U &lt; 400 &gt; 920 Tyr Phe Phe 1 &lt;210&gt; 921 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Tyr Pro Leu Gly

&lt;210&gt; 922 &lt;211&gt; 4 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Tyr Pro Trp Gly &lt;210&gt; 923 545 1300414 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 923

Val Val Tyr Pro Trp Thr Gin 1 5 &lt;210> 924 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt; artificial sequence C) &lt;220> ^ &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 924

Leu Val Val Tyr Pro Trp Thr Gin Arg 1 5 &lt;210&gt; 925 &lt;211&gt; 2 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 925 Pro Leu 1 &lt;210> 926 • &lt;211&gt; 17 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;400〉 926

Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn 1 5 10 15 546 1300414

Gin &lt;210> 927 &lt;211> 8 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 927

Tyr Gly Gly Phe Met Arg Arg Val 1 5 C &lt;210&gt; 928 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400> 928

Ala Lys Ser Gin Gly Gly Ser Asn 1 5

&lt;210&gt; 929 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Leu Glu Asp Gly Pro Lys Phe Leu 1 5 &lt;210&gt; 930 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;;400&gt; 930

Arg Lys Asp Val Tyr 1 5 &lt;210&gt; 931 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; C) Gly Glu Gin Arg Lys Asp Val Tyr Val Gin Leu Tyr Leu 1 5 10 &lt;210> 932 &lt;211> 28 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide &lt;400&gt; 932

Ser Asp Ala Ala Val Asp Thr Ser Ser Glu He Thr Thr Lys Asp Leu 15 10 15

Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn O 20 25 - &lt;210&gt; 933

&lt;211&gt; 10 • &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 933

Tyr Gin Ala Lys Ser Gin Gly Gly Ser Asn 1 5 10 548 1300414 &lt;210> 934 &lt;211&gt; 28 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 934

Ser Asp Ala Ala Val Asp Thr Ser Ser Glu lie Thr Thr Lys Asp Leu 1 5 10 15

Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn 20 25 〇&lt;210> 935 &lt;211> 52 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 935

Tyr Arg Gin Ser Met Asn Asn Phe Gin Gly Leu Arg Ser Phe Gly Cys 1 5 10 15

Arg Phe Gly Thr Cys Thr Val Gin Lys Leu Ala His Gin lie Tyr Gin 20 25 30

Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys He Ser, a 35 40 45

Pro Gin Gly Tyr _ 50 &lt;210> 936 &lt;211> 12 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 936 549 1300414

Tyr Arg Gin Ser Met Asn Asn Phe Gin Gly Leu Arg 1 5 10

&lt;210> 937 &lt;211> 37 &lt;212> PRT . &lt;213>Artificial sequence &lt;220> • &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 937

Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gin Lys Leu Ala His 1 5 10 15 (^) Gin lie Tyr Phe Thr Asp Lys Asp Asn Val Ala Pro Arg Ser Lys lie A 20 25 30

Ser Pro Gin Gly Tyr 35 &lt;210&gt; 938 &lt;211&gt; 31 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 938 O Thr Val Gin Lys Leu Ala His Gin lie Tyr Gin Phe Thr Asp Lys Asp 1 5 10 15

Lys Asp Asn Val Ala Pro Arg Ser Lys lie Ser Pro Gin Gly Tyr * 20 .25 30 &lt;210> 939 &lt;211&gt; 48 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: the winning form 550 1300414 &lt;400> 939

Glu Leu Arg Met Ser Ser Serr Pro Thr Gly Leu Ala Asp Val Lys 15 10 15

Ala Gly Pro Ala Gin Thr Leu He Arg Pro Gin Asp Met Lys Gly Ala 20 25 30

Ser Arg Ser Pro Glu Asp Ser Ser Pro Asp Ala Ala Arg He Arg Val 35 40 45

&lt;210> 940 ~ &lt;211> 33 C ; &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 940

Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val Ser Ser Lys Pro 15 10 15

Gin Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser Ala Pro His.Phe 20 25 30

Leu

&lt;210> 941 &lt;211> 52 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 941

Tyr Arg Gin Ser Met Asn Phe Gin Gly Leu Arg Ser Phe Gly Cys Arg 15 10 15

Phe Gly Thr Cys Thr Val Gin Lys Leu Ala His Gin He Tyr Gin Phe 20 25 30 551 1300414

Thr Asp Lys Asp Gly Val Ala Pro Arg Ser Lys lie Ser Lys lie Ser 35 40 45

Pro Gin Gly Tyr 50 &lt;210&gt; 942 &lt;211&gt; 20 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide Q &lt;4〇〇&gt ; 942

Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp 1 5 10 15

Ala Leu Ser Arg 20 &lt;210> 943 &lt;211> 53 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220> _ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 943

Tyr Arg Gin Ser Met Asn Gin Gly Ser Arg Ser Thr Gly Cys Arg Phe - 15 10 15 -Gly Thr Cys Thr Met Gin Lys Leu Ala His Gin He Tyr Gin He Tyr 20 25 30

Gin Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg Asn Lys lie 35 40 45

Ser Pro Gin Gly Tyr 50 552 1300414 &lt;210&gt; 944 &lt;211&gt; 40 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 944

Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gin Lys Leu Ala His 1 5 10 15

Gin lie Tyr Gin Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg 20 25 30 (3) Asn Lys lie Ser Pro Gin Gly Tyr 35 40 &lt;210> 945 &lt;211> 20 &lt;212> PRT &lt;213 〉Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence··Synthetic peptide&lt;400> 945

Ala Arg Leu Asp Thr Ser Ser Gin Phe Arg Lys Lys Trp Asn Lys Trp 1 5 10 15

Ala Leu Ser Arg 20 &lt;210&gt; 946 &lt;211&gt; 13 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Ala Pro Ser Gly Ala Gin Arg Leu Tyr Gly Phe Gly Leu 1 5 10 553 1300414 &lt;210> 947 &lt;211> 10 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic victory month too &lt;400> 947

Gly Asp Gly Arg Leu Tyr Ala Phe Gly Leu 1 5 10

&lt;210&gt; 948 &lt;211> 9 〇 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 948

Gly Gly Ser Leu Tyr Ser Phe Gly Leu 1 5 &lt;210> 949 &lt;211&gt; 8 &lt;212> PRT &lt; 213 &gt; artificial sequence wide &lt; 220 &gt; 220 &gt; c223 &gt; Description of artificial sequence: synthetic peptide &lt; 400> 949 * Asp Arg Leu Tyr Ser Phe Gly Leu 1 5 &lt;210&gt; 950 &lt;211> 17 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory: &lt;400> 950 554 1300414

Val His His Gin Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn 15 10 15

Lys &lt;210> 951 &lt;211> 11 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory &lt;400&gt; 951

Gly Ser Asn Lys Gly Ala lie He Gly Leu Met 1 5 10 〇 &lt;210&gt; 952 &lt;211&gt; 5 &lt;212> PRT .&lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: The victory of synthesis &lt;400> 952

Arg Glu Arg Met Ser 1 5

&lt;210> 953 &lt;211> 17 U &lt;212> PRT &lt;213&gt; Artificial sequence .&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory - &lt;400&gt; 953

Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gin Val 1 5 10 15

Met &lt;210> 954 &lt;211> 43 555 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val He Ala Thr 35 40 &lt;210> 955 &lt;211> 42 &lt;212> PRT &lt;213>Artificial Sequence &lt;220〉 &lt;223> Description of Artificial Sequence: Synthetic Win Peptide &lt;400> 955

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He lie

Gly Leu Met Val Gly Gly Val Val He Ala 35 40 &lt;210> 956 &lt;211&gt; 40 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400〉,956

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 556 1300414 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40

&lt;210&gt; 957 &lt;211&gt;11 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;&lt;220&gt; ' (3 &lt;223> Description of artificial sequence: synthetic peptide &lt;400&gt; 957

Tyr Glu Val His His Gin Lys Leu Val Phe Phe 1 5 10 &lt;210> 958 &lt;211> 14 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223> Description of Artificial Sequence··Synthesis Peptide &lt;400&gt; 958 'Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met O 1 5 10

, &lt;210&gt; 959 &lt;211> 28 • &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15 557 1300414

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 20 25 &lt;210&gt; 960 &lt;211> 40 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Peptide &lt;400> 960

Val Val Gly Gly Val Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 15 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gin His His Val Glu Tyr Gly 20 25 30

Ser Asp His Arg Phe Glu Ala Asp 35 40 &lt;210&gt; 961 &lt;211&gt; 42 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide 〇&lt;;400&gt; 961

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys ' 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val He Ala 35 40 &lt;210&gt; 962 &lt;211&gt; 40 558 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 962

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He He 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40

&lt;210> 963 &lt;211&gt; 11 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 963

Tyr Glu Val His His Gin Lys Leu Val Phe Phe 15 10 &lt;210&gt; 964 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400&gt; 964

Glu Asp Val Gly Ser Asn Lys Gly Ala He lie Gly Leu Met 15 10 &lt;210> 965 &lt;211&gt; 28 &lt;212> PRT &lt;213>Artificial Sequence 559 1300414 &lt;22Q&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400> 965

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 20 25 &lt;210&gt; 966 &lt;211> 40 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; " &lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400> 966

Val Val Gly Gly Val Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 1 5 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gin His His Val Glu Tyr Gly 20 25 30

Ser Asp His Arg Phe Glu Ala Asp 35 40

&lt;210&gt; 967 &lt;211&gt;42 O &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide ^ &lt;400> 967

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He He 20 25 30

Gly Leu Met Val Gly Gly Val Val lie Ala 560 1300414 35 40 &lt;210&gt; 968 &lt;211> 40 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis Victory &lt;400> 968

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He lie 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt;210&gt; 969 &lt;211&gt; 11 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 969 ◦ Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu 1 5 10 &lt;210&gt; 970 • &lt;211> 5 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Artificial sequence Description: Synthetic wins &lt;400> 970

He He Gly Leu Met 1 5 561 1300414 &lt;210> 971 &lt;211> 4 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Win &lt; 400 〉 971 lie Gly Leu Met 1

&lt;210> 972 &lt;211> 11 &lt;212&gt; PRT 〇 &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 972

Met Leu Gly lie He Ala Gly Lys Asn Ser Gly 1 5 10 &lt;210> 973 &lt;211&gt; 15 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt; C &lt;223&gt; Description of Artificial Sequence: Synthesis胜胜&lt;400> 973 - Asn Tip Cys Lys Arg Gly Arg Lys Gin Cys Lys Thr His Pro His 1 5. 10 15 &lt;210> 974 &lt;211> 20 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt; ' &lt;223&gt; Description of the artificial sequence: Synthetic victory &lt;400&gt; 974 562 1300414

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg 1 5 10 15

His Leu Ser Lys 20 &lt;210&gt; 975 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 975 〇Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly 35 &lt;210> 976 &lt;211&gt; 28 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400> 976

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 20 25 &lt;210&gt; 977 &lt;211&gt; 16 &lt;212> PRT &lt;213&gt; Artificial sequence 563 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic Victory Moon too &lt;400> 977

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 1 5 10 15 &lt;210&gt; 978 &lt;211&gt; 40 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400&gt; 978 C Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt;210> 979 &lt;211> 35 &lt;212&gt; PRT, &lt;213>Artificial Sequence U &lt;22〇&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 979 * His Asp Ser Gly Tyr Glu Val His His Gin Lys Leu Val Phe Phe Ala 15 10 15

Gin Asp Val Gly Ser Asn Lys Gly Ala He lie Gly Leu Met Val Gly 20 25 30

Gly Val Val 35 564 1300414 &lt;210&gt; 980 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 980

Glu Gin Val Thr Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala 1 5 10 15

Val Ala Gin Lys Thr Val Glu Gly Ala Gly Ser lie Ala Ala Ala Thr 20 25 30 〇Gly Phe Val a 35 &lt;210> 981 &lt;211> 24 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 981

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 1 5 10 15 C- Gly Leu Met Val Gly Gly Val Val 20 &lt;210> 982 &lt;211> 11 &lt;212&gt; PRT &lt;213&gt; Manual sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 982

Gly Tyr Val lie lie Lys Pro Leu Val Trp Val 1 5 10 565 1300414 &lt;210&gt; 983 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 983

Val His His Gin Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn 15 10 15

Lys Γ &lt;210&gt; 984 &lt;211&gt; 11 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 984

Gly Ser Asn Lys Gly Ala He lie Gly Leu Met 1 5 10

&lt;210&gt; 985 &lt;211&gt; 5 U &lt;212&gt; PRT &lt;213&gt; Artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide • &lt;400&gt; 985

Arg Glu Arg Met Ser 1 5 &lt;210&gt; 986 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 566 1300414 &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory month too &lt; 400> 986

Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gin Val 1 5 . 10 15

Met

&lt;210> 987 &lt;211> 43 ' &lt;212> PRT J &lt; 213 > artificial sequence &lt;220〉 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 987

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val lie Ala Thr 35 40

&lt;210&gt; 988 &lt;211&gt; 42 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory i too &lt;400> 988

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He He 20 25 30 567 1300414

Gly Leu Met Val Gly Gly Val Val He Ala 35 40 &lt;210&gt; 989 &lt;211> 40 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 989

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt;210&gt; 990 &lt;211> 11 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt; 400> 990

Tyr Glu Val His His Gin Lys Leu Val Phe Phe 5 10 &lt;210> 991 &lt;211> 14 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400&gt; 991

Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met 568 1300414 1 5 10 &lt;210> 992 &lt;211&gt; 28 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400&gt; 992

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys

&lt;210&gt; 993 &lt;211&gt; 40 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 993

Val Val Gly Gly Val Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 15 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gin His His Val Glu Tyr Gly 20 25 30

Ser Asp His Arg Phe Glu Ala Asp 35 40 &lt;210&gt; 994 &lt;211&gt; 42 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt; 400> 994 569 1300414

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val He Ala 35 40 &lt;210&gt; 995 &lt;211&gt; 40 &lt;212> PRT, &lt;213>Artificial Sequence G) &lt;220> &lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 995

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt;210>996,"&lt;211>11 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt; * &lt;223&gt; Description of Artificial Sequence: Synthetic Win Shape &lt;400> 996

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu 1 5 10 &lt;210&gt; 997 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 570 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic peptide &lt;400&gt; 997 lie lie Gly Leu Met 1 5 &lt;210&gt; 998 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic win &lt;400&gt; 998 C lie Gly Leu Met &lt;210> 999 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthesis Victory &lt;400> 999

Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 1 5 10 ϋ &lt;210〉 1000

&lt;211&gt; 15 * &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1000

Asn Trp Cys Lys Arg Gly Arg Lys Gin Cys Lys Thr His Pro His 15 10 15 &lt;210&gt; 1001 &lt;211> 20 571 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: the victory of synthesis &lt;400> 1001

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg 1 5 10 15

His Leu Ser Lys 20

&lt;210> 1002 &lt;211> 38 C &lt;212> PRT &lt;213>Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 1002

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He He 20 25 30

Gly Leu Met Val Gly Gly &lt;210> 1003 • &lt;211&gt; 28 &lt;212&gt; PRT ' &lt;213&gt;Artificial Sequence&lt;220> &lt;223&gt; Description of Artificial Sequence: Synthetic Winning Belly: &lt;400&gt ; 1003

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 572 1300414 20 25 &lt;210&gt; 1004 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic peptide &lt;400> 1004

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 1 5 10 15 &lt;210> 1005 L ) &lt;211>40 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223 〉 Description of artificial sequence: synthetic victory &lt;400&gt; 1005

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val

&lt;210&gt; 1006 &lt;211&gt; 35 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1006

His Asp Ser Gly Tyr Glu Val His His Gin Lys Leu Val Phe Phe Ala 1 5 10 15

Gin Asp Val Gly Ser Asn Lys Gly Ala He He Gly Leu Met Val Gly 573 1300414 20 25 30

Gly Val Val 35 &lt;210> 1007 &lt;211&gt; 35 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt; 1007

Glu Gin Val Thr Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala ◦ 1 5 10 15

Val Ala Gin Lys Thr Val Glu Gly Ala Gly Ser lie Ala Ala Ala Thr 20 25 30

Gly Phe Val 35 &lt;210&gt; 1008 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory I too &lt;400&gt; 1008

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He . 15 10 15

Gly Leu Met Val Gly Gly Val Val 20 &lt;210> 1009 &lt;211&gt; 11 &lt;212> PRT &lt;213&gt; Artificial sequence 574 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;;400> 1009

Gly Tyr Val He He Lys Pro Leu Val Trp Val 1 5 10 &lt;210&gt; 1010 &lt;211> 63 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide 〇&lt;400> 1010

Arg Leu Glu Lys Arg Asp Val Lys Ala Val Cys Ser Gin Glu Ala Met 15 10 15

Thr Gly Pro Cys Arg Ala Val Met Pro Arg Trp Tyr Phe Asp Leu Ser 20 25 30

Lys Gly Lys Cys Val Arg Phe He Tyr Gly Gly Cys Gly Gly Asn Arg 35 40 45

Asn Asn Phe Glu Ser Glu Asp Tyr Cys Met Ala Val Cys Lys Ala 50 55 60 &lt;210> 1011 O &lt;211> 39 &lt;212> PRT ^ &lt;213&gt; Artificial Sequence &lt;220> • &lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 1011

Asn Ser Ser Cys Gly Glu Gly Asn His Leu Pro Thr Thr Pro Cys Tyr 1 5 10 15

Leu Gin Trp Gly Thr His Arg Glu Phe Leu Arg Arg Phe Ser lie Trp 20 25 30 575 1300414

Asn His Gly His Leu His Met 35 &lt;210&gt; 1012 &lt;211&gt; 39 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1012

Ala Gly Arg Gly Lys Gin Gly Gly Lys Val Arg Ala Lys Ala Lys Thr 15 10 15 〇 Arg Ser Ser Arg Ala Gly Leu Gin Phe Pro Val Gly Arg Val His Arg 20 25 30

Leu Leu Arg Lys Gly Asn Tyr 35 &lt;210> 1013 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1013

Thr Arg Ser Ser Arg Ala Gly Leu Gin Phe Pro Val Gly Arg Val His 15 10 15

Arg Leu Leu Arg Lys 20 &lt;210&gt; 1014 &lt;211&gt; 37 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 576 1300414 &lt;400 〉 1014

Lys Trp Lys Leu Phe Lys Lys lie Glu Lys Val Gly Gin Asn lie Arg 1 5 10 15

Pro : Synthetic peptide

Asp Gly lie lie Lys Ala Gly 20

Thr Gin lie Ala Lys 35

&lt;210&gt; 1015 &lt;211> 32 &lt;212&gt; PRT 〇 &lt;213> artificial sequence &lt;220〉 &lt;223&gt; Description of artificial sequence &lt;400> 1015

Ala Val Ala Val Val Gly Gin Ala 25 30

Ser Trp Leu Ser Lys Thr Ala Lys Lys Leu Glu Asn Ser Ala Lys Lys 1 5 10 15

Arg lie Ser Glu Gly lie Ala lie Ala lie Gin Gly Gly Pro Arg Cys 20 25 30

&lt;210> 1016 &lt;211&gt; 31 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 > 1016

Gly He Met Ser lie Val Lys Asp Val Ala Lys Asn Ala Ala Lys Gly 15 10 15

Ala Leu Ser Thr Leu Ser Thr Leu Ser Cys Lys Leu Ala Lys Thr 20 25 30 &lt;210&gt; 1017 &lt;211&gt; 24 577 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of the sequence: the victory of synthesis &lt;400> 1017

Phe Leu Gly Ala Leu Phe Lys Val Ala Ser Lys Val Leu Pro Ser Val 1 5 10 15

Lys Cys Ala He Thr Lys Lys Cys 20

&lt;210> 1018 &lt;211> 13 &lt;212&gt; PRT C/ &lt; 213 > artificial sequence &lt; 220 &lt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 > 1018 lie Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg 1 5 10

&lt;210> 1019 &lt;211&gt; 18 &lt;212> PRT &lt;213>Artificial sequence ·, &lt;220> A &lt;223&gt; Description of artificial sequence: Synthetic victory & w &lt;400> 1019

Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val &quot; 1 5 10 15

Gly Arg &lt;210&gt; 1020 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 578 1300414 &lt;400&gt; 1020

Arg Arg Trp Cys Tyr Arg Lys Cys Tyr Lys Gly Tyr Cys Tyr Arg Lys 1 5 10 15

Cys Arg &lt;210&gt; 1021 &lt;211&gt; 35 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 1021 ("Arg Trp Lys Lie Phe Lys Lys lie Glu Lys Val Gly Gin Asn lie Arg 1 5 10 15

Asp Gly lie Val Lys Ala Gly Pro Ala Val Ala Val Val Gly Gin Ala 20 25 30

Ala Thr lie 35

&lt;210&gt; 1022 &lt;211&gt; 12 &lt;212> PRT "&lt;213> artificial sequence U &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory ‘ &lt;400&gt; 1022

Arg Leu Cys Arg lie Val Val He Arg Val Cys Arg * 1 5 10 &lt;210> 1023 &lt;211> 21 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 579 1300414 &lt;400&gt; 1023

Thr Arg Ser Ser Arg Ala Gly Leu Gin Phe Pro Val Gly Arg Val His 15 10 15

Arg Leu Leu Arg Lys 20 &lt;210&gt; 1024 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; (3 &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1024

Tyr Pro Pro Gly Pro Leu Ala Pro Pro Gin Pro Phe Gly Pro 1 5 10 &lt;210> 1025 &lt;211> 22 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; : Synthetic peptide &lt;400> 1025

Val Asn Pro Gly Val Val Val Arg lie Ser Gin Lys Gly Leu Asp Tyr

Ala Ser Gin Gin Gly Arg 20 &lt;210> 1026 &lt;211> 15 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 1026 580 1300414

Ala Asp Val Leu Thr Thr Gly Ala Gly Asn Pro Val Gly Asp Lys 15 10 15 &lt;210> 1027 &lt;211&gt; 42 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide &lt;400> 1027

Met Ala Ala Val Ser Met Ser Val Ala Leu Arg Gin Ala Leu Trp Gly 15 10 15

Arg Arg Val Ala Thr Val Ala Ala Val Ser Val Ser Lys Val Ser Thr 20 25 30

Arg Ser Leu Ser Thr Ser Thr Trp Arg Leu 35 40 &lt;210&gt; 1028 &lt;211&gt; 23 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt; _ &lt;223&gt; Description of Artificial Sequence: Synthetic Success Shape 0 &lt;400> 1028

Gly ly Gly Lys Phe Lys His Ser Ala Gly Lys Phe Gly Lys Ala Phe - 1 5 10 15 • Val Gly Glu lie Met Lys Ser 20 &lt;210&gt; 1029 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Sequence &lt;220&gt; 581 1300414 &lt;223> Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1029

Leu Arg Asp Leu Val Ser Tyr Cys Arg Ala Arg Gly Lys Gly Arg Glu 1 5 10 15

Arg Met Asn Gly Thr Arg Lys Gly His Leu Leu Tyr Met 20 25 &lt;210&gt; 1030 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220>G"&lt;223&gt; Description of Artificial Sequence : Synthetic win &lt;400&gt; 1030 Ser Gin Asn Tyr 1 &lt;210&gt; 1031 &lt;211> 12 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthesis Victory &lt;400&gt; 1031 r- Arg Leu Cys Arg He Val Val He Arg Val Cys Arg U 1 5 10 &lt;210&gt; 1032 &lt;211> 25 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220 〉 &lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400> 1032

Asn Gin Gly Arg His Phe Cys Gly Gly Ala Leu He His Ala Arg Phe 15 10 15 582 1300414

Val Met Thr Ala Ala Ser Cys Phe Gin 20 25 &lt;210> 1033 &lt;211&gt; 2 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 1033 Pro Phe

&lt;210&gt; 1034 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1034

Cys Asn Leu Ala Val Ala Ala Ala Ser His lie Tyr Gin Asn Gin Phe 1 5 10 15

Val Gin &lt;210&gt; 1035 &lt;211&gt; 19 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1035

Tyr Arg Val Arg Phe Leu Ala Lys Glu Asn Val Thr Gin Asp Ala Glu 15 10 15

Asp Asn Cys 583 1300414 &lt;210> 1036 &lt;211> 15 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 1036

Lys Trp Lys Leu Phe Lys Lys lie Gly Ala Val Leu Lys Val Leu 1 5 10 15

&lt;210&gt; 1037 &lt;211&gt; 35 &lt;212&gt; PRT 〇&lt;213>Artificial sequence &lt;220> &lt;223> Description of artificial sequence: Synthetic victory &lt;400> 1037

Lys Trp Lys Val Phe Lys Lys He Glu Lys Met Gly Arg Asn lie Arg 1 5 10 15

Asn Gly lie Val Lys Ala Gly Pro Ala He Ala Val Leu Gly Glu Ala 20 25 30

Lys Ala Leu 35

O &lt;210> 1038 &lt;211&gt; 12 -&lt;212> PRT &lt;213&gt; Artificial sequence • &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1038

Thr Tyr He Cys Glu Val Glu Asp Gin Lys Glu Glu 1 5 10 &lt;210> 1039 &lt;211&gt; 29 584 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; : Synthetic victory 呔 &lt;400&gt; 1039

Cys Tyr Cys Arg lie Pro Ala Cys lie Ala Gly Glu Arg Arg Tyr Gly 15 10 15

Thr Cys He Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cys 20 25

&lt;210&gt; 1040 &lt;211&gt; 34 〇 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1040

Ala Leu Trp Lys Thr Met Leu Lys Lys Leu Gly Thr Met Ala Leu His 1 5 10 15

Ala Gly Lys Ala Ala Leu Gly Ala Ala Ala Asp Thr lie Ser Gin Gly 20 25 30

Thr Gin

&lt;210> 1041 &lt;211&gt; 24 -&lt;212> PRT • &lt;213>Artificial sequence &lt;220〉 &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1041

Gly Val Leu Ser Asn Val lie Gly Tyr Leu Lys Lys Leu Gly Thr Gly 15 10 15

Ala Leu Asn Ala Val Leu Lys Gin 20 585 1300414 &lt;210&gt; 1042 &lt;211> 6 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;. &lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1042

Val Glu Pro lie Pro Tyr 1 5 &lt;210&gt; 1043 &lt;211> 11 Q &lt;212&gt; PRT ^ &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt; 400> 1043

Arg Arg Trp Gin Trp Arg Met Lys Lys Leu Gly 1 5 10 &lt;210&gt; 1044 &lt;211> 21 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide ◦ &lt;400> 1044

Asp Ala Glu Ala Val Gly Pro Glu Ala Phe Ala Asp Gin Asp Leu Asp - 15 10 15 &quot; Glu Arg Glu Val Arg 20 &lt;210> 1045 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;;220&gt; 586 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory&lt;400> 1045

Ser lie Gly Ser Leu Ala Lys 1 5 &lt;210&gt; 1046 &lt;211&gt; 23 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;; 1046

Gly lie Gly Lys Phe Leu His Ser Ala Gly Lys Phe Gly Lys Ala Phe 15 10 15

Val Gly Glu He Met Lys Ser 20 &lt;210&gt; 1047 &lt;211> 23 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1047

Gly He Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe

Val Gly Glu He Met Asn Ser 20 &lt;210&gt; 1048 &lt;211&gt; 27 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1048

Tyr Leu Val Leu Phe Phe Tyr Pro Leu Asp Phe Thr Phe Val Cys Pro 587 1300414 15 10 15

Thr Glu lie lie Cys Pro Thr Glu lie lie Gly 20 25 &lt;210> 1049 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Win呔&lt;400&gt; 1049

Leu Val Gin Ala Phe Gin Gly Lys Val Asn Val Phe Leu Gin Phe Q 15 10 15 &lt;210> 1050 &lt;211> 19 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide &lt;400> 1050

Gly Leu Phe He lie Asp Tyr Thr Asp Glu Met Gly Glu Val Pro Ala 1 5 10 15

Gly Gly Lys

U &lt;210> 1051 &lt;211> 4 ^ &lt;212> PRT &lt;213&gt;Artificial sequence* &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1051 Asp Glu Val Asp 1 &lt;210&gt; 1052 &lt;211&gt; 4 588 1300414 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 > 1052 Asp Glu Val Asp &lt;210&gt; 1053 &lt;211&gt; 3 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; artificial sequence&lt;220&gt; 〇 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1053 Val Ala Asp 1 &lt;210&gt; 1054 &lt;211> 3 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: Synthetic peptide &lt;400&gt; 1054 17-1 Ala Asp ~ &lt;210&gt; 1055 &lt;211&gt; 27 ♦ &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic β Shengyue too &lt;400&gt; 1055

Asp Pro Met Ser Ser Thr Tyr lie Glu Glu Leu Gly Lys Arg Glu Val 15 10 15 589 1300414

Thr lie Pro Pro Lys Tyr Arg Glu Leu Leu Ala 20 25 &lt;210&gt; 1056 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory呔&lt;400> 1056 Val Ala Asp Met 1 C} &lt;21〇&gt; 1057 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 1057 Asp Glu Val Asp 1

&lt;210&gt; 1058 &lt;211&gt; 20 f ; &lt;212>PRT &lt; 213 > artificial sequence &lt;220> ^ &lt;223&gt; Description of artificial sequence: synthetic peptide • &lt;400&gt; 1058

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 15 10 15

Tyr Val Ala Asp 20 &lt;210> 1059 &lt;211&gt; 7 590 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: Synthetic victory &lt;400&gt; 1059

Tyr Val Ala Asp Ala Pro Lys 1 5 &lt;210> 1060 &lt;211&gt; 20 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;〇&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt;400&gt; 1060

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 1 5 10 15

Asp Glu Val Asp 20 &lt;210> 1061 &lt;211> 4 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt; ^ ) &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1061 - Tyr Val Ala Asp 1 &lt;210> 1062 &lt;211> 4 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1062 591 1300414

Tyr Val Ala Asp 1 &lt;210> 1063 &lt; 211 &gt; 211 &gt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; - &lt; 223 &gt; Description of Artificial Sequence: Synthetic Win &lt; 400 > 1063 Tyr Val Ala Asp &lt;210> 1064,) &lt;211>2 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 1064 Val Phe &lt;210&gt; 1065 &lt;211&gt; 3 &lt;212&gt; PRT / -y &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory 8 too one &lt;400&gt; 1065 , Leu Leu Leu 1 &lt;210> 1066 &lt;211> 4 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 1300414 &lt;400> 1066 Tyr Val Ala Asp &lt;210&gt; 1067 &lt;211> 4 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1067

Val Glu lie Asp

&lt;210&gt; 1068 &lt;211&gt; 1 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1068

Asp &lt;210&gt; 1069

&lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1069

Asp Glu Val Asp Ala Pro Lys 1 5 &lt;210> 1070 &lt;211> 21 &lt;212> PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt; 400> 1070

Asp Met Phe Ser Asp Gly Asn Phe Asn Trp Val Arg Val Val Ala Leu 1 5 10 15

Phe Tyr Phe Ala Ser 20 &lt;210> 1071 &lt;211&gt; 8 &lt;212> PRT &lt;213>Artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400 〉 1071

Ala Asn Arg Leu Phe Gly Glu Lys 1 5 &lt;210> 1072 &lt;211> 19 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide,) &lt;400>1072

Gly Gly Gly Gly Asp He His Gin Gly Phe Gin Ser Leu Leu Thr Glu 1 5 10 15 , Val Asn Lys ' &lt;210> 1073 &lt;211> 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1073 594 1300414

Gly Asn Thr Ala Ala Gin Met Ala Gin lie Leu Ser Phe Asn 1 5 10 &lt;210&gt; 1074 &lt;211&gt; 25 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic Victory Moon too &lt;400> 1074

Gin Gly Leu Trp Leu Met Asn Val Leu Arg Val Gly Trp His His His 1 5 10 15 (,] Leu Gin Pro Arg Thr Val Pro Glu Asn 20 25 &lt;210&gt; 1075 &lt;211> 35 &lt;212〉 PRT &lt;;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1075

Thr Gly His Gly Gly Pro Gin Phe Val Ala Asp His Pro Phe Leu Phe 1 5 10 15 〕Leu He Met His Lys lie Thr Asn Cys lie Leu Phe Phe Gly Arg Phe 20 25 30 , Ser Ser Pro 35 &lt;210> 1076 &lt;211&gt; 9 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400> 1076 595 1300414

Ala Pro Arg Leu Arg Phe Tyr Ser Leu 1 5 &lt;210> 1077 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400> 1077

Ala Pro Arg Leu Arg Phe Tyr Ser 1 5 〇&lt;210&gt; 1078 &lt;211> 7 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 1078

Ala Pro Arg Leu Arg Phe Tyr 1 5 &lt;210> 1079 &lt;211&gt; 5 q &lt;212&gt; PRT 'j &lt;213>Artificial sequence &lt;220〉 ' &lt;223&gt; Description of artificial sequence: synthetic victory Shape, &lt;400> 1079

Arg Leu Arg Phe His 1 5 &lt;210&gt; 1080 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt; 1300414 &lt;223&gt;223 Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1080 Arg Leu Arg Phe Asp 1 5 &lt;210&gt; 1081 &lt;211&gt; 23 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1081

Leu Lys Lys Tyr Lys Val Pro Gin Leu Glu lie Val Pro Asn Ser Ala 15 10 15

Glu Glu Arg Leu His Ser Met. 20 ^ &lt;210&gt; 1082 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt; 400> 1082

Gin Lys Leu Gly Asn Gin Trp Ala Val Gly His Leu Met 1 5 10 * &lt;210&gt; 1083 . &lt;211&gt; 7 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400&gt; 1083

Trp Ala Val Gly His Leu Met 1 5 597 1300414 &lt;210&gt; 1084 &lt;211> 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 1084

Glu Gin Arg Leu Gly Asn Gin Trp Ala Val Gly His Leu Met 1 5 10

&lt;210&gt; 1085 &lt;211&gt; 14 ^ &lt;212> PRT G) &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1085

Glu Gin Arg Leu Gly Asn Gin Trp Ala Val Gly His Leu Leu 1 5 10 &lt;210> 1086 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : The victory of synthesis呔

&lt;400&gt; 1086

Phe Gin Trp Ala Val Gly His Leu 1 5 &lt;210&gt; 1087 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1087

Gin Arg Leu Gly Asn Gin Trp Ala Val Gly Phe Leu Met 1 5 10 598 1300414 &lt;210&gt; 1088 &lt;211> 13 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory 呔 &lt;400&gt; 1088

Gin Arg Leu Gly Asn Gin Trp Ala Val Gly Phe Leu Leu 1 5 10

&lt;210> 1089 &lt;211&gt; 13 O &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory 1 Ϊ too &lt;400&gt; 1089

Gin Arg Tyr Gly Asn Gin Trp Ala Val Gly His Leu Met 1 5 10 &lt;210&gt; 1090 &lt;211> 13 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthetic victory fl too &lt;400> 1090 a Gin Arg Tyr Gly Asn Gin Trp Ala Val Gly Phe Leu Met w 1 5 10 Zero &lt;210&gt; 1091 &lt;211> 21 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: $99 1300414 &lt;400> 1091

Met Pro Leu Pro Pro His Pro Gly His Pro Gly Tyr He Asn Phe Ser 15 10 15

Tyr Glu Val Leu Thr 20 &lt;210&gt; 1092 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide 〇 &lt;400> 1092

Pro Phe Tyr Gly Pro Val 1 5 &lt;210> 1093 &lt;211&gt; 47 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1093

Tyr Leu Tyr Gin Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu

Glu Pro Arg Arg Val Cys Leu Asn Pro Asp Cys Asp Glu Leu Ala Asp ~ 20 25 ,30

His lie Gly Phe Gin Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val 35 40 45 &lt;210&gt; 1094 &lt;211> 6 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt; 600 1300414 &lt;223&gt; Description of the sequence: synthetic peptide &lt;400> 1094

Leu Val Val Tyr Pro Trp 1 5 &lt;210&gt; 1095 &lt;211> 46 &quot;&lt;212&gt; PRT Ϊ &lt;213&gt; artificial sequence; v &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthesis Peptide &lt;400> 1095

Tyr Leu Tyr Gin Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu 15 10 15

Pro Arg Arg Val Cys Leu Asn Pro Asp Cys Asp Glu Leu Ala Asp His 20 25 30 lie Gly Phe Gin Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val 35 40 45 &lt;210&gt; 1096 &lt;211&gt; 13 &lt;212〉 PRT &lt;213>Artificial sequence "-, &lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide? &lt;400&gt; 1096

Gly Phe Gin Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val 1 5 10%: &lt;210> 1097 &lt;211> 13 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic Victory Moon too &lt;400&gt; 1097 601 1300414

Pro Tyr Gin Glu Ala Phe Arg Arg Phe Phe Gly Pro Val 1 5 10 &lt;210&gt; 1098 &lt;211&gt; 48 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt; ζ &lt;223&gt; Description of Artificial Sequence : Synthetic victory 呔 &lt;400&gt; 1098 * Val Pro He Tyr Glu Lys Lys Tyr Gly Gin Val Pro Met Cys Asp Ala 1 5 10 15 (a Gly Glu Gin Cys Ala Val Arg Lys Gly Ala Arg lie Gly Lys Leu Cys 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu 35 40 45

&lt;210&gt; 1099 &lt;211&gt; 48 &lt;212&gt; PRT, &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 1099

Val Pro lie Tyr Glu Lys Lys Tyr Gly Gin Val Pro Met Cys Asp Ala 1 5 10 15 % '

Gly Glu Gin Cys Ala Val Arg Lys Gly Ala Arg lie Gly Lys Leu Cys &quot; 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu 35 40 45 &lt;210> 1100 &lt;211> 48 602 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of the artificial sequence: the victory of the synthesis &lt;400&gt; 1100

Val Pro He Tyr Glu Lys Lys Tyr Gly Gin Val Pro Met Cys Asp Ala 1 5 10 15

Gly Glu Gin Cys Ala Val Arg Lys Gly Ala Arg lie Gly Lys Leu Cys 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu 35 40 45

&lt;210&gt; 1101 &lt;211&gt; 28 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1101

Ala Gly Ala Thr Val Gin Val Thr Leu Asp Gly Val Pro Ala Ala Ala 1 5 10 15

Pro Gly Gin Pro Ala Gin Leu Gin Leu Asn Ala Thr

&lt;210&gt; 1102 ^ &lt;211&gt; 5 &lt;212> PRT I &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: S to synthetic &lt;400> 1102 Phe Leu Phe Leu Phe 1 5 &lt;210&gt; 1103 603 1300414 &lt;211&gt; 30 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1103

Ala Cys Tyr Cys Arg lie Pro Ala Cys He Ala Gly Glu Arg Arg Tyr 1 5 10 15

Gly Thr Cys He Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cys 20 25 30 &lt;210〉 1104

&lt;212&gt; PRT &lt; 213 &gt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1104 Met Leu Phe &lt;210&gt; 1105 &lt;211 &4;&lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 1105 Met Leu Phe Lys 1 &lt;210> 1106 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt; 604 1300414 &lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 1106 Met Leu Phe Lys 1 &lt;210> 1107 &lt;211> 6 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1107

Trp His Val Ala Ala Asn 1 5 &lt;210&gt; 1108 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1108

Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser lie lie Asp Val Tyr 1 5 10 15

His Lys Tyr Ser Leu He Lys Gly Asn 20 25 &lt;210> 1109 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400> 1109

His Trp Asp Thr Thr Gin Ser Leu Lys Gin Leu Glu Glu Arg Ala Ala 1 5 10 15 605 1300414

Trp Asn Val &lt;210&gt; 1110 &lt;211> 20 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt; · 55 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1110

Gly Pro Val Ser Ala Val Leu Thr Glu Leu Arg Cys Thr Cys Leu Arg 1 5 10 15

Val Thr Leu Arg 20 &lt;210&gt; 1111 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 1111 lie Gin Arg Thr Pro Lys lie Gin Val Tyr*Ser Arg His Pro Ala Glu 1 5 10 15

Asn Gly Lys Ser Asn 20 &lt;210&gt; 1112 &lt;211&gt; 11 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Arg Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala 1 5 10 606 1300414 &lt;210> 1113 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 1113

Tyr Ser Asp Asp Glu Gly Ala Ser Trp Ser Asp Leu Asp He Val Ser 1 5 10 15

Phe Ser Lys &lt;210> 1114 &lt;211> 18 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1114

Val Ala Arg Thr Leu Leu Val Phe Glu Val Gin Gin Pro Phe Leu Phe 15 10 15

Val Leu &lt;210&gt; 1115 &lt;211> 14 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 1115

Asp Phe Arg Phe Leu Arg Cys Ser Thr Arg Gin Cys Trp Asn 1 5 10

&lt;210> 1116 &lt;211> 10 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1116

Cys Asn Thr Gly Gin Leu Cys Pro Val Glu 1 5 10 &lt;210&gt; 1117 &quot;&lt;211&gt;&lt;212&gt; PRT # &lt;213&gt;Artificial Sequence&lt;220&gt; _ &lt;223&gt; : The victory of synthesis (a &lt;400>1117

Ser Val Asp Arg Ser Gly Asn Val His His Gin Phe Gin Lys Leu Thr 15 10 15

Leu Glu &lt;210&gt; 1118 &lt;211> 19 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; artificial sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1118

Leu His Glu Trp Thr Lys Pro Glu Asn Leu Asp Phe lie Glu Val Asn 1 5 10 15

Val Leu Pro &lt;210> 1119 &lt;211> 29 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon 608 1300414 &lt;400> 1119

Val Leu Glu Leu Pro Tyr Gin Gly Glu Glu Leu Ser Met Val He Leu 15 10 15

Leu Pro Asp Asp He Glu Asp Glu Ser Thr Gly Leu Lys 20 25 &lt;210&gt; 1120 &lt;211> 19 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Victory &lt;400&gt; 1120

Thr Tyr Gly Ala Asp Leu Ala Ser Val Asp Phe Gin His Ala Ser Glu 1 5 10 15

Asp Ala Arg &lt;210&gt; 1121 &lt;211> 12 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1121

Glu Arg Pro Pro Leu Gin Gin Pro Pro His Arg Asp 1 5 10 &lt;210&gt; 1122 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 1122

Tyr Glu Arg Pro Pro Leu Gin Gin Pro Pro His Arg Asp Lys Lys Pro 1 5 10 15 609 1300414

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 20 25 &lt;210&gt; 1123 &lt;211&gt; 20 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory Moon too &lt;400> 1123

Ser Ala Leu Pro Leu Glu Ser Gly Pro Thr Gly Gin Asp Ser Val Gin 1 5 10 15

Asp Ala Thr. Gly 20 &lt;210&gt; 1124 &lt;211> 31 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Thr Gly Leu Leu Thr Phe Leu Ala Trp Trp His Glu Trp Ala Ser Gin 1 5 10 15

Asp Ser Ser Ser A A A A A A A A A A A A A A A A A A A Description: Synthetic victory month too &lt;400> 1125 Arg Gly Asp Cys 610 1300414 &lt;210&gt; 1126 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220> &lt;223&gt; Artificial sequence Description: Synthetic peptide &lt;400> 1126 Arg Gly Asp Ser &lt;210&gt; 1127 C, &lt;211>4 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence : Synthetic victory &lt;400&gt; 1127 Arg Gly Asp Val 1 &lt;210> 1128 &lt;211&gt; 4 * &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic peptide &quot;&lt;400&gt; 1128 Arg Gly Glu Ser &lt;210&gt; 1129 &lt;211&gt;, &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory 1300414 &lt;400> 1129

Gly Arg Gly Asp Ser Pro Ala 1 5 &lt;210&gt; 1130 &lt;211> 5 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Win &lt; 400 〉 1130 Arg Gly Asp Phe Val 1 5 &lt;210> 1131 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;; 1131

Pro Leu Tyr Lys Lys He He Lys Lyu Leu Ser 1 5 10 &lt;210> 1132 &lt;211&gt; 49 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1132

Glu Cys Glu Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu Lys Glu 1 5 10 15

Gly Thr lie Cys Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys 20 25 30

Asn Gly Lys Thr Cys Asp Cys Pro Arg Asn Pro His Lys Gly Pro Ala 612 1300414 35 40 45

Thr &lt;210&gt; 1133 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence • &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1133

Gly Arg Ala Asp Ser Pro Lys 1 5 c: &lt;210&gt; 1134 &lt;211> 37 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 1134

Phe Asn Lys His Thr Glu lie He Glu Glu Asp Thr Asn Lys Asp Lys 1 5 10 15

Pro Ser Tyr Gin Phe Gly Gly His Asn Ser Val Asp Phe Glu Glu Asp

Thr Leu Pro Lys Val 35 &lt;210> 1135 &lt;211> 16 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1135 '

Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg 633 1300414 1 5 10 15 &lt;210> 1136 &lt;211> 17 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt Description of artificial sequence: synthetic peptide • &lt;400> 1136

Tyr Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val 15 10 15

Arg &lt;210> 1137 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1137

Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg 15 10 one &lt;210> 1138, one &lt;211>14 &lt;212> PRT i &lt;213&gt; artificial sequence &lt;220&gt;#&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400&gt; 1138

Glu Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg 1 5 10

&lt;210&gt; 1139 &lt;211> 14 &lt;212&gt; PRT 6]4 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1139

Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg Tyr 1 5 10 ^ &lt;210〉 1140

&lt;211&gt; 18 ^ &lt;212> PRT &lt; 213 > artificial sequence &lt;220> C &lt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400> 1140

Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg 1 5 10 15

Gly Val &lt;210> 1141 &lt;211〉 8 &lt;212> PRT &lt;213&gt; artificial sequence, a ' &lt;220> ^- &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1141 &quot;Tip Gin Pro Pro Arg Ala Arg lie 1 5 &lt;210> 1142 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 1142 615 1300414

Glu lie Leu Asp Val 1 5 &lt;210> 1143 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt;

Glu lie Leu Asp Val Pro Ser Thr 1 5

&lt;210&gt; 1144 &lt;211> 6 &lt;212> PRT &lt; 213 &gt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;4〇〇&gt; 1144

Gly Arg Ala Asp Ser Pro 1 5 &lt;210> 1145 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220> Synthetic peptide &lt;223&gt; Description of artificial sequence β &lt;400&gt; 1145

Gly Arg Gly Asp Ser 1 5 &lt;210&gt; 1146 &lt;211&gt; 6 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: 1300414 &lt;400&gt ; 1146

Gly Arg Gly Asp Ser Pro 1 5 &lt;210&gt; 1147 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory fl too &lt;400 〉 1147

Gly Arg Gly Asp Ser Pro Cys 1 5

&lt;210&gt; 1148 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1148

Gly Arg Gly Asp Thr Pro 1 5 &lt;210> 1149 &lt;211>5

A &lt;212> PRT &lt;213&gt; artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1149 Gly Arg Gly Glu Ser 1 5 &lt;210&gt; 1150 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 1300414 &lt;220> . &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1150

Gly Arg Gly Glu Ser Pro 1 5 &lt;210> 1151 &lt;211> 5 • &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthetic Winning &Widening;400&gt; 1151

Gly Gly Asp Ser Pro 1 5 &lt;210&gt; 1152 &lt;211&gt; 15 &lt;212> PRT &lt;213>Artificial sequence &lt;220> c223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1152

Gly Gin Gin His His Leu Gly Gly Ala Lys Gin Ala Gly Asp Val 1 5 10 15 (- &lt;210>1153 &lt;211> 3 ^ &lt;212&gt; PRT &lt;213&gt; Artificial Sequence • &lt;220> &lt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt;400> 1153 Gly Pro Arg &lt;210> 1154 &lt;211&gt; 10 618 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: the victory of synthesis &lt;400> 1154

Gly Arg Gly Asp Ser Pro Ala Ser Ser Lys 1 5 10 &lt;210> 1155 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win呔&lt;400> 1155

Gly Gly Arg Gly Asp Ser Pro Cys Ala 1 5 &lt;210&gt; 1156 &lt;211&gt; 6 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 1156

Gly Arg Gly Asp Ser Pro 1 5 &lt;210> 1157 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1157

Gly Arg Gly Asp Asn Pro 1 5 619 1300414 &lt;210&gt; 1158 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Peptide&lt;400&gt; 1158

Trp Gin Pro Pro Arg Ala Arg lie 1 5

&lt;210&gt; 1159 &lt;211&gt; 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt; Synthetic peptide &lt;223&gt; Description of artificial sequence &lt;400> 1159 Tyr lie Gly Ser Arg 1 5 &lt ;210> 1160 &lt;211> 3 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220> /一&lt;223> Description of artificial sequence: Synthetic victory (a &lt;400>1160 Leu Asp Val &lt ;210&gt; 1161 &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Leu Asp Val Pro Ser 1300414 &lt;210&gt; 1162 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory ‘ &lt;400〉 1162

Lys Gly Asp Ser w 1 &lt;210> 1163 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Gly Ala Val Ser Thr Ala 1 5

&lt;210> 1164 &lt;211> 6 &lt;212&gt; PRT, &lt;213&gt; artificial sequence &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1164

Trp Thr Val Pro Thr Ala &lt;210> 1165 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 621 1300414 &lt;400&gt; 1165 Arg Gly Asp Ser Pro 1 5 &lt;210&gt; 1166 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory fl too &lt;400 〉 1166

Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu 1 5 10

&lt;210> 1167 &lt;211> 4 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 1167 Arg Glu Asp Val 1 &lt;210&gt; 1168 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1168

Arg Gly Asp Ser Pro Ala Ser Ser Lys Pro 1 5 10 &lt;210&gt; 1169 &lt;211> 4 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 622 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence &lt;400&gt; 1169 Arg Gly Asp Thr 1 Synthetic victory

&lt;210> 1170 &lt;211> 3 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence = synthetic peptide

&lt;400> 1170 Arg Asp Ser &lt;210&gt; 1171 &lt;211&gt; 5 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence &lt;400> 1171 Ser Asp Gly Arg Gly 1 5 &lt;210&gt; 1172 &lt;211&gt; 4 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence &lt;400&gt; 1172 Ser Asp Gly Arg 1 Synthetic peptide Synthetic peptide &lt;210> 1173 &lt;211> 5 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial sequence&lt;220&gt;, &lt;223&gt; Description of artificial sequence: Synthetic victory&lt;400&gt; 1173 Tyr Arg Gly Asp Ser 1 5 ' &lt;210&gt; 1174 &lt;211> 42 e &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220&gt;: &lt;223&gt; Description of Artificial Sequence: Synthetic Victory fl. 400> 1174

Tyr Ala Lys Leu Leu Gly His Gin Asn Leu Lys Gin Lys lie Lys His 1 5 10 15

Val Val Lys Leu Lys Asp Glu Asn Ser Gin Leu Lys Ser Glu Val Ser 20 25 30

Lys Leu Arg Cys Gin Leu Ala Lys Lys Lys 35 40 &lt;210&gt; 1175 Plant, &lt;211>4 &lt;212>PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence" Winning &lt;400&gt; 1175 Phe Met Arg Phe 1 &lt;210> 1176 &lt;211&gt; 4 &lt;212> PRT &lt;213&gt; Artificial sequence 624 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis Victory &lt;400> 1176 Phe Met Arg Phe

&lt;210&gt; 1177 &lt;211> 4 ' &lt;212> PRT &lt;213&gt; Artificial sequence·, &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide ' &lt;400> 1177 J Phe Met Arg Phe &lt;210&gt; 1178 &lt;211&gt; 4 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt;223; Description of artificial sequence: synthetic victory &lt;400&gt; 1178 Phe Met Arg Phe 1

&lt;210> 1179 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> Synthetic peptide &lt;223&gt; Description of artificial sequence &lt;400&gt; 1179 Leu Pro Leu Arg Phe 1 5

&lt;210&gt; 1180 &lt;211&gt; 6 &lt;212&gt; PRT 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1180

Tyr Leu Pro Leu Arg Phe 1 5 &lt;210&gt; 1181 &quot;&lt;211&gt; 3 &lt;212> PRT ' &lt;213&gt; Artificial Sequence &lt;220> „ &lt;223&gt; Description of Artificial Sequence: Synthetic Winning , &lt;400> 1181 Trp Arg Phe &lt;210&gt; 1182 &lt;211&gt; 5 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt ; 1182

Tyr Phe Met Arg Phe

&lt;210&gt; 1183 &lt;211&gt; 4 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1183 Tyr Met Arg Phe 1 &lt;210&gt; 1184 1300414 &lt;211> 8 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt;

Ser Asp Arg Asn Phe Leu Arg Phe 1 5 &lt;210&gt; 1185 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213>Artificial sequence v_~&lt;220&gt;&lt;223&gt; Description of artificial sequence: victory of synthesis &lt;400&gt; 1185

Ser Asp Arg Asn Phe Leu Arg Phe 1 5 &lt;210&gt; 1186 &lt;211&gt; 6 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400>1186 — Asp Pro Phe Leu Arg Phe 1 5 &lt;210&gt; 1187 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Too 4001 1187

Glu lie Leu Glu Val Pro Ser Thr 1300414 &lt;210&gt; 1188 &lt;211> 30 &lt;212> PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt ; 1188

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Val 1 5 10 15

Gly Asn His Arg Ser Phe Ser Asp Lys Asn Gly Leu Thr Ser 20 25 30 &lt;210&gt; 1189 &lt;211&gt; 19 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 1189

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Val 1 5 10 15

Gly Asn His &lt;210> 1190 &lt;211> 30 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1190

Met Ala Arg Gly Ser Ala Leu Leu Leu Ala Ser Leu Leu Leu Ala Ala 15 10 15

Ala Leu Ser Ala Ser Ala Gly Leu Trp Ser Pro Ala Lys Glu 20 25 30 628 1300414 &lt;210&gt; 1191 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: The victory of synthesis &lt;400> 1191

Glu Leu Arg Pro Glu Asp Asp Met Lys Pro Gly Ser Phe Asp Arg Ser 15 10 15 lie Pro Glu Asn Asn He Met Arg 20

&lt;210&gt; 1192 &lt;211&gt; 35 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Thr lie He Glu Phe Leu Ser Phe Leu His Leu Lys Glu Ala Gly Ala 1 5 10 15

Leu Asp Arg Leu Leu Asp Leu Pro Ala Ala Ala Ser Ser Glu Asp He 20 25 30

Glu Arg Ser 35 &lt;210> 1193 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1193

Gly Tip Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala lie 629 1300414 15 10 15

Asp Asn His Arg Ser Phe His Asp Lys Tyr Gly Leu Ala 20 25 &lt;210&gt; 1194 &lt;211&gt; 16 &lt;212> PRT ^ &lt;213>Artificial Sequence &lt;220&gt; ^ &lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400〉 1194

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala He &lt;210&gt; 1195 &lt;211&gt; 29 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory 呔&lt;400&gt; 1195

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala He 15 10 15 I. Asp Asn His Arg Ser Phe Ser Asp Lys His Gly Leu Thr 20 25 &lt;210&gt; 1196 &lt;211> 40 &lt;212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;&lt; 223 &gt; Description of Artificial Sequence: Synthetic Victory: &lt;400 > 1196

Thr Lys Glu Lys Arg Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu 15 10 15 630 1300414

Gly Pro His Ala He Asp Asn His Arg Ser Phe Ser Asp Lys His Gly 20 25 30

Leu Thr Gly Lys Arg Glu Leu Pro 35 40

&lt;210&gt; 1197 &lt;211&gt; 21 • &lt;212> PRT &lt; 213 > artificial sequence ^ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1197

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Gly 1 5 10 15

Phe Ser Pro Phe Arg 20 &lt;210&gt; 1198 &lt;211&gt; 20 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Ala 15 10 15

Leu Ala Leu Ala 20 &lt;210&gt; 1199 &lt;211> 24 &lt;212&gt; PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &gt; 631 1300414 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Win S too &lt;400> 1199

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Arg Pro Lys 1 5 10 15

Pro Gin Gin Trp Phe Trp Leu Leu 20

• &lt;210> 1200 &lt;211&gt; 41 ' &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220> [] &lt;223> Description of artificial sequence: synthetic peptide &lt;400&gt; 1200

Glu Leu Glu Pro Glu Asp Glu Ala Arg Pro Gly Gly Phe Asp Arg Leu 1 5 10 15

Gin Ser Glu Asp Lys Ala lie Arg Thr He Met Glu Phe Leu Ala Phe 20 25 30

Leu His Leu Lys Glu Ala Gly Ala Leu 35 40

&lt;210&gt; 1201 - ' &lt;211> 26 O &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1201

Leu Gin Ser Glu Asp Lys Ala He Arg Thr lie Met Glu Phe Leu Ala 1 5 10 15

Phe Leu His Leu Lys Glu Ala Gly Ala Leu 20 25 &lt;210&gt; 1202 632 1300414 &lt;211> 17 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory B too &lt;400> 1202

Thr lie Met Glu Phe Leu Ala Phe Leu His Leu Lys Glu Ala Gly Ala 1 5 10 15

Leu &lt;210> 1203 &lt;211&gt; 20 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1203

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Gin Gin Phe 1 5 10 15

Phe Gly Leu Met 20 &lt;210&gt; 1204 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1204

Gly Trp Thr Leu Asn Thr Ala Trp Trp Leu Leu Gly Pro His Ala 15 10 15 &lt;210&gt; 1205 &lt;211> 15 &lt;212> PRT &lt;213&gt; Artificial sequence 633 1300414 &lt;220&gt;&lt;223&gt; Description of the sequence: the winning form &lt;400> 1205

Gly Trp Thr Leu Asn Thr Ala Trp Trp Leu Leu Gly Pro His Ala 15 10 15 &lt;210> 1206 &lt;211> 20 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic victory 呔 &lt;400&gt; 1206

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Ala 15 10 15

Leu Ala Leu Ala 20 &lt;210> 1207 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1207

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Arg Pro Lys 1 5 10 15

Pro Gin Gin Trp Phe Trp Leu Leu 20 &lt;210&gt; 1208 &lt;211&gt; 12 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Win 0 too &lt;400&gt; 1208 634 1300414

Asp Glu Pro Asn Ser Asp Gin Phe lie Gly Leu Met 1 5 10 &lt;210> 1209 &lt;211&gt; 120 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt; - &lt;223> Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 1209 ' Lys Lys Lys Asp Lys Val Lys Lys Gly Gly Pro Gly Ser Glu Cys Ala 1 5 10 15 [1: Glu Trp Ala Trp Gly Pro Cys Thr Pro Ser Ser Lys Asp Cys Gly Val 20 25 30

Gly Phe Arg Glu Gly Thr Cys Gly Ala Gin Thr Gin Arg lie Arg Cys 35 40 45

Arg Val Pro Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys Lys Lys 50 55 60

Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr Lys Val Arg 65 70 75 80

Gin Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gin Cys Gin Glu Thr

Lie Arg Val Thr Lys Pro Cys Thr Pro Lys Thr Lys Ala Lys Ala Lys 100 105 110

Ala Lys Lys Gly Lys Gly Lys Asp 115 120 &lt;210&gt; 1210 &lt;211&gt; 61 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt; 635 1300414 &lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1210

Ala Asp Cys Lys Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr 1 5 10 15

Gly Thr Lys Val Arg Gin Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala 20 25 30

Gin Cys Gin Glu Thr lie Arg Val Thr Lys Pro Cys Thr Pro Lys Thr * 35 40 45 —Lys Ala Lys Ala Lys Ala Lys Lys Gly Lys Gly Lys Asp Two: 50 55 60 &lt;210> 1211 &lt;211&gt; 10 &lt ;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1211

Cys His Ser Gly Tyr Val Gly Val Arg Cys 1 5 10 /1 ' &lt;210>1212, one &lt;211>13 &lt;212&gt; PRT ~ &lt;213&gt; Artificial Sequence &lt;220> • &lt;223&gt; Description of the sequence: Synthetic victory &lt;400&gt; 1212

Ala Asn Phe Leu Val Trp Glu lie Val Arg Lys Lys Pro 1 5 10

&lt;210&gt; 1213 &lt;211&gt; 50 &lt;212> PRT 636 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1213

Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gin Phe Cys 1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gin Glu Asp Lys Pro Ala Cys 20 25 30

Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu 35 40 45

Leu Ala 50 &lt;210> 1214 &lt;211> 50 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1214

Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr.Gln Tyr Cys 1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gin Glu Glu Lys Pro Ala Cys 20 25 30

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu 35 40 45

Leu Ala 50 &lt;210> 1215 &lt;211> 10 &lt;212> PRT &lt;213&gt; Artificial sequence 637 1300414 &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1215

Cys His Ser Gly Tyr Val Gly Val Arg Cys 1 5 10 &lt;210&gt; 1216 &lt;211> 10 -&lt;212&gt; PRT &lt;213&gt;Artificial Sequence One&lt;220&gt;&lt;223&gt;胜^ &lt;400&gt; 1216 D Cys His Ser Gly Tyr Val Gly Val Arg Cys 1 5 10 &lt;210> 1217 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 1217

Pro Pro Gly His Phe Lys 1 5 "&lt;210> 1218 &lt;211&gt; 6 ' &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 1218

Arg Thr Gly Gin Tyr Lys 1 5 &lt;210&gt; 1219 &lt;211> 11 638 1300414 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt; 400> 1219

Phe Asn Leu Pro Leu Gly Asn Tyr Lys Lys Pro 1 5 10 &lt;210> 1220 ^ &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence (J &lt; 220> &lt;223> Description of Artificial Sequence : Synthetic peptide &lt;400> 1220

Pro Ala Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His 1 5 10 15

Phe Lys Asp Pro Lys Arg Leu Tyr 20

&lt;210> 1221 &lt;211&gt; 10 &lt;212> PRT

&lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1221

His Ala Glu Lys His Trp Phe Val Gly Leu 1 5 10 &lt;210&gt; 1222 &lt;211> 12 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success Limb: 639 1300414 &lt;400> 1222

Cys Met His lie Glu Ser Leu Asp Ser Tyr Thr Cys 1 5 10 &lt;210&gt; 1223 &lt;211> 12 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence^ &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide ^ &lt;400&gt; 1223

Asp Val Val Asp Ala Asp Glu Tyr Leu lie Pro Gin 1 5 10

&lt;210> 1224 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1224

Cys Tyr Ala Ala Pro Leu Lys Pro Ala Lys Ser Cys 1 5 10

&lt;210&gt; 1225 &lt;211> 18 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1225

Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro 1 5 10 15

Gin Thr &lt;210&gt; 1226 640 1300414 &lt;211> 14 &lt;212&gt; PRT . &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400> 1226

Ala Leu Leu Glu Thr Tyr Cys Ala Thr Pro Ala Lys Ser Glu 1 5 10 &lt;210&gt; 1227 &lt;211&gt; 12 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic Skin &lt;400&gt; 1227

Ly Arg Ala Pro Gin Thr 1 5 10 &lt;210&gt; Peptide &lt;400&gt; 1228

Ser Arg Val Ser Arg Arg Ser Arg 1 5 &lt;210> 1229 &lt;211> 9 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;;400> 1229

Tyr Ser Arg Val Ser Arg Arg Ser Arg 1 5 64] 1300414 &lt;210> 1230 &lt;211> 3 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1230 -Gly His Lys 1

&lt;210> 1231 &lt;211&gt; 22 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1231

Ser Val Arg Val Glu Gin Val Val Lys Pro Pro Gin Asp Lys Thr Glu 1 5 10 15

Ser Glu Asn Thr Ser Asp 20 &lt;210> 1232

&lt;211&gt; 24 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1232

Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly 1 5 10 15

Glu Trp Gin Trp Ser Val Cys Val 20 &lt;210> 1233 642 1300414 &lt;211> 6 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt;;400&gt; 1233

Ser Phe Leu Pro Ser Ser 1 5 &lt;210> 1234 ' &lt;211&gt; 15 &lt;212> PRT &lt;213&gt; Artificial sequence (J &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;;400&gt; 1234

Ser Ala Gin Thr Asn Arg His lie Leu Arg Phe Asn Arg Pro Phe 1 5 10 15 &lt;210> 1235 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide

&lt;400> 1235

He Pro Val Lys Gin Ala Val His Gly Gin Phe Leu Leu Pro Lys Gin 15 10 15

Glu Lys &lt;210&gt; 1236 &lt;211&gt; 18 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide 643 1300414 &lt;400> 1236

Leu Ala Gly Glu Gly Gin Glu Ala Ala Pro Leu Asp Gly Val Leu 1 5 10 15

Ala Asn &lt;210> 1237 ‘ &lt;211&gt; 14 &lt;212> PRT -&lt;213&gt; artificial sequence &lt;220> _ &lt;223&gt; Description of artificial sequence: synthetic victory ; :;&lt;400> 1237

Ala Leu Lys Arg Gin Gly Arg Thr Leu Tyr Gly Phe Gly Gly 1 5 10 &lt;210&gt; 1238 &lt;211> 30 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence : Synthetic peptide &lt;400> 1238

Gly Met Asp Val Leu Gly Arg Pro Lys lie Pro Leu Glu Thr Pro Ala

Tyr Thr Gly Gin Pro Trp His Cys Gin His Cys Phe Leu Leu 20 25 30 &lt;210&gt; 1239 &lt;211> 43 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 1239

Met Asn Thr He Thr lie Cys Lys Phe Asp Val Leu Asp Ala Glu Leu 644 1300414 15 10 15

Leu Ser Thr Val Glu Gly Gly Tyr Ser Gly Lys Asp Cys Leu Lys Asp 20 25 30

Met Gly Gly Tyr Ala Leu Ala Gly Ala Gly Ser 35 40 - &lt;210> 1240

&lt;211> 38 • &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220> CD &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1240

Gly Ala Asp Lys Thr Val Lys Gly Pro Asp Gly Leu Thr Ala Leu Glu 1 5 10 15

Ala Thr Asp Asn Gin Ala He Asp Tyr Gly Gly Phe Met Glu Val Val 20 25 30

Tyr Val Asp Ala Thr Lys 35

&lt;210&gt; 1241 &lt;211> 16 广' &lt;212>PRT &lt; 213 &gt; artificial sequence &lt;220&gt; ' &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1241 ' Cys Lys Gin Leu Gin Arg Asp Arg Gin Val Tyr Arg Ala Thr His Arg 15 10 15 &lt;210> 1242 &lt;211> 17 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220> 645 1300414 &lt;223&gt; Artificial sequence Description: Synthetic wins &lt;400&gt; 1242

Cys Glu Gly Asn Val Arg Val Ser Arg Glu Leu Ala Gly His Thr Gly 1 5 10 15

Tyr &lt;210&gt; 1243 -&lt;211> 16 &lt;212> PRT K &lt; 213 > artificial sequence &lt;220> ^ &lt;223&gt; Description of artificial sequence: synthetic victory (:::) &lt; 4 〇〇&gt; 1243

Cys Gly Ala Gly Glu Ser Gly Lys Ser Thr lie Val Lys Gin Met Lys 1 5 10 15 &lt;210> 1244 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400&gt; 1244

Cys Asn Leu Lys Glu Asp Gly lie Ser Ala Ala Lys Asp Val Lys

&lt;210> 1245 &lt;211> 16 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1245

Cys Lys Gin Leu Gin Lys Asp Lys Gin Val Tyr Arg Ala Thr His Arg 1 5 10 15 &lt;210&gt; 1246 646 1300414 &lt;211> 11 &lt;212> PRT &lt;213>Artificial Sequence &lt;220〉 &lt;223&gt Description of the artificial sequence: the winning form &lt;400&gt; 1246

Glu Glu Gin Gly Met Leu Pro Glu Asp Leu Ser 1 5 10

&lt;210> 1247 &lt;211&gt; 15 &lt;212> PRT &lt; 213 > artificial sequence c J &lt; 220 &gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1247

Pro Gly Thr Cys Glu lie Cys Ala Tyr Ala Ala Cys Thr Gly Cys 1 5 10 15 &lt;210> 1248 &lt;211> 15 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description: Synthetic peptides '&lt;400>1248 (1/pr〇Asn Thr Cys Glu lie Cys Ala Tyr Ala Ala Cys Thr Gly Cys 15 10 15 &lt;210> 1249 &lt;211&gt; 16 &lt;212〉 PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1249

Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu 15 10 15 647 1300414 &lt;210> 1250 &lt;211> 32 &lt;212&gt; PRT &lt;213&gt; Manual Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic win 0 too &lt;400&gt; 1250

Ser Thr Pro Leu Met Ser Trp Pro Trp Ser Pro Ser Ala Leu Arg Leu 1 5 10 15

Leu Gin Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn Cys His Arg 20 25 30 &lt;210&gt; 1251 &lt;211> 33 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory 呔 &lt;400&gt; 1251

Tyr Ser Thr Pro Leu Met Ser Trp Pro Trp Ser Pro Ser Ala Leu Arg 15 10 15

Leu Leu Gin Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn Cys His 20 25 30

Arg &lt;210&gt; 1252 &lt;211> 31 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory month too &lt;400&gt; 1252

His Asn Lys Gin Glu Gly Arg Asp His Asp Lys Ser Lys Gly His Phe 15 10 15 648 1300414

His Arg Val Val He His His Lys Gly Gly Lys Ala His Arg Gly 20 25 30 &lt;210&gt; 1253 &lt;211&gt;32 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic wins &lt;400> 1253

Tyr His Asn Lys Gin Glu Gly Arg Asp His Asp Lys Ser Lys Gly His 15 10 15

Phe His Arg Val Val He His His Lys Gly Gly Lys Ala His Arg Gly 20 25 30 &lt;210> 1254 &lt;211&gt; 32 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic peptide &lt;400> 1254

Ser Thr Ala Pro Leu Pro Trp Pro Trp Ser Pro Ala Ala Leu Arg Leu 1 5 10 15

Leu Gin Arg Pro Pro Glu Glu Pro Ala Val His Ala Asp Cys His Arg 20 25 30 &lt;210&gt; 1255 &lt;211> 33 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory fl too &lt;400> 1255

Tyr Ser Thr Ala Pro Leu Pro Trp Pro Trp Ser Pro Ala Ala Leu Arg 649 1300414 15 10 15

Leu Leu Gin Arg Pro Pro Glu Glu Pro Ala Val His Ala Asp Cys His 20 25 30

Arg &lt;210> 1256 -&lt;211&gt; 17 &lt;212&gt; PRT e &lt;213&gt;Artificial sequence &lt;220> ^ &lt;223&gt; Description of artificial sequence: Synthetic victory 〇 &lt;400> 1256

Val Gin Gly Glu Thr Ser Asn Asp Lys lie Pro Val Ala Leu Gly Leu 1 5 10 15

Lys &lt;210> 1257 &lt;211> 72 &lt;212> PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic peptide, 1 &lt; 400 > 1257 (\ y Ala Pro Val Ala Asn Glu Leu Arg Cys Gin Cys Leu Gin Thr Val Ala 1 5 10 15

Gly lie His Phe Lys Asn lie Gin Ser Leu Lys Val Met Pro Pro Gly ^ 20 25 30

Pro His Cys Thr Gin Thr Glu Val He Ala Thr Leu Lys Asn Gly Arg 35 40 45

Glu Ala Cys Leu Asp Pro Glu Ala Pro Met Val Gin Lys lie Val Gin 50 55 60 650 1300414

Lys Met Leu Lys Gly Val Pro Lys 65 70 &lt;210&gt; 1258 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt;400&gt; 1258

Val Gin Gly Glu Glu Ser Asn Asp Lys 1 5 &lt;210> 1259 )&lt;211> 13 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1259 lie Leu Asn Gly lie Asn Asn Tyr Lys Asn Pro Lys Leu 1 5 10 &lt;210&gt; 1260 &lt;211> 22 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic peptide &lt;400&gt; 1260

Phe Val Gin Gly Glu Ala He Pro Met Ser He Pro Pro Glu Asp Lys 1 5 10 15 lie Pro Val Ala Leu Gly 20

&lt;210> 1261 &lt;211&gt; 13 &lt;212&gt; PRT 651 13 and 14 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223> Description of artificial sequence: Synthetic victory 0 too &lt;400> 1261

Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala 1 5 10 &lt;210&gt; 1262 • &lt;211> 21 &lt;212&gt; PRT ” &lt;213&gt; Artificial Sequence &lt;220> One &lt;223> Artificial Sequence Description··Comprehensive victory (2) &lt;4〇〇>1262

Met Val Lys Gin He Glu Ser Lys Thr Ala Phe Gin Glu Ala Leu Asp 15 10 15

Ala Ala Gly Asp Lys 20 &lt;210> 1263 &lt;211> 10 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt; I. &lt;223> Description of Artificial Sequence: Synthetic peptide, one &lt; 400>1263

Ala Tyr Val His Asp Ala Pro Val Arg Ser ~ 1 5 10 &lt;210&gt; 1264 &lt;211> 7 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory too &lt;400&gt; 1264

Pro Arg Lys Leu Tyr Asp Lys 652 1300414 1 5 &lt;210> 1265 &lt;211&gt; 12 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220>. &lt;223> Description of Artificial Sequence: Synthetic Success &lt;400〉 1265

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Lys 1 5 10 &lt;210> 1266 &lt;211> 24 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis The skin of the skin &lt;400> 1266

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn 1 5 10 15

Pro Arg Lys Leu Tyr Asp Tyr Lys 20 &lt;210> 1267 &lt;211&gt; 12 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon too&lt;400&gt; 1267

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Lys 1 5 10

&lt;210> 1268 &lt;211&gt; 8 &lt;212> PRT 653 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1268

Pro Arg Lys Leu Tyr Asp Tyr Lys 1 5 &lt;210&gt; 1269 ^ &lt;211&gt; 12 &lt;212&gt; PRT —&lt;213&gt; Artificial Sequence &lt;220〉 / _ &lt;223&gt; Description of Artificial Sequence: Synthesis Peptide CJ &lt;400>1269

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Lys 1 5 10 &lt;210> 1270 &lt;211&gt; 11 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400〉 1270

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr

&lt;210&gt; 1271 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1271

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn 1 5 10 15

Pro Arg Lys Leu Tyr Asp Tyr Lys 654 20 1300414 &lt;210&gt; 1272 &lt;211&gt; 23 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 1272

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn 1 5 10 15

Pro Arg Lys Leu Tyr Asp Tyr

&lt;210> 1273 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1273

Arg Lys Leu Tyr Asp Tyr Lys 1 5 &lt;210&gt; 1274 &lt;211&gt; 6 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;; 1274

Arg Lys Leu Tyr Asp Tyr 1 5

&lt;210&gt; 1275 &lt;211&gt; 7 &lt;212&gt; PRT 655 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1275

Pro Arg Lys Leu Tyr Asp Lys 1 5 &lt;210&gt; 1276 ^ &lt;211&gt; 6 &lt;212&gt; PRT Λ &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 〇 &lt;400&gt; 1276

Pro Arg Lys Leu Tyr Asp 1 5 &lt;210&gt; 1277 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1277 A 'Pro Arg Lys Leu Tyr Asp Tyr Lys ” 1 5 &lt;210&gt; 1278 &lt;211> 4 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Winning &lt;400&gt; 1278 Asp Gly Glu Ala 1300414 &lt;210> 1279 &lt;211&gt; 6 &lt;212&gt; PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220 &gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400〉 1279

Leu Gly Thr lie Pro Gly ** 1 5

' &lt;210> 1280 &lt;211> 23 &lt;212&gt; PRT O &lt;2i3>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Victory &lt;400> 1280

Asn lie Ser Ser Glu Glu Lys Ala Ser Trp Thr Arg Pro Glu Lys Gin 1 5 10 15

Glu Thr Leu Asp Gly His Met 20

&lt;210&gt; 1281 &lt;211> 17 &lt;212> PRT f I. <213> Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1281

Phe Asn Leu Asp Val Arg Phe Leu Val Val Lys Glu Ala Val Asn Pro ^ 1 5 10 15

Gly &lt;210> 1282 &lt;211> 17 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 657 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1282

Ala Pro Arg Gin Arg Gin Thr Leu Val Leu Phe Pro Gly Asp Leu Arg 15 10 15

Thr &lt;210&gt; 1283 &lt;211&gt;24 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1283

Cys Ser Cys Ser Pro Val His Pro Gin Gin Ala Phe Cys Asn Ala Asp 15 10 15

Val Val He Arg Ala Lys Ala Val 20 &lt;210&gt; 1284 &lt;211&gt; 24 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt ; 1284

Cys Ser Cys Ser Pro Val His Pro Gin Gin Ala Phe Cys Asn Ala Asp 1 5 10 15

Val Val He Arg Ala Lys Ala Val 20

&lt;210> 1285 &lt;211> 13 &lt;212> PRT 658 1300414 &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1285

Asn Val lie Gin lie Ser Asn Asp Leu Glu Asn Leu Arg 1 5 10 &lt;210&gt; 1286 &lt;211&gt; 35 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400&gt; 1286

Val Pro He Gin Lys Val Gin Asp Asp Thr Lys Thr Leu lie Lys Thr 15 10 15

He Val Thr Arg He Asn Asp lie Ser His Thr Gin Ser Val Ser Ser 20 25 30

Lys Gin Lys 35 &lt;210&gt; 1287 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1287

Tyr Lys Val Gin Asp Asp Thr Lys Thr Leu He Lys Thr He Val 1 5 10 15 &lt;210&gt; 1288 &lt;211> 15 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic peptide 659 1300414 &lt;400&gt; 1288 Ser Cys Ser Leu Pro Gin Thr Ser Gly Leu Gin Lys Pro Glu Ser 1 5 10 15 &lt;210&gt; 1289 &lt;211&gt; 10 &lt;212> PRT &lt; 213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide • &lt;400&gt; 1289

Glu Asp Val Asp His Val Phe Leu Arg Phe 1 5 10 &lt;210&gt; 1290 &lt;211> 7 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400&gt; 1290

Thr Ser Phe Thr Pro Arg Leu 1 5

&lt;210&gt; 1291 &lt;211&gt;8~/&lt;212>PRT &lt;213&gt; Artificial sequence &lt;220&gt; _ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1291

Asp Pro Ala Phe Asn Ser Trp Gly 1 5 &lt;210&gt; 1292 &lt;211> 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 660 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory : &lt;400&gt; 1292

Asp Pro Gly Phe Ser Ser Trp Gly 1 5 &lt;210> 1293 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt;1293; Asp Gin Gly Phe Asn Ser Trp Gly 1 5 &lt;210> 1294 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 1294

Asp Ala Ser Phe His Ser Trp Gly 1 5 &lt;210&gt; 1295 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; </ RTI> artificial sequence &lt; 220 &gt;&lt; 223 &gt; 223 > Description of artificial sequence: synthetic victory &lt; 400> 1295

Gly Ser Gly Phe Ser Ser Trp Gly &lt;210> 1296 &lt;211&gt; 8 1300414 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win)) Too ;400&gt; 1296

Asp Pro Ala Phe Ser Ser Trp Gly 1 5 • &lt;210&gt; 1297

&lt;211〉 8 ^ &lt;212> PRT &lt;213&gt; Artificial sequence _ &lt;220〉 ID &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1297

Gly Ala Ser Phe Tyr Ser Trp Gly &lt;210&gt; 1298 &lt;211&gt; 10 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1298 lie lie Gly Gly Arg Glu Ser Arg Pro His 1 5 10 &lt;210&gt; 1299 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory fl too &lt;400> 1299

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 1 5 10 15 662

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 20 25 30*

Gin Arg Val Lys Asn Lys 35 &lt;210> 1300 • &lt;211> 30 &lt;212&gt; PRT, &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory U &lt; 400> 1300

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Arg Gin 1 5 10 15

Leu Ala Val Arg Arg Tyr Leu Ala Ala Val Leu Gly Lys Arg 20 25 30 &lt;210> 1301 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220〉

&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1301

Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Met Ala Val Lys Lys Tyr 15 10 15

Leu Ala Ala Val Leu 20 &lt;210> 1302 &lt;211> 38 &lt;212> PRT &lt;213&gt;Artificial sequence&lt;220&gt; 663 1300^ &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt ; 1302

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 20 25 30

Gin Arg lie Lys Asn Lys 35 &lt;210> 1303 &lt;211> 27 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic victory &lt;400> 1303

His Ser Asp Gly He Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu 20 25 &lt;210> 1304 &lt;211&gt; 22 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Win Peptide &lt;400> 1304

Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin Met Ala Val Lys Lys 1 5 10 15

Tyr Leu Ala Ala Val Leu 20 &lt;210> 1305 &lt;211&gt; 38 664 1300414 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 1305

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 1 5 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 20 25 30

Gin Arg Val Lys Asn Lys 35 &lt;210&gt; 1306 &lt;211> 33 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1306

Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin Met Ala Val Lys Lys 15 10 15

Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys Gin Arg Val Lys Asn 20 25 30

Lys • &lt;210> 1307 &lt;211> 23 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1307

Gin Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr 665 1300414 1 5 10 15

Lys Gin Arg Val Lys Asn Lys. 20 &lt;210&gt; 1308 &lt;211> 11 &lt;212> PRT-&lt;213&gt; Artificial Sequence&lt;220>-&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 1308

Gly Lys Arg Tyr Lys Gin Arg Val Lys Asn Lys 1 5 10 &lt;210> 1309 &lt;211> 8 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 1309

Tyr Lys Gin Arg Val Lys Asn Lys 1 5

' &lt;210> 1310 J &lt;211&gt; 29 &lt;212&gt; PRT • &lt;213&gt;Artificial sequence &lt;220&gt; • &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1310

Asp Val Ala His Gly He Leu Asn Glu Ala Tyr Arg Lys Val Leu Asp 15 10 15

Gin Leu Ser Ala Gly Lys His Leu Gin Ser Leu Val Ala 20 25 666 1300414 &lt;210&gt; 1311 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic victory 呔 &lt;400&gt; 1311

Asp Val Ala His Glu He Leu Asn Glu Ala Tyr Arg Lys Val Leu Asp . 1 5 10 15 , Gin Leu Ser Ala Arg Lys Tyr Leu Gin Ser Met Val Ala 20 25 (1, &lt;210>1312 &lt;211&gt; 20 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1312

Ser Asp Glu Asp Ser Asp Gly Asp Arg Pro Gin Ala Ser Pro Gly Leu 1 5 10 15

Gly Pro Gly Pro 20

&lt;210> 1313 -&lt;211> 52 &lt;212&gt; PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 1313

Gly Glu Ser Arg Ser Glu Ala Leu Ala Val Asp Gly Ala Gly Lys Pro 15 10 15

Gly Ala Glu Glu Ala Gin Asp Pro Glu Gly Lys Gly Glu Gin Glu His 667 1300414 20 25 30

Ser Gin Gin Lys Glu Glu Glu Glu Glu Met Ala Val Val Pro Gin Gly 35 40 45

Leu Phe Arg Gly 50 &lt;210&gt; 1314 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1314

Pro Glu Gly Lys Gly Glu Gin Glu His Ser Gin Gin Lys Glu Glu Glu 15 10 15

Glu Glu Met Ala Val Val Pro Gin Gly Leu Phe Arg Gly 20 25 &lt;210&gt; 1315 &lt;211&gt; 16 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1315

Glu Glu Glu Glu Glu Met Ala Val Val Pro Gin Gly Leu Phe Arg Gly 15 10 15 &lt;210&gt; 1316 &lt;211> 49 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory &lt;400> 1316 668 1300414

Gly Trp Pro Gin Ala Pro Ala Met Asp Gly Ala Gly Lys Thr Gly Ala 15 10 15

Glu Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg 20 25 30

Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg 35 40 45

Gly &lt;210&gt; 1317 &lt;211&gt; 48 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1317

Gly Trp Pro Gin Ala Pro Ala Asp Gly Ala Gly Lys Thr Gly Ala Glu 15 10 15

Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg Gin 20 25 30

Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg Gly 35 40 45 &lt;210&gt; 1318 -&lt;211> 49 &lt;212> PRT • &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of the artificial sequence: the winning form &lt;400> 1318

Tyr Gly Trp Pro Gin Ala Pro Ala Asp Gly Ala Gly Lys Thr Gly Ala 15 10 15

Glu Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg 669 1300414 20 25 30

Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg 35 40 45

Gly &lt;210> 1319 -&lt;211&gt; 50 &lt;212&gt;PRT~&lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1319

Tyr Gly Trp Pro Gin Ala Pro Ala Met Asp Gly Ala Gly Lys Thr Gly 15 10 15

Ala Glu Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser 20 25 30

Arg Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe 35 40 45

Arg Gly 50 &lt;210> 1320 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1320

Leu Ser Phe Arg Ala Pro Ala Tyr Gly Phe Arg Gly Pro Gly Leu Gin 15 10 15

Leu Arg Arg 670 1300414 &lt;210&gt; 1321 &lt;211> 51 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: Synthetic victory &lt;400&gt; 1321

Asp Asp Gly Gin Ser Glu Ser Gin Ala Val Asn Gly Lys Thr Gly Ala 15 10 15

Ser Glu Ala Val Pro Ser Glu Gly Lys Gly Glu Leu Glu His Ser Gin 20 25 30

Gin Glu Glu Asp Gly Glu Glu Ala Met Ala Gly Pro Pro Gin Gly Leu 35 40 45

Phe Pro Gly 50 &lt;210> 1322 &lt;211&gt; 52 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1322

Tyr Asp Asp Gly Gin Ser Glu Ser Gin Ala Val Asn Gly Lys Thr Gly 15 10 15

Ala Ser Glu Ala Val Pro Ser Glu Gly Lys Gly Glu Leu Glu His Ser 20 25 30

Gin Gin Glu Glu Asp Gly Glu Glu Ala Met Ala Gly Pro Gin Gly 35 40 45

Leu Phe Pro Gly 67] 1300414 50 &lt;210&gt; 1323 &lt;211&gt; 26 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Peptide^ &lt;400 〉 1323

Gly Glu Leu Glu His Ser Gin Gin Glu Glu Asp Gly Glu Glu Ala Met 15 10 15

Ala Gly Pro Pro Gin Gly Leu Phe Pro Gly 20 25 &lt;210&gt; 1324 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 1324

Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg 1 5 10 15

Gly &lt;210> 1325 &lt;211&gt; 2 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt; 1325 Pro Gly 1 &lt; 210> 1326 672 1300414 &lt;211&gt; 1 &lt;212&gt; PRT &lt;213&gt;Artificial sequence&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1326 Lys 1 &lt;210&gt; 1327 '&lt;211> 4 &lt;212> PRT &lt;213&gt;Artificial sequence ' &lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1327 Gly Phe Ala Asp 1 &lt;210> 1328 &lt;211&gt; 6 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1328 j Asp Tyr Val Pro Met Leu 1 5 &lt;210 〉 1329 • &lt;211> 6 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400> 1329

Asp Tyr Val Pro Met Leu 13004Μ &lt;210> 1330 &lt;211> 11 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1330

Gin Lys Arg Pro Ser Gin Arg Ser Lys Tyr Leu 1 5 10 &lt;210> 1331 &lt;211> 12 / &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 1331

Pro Leu Ser Arg Thr Leu Ser Val Ala Ala Lys Lys 1 5 10 &lt;210&gt; 1332 &lt;211> 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 1332

Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gin Pro Gly Tyr 1 5 10 &lt;210> 1333 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400> 1333 674 1300414

Arg Gly Tyr Ser Leu Gly 1 5 &lt;210> 1334 &lt;211> 13 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1334

Lys Lys Ala Leu Arg Arg Gin Glu Ala Val Asp Ala Leu 1 5 10 &lt;210> 1335 &lt;211> 25 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic peptide &lt;400> 1335

He Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg lie Asn Glu Arg 15 10 15

Met Pro Pro Arg Arg Asp Ala Met Pro 20 25 &lt;210&gt; 1336 &lt;211> 20 -&lt;212&gt; PRT &lt;213&gt;Artificial Sequence&quot;&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 1336

Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala He Leu Thr 15 10 15

Thr Met Leu Ala 20 675 1300414 &lt;210&gt; 1337 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt; 1337

Pro Leu Ser Arg Thr Leu Ser Val Ser Ser 1 5 10 &lt;210&gt; 1338 &lt;211&gt; 10 &lt;212&gt;PRT)&lt;213&gt;ArtificialSequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1338

Pro Leu Arg Arg Thr Leu Ser Val Ala Ala 1 5 10 &lt;210> 1339 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success Peptide &lt;400> 1339

Leu Gin Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly 1 5 10 15

Leu &lt;210> 1340 &lt; 211 &gt; 211 &gt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt;&lt; 223 > Description of artificial sequence: synthetic victory 676 1300414 &lt; 400 > 1340

Cys Leu Arg Arg Ala Ser Leu Gly &lt;210> 1341 &lt;211&gt; 7 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt;223; Description of Artificial Sequence: Synthetic Peptide ' &lt; 400> 1341

Phe Lys Lys Ser Phe Lys Leu 1 5 &lt;210&gt; 1342 &lt;211> 13 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400 〉 1342

Lys Lys Ala Leu His Arg Gin Glu Thr Val Asp Ala Leu 1 5 10 &lt;210&gt; 1343 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400> 1343

Lys Arg Thr Leu Arg Arg 1 5 &lt;210&gt; 1344 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 677 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1344

Arg Thr Lys Arg Ser Gly Ser Val Tyr Glu Pro Leu Lys lie 1 5 10 &lt;210&gt; 1345 &lt;211&gt; 26 .&lt;212&gt; PRT &lt;213&gt; Artificial Sequence. &lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400&gt; 1345

Gly lie Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 lie Ser Trp lie Lys Arg Lys Arg Gin Gin 20 25 &lt;210> 1346 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory&lt;400> 1346

Arg Arg Lys Ala Ser Gly Pro Pro Val 1 5 &lt;210> 1347 _ &lt;211> 17 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Too too <400> 1347

Arg Phe Ala Arg Lys Gly Ala Leu Arg Gin Lys Asn Val His Glu Val 15 10 15 678 1300414

Lys &lt;210> 1348 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;, &lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400&gt; 1348 - Arg Phe Ala Arg Lys Gly Ala Leu Glu Gin Lys Asn Val His Glu Val 15 10 15

Lys Asn &lt;210&gt; 1349 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400>1:349

Ser Phe Val Asn Ser Glu Phe Leu Lys Pro Glu Val Lys Ser 1 5 10

&lt;210&gt; 1350 &lt;211&gt;11 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1350

Ser Tyr Thr Asn Pro Glu Phe Val He Asn Val 1 5 10 &lt;210&gt; 1351 &lt;211> 15 679 1300414 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; The victory of synthesis &lt;400〉 1351

Ala Gly Asn Lys Val He Ser Pro Ser Glu Asp Arg Arg Gin Cys 15 10 15 &lt;210> 1352 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic peptide &lt;400&gt; 1352

Gly Pro Lys Thr Pro Glu Glu Lys Thr Ala Asn Thr lie Ser Lys Phe 1 5 10 15

Asp Cys &lt;210> 1353 &lt;211> 29 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1353

Leu Leu Tyr Glu Met Leu Ala Gly Gin Ala Pro Phe Glu Gly Glu Asp 1 5 10 15 ^ Glu Asp Glu Leu Phe Gin Ser He Met Glu His Asn Val 20 25 &lt;210> 1354 &lt;211> 14 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 680 1300414 &lt; 223 &gt; Description of artificial sequence: synthetic victory &lt; 400 > 1354

Asn Tyr Pro Leu Glu Leu Tyr Glu Arg Val Arg Thr Gly Cys &lt;210&gt; 1355 &lt;211&gt; 9 &lt;212&gt; PRT - &lt;213&gt; Artificial Sequence &lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon too &lt;400&gt; 1355

Val Arg Lys Arg Thr Leu Arg Arg Leu &lt;210> 1356 &lt;211&gt; 8 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;; 1356

Cys Asp Asn Gin He Lys Lys Met 1 5

1357 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic i Shengyuetai &lt;400> 1357 He Tyr Gly Glu Phe 1 5

&lt;210&gt; 1358 &lt;211> 5 &lt;212&gt; PRT 681 1300414 &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1358 He Tyr Gly Glu Phe 1 5 &lt;210> 1359 ^ &lt;211> 17 &lt;212> PRT _ &lt; 213 &gt; artificial sequence &lt; 220 &gt;&lt; 223 &gt; Description of artificial sequence: synthetic peptide Γ ^; &lt;400&gt; 1359

Thr Tyr Ala Asp Phe lie Ala Ser Gly Arg Thr Gly Arg Arg Asn Ala 15 10 15 lie &lt;210> 1360 &lt;211&gt; 11 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic victory month too

&lt;400&gt; 1360

Gin Lys Arg Pro Ser Gin Arg Ser Lys Tyr Leu 1 5 10 &lt;210&gt; 1361 &lt;211> 9 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1361

Arg Arg Glu Glu Glu Thr Glu Glu Glu 1 5 682 1300414 &lt;210> 1362 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory Peptide &lt;400&gt; 1362 i Arg Arg Lys Ala Ser Gly Pro 1 5 &lt;210> 1363 &lt;211> 13 r, &lt;212> PRT, a / &lt; 213 > artificial sequence &lt; 220 &lt; 223 &gt; Description of the artificial sequence: the victory of the synthesis &lt;400&gt; 1363

Arg Arg Leu lie Glu Asp Asn Glu Tyr Thr Ala Arg Gly 1 5 10 &lt;210&gt; 1364 &lt;211> 15 &lt;212> PRT &lt;213>Artificial sequence &lt;220> C) &lt;223&gt; Artificial sequence Description: Synthetic peptide &lt;400&gt; 1364 -Pro Leu Ala Arg Thr Leu Ser Val Ala Gly Leu Pro Gly Lys Lys 15 10 15 &lt;210> 1365 &lt;211> 32 &lt;212> PRT &lt;213&gt; Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthetic Victory Moon &lt;400&gt; 1365 683 1300414

Lys Glu Ala Lys Glu Lys Arg Gin Glu Gin lie Ala Lys Arg Arg Arg 15 10 15

Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Gly Gly Ser Gin Lys 20 25 30 ^ &lt;210> 1366 &lt;211&gt; 20 , &lt;212> PRT &lt; 213 > Artificial Sequence &lt;220&gt; ( &lt;223&gt Description of artificial sequence: synthetic peptide - ' &lt;400> 1366

Tyr Ser Phe Val His His Gly Phe Phe Asn Phe Arg Val Ser Trp Arg 1 5 10 15

Glu Met Leu Ala 20 &lt;210> 1367 &lt;211> 21 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;:223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1367 &quot ;Val Ala Pro Ser Asp Ser lie Gin Ala Glu Glu Trp Tyr Phe Gly Lys 1 5 10 15 lie Thr Arg Arg Glu 20 &lt;210&gt; 1368 &lt;211> 6 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence 684 1300414 &lt;220〉 &lt;223> Description of artificial sequence: Synthetic victory &lt;400&gt; 1368

His Arg His Phe Leu Arg 1 5 &lt;210> 1369 &lt;211&gt; 25 &lt;212> PRT, &lt;213&gt; Artificial Sequence &lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide&lt; 400> 1369

Arg Cys Leu Gly Thr Val Gin Gly Gin Phe Pro Leu Cys Tyr His Phe J 1 5 10 15

Leu Ser Ala Pro Gly Arg Phe Gin Glu 20 25 &lt;210> 1370 &lt;211> 14 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400&gt; 1370

Met Tyr Ser Asn Val He Gly Thr Val Thr Ser Gly Lys Arg 1 5 10 ^ &lt;210&gt; 1371 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic victory fl too &lt;400> 1371

Phe Tyr Lys Ala Asp Gly Val Val Phe Ser lie Tyr Asp Val Pro Gly 15 10 15 685 1300414

Arg Gin Val Pro Leu Ser Ala Arg Gly 20 25 &lt;210&gt; 1372 &lt;211> 20 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide ^ &lt;400&gt; 1372

Trp Ser Pro Gin Glu Glu Asp Arg lie lie Glu Gly Gly lie Tyr Asp 15 10 15

Ala Asp Leu Asn 20 &lt;210&gt; 1373 &lt;211&gt; 20 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1373

Val Ser Ser Ala Glu Gly Trp His Gly Asn Val Thr Leu Asn lie Arg 15 10 15

Pro Ser Thr Gly 20 &lt;210> 1374 &lt;211> 11 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 1374

Cys Ser Pro Cys His Ala Met Lys Met Asn lie 1 5 10 &lt;210&gt; 1375 686 1300414 &lt;211> 27 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthetic victory &lt;400&gt; 1375

Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn Gly Gly Cys Thr Pro 1 5 10 15

Leu Leu Pro Arg Gly Gly Gly Leu Ala Ala Leu 20 25 &lt;210> 1376; &lt;211> 33 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 1376

Met Ala Pro Glu Glu He He Met Asp Arg Pro Phe Leu Phe Val Val 1 5 10 15

Arg His Asn Pro Thr Gly Thr Val Leu Phe Met Gly Gin Val Met Glu 20 25 30

Pro &lt;210> 1377 ^ &lt;211&gt; 36 &lt;212&gt; PRT ' &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1377

Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly 1 5 10 15

Thr Phe Glu Cys He Cys Gly Pro Asp Ser Ala Leu Val Arg His lie 687 1300414 20 25 30

Gly Thr Asp Cys 35 &lt;210> 1378 &lt;211> 24 &lt;212&gt; PRT * &lt;213&gt; Artificial sequence &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1378

His Pro Pro Cys Cys Leu Tyr Gly Lys Cys Arg Arg Tyr Pro Gly Cys

Ser Ser Ala Ser Cys Cys Gin Leu 20 &lt;210&gt; 1379 &lt;211> 48 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 1379

Glu Asp Asn Cys lie Ala Glu Asp Tyr Gly Lys Cys Thr Trp Gly Gly 15 10 15

Thr Lys Cys Cys Arg Gly Arg Pro Cys Arg Cys Ser Met lie Gly Thr 20 25 30

Asn Cys Glu Cys Thr Pro Arg Leu He Met Glu Gly Leu Ser Phe Ala 35 40 45 &lt;210&gt; 1380 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 688 1300414 &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic peptide / &lt;400&gt; 1380

Gly Gly Cys Leu Pro His Asn Arg Phe Cys Asn Ala Leu Ser Gly Pro 1 5 10 15

Arg Cys Cys Ser Gly Leu Lys Cys Lys Glu Leu Ser lie Trp Asp Ser 20 25 30

Arg Cys Leu 35 &lt;210> 1381 &lt;211&gt; 18 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Cys Asn Cys Lys Ala Pro Glu Thr Ala Leu Cys Ala Arg Arg Cys Gin 1 5 10 15

Gin His &lt;210&gt; 1382 &lt;211&gt; 60 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Trp Gin Pro Pro Trp Tyr Cys Lys Glu Pro Val Arg He Gly Ser Cys 1 5 10 15

Lys Lys Gin Phe Ser Ser Phe Tyr Phe Lys Trp Thr Ala Lys Lys Cys 20 25 30

Leu Pro Phe Leu Phe Ser Gly Cys Gly Gly Asn Ala Asn Arg Phe Gin 689 1300414 35 40 45

Thr lie Gly Glu Cys Arg Lys Lys Cys Leu Gly Lys 50 55 60 &lt;210&gt; 1383 &lt;211> 60 &lt;212&gt; PRT • &lt;213>Artificial Sequence &lt;220&gt;-&lt;223&gt; : Synthetic victory 呔 &lt;400&gt; 1383

Arg He Cys Tyr He His Lys Ala Ser Leu Pro Arg Ala Thr Lys Thr J 1 5 10 15

Cys Val Glu Asn Thr Cys Tyr Lys Met Phe He Arg Thr Gin Arg Glu 20 25 30

Tyr lie Ser Glu Arg Gly Cys Gly Cys Pro Thr Ala Met Trp Pro Tyr 35 40 45

Gin Thr Glu Cys Cys Lys Gly Asp Arg Cys Asn Lys 50 55 60 , ' &lt;210&gt; 1384 &lt;211>36 &lt;212> PRT —&lt;213&gt;Artificial Sequence&lt;220&gt;'&lt;223>Artificial Sequence Description: The victory of synthesis &lt;400> 1384

Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val Cys 1 5 10 15

Gin Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys Cys 20 25 30 690 1300414

Arg Cys Tyr Ser 35 &lt;210&gt; 1385 &lt;211&gt; 36 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;-&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1385

Met Cys Met Pro Cys Phe Thr Thr Asp His Gin Met Ala Arg Lys Cys 15 10 15

Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gin 20 25 30

Cys Leu Cys Arg 35 &lt;210&gt; 1386 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1386

Glu Cys Cys Asn Pro Ala Cys Gly Arg His Tyr Ser Cys 1 5 10 &lt;210&gt; 1387 &lt;211&gt; 31 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Synthetic peptide &lt;400&gt; 1387

Ala Cys Ser Gly Arg Gly Ser Arg Cys Gin Cys Cys Met Gly Leu Arg 15 10 15 691 1300414

Cys Gly Arg Gly Asn Pro Gin Lys Cys lie Gly Ala His Asp Val 20 25 30 &lt;210&gt; 1388 &lt;211> 14 &lt;212> PRT &lt;213&gt; Artificial Sequence* &lt;220> &lt;223>Artificial Sequence Description: Synthetic win 0 too ^ &lt;400&gt; 1388

Gly Arg Cys Cys His Pro Ala Cys Gly Lys Asn Tyr Ser Cys 1 5 10

&lt;210&gt; 1389 &lt;211&gt; 17 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1389

Arg Asp Cys Cys Tyr His Pro Thr Cys Asn Met Ser Asn Pro Gin He 1 5 10 15

Cys &lt;210>1390 &lt;211> 13 ~ &lt;212&gt; PRT &lt;213&gt; Artificial sequence • &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory Jfe &lt;400> 1390

Tyr Cys Cys His Pro Ala Cys Gly Lys Asn Phe Asp Cys 1 5 10 &lt;210> 1391 &lt;211> 12 692 1300414 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: Synthetic Victory Moon too &lt;400&gt; 1391

Gly Cys Cys Ser Asp Pro Arg Cys Ma Trp Arg Cys 15 10 ^ &lt;210&gt; 1392 &lt;211> 13 .&lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; (One, &lt;223&gt; Labor Description of the sequence: Synthetic peptide &lt;400> 1392

He Cys Cys Asn Pro Ala Cys Gly Pro Lys Tyr Ser Cys 1 5 10 &lt;210> 1393 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 1393

Arg Asp Cys Cys Thr Arg Lys Cys Lys Asp Arg Arg Cys Lys Met Lys 15 10 15

Cys Cys Ala &lt;210> 1394 &lt;211&gt;24 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory limb: &lt;400&gt; 1394 693 1300414

Cys Lys Ser Gly Ser Ser Cys Ser Thr Ser Tyr Asn Cys Cys Arg Ser 15 10 15

Cys Asn Tyr Thr Lys Arg Cys Tyr 20 &lt;210&gt; 1395 &lt;211&gt; 25 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt;223 Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 1395

Cys Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys 1 5 10 15

Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 &lt;210&gt; 1396 &lt;211&gt; 26 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;;400&gt; 1396

Cys Lys Gly Lys Gly Ala Pro Cys Arg Lys Thr Met Tyr Asp Cys Cys 15 10 15

Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys 20 25 &lt;210> 1397 &lt;211&gt; 26 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory 694 1300414 &lt;400〉 1397

Cys Lys Leu Lys Gly Gin Ser Cys Arg Lys Thr Ser Tyr Asp Cys Cys 15 10 15

Ser Gly Ser Cys Gly Arg Ser Gly Lys Cys 20 25 &lt;210&gt; 1398 &lt;211&gt; 10 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1398

Lys Thr Lys Cys Lys Phe Leu Lys Lys Cys 1 5 10 &lt;210&gt; 1399 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400> 1399

Arg Asp Cys Cys Thr Lys Lys Cys Lys Asp Arg Gin Cys Lys Gin Arg 1 5 10 15

Cys Cys Ala &lt;210> 1400 &lt;211&gt; 37 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1400

Glu Phe Thr Asp Val Asp Cys Ser Val Ser Lys Glu Cys Trp Ser Val 15 10 15 695 1300414

Cys Lys Asp Leu Phe Gly Val Asp Arg Gly Lys Cys Met Gly Lys Lys 20 25 30

Cys Arg Cys Tyr Gin 35 &lt;210&gt; 1401 . &lt;211> 37 &lt;212> PRT, &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide '1 &lt; 400> 1401

Gly Val Glu lie Asn Val Lys Cys'Ser Gly Ser Pro Gin Cys Leu Lys 1 5 10 15

Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys 20 25 30

Cys His Cys Thr Pro 35 &lt;210&gt; 1402 &lt;211> 37 &lt;212> PRT _ )&lt;213>Artificial sequence &lt;220> -&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;; 1402

Gly Val Glu lie Asn Val Lys Cys Ser Gly Ser Pro Gin Cys Leu Lys 1 5 10 15

Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Gys Met Asn Arg Lys 20 25 30

Cys His Cys Thr Pro 35 696 1300414 &lt;210&gt; 1403 &lt;211&gt; 22 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1403 lie Lys Cys Asn Cys Lys Arg His Val lie Lys Pro His lie Cys Arg 1 5 10 15

Lys lie Cys Gly Lys Asn 20

&lt;210> 1404 &lt;211> 39 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1404

Thr lie He Asn Val Lys Cys Thr Ser Pro Lys Gin Cys Leu Pro Pro 1 5 10 15

Cys Lys Ala Gin Phe Gly Gin Ser Ala Gly Ala Lys Cys Met Asn Gly 20 25 30

Lys Cys Lys Cys Tyr Pro His 35 -&lt;210&gt; 1405 &lt;211&gt; 4 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning: &lt;400&gt; 1405 Phe Asp Arg Ala 697 1300414 1 &lt;210&gt; 1406 &lt;211&gt; 44 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory&lt;400&gt; 1406

Ala Asp Cys Ser Ala Thr Gly Asp Thr Cys Asp His Thr Lys Lys Cys 1 5 10 15

Cys Asp Asp Cys Tyr Thr Cys Arg Cys Gly Thr Pro Trp Gly Ala Asn 20 25 30

Cys Arg Cys Asp Tyr Tyr Lys Ala Arg Cys Asp Thr 35 40 &lt;210&gt; 1407 &lt;211> 31 &lt;212> PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400> 1407

Ala Phe Cys Asn Leu Arg Met Cys Gin Leu Ser Cys Arg Ser Leu Gly 1 5 10 15

Leu Leu Gly Lys Cys lie Gly Asp Lys Cys Glu Cys Val Lys His • 20 25 30 ^ &lt;210&gt; 1408 &lt;211> 35 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of the sequence: Synthetic victory &lt;400&gt; 1408

Arg Ser Cys He Asp Thr He Pro Lys Ser Arg Cys Thr Ala Phe Gin 698 1300414 1 5 10 15

Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys 20 25 30

Gly Thr Cys 35 . &lt;210&gt; 1409 &lt;211> 14 -&lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide, one &lt;400&gt; 1409

Phe Leu Pro Leu lie Leu Gly Lys Leu Val Lys Gly Leu Leu 1 5 10 &lt;210&gt; 1410 &lt;211> 14 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; : Synthetic peptide &lt;400&gt; 1410

He Asn Leu Lys Ala He Ala Ala Leu Val Lys Lys Val Leu - &lt;210&gt; 1411 &lt;211&gt; 14 e &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic peptide &lt;400> 1411 lie Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys lie Leu 1 5 10 699 1300414 &lt;210> 1412 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213>Artificial sequence&lt;213&gt;;220>&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1412

He Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Ala Leu Leu . 1 5 10

^ &lt;210&gt; 1413 &lt;211&gt; 14 &lt;212> PRT (〕 &lt; 213 > artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1413

He Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Arg Leu Leu 1 5 10 &lt;210> 1414 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;〇&lt;223&gt; Artificial Sequence Description: Synthetic peptide C j &lt;4〇〇&gt; 1414 lie Asn Leu Lys Ala Lys Ala Ala Leu Ala Lys Lys Leu Leu ^ 1 5 10 * &lt;210&gt; 1415 &lt;211&gt; 14 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win &lt;400&gt; 1415

He Asn Trp Lys Gly He Ala Ala Met Ala Lys Lys Leu Leu 700 1300414 1 5 10 &lt;210> 1416 &lt;211&gt; 21 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400> 1416

Phe Met Ser Ser His Gin Ser Gin Ala Ser Leu Glu Leu Ala lie Lys 1 5 10 15

Gin Trp Gly Ser Gin 20 &lt;210&gt; 1417 &lt;211&gt; 20 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1417

Phe Asn Lys lie Thr Pro Asn Leu Ala Glu Phe Ala Phe Ser Leu Tyr 1 5 10 15

Arg Gin Leu Ala 20 &lt;210&gt; 1418 -&lt;211> 34 &lt;212&gt; PRT • &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1418

Trp Ser Pro Lys Glu Glu Asp Arg lie lie Pro Gly Gly He Tyr Asn 1 5 10 15

Ala Asp Leu Asn Asp Glu Trp Val Gin Arg Ala Leu His Phe Ala He 701

I3004H 20 25 30

Ser Glu &lt;210&gt; 1419 &lt;211> 36 &lt;212> PRT ~ &lt;213>Artificial sequence &lt;220&gt;&gt;&lt;223> Description of artificial sequence: synthetic peptide &lt;400&gt; 1419

Tyr Thr Ser Leu lie His Ser Leu lie Glu Glu Ser Gin Asn Gin Gin

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe 35 &lt;210> 1420 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220> tj &lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400> 1420 ~ Asn Asn Leu Leu Arg Ala lie Glu Ala Gin Gin His Leu Leu Gin Leu .1 5 10 15

Thr Val Trp Gin He Lys Gin Leu Gin Ala Arg lie Leu Ala Val Glu 20 25 30

Arg Tyr Leu Lys Asp Gin 35 &lt;210> 1421 702 1300414 &lt;211&gt; 36 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400 〉 1421

Tyr Thr Asn Thr He Tyr Thr Leu Leu Glu Glu Ser Gin Asn Gin Gin 1 5 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe 35 &lt;210&gt; 1422 &lt;211> 36 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1422

Tyr Thr Gly Lie lie Tyr Asn Leu Leu Glu Glu Ser Gin Asn Gin Gin 1 5 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Asn Leu 20 25 30

Trp Asn Trp Phe 35

&lt;210> 1423 &lt;211&gt; 36 &lt;212> PRT &lt;213&gt; Artificial sequence . &lt;220> &lt;223> Description of artificial sequence: Synthetic victory month too &lt;400> 1423 703 1300414

Tyr Thr Ser Leu lie Tyr Ser Leu Leu Glu Lys Ser Gin Thr Gin Gin 1 5 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe 35 &lt;210&gt; 1424 &lt;211> 36 &lt;212&gt; PRT &lt;213&gt; Artificial sequence j &lt;220&gt; ^ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1424

Leu Glu Ala Asn He Ser Lys Ser Leu Glu Gin Ala Gin lie Gin Gin 1 5 10 15

Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp lie Phe 20 25 30

Gly Asn Trp Phe 35 &lt;210&gt; 1425 &lt;211> 36 &lt;212> PRT &lt;213&gt; Artificial Sequence -&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide ^ &lt;400&gt; 1425

Leu Glu Ala Asn He Ser Gin Ser Leu Glu Gin Ala Gin He Gin Gin 1 5 10 15

Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp Val Phe 20 25 30

Thr Asn Trp Leu 704 1300414 35 &lt;210> 1426 &lt;211&gt; 41 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide. &lt;400&gt; 1426

Cys Gly Gly Asn Asn Leu Leu Arg Ala lie Glu Ala Gin Gin His Leu 1 5 10 15

Leu Gin Leu Thr Val Tip Gly lie Lys Gin Leu Gin Ala Arg lie Leu ) 20 25 30

Ala Val Glu Arg Tyr Leu Lys Asp Gin 35 40 &lt;210&gt; 1427 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 1427

Gin Gin Leu Leu Asp Val Val Lys Arg Gin Gin Glu Met Leu Arg Leu )1 5 10 15

Thr Val Trp Gly Thr Lys Asn Leu Gin Ala Arg Val THr Ala He Glu 20 25 30

Lys Tyr Leu Lys Asp Gin 35 &lt;210> 1428 &lt;211> 46 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 705 1300414 &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400 〉 1428

Tyr Thr Ser Val lie Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys 1 5 10 15

Cys Asn Gly Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp Lys Tyr 20 25 30

Lys Asn Ala Val Thr Glu Leu Gin Leu Leu Met Gin Ser Thr 35 40 45 &lt;210&gt; 1429 &lt;211&gt; 54 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic Victory &lt;400&gt; 1429

Ala Ser Gly Val Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val 1 5 10 15

Asn Lys He Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser 20 25 30

Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr 35 40 45 lie Asp Lys Gin Leu Leu 50 &lt;210> 1430 &lt;211&gt; 53 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt ; &lt;223&gt; Description of artificial sequence··Comprehensive victory&lt;400&gt; 1430 706 1300414

Gly Glu Pro He He Asn Phe Tyr Asp Pro Leu Val Phe Pro Ser Asp 1 5 10 15

Glu Phe Asp Ala Ser He Ser Gin Val Asn Glu Lys He Asn Gin Ser 20 25 30

Leu Ala Phe He Arg Lys Ser Asp Glu Leu Leu His Asn Val Asn Ala 35 40 45

Gly Lys Ser Thr Thr 50 &lt;210> 1431 &lt;211> 48 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt; 1431

Tyr Thr Ser Val lie Thr He Glu Leu Ser Asn lie Lys Glu Asn Lys 1 5 10 15

Cys Asn Gly Thr Asp Ala Lys Val Lys Leu He Lys Gin Glu Leu Asp 20 25 30

Lys Tyr Lys Asn Ala Val Thr Glu Leu Gin Leu Leu Met Gin Ser Thr 35 40 45 &lt;210> 1432 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Artificial Sequence Description: The victory of synthesis &lt;400&gt; 1432

Tyr Thr Ser Val lie Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys 1 5 10 15 707 1300414

Cys Asn Gly Asp Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp Lys 20 25 30

Tyr Lys &lt;210> 1433 &lt;211> 34 -&lt;212&gt; PRT &lt;213&gt; Artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1433

Thr Ser Val lie Thr He Glu Leu Ser Asn He Lys Glu Asn Lys Cys — 1 5 10 15

Asn Gly Asp Ala Lys Val Lys Leii lie Lys Gin Glu Leu Asp Lys Tyr 20 25 30

Lys Asn &lt;210&gt; 1434 &lt;211> 34 &lt;212&gt; PRT &lt; 213 &gt; 213 > artificial sequence, ~ ' &lt; 220 > &lt; 223 > Description of artificial sequence: synthetic victory &lt;4〇〇&gt; 1434 • Val lie Thr He Glu Leu Ser Asn He Lys Glu Asn Lys Cys Asn Gly 1 5 10 15

Asp Ala Lys Val Lys Leu He Lys Gin Glu Leu Asp Lys Tyr Lys Asn 20 25 30

Ala Val &lt;210> 1435 &lt;211> 34 708 1300414 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1435

Val He Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys Met Asn Gly 1 5 10 15

Asp Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp Lys Tyr Lys Asn 20 25 30

Ala Val &lt;210&gt; 1436 &lt;211> 33 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1436

Val Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie 15 10 15

Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val 20 25 30

Ser &lt;210&gt; 1437 &lt;211> 33 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1437

Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie Ala 1 5 10 15 709 1300414

Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser 20 25 30

Val &lt;210&gt; 1438 &lt;211&gt; 33 &lt;212&gt; PRT, &lt;213&gt; artificial sequence &lt;220&gt; • &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1438

Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie Ala Leu J 1 5 10 15

Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val 20 25 30

Leu &lt;210> 1439 &lt;211> 33 &lt;212> PRT &lt;213>Artificial sequence &lt;220> 1 &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1439

Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys He Ala Leu Leu ^ 1 5 10 15

Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu 20 25 30

Thr

&lt;210> 1440 &lt;211&gt; 33 &lt;212> PRT 710 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 1440

Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie Ala Leu Leu Ser 1 5 10 15

Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr 20 25 30

Ser &lt;210&gt; 1441 , )&lt;211&gt; 33 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1441

Leu Glu Gly Glu Val Asn Lys He Ala Leu Leu Ser Thr Asn Lys Ala 1 5 10 15

Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu 20 25 30

Asp &lt;210> 1442 ~ &lt;211> 33 &lt;212&gt; PRT -&lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1442

Gly Glu Val Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val 15 10 15 71] 1300^

Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu 20 25 30

Lys &lt;210&gt; 1443 &lt;211&gt; 33 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;4〇〇&gt; 1443

Glu Val Asn Lys He Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser 1 5 10 15

Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys 20 25 30

Asn &lt;210> 1444 &lt;211&gt; 33 &lt;212> PRT &lt;213&gt; artificial sequence * &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic victory)} too &lt;4〇〇> 1444

Val Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu 1 5 10 15

Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn 20 25 30

Tyr

&lt;210> 1445 &lt;211> 33 &lt;212&gt; PRT 712 1300414 &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;4〇〇&gt; 1445

Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser 1 5 10 15

Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr 20 25 30 lie &lt;210&gt; 1446 &lt;211> 33 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: the winning form &lt;4〇〇&gt; 1446

Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn 1 5 10 15

Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr He 20 25 30

Asp &lt;210&gt; 1447 &lt;211> 33 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory&lt;4〇〇&gt; 1447 lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly 15 10 15

Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr lie Asp 713 1300414 20 25 30

Lys &lt;210&gt; 1448 &lt;211&gt; 33 &lt;212> PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;4〇〇&gt; 1448

Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val 1 5 10 15

Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr lie Asp Lys 20 25 30

Gin &lt;210> 1449 &lt;211&gt; 70 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;4〇〇&gt; 1449

Gly Thr He Ala Leu Gly Val Ala Thr Ser Ala Gin He Thr Ala Ala 15 10 15

Val Ala Leu Val Glu Ala Lys Gin Ala Arg Ser Asp He Glu Lys Leu 20 25 30

Lys Glu Ala He Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser 35 40 45

Ser lie Gly Asn Leu lie Val Ala lie Lys Ser Val Gin Asp Tyr Val 50 55 60 714

1300414

Asn Lys Glu lie Val Pro 65 70 &lt;210&gt; 1450 &lt;211&gt; 56 &lt;212> PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1450 * - Tyr Thr Pro Asn Asp lie Thr Leu Asn Asn Ser Val Ala Leu Asp Pro 1 5 10 15 One lie Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu — 20 25 30

Ser Lys Glu Trp He Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly 35 40 45

Asn Trp His Gin Ser Ser Thr Thr 50 55 &lt;210&gt; 1451 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt; GD &lt;223&gt;223 Description of Artificial Sequence: Synthetic Winning &lt;;400〉 1451 -Thr Leu Asn Asn Ser Val Ala Leu Asp Pro lie Asp lie Ser He Glu 15 10 15

Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp He Arg 20 25 30

Arg Ser Asn 35 &lt;210&gt; 1452 7]5 1300414 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory JJ too &lt;400&gt ; 1452

Leu Asn Asn Ser Val Ala Leu Asp Pro He Asp lie Ser lie Glu Leu 1 5 10 15

Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp He Arg Arg 20 25 30

Ser Asn Gin

&lt;210&gt; 1453 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 1453

Asn Asn Ser Val Ala Leu Asp Pro He Asp He Ser He Glu Leu Asn 1 5 10 15 , --- Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp He Arg Arg Ser A 20 25 30

Asn Gin Lys 35 &lt;210> 1454 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400> 1454 7] 6 1300414

Asn Ser Val Ala Leu Asp Pro lie Asp lie Ser He Glu Leu Asn Lys 1 5 10 15

Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn 20 25 30

Gin Lys Leu 35 &lt;210&gt; 1455 &lt;211> 35 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 223 &gt; 223 &gt; 223 &gt; Description of the artificial sequence: the victory of the synthesis &lt;400 > 1455

Ser Val Ala Leu Asp Pro He Asp lie Ser He Glu Leu Asn Lys Ala 15 10 15

Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin 20 25 30

Lys Leu Asp 35 &lt;210> 1456 &lt;211> 35 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 1456

Val Ala Leu Asp Pro He Asp He Ser He Glu Leu Asn Lys Ala Lys 15 10 15

Ser Asp Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys 20 25 30 717 1300414

Leu Asp Ser 35 &lt;210> 1457 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1457

Ala Leu Asp Pro He Asp He Ser He Glu Leu Asn Lys Ala Lys Ser 1 5 10 15

Asp Leu Glu Glu Ser Lys Glu Trp He Arg Arg Ser Asn Gin Lys Leu 20 25 30

Asp Ser lie 35 &lt;210&gt; 1458 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Leu Asp Pro He Asp He Ser lie Glu Leu Asn Lys Ala Lys Ser Asp

-Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp 20 25 30

Ser lie Gly 35 &lt;210> 1459 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 718 1300414 &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 1459

Asp Pro He Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu 15 10 15

Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Ly's Leu Asp Ser 20 25 30 lie Gly Asn ' 35 &lt;210> 1460 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;;223> Description of artificial sequence: synthetic peptide &lt;400> 1460

Pro lie Asp He Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu 1 5 10 15

Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser lie 20 25 30 r -, Gly Asn Trp ''-35 &lt;210&gt; 1461 &lt;211&gt; 35 &lt;212> PRT &lt;213> Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 1461 lie Asp He Ser He Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu 15 10 719 1300414

Ser Lys Glu Trp He Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly 20 25 30

Asn Trp His 35 &lt;210&gt; 1462 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1462

Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser 15 10 15

Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser He Gly Asn 20 25 30

Trp His Gin 35 &lt;210&gt; 1463 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide-&lt;400&gt; 1463 lie Ser Lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys ^ 15 10 15

Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser He Gly Asn Trp 20 25 30

His Gin Ser 35 720 1300414 &lt;210> 1464 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1464

Ser He Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu . 1 5 10 15 -Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly Asn Trp His 20 25 30 )Gin Ser Ser 35 &lt;210&gt; 1465 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1465 lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp 15 10 15

Lie Arg Arg Ser Asn Gin Lys Leu Asp Ser He Gly Asn Trp His Gin 20 25 30

Ser Ser Thr 35 &lt;210> 1466 &lt;211> 35 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory fl 721 1300414 &lt;400> 1466

Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp lie 1 5 10 15

Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly Asn Trp His Gin Ser 20 25 30

Ser Thr Thr - 35

&lt;210> 1467 &lt;211&gt; 35 &lt;212> PRT C3 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1467

Thr Ala Ala Val Ala Leu Val Glu Ala Lys Gin Ala Arg Ser Asp lie 1 5 10 15

Glu Lys Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser 20 25 30

Val Gin Ser 35, &lt;210>1468 &lt;211&gt; 35 &quot;&lt;212&gt; PRT &lt;213&gt; Artificial Sequence • &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon &lt;400 〉 1468

Ala Val Ala Leu Val Glu Ala Lys Gin Ala Arg Ser Asp lie Glu Lys 15 10 15

Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin 20 25 30 722 1300414

Ser Ser lie 35 &lt;210> 1469 &lt;211> 35 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;-&lt;223&gt; Description of artificial sequence: Synthetic victory 0 too &lt;400> 1469 v Leu Val Glu Ala Lys Gin Ala Arg Ser Asp He Glu Lys Leu Lys Glu 15 10 15

Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie 20 25 30

Gly Asn Leu 35 &lt;210&gt; 1470 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon, &lt;400> 1470

Val Glu Ala Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala 15 10 15 lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly ' 20 25 30

Asn Leu lie 35

&lt;210&gt; 1471 &lt;211&gt; 35 &lt;212&gt; PRT 723 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;4〇〇&gt; 1471

Glu Ala Lys Gin Ala Arg Ser Asp He Glu Lys Leu Lys Glu Ala He 1 5 10 15

Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser He Gly Asn 20 25 30

Leu lie Val 35 &lt;210> 1472 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic peptide &lt;400&gt; 1472

Ala Lys Gin Ala Arg Ser Asp He Glu Lys Leu Lys Glu Ala lie Arg 15 10 15

Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu 20 25 30 lie Val Ala 35 &lt;210&gt; 1473 &lt;211> 35 &lt;212> PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence: : Synthetic Peptide &lt;400> 1473

Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala lie Arg Asp 15 10 15 724 1300414

Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser He Gly Asn Leu lie 20 25 30

Val Ala lie 35 &lt;210&gt; 1474 -&lt;211&gt; 35 &lt;212&gt; PRT -&lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide J &lt; 400 > 1474

Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala He Arg Asp Thr 15 10 15

Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu He Val 20 25 30

Ala He Lys 35 &lt;210&gt; 1475 &lt;211> 35, &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt; ~ &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;4〇〇&gt ; 1475

Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala He Arg Asp Thr Asn 1 5 10 15

Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu lie Val Ala 20 25 30

He Lys Ser 35 725 1300414 &lt;210> 1476 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1476

Arg Ser Asp He Glu Lys Leu Lys Glu Ala He Arg Asp Thr Asn Lys 15 10 15

Ala Val Gin Ser Val Gin Ser Ser He Gly Asn Leu lie Val Ala He 20 25 30

Lys Ser Val 35 &lt;210&gt; 1477 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Ser Asp He Glu Lys Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala 1 5 10 15

Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu He Val Ala lie Lys 20 25 30

Ser Val Gin 35 &lt;210> 1478 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt; 726 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1478

Lys Leu Lys Glu Ala He Arg Asp Thr Asn Lys Ala Val Gin Ser Val 1 5 10 15

Gin Ser Ser lie Gly Asn Leu lie Val Ala lie Lys Ser Val Gin Asp 20 25 30 • Tyr Val Asn 35

&lt;210&gt; 1479 &lt;211> 35 C2) &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: victory of synthesis &lt;400> 1479

Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin 15 10 15

Ser Ser lie Gly Asn Leu lie Val Ala lie Lys Ser Val Gin Asp Tyr 20 25 30

Val Asn Lys 35

&lt;210> 1480 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1480

Ala He Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie 15 10 15

Gly Asn Leu He Val Ala lie Lys Ser Val Gin Asp Tyr Val Asn Lys 20 25 30 727 1300414

Glu lie Val 35 &lt;210&gt; 1481 &lt;211> 47 &lt;212&gt; PRT &lt;213&gt; Artificial sequence, &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory - &lt;400&gt;

Thr Trp Gin Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie 1 5 10 15

Thr Ala Leu Leu Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr 20 25 30

Glu Leu Gin Lys Leu Asn Ser Trp Asp Val Phe Gly Asn Trp Phe 35 40 45 &lt;210&gt; 1482 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt; _ &lt;223&gt; Artificial Sequence Description: Synthetic win, -J &lt;400&gt; 1482

Trp Gin Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn He Thr &quot; 15 10 15 _ Ala Leu Leu Glu Glu Ala Gin He Gin Gin Glu Lys Asn Met Tyr Glu 20 25 30

Leu Gin Lys 35 &lt;210> 1483 &lt;211&gt; 35 728 1300414 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Winning &lt;400> 1483

Gin Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala 15 10 15

Leu Leu Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu 20 25 30

Gin Lys Leu 35 &lt;210> 1484 &lt;211> 35 &lt;212> PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1484

Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu 15 10 15

Leu Glu Glu Ala Gin He Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin 20 25 30

Lys Leu Asn 35 &lt;210&gt; 1485 &lt;211&gt; 35 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 0 too &lt;400&gt; 1485

Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu 729 1300414 1 5 10 15

Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys 20 25 30

Leu Asn Ser 35 ^ &lt;210&gt; 1486 &lt;211&gt; 35 ^ &lt;212&gt;PRT &lt;213&gt; artificial sequence &lt;220&gt; GIT &lt;223&gt;223 Description of artificial sequence: synthetic victory &lt;400&gt; 1486

Glu Arg Lys Val Asp Phe Leu Glu Glu Asn He Thr Ala Leu Leu Glu 15 10 15

Glu Ala Gin He Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu 20 25 30

Asn Ser Trp 35

&lt;210&gt; 1487 &lt;211>35 L- &lt;212>PRT &lt;213&gt; Artificial sequence &lt;220&gt; _ &lt;223&gt;223 Description of artificial sequence: synthetic peptide &lt;400&gt; 1487

Arg Lys Val Asp Phe Leu Glu Glu Asn He Thr Ala Leu Leu Glu Glu 1 5 10 15

Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn 20 25 30

Ser Trp Asp 730 1300414 35 &lt;210&gt; 1488 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400&gt; 1488

Lys Val Asp Phe Leu Glu Glu Asn He Thr Ala Leu Leu Glu Glu Ala 1 5 10 15

Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser 20 25 30

Trp Asp Val 35 &lt;210&gt; 1489 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu Glu Glu Ala Gin 1 5 10 15 lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp 20 25 30

Asp Val Phe 35 &lt;210> 1490 &lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 731 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1490

Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu Glu Glu Ala Gin He 15 10 15

Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp 20 25 30 -Val Phe Gly 35

&lt;210> 1491 &lt;211&gt; 35 (:::; &lt;212>PRT &lt;213&gt; artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1491

Phe Leu Glu Glu Asn He Thr Ala Leu Leu Glu Glu Ala Gin lie Gin 1 5 10 15

Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp Val 20 25 30

Phe Gly Asn &lt;210> 1492 &lt;211> 35 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1492

Pro Asp Ala Val Tyr Leu His Arg lie Asp Leu Gly Pro Pro lie Ser 15 10 15

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala He Ala Lys ΊΎ1 1300414 20 25 30

Leu Glu Asp 35 &lt;210> 1493 &lt;211> 34 &lt;212&gt; PRT -&lt;213>Artificial sequence &lt;220&gt; ‘ &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400〉 1493

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys

Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie Leu Arg Ser 20 25 30

Met Lys &lt;210&gt; 1494 &lt;211> 34 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt; f, &lt;223&gt; Description of artificial sequence: synthetic victory &lt;4〇〇&gt; 1494

Leu His Arg He Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp 1 5 10 15

Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu 20 25 30

Leu Leu

&lt;210&gt; 1495 &lt;211> 34 &lt;212> PRT 733

1300414 &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1495

His Arg lie Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val 1 5 10 15

Gly Thr Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu 20 25 30 . Leu Glu

&lt;210> 1496, -1, &lt;211>34 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1496

Arg lie Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly 1 5 10 15

Thr Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu 20 25 30

Glu Ser

&lt;210&gt; 1497

• &lt;211> 34 &lt;212&gt; PRT ♦ &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Wins &lt;400> 1497 lie Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr 15 10 15

Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu 734 1300414 20 25 30

Ser Ser &lt;210&gt; 1498 &lt;211> 34 &lt;212&gt; PRT &lt;213&gt; Artificial sequence ~ &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1498

Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn '15 10 15

Leu Gly Asn Ala He Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser 20 25 30

Ser Asp &lt;210> 1499 &lt;211&gt; 34 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1499

Leu Gly Pro Pro He Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu 1 5 10 15 , Gly Asn Ala He Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser 20 25 30

Asp Gin &lt;210&gt; 1500 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt; 735 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly 15 10 15

Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp 20 25 30

Gin He

&lt;210&gt; 1501 &lt;211&gt; 34 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1501

Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn 15 10 15

Ala He Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin 20 25 30

He Leu &lt;210&gt;1502)&lt;211> 34 &lt;212> PRT -&lt;213&gt; artificial sequence &lt;220&gt; • &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1502

Pro He Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala 1 5 10 15 lie Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie 20 25 30 736 1300414

Leu Arg &lt;210&gt; 1503 &lt;211> 34 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory - &lt;400> 1503

Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala He Ala 1 5 10 15

Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie Leu Arg 20 25 30

Ser Met &lt;210> 1504 &lt;211> 34 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1504

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys 1 5 10 15

Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie Leu Arg Ser 20 25 30

Met Lys &lt;210&gt; 1505 &lt;211> 22 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt; 737 130041^ &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1505

Tyr Leu Cys Glu Phe Cys Leu Lys Tyr Gly Arg Ser Leu Lys Cys Leu 1 5 10 15

Gin Arg His Leu Thr Lys 20 &lt;210> 1506 &lt;211> 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1506

Ala Ser Thr Thr Thr Asn Tyr Thr 1 5 &lt;210&gt; 1507 &lt;211&gt; 8 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt; 400> 1507

Ala Ser Thr Thr Thr Asn Tyr Thr 1 5 ^ &lt;210&gt; 1508 &lt;211&gt; 8 * &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Winning &lt;400〉 1508

5 738 1300414 &lt;210&gt; Peptide &lt;400> 1509

Glu Leu Asp Lys Trp Ala 1 5 &lt;210> 1510 &lt;211&gt; 11 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt; 221 &gt; 223 &gt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1510

Arg Gly Val Val Asn Ala Ser Ser Arg Leu Ala 1 5 10 &lt;210&gt; 1511 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1511

Arg Gly Arg Arg Gin Pro He Pro Lys Ala 1 5 10 &lt;210&gt; 1512 • &lt;211> 23 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthesis Peptide &lt;400> 1512

Leu Thr Thr Gly Ser Val Val He Val Gly Arg He lie Leu Ser Gly 1 5 10 15 739 1300414

Arg Pro Ala Val Val Pro Asp 20 &lt;210> 1513 &lt;211&gt; 14 &lt;212> PRT &lt;213>Artificial Sequence-&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt ; 1513

Gly Ser Val Val lie Val Gly Arg lie lie Leu Ser Gly Arg 1 5 10 &lt;210&gt; 1514 &lt;211&gt; 27 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; : Synthetic victory 呔 &lt;400&gt; 1514

Pro Leu Gly Phe Phe Pro Asp His Gin Leu Asp Pro Ala Phe Gly Ala 1 5 10 15

Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro

&lt;210&gt; 1515 &lt;211&gt; 26 • &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1515

Met Gin Trp Asn Ser Thr Thr Phe His Gin Thr Leu Gin Asp Pro Arg 1 5 10 15

Val Arg Gly Leu Tyr Phe Pro Ala Gly Gly 740 1300414 20 25 &lt;210> 1516 &lt;211> 11 &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Winning &lt;400> 1516

Met Gin Trp Asn Ser Thr Ala Phe His Gin Thr 1 5 10 &lt;210&gt; 1517 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 1517

Tyr Gly Ala Val Val Asn Asp Leu 1 5 &lt;210&gt; 1518 &lt;211> 21 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1518

Cys Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn 1 5 10 15

Gly Ser Leu Ala Glu 20

&lt;210> 1519 &lt;211> 7 &lt;212&gt; PRT 741 1300414 &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic Shengtongtai &lt;400> 1519

Ser Glu Asn Tyr Pro He Val 1 5 &lt;210&gt; 1520 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 1520

Lys Ala Arg Val Phe Glu Ala &lt;210> 1521 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1521

Arg lie Gin Arg Gly Pro Gly Arg Ala Phe Val Thr lie Gly Lys 1 5 10 15 &lt;210> 1522 -&lt;211&gt; 8 &lt;212&gt; PRT • &lt;213>Artificial Sequence&lt;220&gt;&lt;223&gt; Description of the artificial sequence: the victory of synthesis &lt;400&gt; 1522

Ala Ser Thr Thr Thr Asn Tyr Thr 1 5 742 1300414 &lt;210&gt; 1523 &lt;211&gt; 8 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt;400> 1523 • Ala Ser Thr Thr Thr Asn Tyr Thr 1 5

&lt;210&gt; 1524 _ &lt;211&gt; 15 C ^ &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1524

Arg lie Gin Arg Gly Pro Gly Arg Ala Phe Val Thr lie Gly Lys 1 5 10 15 &lt;210> 1525 &lt;211&gt; 38 &lt;212&gt; PRT &lt;213&gt; Artificial sequence f, &lt;220> W &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1525

Asn Asn Leu Leu Arg Ala lie Glu Ala Gin Gin His Leu Leu Gin Leu ,1 5 10 15

Thr Val Trp Gly He Lys Gin Leu Gin Ala Arg He Leu Ala Val Glu 20 25 30

Arg Tyr Leu Lys Asp Gin 35 &lt;210&gt; 1526 743 1300414 &lt;211> 10 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; 223> Description of Artificial Sequence: Synthetic Peptide &lt;400 〉 1526

Arg Gly Pro Gly Arg Ala Phe Val Thr He 1 5 10 &lt;210&gt; 1527 &lt;211> 3 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win月太&lt;400> 1527 Phe Phe Gly &lt;210&gt; 1528 &lt;211> 36 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400&gt; 1528

Tyr Thr Ser Leu lie His Ser Leu He Glu Glu Ser Gin Asn Gin Gin 1 5 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe 35

&lt;210> 1529 &lt;211&gt; 2 &lt;212&gt; PRT 744 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1529 Thr Gin 1 &lt; 210> 1530 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt;Artificial sequence&lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1530

Trp His Trp Leu Gin Leu 1 5 &lt;210> 1531 &lt;211> 5 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1531 Gly Pro Gly Ala Gly 1 5

&lt;210> 1532 -&lt;211&gt; 2 &lt;212&gt; PRT • &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory fl too &lt;400> 1532 His Gly 1 &lt ;210&gt; 1533 1300414 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory: &lt;400> 1533 Phe Val Phe Leu Met 1 5 &lt;210&gt; 1534 -&lt;211&gt; 3 &lt;212&gt; PRT &lt;213>Artificial sequence::&lt;220> ~ &lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400&gt; 1534 Thr Ser Lys 1 &lt;210&gt; 1535 &lt;211&gt; 3 &lt;212> PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1535 Lys His Gly &lt;210&gt; 1536 &lt;211&gt; 16 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Lys Asn Arg Trp Glu Asp Pro Gly Lys Gin Leu Tyr Asn Val Glu Ala 15 10 15 746 1300414 &lt;210&gt; 1537 &lt;211&gt; 10 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic victory too &lt;400> 1537 .Leu Arg Ala His Ala Val Asp Val Asn Gly 1 5 10 &lt;210> 1538 &lt;211&gt; 14

r, 'V&lt;212&gt; PRT , / ^ &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1538

Trp Ser Lys Met Asp Gin Leu Ala Lys Glu Leu Thr Ala Glu 1 5 10 &lt;210&gt; 1539 &lt;211> 4 &lt;212> PRT &lt;213&gt; Artificial sequence. One... &lt;220&gt; (J c223 〉 Description of artificial sequence: Synthetic peptide &lt;400&gt; 1539 Thr Pro Arg Lys 1 &lt;210&gt; 1540 &lt;211&gt; 12 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220> &lt;223&gt; Description of the sequence: Synthetic Victory Moon too &lt;400&gt; 1540 747 1300414

Gly Glu Leu Gin Asn Gin Leu He Arg Lys Ser Asn &lt;210&gt; 1541 &lt;211&gt; 17 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt; e &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Win呔&lt;400> 1541 • Gly Glu Tyr Gin Lys Met Leu Asn Leu Arg Ala Glu Val Lys Lys Asn 1 5 10 15 &lt;210&gt; 1542 &lt;211> 9 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence&lt; 220> &lt;223&gt; Description of artificial sequence: Synthetic victory month too &lt;400> 1542

Pro Phe Cys Asn Ala Phe Thr Gly Cys 1 '5

1543 &lt;212> PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory B too &lt;400> 1543

Glu Lys Ala His Asp Gly Gly Arg 1 5

&lt;210> 1544 &lt;211&gt; 14 &lt;212&gt; PRT 748 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: S-synthesis J|Too &lt;400&gt;

Pro Phe Thr Arg Asn Tyr Tyr Val Arg Ala Val Leu His Leu 1 5 10 &lt;210&gt; 1545 .&lt;211&gt; 39 &lt;212> PRT -&lt;213&gt; Artificial Sequence &lt;220> &lt;223&gt; Artificial Sequence Description: Synthetic peptide ' &lt;400> 1545

Ala Pro Arg Leu Pro Gin Cys Gin Gly Asp Asp Gin Glu Lys Cys Leu 15 10 15

Cys Asn Lys Asp Glu Cys Pro Pro Gly Gin Cys Arg Phe Pro Arg Gly 20 25 30

Asp Ala Asp Pro Tyr Cys Glu 35

&lt;210> 1546 &lt;211&gt; 8 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1546

Lys Gly Asp Glu Glu Ser Leu Ala 1 5 &lt;210&gt; 1547 &lt;211&gt; 9 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt; 749 1300414 &lt;223&gt; Description of Artificial Sequence: Synthetic Victory &lt;400&gt; 1547

Trp Ala Gly Gly Asp Ala Ser Gly Glu 1 5 &lt;210&gt; 1548 &lt;211&gt; 20 &lt;212> PRT .&lt;213&gt; Artificial Sequence &lt;220&gt; Acoustic c223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;;400&gt; 1548

Gin Ala Thr Val Gly Asp Val Asn Thr Asp Arg Pro Gly Leu Leu Asp :1 5 10 15

Leu Lys Tyr Tyr 20 &lt;210&gt; 1549 &lt;211&gt; 17 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1549

Thr Lys Arg Arg Ala lie Gly Phe Lys Lys Leu Ala Glu Ala Val Lys 15 10 15

Cys &lt;210> 1550 &lt;211> 8 &lt;212> PRT &lt; 213 > artificial sequence &lt; 220 &lt; 223 &gt; Description of artificial sequence: synthetic victory &lt;400 > 1550

Ser lie lie Asn Phe Glu Lys Leu 750 1300414 1 5 &lt;210&gt; 1551 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory H Too ^ &lt;400&gt; 1551

Phe Gin Val Val Cys Gly , 1 5

&lt;210&gt; 1552, I, &lt;211&gt; 6, ~ &lt;212>PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1552

Ala Arg Met Ala Pro Glu 1 5

&lt;210> 1553 &lt;211> 4 &lt;212&gt; PRT '&lt;213> Artificial sequence ¢3 &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic S-form-&lt;400&gt; 1553 Gly Gin Pro Arg &lt;210> 1554 &lt;211&gt; 3 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic flori: 1300414 &lt;400&gt; 1554 Thr Val Leu 1 &lt;210&gt; 1555 &lt;211&gt; 49 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1555

Leu Leu Ser Lys Arg Gly His Cys Pro Arg lie Leu Phe Arg Cys Pro 1 5 10 15

Leu Ser Asn Pro Ser Asn Lys Cys Trp Arg Asp Tyr Asp Cys Pro Gly 20 25 30

Val Lys Lys Cys Cys Glu Gly Phe Cys Gly Lys Asp Cys Leu Tyr Pro 35 40 45

Lys &lt;210&gt; 1556 &lt;211> 10 &lt;212&gt; PRT &lt;213&gt; artificial sequence -&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400> 1556

Gly Phe Asp Leu Asn Gly Gly Gly Val Gly 1 5 10 &lt;210&gt; 1557 &lt;211> 18 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 752 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthesis Victory &lt;400〉 1557

Ala Val Gin Ser Lys Pro Pro Ser Lys Arg Asp Pro Pro Lys Met Gin 1 5 10 15

Thr Asp • &lt;210&gt; 1558

&lt;211&gt; 4 - &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt; (C2) &lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1558 Thr Lys Pro Arg 1 &lt;210&gt 1559 &lt;211> 11 &lt;212&gt; PRT &lt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt;

Tyr Leu Asn Phe Thr Pro Asn Trp Gly Thr Tyr 1 5 10 &lt;210> 1560 &lt;211&gt; 5 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400> 1560 Asp Leu Trp Gin Lys 1 5 753 1300414 &lt;210&gt; 1561 &lt;211> 17 &lt;212> PRT &lt; 213 &gt; 213 > Artificial Sequence &lt;220 &lt; 223 &gt; 223 &gt; Description of Artificial Sequence: Synthetic victory &lt;400&gt; 1561

Trp Tyr Glu Pro He Tyr Leu Gly Gly Val Phe Gin Leu Glu Lys Gly 1 5 10 15

Asp &lt;210> 1562 &lt;211&gt; 39 &lt;212&gt; PRT &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1562

Ala Pro Arg Leu Pro Gin Cys Gin Gly Asp Gin Glu Lys Cys Leu Cys 1 5 10 15

Asn Lys Asp Glu Cys Pro Pro Gly Gin Cys Arg Phe Pro Arg Gly Asp 20 25 30

Ala Asp Pro Tyr Cys Glu Asp 35 -&lt;210> 1563 &lt;211&gt; 4 ^ &lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1563 Thr Lys Pro Arg 1300414 &lt;210> 1564 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1564

Glu Glu Val Val Ala Cys 1 5 -&lt;210> 1565 &lt;211> 4 &lt;212> PRT Ί &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory fl too &lt ;400&gt; 1565

Ser Asp Lys Pro &lt;210&gt; 1566 &lt;211&gt; 6 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt; 1566

Arg Phe Trp He Asn Lys 1 5 &lt;210&gt; 1567 &lt;211&gt; 13 &lt;212&gt; PRT &lt;213>Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory 0 too &lt;400&gt ; 1567

Cys Gly Tyr Gly Pro Lys Lys Lys Arg Lys Val Gly Gly 755 1300414 1 5 &lt;210> 1568 &lt;211&gt; 1 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence : Synthetic peptide &lt;400&gt; 1568

Leu &lt;210&gt; 1569 &lt;211&gt; 5 &lt;212&gt; PRT &lt; 213 &gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1569 Asp Asp Asp Asp Asp 1 5 &lt;210&gt; 1570 &lt;211&gt; 6 &lt;212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &lt; 223 &gt; 223 &gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Asp Asp Asp Asp Asp Asp 1 5 &lt;210> 1571 &lt;211&gt; 8 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory 1300414 &lt;400 〉 1571

Asn Pro Asn Ala Asn Pro Asn Ala 1 5 &lt;210> 1572 &lt;211&gt; 8 &lt;212> PRT &lt; 213 &gt; Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: Synthetic Victory Moon too &lt ;400> 1572

Val Ala lie Thr Val Leu Val Lys 1 5 &lt;210> 1573 &lt;211> 6 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Victory Moon too &lt ;400&gt; 1573

Val Gly Val Arg Val Arg 1 5 &lt;210> 1574 &lt;211> 4 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win 1Ϊ太&lt;400&gt 1574 Val He His Ser 1 &lt;210> 1575 &lt;211> 5 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 1300414 &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1575 Val Pro Asp Pro Arg 1 5 &lt;210> 1576 &lt;211> 4 .&lt;212&gt; PRT &lt; 213 &gt; Artificial Sequence • &lt;220 &lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Success &lt; 400> 1576 (Val Thr Cys Gly &lt; 210 > 1577 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;&lt; 223 &gt; 223 > Description of Artificial Sequence: Synthetic Peptide &lt;400&gt; 1577 Arg Ser Arg 1 , a &lt;210&gt; 1578 &lt;211&gt; 11 &lt;212> PRT &lt; 213 &gt; artificial sequence, 220 &lt; 223 &gt; 223 &gt; 223 manual; description of the artificial sequence: 3 too &lt;400&gt; 1578

Ser Ala Lys Leu Cys Pro Gly Gly Asn Cys Val 1 5 10 &lt;210&gt; 1579 &lt;211> 6 758 1300414 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223> Description of Artificial Sequence: The victory of synthesis &lt;400〉 1579

Asp His Ala Arg Trp Lys 1 5 &lt;210&gt; 1580 &lt;211&gt; 7 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400&gt; 1580

Pro Gin Asp Pro Gin Asp Leu 1 5 &lt;210&gt; 1581 &lt;211&gt; 6 &lt;212&gt; PRT &lt; 213 &gt; 213 &gt;&lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory/ &lt; 400〉 1581

Gin His Phe Arg Trp Gly 1 5 &lt;210&gt; 1582 &lt;211&gt; 19 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1582

Asn Gin Glu Gin Val Ser Pro Leu Thr Leu Leu Lys Leu Gly Asn Gin 15 10 15 759 1300414

Glu Pro Gly &lt;210> 1583 &lt;211> 20 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt;

Leu Ser Ala Leu Ser Leu Asp Glu Pro Phe He Gin Lys Asp Val Glu 1 5 10 15

Leu Arg He Met 20 &lt;210&gt; 1584 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400&gt;

Ala Pro Glu Ala Gin Val Ser Val Gin Pro Asn Phe Gin Gin Asp 1 5 10 15 &lt;210&gt; 1585 &lt;211&gt; 27 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description: Synthetic peptide &lt;400&gt; 1585

Glu Tyr Gly Gly Thr Lys Val Leu Asp Asp Lys Asp Tyr Phe Leu Phe 15 10 15

Arg Asp Gly Asp He Leu Gly Lys Tyr Val Asp 20 25 760 1300414 &lt;210&gt; 1586 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 1586

Lys Ala Tyr lie Asn Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly He 1 5 10 15 &lt;210&gt; 1587 &lt;211> 24 &lt;212> PRT &lt; 213 > Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic victory &lt;400&gt; 1587

Ser Gin Gin Ser Ser Serr Gly Gin Gin Ser Glu Lys Pro Tyr Gin 1 5 10 15

Cys Asp Phe Lys Asp Cys Glu Arg 20 &lt;210> 1588 &lt;211> 15 )&lt;212> PRT &lt;213&gt;Artificial Sequence-&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Peptide^ &lt;400&gt; 1588

Ala Thr Glu Ser He Ala Tyr Leu Ala Pro Pro Tyr Ala Phe Arg 1 5 10 15 &lt;210&gt; 1589 &lt;211> 16 &lt;212> PRT &lt;213&gt; Artificial sequence 761 1300414 &lt;220&gt;&lt;223&gt; Description of the artificial sequence: Synthetic Victory Moon too &lt;400&gt; 1589

Lys Arg Lys Arg Ser Glu Met Leu Phe Arg Gly Arg Arg Ala Ser Gin 1 5 10 15 &lt;210&gt; 1590 &lt;211&gt; 13 &lt;212> PRT &lt;213&gt; Artificial Sequence &lt;220&gt;&lt;223&gt; Description of the sequence: Synthetic peptide &lt;400> 1590 ^ Val Ser His Pro Tyr Ser Gin His Leu Glu Gly Lys Gly 1 5 10 &lt;210&gt; 1591 &lt;211> 7 &lt;212> PRT &lt;213&gt; Sequence &lt;220> &lt;223> Description of Artificial Sequence: Synthetic Winning &lt;400&gt; 1591

Ala Leu Thr Asp Phe Phe Arg 1 5 &lt;210&gt; 1592 &lt;211&gt; 20 - &lt;212> PRT &lt;213&gt; Artificial sequence * &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;;400> 1592

Gin Ala lie Gly Leu Met Gly Tyr Arg Leu Ser Pro Gin Thr Leu Thr 1 5 10 15

Thr lie Val Lys 20 762 1300414 &lt;210&gt; 1593 &lt;211&gt; 17 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400&gt;

Met Gly Phe Asn Ala Phe Lys Glu Leu Trp Ala Ala Leu Asn Ala Trp 1 5 10 15

Lys &lt;210&gt; 1594 &lt;211&gt; 16 &lt;212&gt; PRT &lt;213&gt;Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1594

Glu Val Gin Leu Val Glu Ser Gly Val Gly Leu Val Gin Pro Gly Asp 1 5 10 15 &lt;210> 1595 &lt;211> 17 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220>, &lt;223&gt; Description of the artificial sequence: synthetic peptide &lt;400> 1595

Glu Leu Asp Ala Lys He Pro Ser Thr Gly Asp Ala Thr Glu Trp Arg 1 5 10 15

Asn

&lt;210> 1596 &lt;211> 20 &lt;212&gt; PRT 763 1300414 &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1596

Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly 1 5 10 15

Val Thr Ser Ala 20 &lt;210> 1597 &lt;211&gt; 20 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1597

Gly Lys Glu lie Leu Val Gly Asp Val Gly Gin Thr Val Asp Asp Pro 1 5 10 15

Tyr Ala Thr Phe 20 &lt;210&gt; 1598 &lt;211&gt;15)&lt;212> PRT &lt;213>Artificial sequence ' &lt;220> &lt;223&gt; Description of artificial sequence: synthetic peptide ^ &lt;400&gt; 1598

Glu Leu Ser Leu Ala Gly Asn Glu Leu Gly Asp Glu Gly Ala Arg 15 10 15 &lt;210> 1599 &lt;211&gt; 22 &lt;212&gt; PRT &lt;213&gt; Artificial sequence 764 1300414 &lt;220> &lt;223&gt; Description of the sequence: the victory of synthesis &lt;400&gt; 1599

Met Phe lie Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro Asp Gly 1 5 10 15

Phe Leu Ser Glu Leu Thr 20 &lt;210> 1600 &lt;211> 35 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide &lt;400> 1600

Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe He Gly lie lie lie Asp 1 5 10 15

Asn Phe Trp Gin Gin Lys Lys Lys Leu Gly Gly Lys Asp He Phe Met 20 25 30

Thr Glu Glu 35 &lt;210> 1601

&lt;212> PRT • &lt;213&gt;Artificial sequence &lt;220> Λ &lt;223> Description of artificial sequence: synthetic peptide &lt;400> 1601

Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg Glu Gly Phe Arg Gly 15 10 15

Glu Glu Gly Asp Pro Gly Leu Pro Gly Ala Ala 20 25 765 1300414 &lt;210&gt; 1602 &lt;211&gt; 21 &lt;212> PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400&gt; 1602

Cys Lys Thr Cys Gin Arg Lys Phe Ser Arg Ser Gly His Leu Lys Thr 1 5 10 15

His Thr Arg Thr His 20

&lt;210> 1603 &lt;211&gt; 15 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: Synthetic victory &lt;400> 1603

His Val Ser Ser Glu Ala Phe Arg Met Cys Asp Val Cys Leu Glu 1 5 10 15

&lt;210&gt; 1604 &lt;211> 5 &lt;212&gt; PRT GI) &lt;213&gt; Artificial Sequence &lt;220&gt;-&lt;223&gt; Description of Artificial Sequence: Synthetic Success &lt;400> 1604 Pro His Ser Arg Asn 1 5 &lt;210> 1605 &lt;211> 5 &lt;212> PRT &lt;213&gt; Artificial sequence &lt;220&gt; 766 1300414 &lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1605 Pro His Ser Cys Asn 1 5 &lt;210&gt; 1606 &lt;211&gt; 28 &lt;212&gt; PRT &lt;213&gt; Artificial Sequence &lt;220&gt; Sound &lt;223&gt; Description of Artificial Sequence: Synthetic Peptide &lt;400> 1606

Met Gly Pro Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu 1 5 10 15

Leu Val Val Met Ala Gly Val Ala Pro Val Trp Ala 20 25 &lt;210> 1607 &lt;211> 15 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Peptide &lt;400〉 1607

Met Val Lys Ser His lie Gly Ser Trp lie Leu Val Leu Phe Val -&lt;210&gt; 1608 &lt;211&gt; 9 '&lt;212>PRT &lt;213>Artificial Sequence &lt;220> &lt;223&gt; Description of Artificial Sequence : Synthetic wins &lt;400〉 1608

Cys Ser Leu Pro Gly Ser Ala Ala Ala 1 5 767 1300414 &lt;210&gt; 1609 &lt;211&gt; 15 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Success Peptide &lt;400> 1609

Arg Gly Leu Lys Arg Gin Ser Asp Glu Arg Lys Arg Asp Arg Glu 15 10 15

, &lt;210&gt; 1610 &lt;211> 57 &lt;212&gt; PRT (one &lt;213> artificial sequence &lt;220> &lt;223&gt; Description of artificial sequence: synthetic victory JJ too &lt;400> 1610

Gly Arg Ser His Met Val Leu Asn Ser Ala Leu Glu Gly Ala Arg Gly 1 5 10 15

Gly Pro Gly Gly Glu Glu He Pro Glu Arg Phe Ser He Pro Glu Leu 20 25 30

Gin Trp Met Leu Ser Asn Ala Glu Leu Ala Pro Val Gin Ala Asp Glu 35 40 45

Pro Pro Gin Ser Arg Met Asp Leu Val 50 55 &lt;210> 1611 &quot;&lt;211&gt; 35 &lt;212&gt; PRT &lt;213&gt;Artificial Sequence&lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthetic Win Peptide &lt;400> 1611

Gin Ala Arg Ala Val Gly Leu Ala Gly Thr Ser Arg Ala Phe Leu Ser 15 10 15 768 1300414

Ser Arg Leu Gin Asp Leu Tyr Ser lie Val Arg Arg Ala Asp Arg Ala 20 25 30

Ala Val Met 35 &lt;210&gt; 1612 &lt;211&gt; 15 &lt;212> PRT &lt;213&gt; artificial sequence &lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic victory &lt;400&gt; 1612

Met Val Lys Ser His lie Gly Ser Trp lie Leu Val Leu Phe Val 15 10 15 &lt;210> 1613 &lt;211&gt; 29 &lt;212&gt; PRT &lt;213>Artificial Sequence &lt;220> &lt;223>Artificial Sequence Description: The victory of synthesis &lt;400> 1613

Leu Arg Asp Leu Val Ser Tyr Cys Arg Ala Arg Gly Lys Gly Arg Glu 15 10 15

Arg Met Asn Gly Thr Arg Lys Gly His Leu Leu Tyr Met 20 25 &lt;210&gt; 1614 &lt;211&gt; 33 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt;&lt;223&gt; Description of Artificial Sequence: Synthesis Victory &lt;400&gt; 1614

Gly Lys Arg Ser Ser Pro Glu Thr Leu lie Ser Asp Leu Leu Met Arg 769 1300414 1 5 10 15

Glu Ser Thr Glu Asn Val Pro Arg Thr Arg Leu Glu Asp Pro Ala Met 20 25 30

Trp &lt;210> 1615 ^ &lt;211> 30 &quot;&lt;212&gt; PRT, &lt;213&gt; artificial sequence &lt;220&gt;&lt;223&gt; Description of artificial sequence: synthetic peptide (£^-) &lt;400&gt; 1615

Asp Val Glu Pro Leu Leu Gly Phe Leu Ser Pro Lys Ser Gly Gin Glu 1 5 10 15

Asn Glu Val Asp Asp Phe Pro Tyr Lys Gly Gin Gly Glu Leu 20 25 30 &lt;210&gt; 1616 &lt;211&gt; 20 &lt;212> PRT &lt;213>Artificial Sequence &lt;220&gt; _ &lt;223&gt; Artificial Sequence Description: the winning form

Cj &lt;400>1616

Phe Cys Lys Cys Arg Leu Glu Pro Met Lys Ala Thr Cys Asp lie Ser • 1 5 10 15

Glu Cys Pro Glu 20 &lt;210&gt; 1617 &lt;211&gt; 20 &lt;212&gt; PRT &lt;213&gt; Artificial sequence &lt;220&gt; 770 1300414 &lt;223&gt; 223> Description of artificial sequence: synthetic peptide &lt;400> 1617

Lys Ser His Gly Arg Thr Gin Asn Pro Val Val His Phe Phe Lys Asn 1 5 10 15

He Val Thr Pro 20

m

Claims (1)

1300414 Patent Application No. 94112549 Application for the application of the patent for the benefit of the patent. Announcement 1. A modified therapeutic peptide which forms a stabilized therapeutic peptide conjugate, characterized in that it comprises SEQ ID NO. 397 or 398 or is therapeutically active a fragment that attaches a reactive group to an amino acid position in the peptide that reacts with a thiol group on the albumin to form a stable covalent bond Containing a maleimide group to form the stabilized therapeutic peptide conjugate. 2. The peptide as claimed in claim 1, wherein the reactive group is attached to the carboxy terminal amino acid. 3. The peptide of claim 1, wherein the reactive group is attached to the amino terminal amino acid. 4. The peptide of claim 1, wherein the reactive group is coupled to the therapeutic peptide by an oleic acid and/or a linking group. 5. The peptide of claim 2, wherein the reactive group is coupled to the therapeutic peptide by an lysine and/or a linking group. 6. The peptide of claim 3, wherein the reactive group is coupled to the therapeutic peptide by an lysine and/or a linking group. 7. The peptide according to any one of claims 1 to 6, wherein the peptide is SEQ ID NO: 397 or a peptide having a therapeutically active fragment thereof. 8. The peptide according to any one of claims 1 to 6, wherein the peptide is SEQ ID NO: 398 or a peptide having a therapeutically active fragment thereof. 9. The peptide of any one of claims 1 to 6, wherein the peptide is the peptide of SEQ ID NO: 398. 1300414 ιο - a stabilized therapeutic peptide conjugate comprising: albumin, and a modified therapeutic peptide comprising SEQ ID NO: 397 or 398 'or The amino acid sequence of the active fragment, and a reactive group containing a maleimide group, are covalently bonded to one of the thiol groups on the albumin. 11. The conjugate of claim 10, wherein the reactive group is attached to the carboxy terminal amino acid. 12. The conjugate of claim 1, wherein the reactive group is attached to the amino terminal amino acid. 13. The conjugate of claim 10, wherein the reactive group is coupled to the therapeutic peptide by an lysine and/or a linking group. 14. The conjugate of claim n, wherein the reactive group is coupled to the therapeutic peptide by an oleic acid and/or a linking group. 15. The conjugate of claim 12, wherein the reactive group is coupled to the therapeutic peptide by an lysine and/or a linking group. The conjugate of any one of claims 1 to 15, wherein the peptide is SEQ ID NO: 397 or a peptide having a therapeutically active fragment thereof. The conjugate of any one of clauses 1 to 15, wherein the peptide is SEQ ID NO: 398 or a peptide having a therapeutically active fragment thereof. The conjugate of any one of claims 10 to 15, wherein the peptide is the peptide of SEQ ID NO: 398. 19. A method for increasing the in vivo half-life of a therapeutic peptide in vitro comprising a SEQ ID NO: 397 or 398 or a therapeutically 1300414 active fragment thereof, the method comprising: (a The peptide is modified by coupling a reactive group containing a maleimide group to an amino acid of the peptide, the reactive group being reactive with the functional group on albumin Forming a covalent bond; (b) forming a covalent bond between the reactive group and the reactive functional group on the albumin to form a peptide-albumin conjugate, thereby increasing the half-life, While maintaining the therapeutic activity of the therapeutic peptide; and (C) analyzing the therapeutic activity of the peptide-albumin conjugate, and the in vivo half-life of the peptide-albumin conjugate; confirming the peptide The albumin conjugate has an increased half-life compared to the therapeutic peptide; the end 3 endures the peptide-albumin conjugate retaining the therapeutic activity of the therapeutic peptide. 20. The method of claim 19, wherein the reactive group is coupled to the peptide by an lysine and/or a linking group. The method of claim 19, wherein one or more of the amino acids are synthesizers. The method of any one of claims 19 to 21, wherein the peptide is SEQ ID NO: 397 or a peptide having a therapeutically active fragment thereof. The method of any one of claims 19 to 21, wherein the peptide is SEQ ID NO: 398 or a peptide having an active fragment thereof. The method of any one of claims 19 to 21, wherein the peptide is the peptide of SEQ ID NO: 398. 25. A method for increasing the in vivo half-life of 1300414 of a therapeutic peptide in vitro, the peptide comprising SEQ ID NO. 397 or 398 or a therapeutically active fragment thereof, the method comprising: (a) modifying the peptide by coupling a reactive group containing a cis-indenyldiimide group to an amino acid of the peptide to form a modified peptide, such that the modified peptide has therapeutic Reactive, the reactive group can form a covalent bond with a reactive functional group on albumin; (b) forming a covalent bond between the reactive entity and a reactive functional group on albumin to form a a peptide-albumin conjugate whereby the half-life of the peptide is increased while retaining the therapeutic activity of the therapeutic peptide; and (c) analyzing the therapeutic activity of the peptide-albumin conjugate, and The half-life of the peptide _ albumin conjugate; it is confirmed that the peptide-albumin conjugate has an increased half-life compared to the therapeutic peptide, and it is confirmed that the peptide-albumin conjugate retains the Therapeutic activity of therapeutic peptides. 26. The method of claim 25, wherein the reactive group is transposed to the carboxy terminal amino acid, the amine terminal amino acid or an amine located between the carboxy terminal and the amine end Base acid. The method of claim 25, wherein the reactive group is coupled to the peptide by a linking group. 28. The method of claim 26, wherein the reactive group is coupled to the peptide by a linking group. 29. The method of claim 25, wherein one or more of the amino acids are synthesizers. The method of any one of claims 25 to 29, wherein the 1300414 peptide is SEQ ID NO: 397 or a peptide having a therapeutically active fragment thereof. The method of any one of claims 25 to 29, wherein the peptide is SEQ ID NO: 398 or a peptide having a therapeutically active fragment thereof. The method of any one of claims 25 to 29, wherein the peptide is the peptide of SEQ ID NO: 398. 33. The modified therapeutic victory according to any one of claims 4 to 6 wherein the δ-helium linkage group is a polyethoxyamino acid. _ 34. The modified therapeutic peptide according to claim 33, wherein the polyethoxymethyl acid is selected from (2-amino)ethoxy acetic acid (ΑΕΑ) or [2-(2) -Amino)ethoxy]ethoxyacetic acid (AEEA). 35. The modified therapeutic peptide of claim 1, wherein the maleimide-containing reactive group is selected from the group consisting of τ&quot;-cis-butyl diimide-butyrate (GMBA) or maleimide propionic acid (MPA). The therapeutic peptide conjugate of any one of claims 13-15, wherein the linking group is a polyethoxyamino acid. The therapeutic peptide conjugate of claim 36, wherein the polyethoxylated acid is selected from the group consisting of (2-amino)ethoxyacetic acid (AEA) or [2-( 2-Amino)ethoxy]ethoxyacetic acid (AEEA). 38. The therapeutic peptide conjugate of claim 1, wherein the maleimide-containing reactive group is selected from the group consisting of T-s-butyleneimine-butyraldehyde oxime Amine (GMB A) or maleimide propionic acid (MPA). 39. The method of claim 2, wherein the linking group is a polyethoxylated amino acid. 40. The method of claim 39, wherein the polyethoxylated amino acid 1300414 is selected from the group consisting of (2-amino)ethoxyacetic acid (AEA) or [2-(2-amino)ethyl Oxy] ethoxyacetic acid (AEEA). 41. The method of claim 19, wherein the maleic acid-containing reactive group is selected from the group consisting of r-maleimide-butyraldehyde decylamine (GMBA) or It is maleimide propionic acid (MPA). 42. The method of any one of claims 27-28, wherein the linking group is a polyethoxylated amino acid. 43. The method of claim 42, wherein the polyethoxylated amino acid is selected from the group consisting of (2-amino)ethoxyacetic acid (AEA) or [2-(2-amino)ethyl Oxy] ethoxyacetic acid (AEEA). 44. The method of claim 25, wherein the maleimide-containing reactive group is selected from the group consisting of 7-maleimide-butyraldehyde oxime (GMBA) or cis Butylene diimine propionate (MPA).